PROGRAM
1G506sT
1G506sT
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
2015<br />
19th Annual Scientific Assembly<br />
<strong>PROGRAM</strong><br />
September 26 – 29, 2015<br />
Gaylord National Harbor • National Harbor, Maryland<br />
Sessions Begin Saturday morning at 10:30am
NEW<br />
Add Corlanor ® to maximally tolerated doses of beta-blockers and help<br />
give appropriate patients with stable, symptomatic chronic heart failure...<br />
MORE HOME. LESS HOSPITAL.<br />
Learn how you can DO MORE with Corlanor ® to reduce the risk<br />
of hospitalization for worsening heart failure 1<br />
CorlanorHCP.com<br />
Indication<br />
Corlanor ® (ivabradine) is indicated to reduce the risk of hospitalization<br />
for worsening heart failure in patients with stable, symptomatic<br />
chronic heart failure with left ventricular ejection fraction ≤ 35%, who<br />
are in sinus rhythm with resting heart rate ≥ 70 beats per minute and<br />
either are on maximally tolerated doses of beta-blockers or have a<br />
contraindication to beta-blocker use.<br />
Important Safety Information<br />
Contraindications: Corlanor ® is contraindicated in patients with<br />
acute decompensated heart failure, blood pressure < 90/50 mmHg,<br />
sick sinus syndrome, sinoatrial block, 3 rd degree atrioventricular<br />
block (unless a functioning demand pacemaker is present), a resting<br />
heart rate < 60 bpm prior to treatment, severe hepatic impairment,<br />
pacemaker dependence (heart rate maintained exclusively by the<br />
pacemaker), and concomitant use of strong cytochrome P450 3A4<br />
(CYP3A4) inhibitors.<br />
Fetal Toxicity: Corlanor ® may cause fetal toxicity when administered<br />
to a pregnant woman based on embryo-fetal toxicity and cardiac<br />
teratogenic effects observed in animal studies. Advise females to use<br />
effective contraception when taking Corlanor ® .<br />
Atrial Fibrillation: Corlanor ® increases the risk of atrial fibrillation.<br />
The rate of atrial fibrillation in patients treated with Corlanor ®<br />
compared to placebo was 5% vs. 3.9% per patient-year, respectively.<br />
Regularly monitor cardiac rhythm. Discontinue Corlanor ® if atrial<br />
fibrillation develops.<br />
Bradycardia and Conduction Disturbances: Bradycardia, sinus<br />
arrest and heart block have occurred with Corlanor ® . The rate of<br />
bradycardia in patients treated with Corlanor ® compared to placebo<br />
was 6% (2.7% symptomatic; 3.4% asymptomatic) vs. 1.3% per<br />
patient-year, respectively. Risk factors for bradycardia include sinus<br />
node dysfunction, conduction defects, ventricular dyssynchrony, and<br />
use of other negative chronotropes. Concurrent use of verapamil or<br />
diltiazem also increases Corlanor ® exposure, contributes to heart rate<br />
lowering, and should be avoided. Avoid use of Corlanor ® in patients<br />
with 2 nd degree atrioventricular block unless a functioning demand<br />
pacemaker is present.<br />
Adverse Reactions: The most common adverse reactions reported<br />
at least 1% more frequently with Corlanor ® than placebo and that<br />
occurred in more than 1% of patients treated with Corlanor ® were<br />
bradycardia (10% vs. 2.2%), hypertension or increased blood pressure<br />
(8.9% vs. 7.8%), atrial fibrillation (8.3% vs. 6.6%), and luminous<br />
phenomena (phosphenes) or visual brightness (2.8% vs. 0.5%).<br />
Please see Brief Summary of full Prescribing Information<br />
on adjacent page.<br />
Reference: 1. Corlanor ® (ivabradine) Prescribing Information, Amgen.<br />
© 2015 Amgen Inc. All rights reserved. Not for reproduction. USA-998-106020
Corlanor ® (ivabradine)<br />
BRIEF SUMMARY OF PRESCRIBING INFORMATION<br />
Please see package insert for full Prescribing Information<br />
1. INDICATIONS AND USAGE<br />
Corlanor is indicated to reduce the risk of hospitalization for<br />
worsening heart failure in patients with stable, symptomatic<br />
chronic heart failure with left ventricular ejection fraction<br />
≤ 35%, who are in sinus rhythm with resting heart rate ≥ 70<br />
beats per minute and either are on maximally tolerated doses<br />
of beta-blockers or have a contraindication to beta-blocker use.<br />
4. CONTRAINDICATIONS<br />
Corlanor is contraindicated in patients with:<br />
• Acute decompensated heart failure<br />
• Blood pressure less than 90/50 mmHg<br />
• Sick sinus syndrome, sinoatrial block, or 3 rd degree AV block,<br />
unless a functioning demand pacemaker is present<br />
• Resting heart rate less than 60 bpm prior to treatment [see<br />
Warnings and Precautions (5.3)]<br />
• Severe hepatic impairment [see Use in Specific Populations<br />
(8.6)]<br />
• Pacemaker dependence (heart rate maintained exclusively by<br />
the pacemaker) [see Drug Interactions (7.3)]<br />
• Concomitant use of strong cytochrome P450 3A4<br />
(CYP3A4) inhibitors [see Drug Interactions (7.1)]<br />
5. WARNINGS AND PRECAUTIONS<br />
5.1 Fetal Toxicity<br />
Corlanor may cause fetal toxicity when administered to a pregnant<br />
woman based on findings in animal studies. Embryo-fetal toxicity<br />
and cardiac teratogenic effects were observed in fetuses of<br />
pregnant rats treated during organogenesis at exposures 1<br />
to 3 times the human exposures (AUC 0-24hr ) at the maximum<br />
recommended human dose (MRHD) [see Use in Specific<br />
Populations (8.1)]. Advise females to use effective contraception<br />
when taking Corlanor [see Use in Specific Populations (8.3)].<br />
5.2 Atrial Fibrillation<br />
Corlanor increases the risk of atrial fibrillation. In SHIFT, the rate<br />
of atrial fibrillation was 5.0% per patient-year in patients treated<br />
with Corlanor and 3.9% per patient-year in patients treated with<br />
placebo [see Clinical Studies (14)]. Regularly monitor cardiac<br />
rhythm. Discontinue Corlanor if atrial fibrillation develops.<br />
5.3 Bradycardia and Conduction Disturbances<br />
Bradycardia, sinus arrest, and heart block have occurred<br />
with Corlanor. The rate of bradycardia was 6.0% per patientyear<br />
in patients treated with Corlanor (2.7% symptomatic;<br />
3.4% asymptomatic) and 1.3% per patient-year in patients<br />
treated with placebo. Risk factors for bradycardia include<br />
sinus node dysfunction, conduction defects (e.g., 1 st or 2 nd<br />
degree atrioventricular block, bundle branch block), ventricular<br />
dyssynchrony, and use of other negative chronotropes (e.g.,<br />
digoxin, diltiazem, verapamil, amiodarone). Concurrent use<br />
of verapamil or diltiazem will increase Corlanor exposure,<br />
may themselves contribute to heart rate lowering, and should<br />
be avoided [see Clinical Pharmacology (12.3)]. Avoid use of<br />
Corlanor in patients with 2 nd degree atrioventricular block,<br />
unless a functioning demand pacemaker is present [see<br />
Contraindications (4) and Dosage and Administration (2)].<br />
6. ADVERSE REACTIONS<br />
Clinically significant adverse reactions that appear in other<br />
sections of the labeling include:<br />
• Fetal Toxicity [see Warnings and Precautions (5.1)]<br />
• Atrial Fibrillation [see Warnings and Precautions (5.2)]<br />
• Bradycardia and Conduction Disturbances [see Warnings and<br />
Precautions (5.3)]<br />
6.1 Clinical Trials Experience<br />
Because clinical trials are conducted under widely varying<br />
conditions, adverse reaction rates observed in the clinical trials of<br />
a drug cannot be directly compared to rates in the clinical trials of<br />
another drug and may not reflect the rates observed in practice.<br />
In the Systolic Heart failure treatment with the I f inhibitor<br />
ivabradine Trial (SHIFT), safety was evaluated in 3260 patients<br />
treated with Corlanor and 3278 patients given placebo. The<br />
median duration of Corlanor exposure was 21.5 months.<br />
The most common adverse drug reactions in the SHIFT trial are<br />
shown in Table 2 [see also Warnings and Precautions (5.2), (5.3)].<br />
Table 2. Adverse Drug Reactions with Rates ≥ 1.0% Higher<br />
on Ivabradine than Placebo occurring in > 1% on ivabradine<br />
in SHIFT<br />
Ivabradine<br />
N=3260<br />
Placebo<br />
N=3278<br />
Bradycardia 10% 2.2%<br />
Hypertension, blood<br />
pressure increased<br />
8.9% 7.8%<br />
Atrial fibrillation 8.3% 6.6%<br />
Phosphenes, visual<br />
brightness<br />
2.8% 0.5%<br />
Luminous Phenomena (Phosphenes)<br />
Phosphenes are phenomena described as a transiently<br />
enhanced brightness in a limited area of the visual field, halos,<br />
image decomposition (stroboscopic or kaleidoscopic effects),<br />
colored bright lights, or multiple images (retinal persistency).<br />
Phosphenes are usually triggered by sudden variations in<br />
light intensity. Corlanor can cause phosphenes, thought to be<br />
mediated through Corlanor’s effects on retinal photoreceptors<br />
[see Clinical Pharmacology (12.1)]. Onset is generally within<br />
the first 2 months of treatment, after which they may occur<br />
repeatedly. Phosphenes were generally reported to be of mild to<br />
moderate intensity and led to treatment discontinuation in < 1%<br />
of patients; most resolved during or after treatment.<br />
6.2 Postmarketing Experience<br />
Because these reactions are reported voluntarily from a<br />
population of uncertain size, it is not always possible to<br />
estimate their frequency reliably or establish a causal<br />
relationship to drug exposure.<br />
The following adverse reactions have been identified during<br />
post-approval use of Corlanor: syncope, hypotension,<br />
angioedema, erythema, rash, pruritus, urticaria, vertigo,<br />
diplopia, and visual impairment.<br />
7. DRUG INTERACTIONS<br />
7.1 Cytochrome P450-Based Interactions<br />
Corlanor is primarily metabolized by CYP3A4. Concomitant<br />
use of CYP3A4 inhibitors increases ivabradine plasma<br />
concentrations, and use of CYP3A4 inducers decreases them.<br />
Increased plasma concentrations may exacerbate bradycardia<br />
and conduction disturbances.<br />
The concomitant use of strong CYP3A4 inhibitors is<br />
contraindicated [see Contraindications (4) and Clinical<br />
Pharmacology (12.3)]. Examples of strong CYP3A4 inhibitors<br />
include azole antifungals (e.g., itraconazole), macrolide<br />
antibiotics (e.g., clarithromycin, telithromycin), HIV protease<br />
inhibitors (e.g., nelfinavir), and nefazodone.<br />
Avoid concomitant use of moderate CYP3A4 inhibitors when<br />
using Corlanor. Examples of moderate CYP3A4 inhibitors<br />
include diltiazem, verapamil, and grapefruit juice [see Warnings<br />
and Precautions (5.3) and Clinical Pharmacology (12.3)].<br />
Avoid concomitant use of CYP3A4 inducers when using<br />
Corlanor. Examples of CYP3A4 inducers include St. John’s<br />
wort, rifampicin, barbiturates, and phenytoin [see Clinical<br />
Pharmacology (12.3)].<br />
7.2 Negative Chronotropes<br />
Most patients receiving Corlanor will also be treated with a betablocker.<br />
The risk of bradycardia increases with concomitant<br />
administration of drugs that slow heart rate (e.g., digoxin,<br />
amiodarone, beta-blockers). Monitor heart rate in patients<br />
taking Corlanor with other negative chronotropes.<br />
7.3 Pacemakers<br />
Corlanor dosing is based on heart rate reduction, targeting<br />
a heart rate of 50 to 60 beats per minute [see Dosage and<br />
Administration (2)]. Patients with demand pacemakers set to<br />
a rate ≥ 60 beats per minute cannot achieve a target heart rate<br />
< 60 beats per minute, and these patients were excluded from<br />
clinical trials [see Clinical Studies (14)]. The use of Corlanor is<br />
not recommended in patients with demand pacemakers set to<br />
rates ≥ 60 beats per minute.<br />
8. USE IN SPECIFIC POPULATIONS<br />
8.1 Pregnancy<br />
Risk Summary<br />
Based on findings in animals, Corlanor may cause fetal harm<br />
when administered to a pregnant woman. There are no<br />
adequate and well-controlled studies of Corlanor in pregnant<br />
women to inform any drug-associated risks. In animal<br />
reproduction studies, oral administration of ivabradine to<br />
pregnant rats during organogenesis at a dosage providing 1 to<br />
3 times the human exposure (AUC 0-24hr ) at the MRHD resulted in<br />
embryo-fetal toxicity and teratogenicity manifested as abnormal<br />
shape of the heart, interventricular septal defect, and complex<br />
anomalies of primary arteries. Increased postnatal mortality was<br />
associated with these teratogenic effects in rats. In pregnant<br />
rabbits, increased post-implantation loss was noted at an<br />
exposure (AUC 0-24hr ) 5 times the human exposure at the MRHD.<br />
Lower doses were not tested in rabbits. The background risk<br />
of major birth defects for the indicated population is unknown.<br />
The estimated background risk of major birth defects in the U.S.<br />
general population is 2 to 4%, however, and the estimated risk<br />
of miscarriage is 15 to 20% in clinically recognized pregnancies.<br />
Advise a pregnant woman of the potential risk to the fetus.<br />
Clinical Considerations<br />
Disease-associated maternal and/or embryo/fetal risk<br />
Stroke volume and heart rate increase during pregnancy,<br />
increasing cardiac output, especially during the first trimester.<br />
Pregnant patients with left ventricular ejection fraction less<br />
than 35% on maximally tolerated doses of beta-blockers may<br />
be particularly heart-rate dependent for augmenting cardiac<br />
output. Therefore, pregnant patients who are started on<br />
Corlanor, especially during the first trimester, should be followed<br />
closely for destabilization of their congestive heart failure that<br />
could result from heart rate slowing.<br />
© 2015 Amgen Inc. All rights reserved. Not for reproduction. USA-998-106020, v2 05/15<br />
Monitor pregnant women with chronic heart failure in 3 rd<br />
trimester of pregnancy for preterm birth.<br />
Data<br />
Animal Data<br />
In pregnant rats, oral administration of ivabradine during<br />
the period of organogenesis (gestation day 6-15) at doses of<br />
2.3, 4.6, 9.3, or 19 mg/kg/day resulted in fetal toxicity and<br />
teratogenic effects. Increased intrauterine and post-natal<br />
mortality and cardiac malformations were observed at doses<br />
≥ 2.3 mg/kg/day (equivalent to the human exposure at the MRHD<br />
based on AUC 0-24hr ). Teratogenic effects including interventricular<br />
septal defect and complex anomalies of major arteries were<br />
observed at doses ≥ 4.6 mg/kg/day (approximately 3 times the<br />
human exposure at the MRHD based on AUC 0-24hr ).<br />
In pregnant rabbits, oral administration of ivabradine during the<br />
period of organogenesis (gestation day 6-18) at doses of 7, 14,<br />
or 28 mg/kg/day resulted in fetal toxicity and teratogenicity.<br />
Treatment with all doses ≥ 7 mg/kg/day (equivalent to the<br />
human exposure at the MRHD based on AUC 0-24hr ) caused an<br />
increase in post-implantation loss. At the high dose of 28 mg/kg/<br />
day (approximately 15 times the human exposure at the MRHD<br />
based on AUC 0-24hr ), reduced fetal and placental weights were<br />
observed, and evidence of teratogenicity (ectrodactylia observed<br />
in 2 of 148 fetuses from 2 of 18 litters) was demonstrated.<br />
In the pre- and postnatal study, pregnant rats received<br />
oral administration of ivabradine at doses of 2.5, 7, or<br />
20 mg/kg/day from gestation day 6 to lactation day 20. Increased<br />
postnatal mortality associated with cardiac teratogenic findings<br />
was observed in the F1 pups delivered by dams treated at the<br />
high dose (approximately 15 times the human exposure at the<br />
MRHD based on AUC 0-24hr ).<br />
8.2 Lactation<br />
Risk Summary<br />
There is no information regarding the presence of ivabradine in<br />
human milk, the effects of ivabradine on the breastfed infant, or<br />
the effects of the drug on milk production. Animal studies have<br />
shown, however, that ivabradine is present in rat milk [see Data].<br />
Because of the potential risk to breastfed infants from exposure<br />
to Corlanor, breastfeeding is not recommended.<br />
Data<br />
Lactating rats received daily oral doses of [ 14 C]-ivabradine<br />
(7 mg/kg) on post-parturition days 10 to 14; milk and maternal<br />
plasma were collected at 0.5 and 2.5 hours post-dose on<br />
day 14. The ratios of total radioactivity associated with [ 14 C]-<br />
ivabradine or its metabolites in milk vs. plasma were 1.5 and<br />
1.8, respectively, indicating that ivabradine is transferred to milk<br />
after oral administration.<br />
8.3 Females and Males of Reproductive Potential<br />
Contraception<br />
Females<br />
Corlanor may cause fetal harm, based on animal data. Advise<br />
females of reproductive potential to use effective contraception<br />
during Corlanor treatment [see Use in Specific Populations (8.1)].<br />
8.4 Pediatric Use<br />
Safety and effectiveness in pediatric patients have not been<br />
established.<br />
8.5 Geriatric Use<br />
No pharmacokinetic differences have been observed in elderly<br />
(≥ 65 years) or very elderly (≥ 75 years) patients compared to<br />
the overall population. However, Corlanor has only been studied<br />
in a limited number of patients ≥ 75 years of age.<br />
8.6 Hepatic Impairment<br />
No dose adjustment is required in patients with mild or moderate<br />
hepatic impairment. Corlanor is contraindicated in patients with<br />
severe hepatic impairment (Child-Pugh C) as it has not been studied<br />
in this population and an increase in systemic exposure is anticipated<br />
[see Contraindications (4) and Clinical Pharmacology (12.3)].<br />
8.7 Renal Impairment<br />
No dosage adjustment is required for patients with creatinine<br />
clearance 15 to 60 mL/min. No data are available for patients<br />
with creatinine clearance below 15 mL/min [see Clinical<br />
Pharmacology (12.3)].<br />
10. OVERDOSAGE<br />
Overdose may lead to severe and prolonged bradycardia. In<br />
the event of bradycardia with poor hemodynamic tolerance,<br />
temporary cardiac pacing may be required. Supportive treatment,<br />
including intravenous (IV) fluids, atropine, and intravenous betastimulating<br />
agents such as isoproterenol, may be considered.<br />
This Brief Summary is based on the Corlanor ® Prescribing<br />
Information v1, 04/15<br />
Corlanor ® (ivabradine)<br />
Manufactured for: Amgen Inc.<br />
One Amgen Center Drive<br />
Thousand Oaks, California 91320-1799<br />
Patent: http://pat.amgen.com/Corlanor/
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Table of Contents<br />
President’s Message ..................................................................................5<br />
About the HFSA ........................................................................................7<br />
Executive Council ......................................................................................8<br />
Scientific Program Committee .................................................................. 8<br />
General Meeting Information .....................................................................9<br />
Business Meeting .................................................................................... 10<br />
Scientific Meeting and Satellite Supporters ............................................. 12<br />
Continuing Education Information .......................................................... 13<br />
Speaker Disclosure Information .............................................................. 13<br />
Scientific Program Learning Objectives ..................................................14<br />
Abstract Reviewers ..................................................................................16<br />
Scientific Program and Satellite Symposium Faculty ..............................17<br />
Program-at-a-Glance ................................................................................22<br />
Special Events and Activities in the Exhibit Hall .....................................26<br />
Award Listing………………………………….. .....................................27<br />
Saturday, September 26<br />
Scientific Sessions and Satellite Symposia ...............................................29<br />
Sunday, September 27<br />
Satellite Symposia ....................................................................................35<br />
Morning Scientific Program .....................................................................36<br />
Noon Hour Activities ...............................................................................39<br />
Afternoon Scientific Program ..................................................................42<br />
Monday, September 28<br />
Satellite Symposia ................................................................................... 46<br />
Award Sessions……. .............................................................................. 48<br />
Scientific Program ................................................................................... 49<br />
Tuesday, September 29<br />
Scientific Program ................................................................................... 60<br />
Posters<br />
Poster Reception I - Saturday Poster Presenters………………........…….…65<br />
Poster Reception II - Sunday Poster Presenters…………….......…………..83<br />
Exhibit Hall<br />
Industry Expert Theaters ....................................................................... 100<br />
Clinical Trial Row ..................................................................................102<br />
List of Exhibitors ................................................................................ ...107<br />
Exhibit Hall Floor Plan .......................................................................... 108<br />
Exhibitor Descriptions ........................................................................... 109<br />
Speaker/Author Index ............................................................................ 117<br />
Gaylord National Harbor Meeting Rooms Floor Plan ........................... 132<br />
Notes ............................................................................................... ...... 135<br />
Dates to Remember ............................................................................... 138<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
4
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
President’s Message<br />
Dear Colleagues,<br />
Welcome to the 19th Annual Heart Failure Society of America Scientific Meeting. The HFSA<br />
Strategic Plan has articulated that our core purpose is to reduce the burden of heart failure to<br />
patients and society through prevention, treatment, and discovery. We have made major strides<br />
in this purpose in 2015. Following our core values of excellence, multidisciplinary endeavors,<br />
inclusiveness, integrity, innovation, and collaboration, we have continued to improve the things<br />
we did well and have begun a number of new initiatives.<br />
1. HFSA Annual Scientific Meeting. We offer thanks to the Program Committee Chairs—<br />
Gregg Fonarow, MD, Debra Moser, DNSc, RN, Mona Fiuzat, PharmD, and John Burnett, Jr.,<br />
MD, who have done a great job in making the program both exciting and comprehensive. This<br />
year’s program has 75 educational sessions, 280 faculty, 350 posters, and nearly 50 exhibitors,<br />
with an anticipated attendance of more than 1,800 heart failure specialists. The program<br />
reflects the excitement for new medical and device therapies that have been approved in the past<br />
year, and is designed to provide up-to-date summaries of new therapies as well as to stimulate<br />
discussion. We have added a PharmD chair to the program committee to reflect the important<br />
contributions of Pharmacy to the practice of Heart Failure and Transplantation. The entire Program<br />
Committee membership also reflects the HFSA goal to include and encourage young heart<br />
failure practitioners in both clinical activity and research, and we give many thanks to the entire<br />
committee for your hard work.<br />
2. Publication of the Journal of Cardiac Failure and eleven education modules providing<br />
practical information on specific topics that are useful to patients and their families in the care<br />
and treatment of those with heart failure. We thank Gary Francis, MD for his outstanding work<br />
as the recent Editor of JCF and welcome Paul J. Hauptman, MD as our new Editor. Paul has<br />
an exciting vision for the journal and he encourages your ideas and contributions to JCF, and<br />
would love to consider your state of the art manuscripts for publication. The next iteration of<br />
Heart Failure Practice guidelines will be ACC/AHA/HFSA Heart Failure Guidelines and will be<br />
published simultaneously in JACC, Circulation, and JCF.<br />
3. Comprehensive Heart Failure Review Course. The Heart Failure Board Review Course<br />
alternates every other year with a Heart Failure Review Course with the Board Review Course<br />
held the year of the Advanced Heart Failure and Transplantation American Board of Internal<br />
Medicine Examination. The 2015 Comprehensive Heart Failure Review and Update is scheduled<br />
for October 22-25, 2015 in Tampa, Florida. The 2015 HF Review Course is designed<br />
by and for cardiologists, internists, nurses, clinical pharmacists and other health professionals<br />
with a special interest in heart failure. Thanks go to Barry Greenberg, MD for his long-term<br />
leadership spearheading this state of the art program and to his co-chairs, J. Herbert Patterson,<br />
PharmD and Sara C. Paul, DNP, FNP for their work in planning this year’s course.<br />
4. Successful Advocacy Efforts resulting in the approval of a Medicare payment reform bill<br />
that includes the repeal of the flawed Sustainable Growth Rate (SGR) Formula. The Advocacy<br />
Committee under Joe Hill’s leadership has been instrumental in the approval of HFSA’s request<br />
for a provider taxonomy code to designate specialists in advanced heart failure and transplant<br />
cardiology by the National Uniform Claim Committee (NUCC). The taxonomy code was<br />
approved July 1, 2015 and will be effective on October 1, 2015. See HFSA’s website for more<br />
information.<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
5
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
5. Continued Research and Travel Grant Awards<br />
Many thanks to Medtronic for allowing HFSA to award research funds to fellows for important<br />
research, project assistance and travel grants. With these funds, many more Early Career heart<br />
failure fellows will have new opportunities to pursue their research and to attend the HFSA<br />
Annual Meeting and Review course. Additionally, two grants made possible by St. Jude Medical<br />
are available for specific research on implantable devices. See the HFSA website for more<br />
information.<br />
6. Launch of HFSA’s Quality Care Initiative – This is a multi-organizational effort to identify<br />
and establish benchmarks to improve the standards of quality care for those impacted by heart<br />
failure. The first collaboration of this kind included 18 associations involved in heart failure.<br />
Thanks to our founding partner, AMGEN and Silver level partner, Bayer, for their sponsorship<br />
of this important endeavor. Paul Heidenreich, MD and Nancy Albert, PhD, CNS chaired this<br />
one day symposium, which was designed to improve quality of care for heart failure patients<br />
through a collaborative effort. The first meeting was held in Chicago in June and four projects<br />
have been developed. We will be publishing a white paper early next year as the first step in<br />
this important initiative. Please read the HFSA Press Release HFSA Says Heart Failure is Not<br />
an Option for more information.<br />
7. Development of Patient Health Fair Day in collaboration with the American Association<br />
of Heart Failure Nurses (AAHFN). Patient Health Fair Days are being developed to improve<br />
the health and well-being of the heart failure community by connecting patients and caregivers<br />
to multi-disciplinary heart failure experts and resources. In collaboration with the AAHFN, the<br />
HFSA will host the first biannual “Patient Day” in advance of our scientific sessions. These<br />
meetings will be held in advance of HFSA and the AAHFN annual meetings and program<br />
materials will be designed to allow dissemination to our membership and will be available on<br />
our website. This year’s chairs are Shashank Desai, MD and Robin Trupp, PhD, ACNP-BC.<br />
“Patient Day” will be a five hour session for heart failure patients and their caregivers designed<br />
to give a broad overview of pathophysiology, standard heart failure care, and “what’s new in<br />
heart failure.” Patients and caregivers will be able to then select four of eight breakout sessions<br />
that will be designed to cover smaller topics such as diet, medications, participation in clinical<br />
trials, helpful tips for caregivers, and psychological aspects of heart failure. We hope to develop<br />
these programs for MendedHearts for presentation in their chapter meetings. Novartis will<br />
be awarding a national “Caregivers Award.” Thanks to St. Jude Medical, Novartis Pharmaceuticals<br />
Corporation and Amgen for supporting this important program for patients.<br />
8. Development of the HFSA Fellows Designation (to be announced at this meeting) to recognize<br />
significant contributions to the field of heart failure. Designation will be available to members<br />
who meet the criteria and have maintained continuous membership for two or more years.<br />
I would like to also thank Michele Blair, CEO of HFSA for her outstanding work in leading our<br />
organization to financial stability and for creating the organizational stability that allows all of<br />
these things to happen.<br />
Thanks so much for attending the meeting. We would love to hear your thoughts if you have<br />
ideas for new programs or for improvements to old ones. We are excited about this meeting and<br />
about the future of the HFSA in providing leadership for the care of patients with heart failure.<br />
Sincerely,<br />
JoAnn Lindenfeld, MD<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
6
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
About the HFSA<br />
The Heart Failure Society of America (HFSA) represents the first organized effort by heart<br />
failure experts from the Americas to provide a forum for all those interested in heart failure<br />
research and patient care.<br />
The HFSA is dedicated to:<br />
Promoting research related to all aspects of heart failure and to providing a forum for presentation<br />
of basic, clinical and population-based research.<br />
Educating health care professionals through programs, publications, and other media in the<br />
areas of basic science, clinical medicine, patient management, and social, ethical and economic<br />
issues to enable them to diagnose and treat heart failure and concomitant medical conditions<br />
more effectively.<br />
Encouraging primary and secondary preventive measures to reduce the incidence of heart<br />
failure; serving as a resource for government, private industry, and health care providers to<br />
facilitate the establishment of programs and policies that will better serve the patient.<br />
Enhancing quality and duration of life in those with heart failure.<br />
Promoting and facilitating the formal training of physicians, scientists and allied health care<br />
providers in the field of heart failure.<br />
Society Membership Information<br />
Membership in the Society is open to all health care professionals with an interest in cardiovascular<br />
medicine.<br />
For information about the HFSA or to become a member, call or write:<br />
Heart Failure Society of America, Inc.<br />
6707 Democracy Blvd., Suite 925<br />
Bethesda, MD 20817<br />
Phone: 301-312-8635<br />
Fax: 888-213-4417<br />
E-mail: info@hfsa.org<br />
Interested participants can also visit the HFSA booth located near the Maryland C meeting<br />
room or visit the HFSA web site at www.hfsa.org<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
7
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Executive Council<br />
JoAnn Lindenfeld, MD - President<br />
Mandeep R. Mehra, MD - Vice President<br />
Christopher M. O'Connor, MD, FACC - Treasurer<br />
Sara C. Paul, DNP, FNP - Secretary<br />
Thomas Force, MD - Immediate Past President<br />
Jonathan D. Rich, MD<br />
Jonathan Howlett, MD, FACC<br />
Biykem Bozkurt, MD, PhD<br />
Corrine Y. Jurgens, RN, PhD<br />
Heather J. Ross, MD<br />
James E. Udelson, MD<br />
Javed Butler, MD, MPH<br />
John C. Burnett Jr., MD<br />
John R. Teerlink , MD<br />
Joseph A. Hill, MD, PhD<br />
Nancy M. Albert, PhD, CHFN<br />
Paul J. Mather, MD<br />
Sharon A. Hunt, MD, MACC<br />
Steven R. Houser, PhD<br />
Susan E. Ammon, NP-C, CHFN<br />
Jay N. Cohn, MD, MACP<br />
Monica R. Shah, MD<br />
Journal of Cardiac Failure<br />
Paul Hauptman, MD<br />
2015 Annual Meeting Program Committee<br />
Co-Chairs:<br />
John C. Burnett, Jr., MD<br />
Mona Fiuzat, PharmD<br />
Gregg Fonarow, MD<br />
Debra Moser, DNSc, RN<br />
Members<br />
Larry Allen, MD, MHS<br />
Amrut V. Ambardekar, MD<br />
Barry A. Borlaug, MD<br />
Javed Butler, MD, MPH<br />
Sheryl L. Chow, PharmD<br />
Patricia M. Davidson, PhD, MEd, RN, FAAN<br />
Victoria Vaughan Dickson, RN, PhD<br />
Mark Drazner, MD, MSc<br />
Peter M. Eckman, MD<br />
James C. Fang, MD<br />
Adrian F. Hernandez, MD<br />
James Louis Januzzi, MD<br />
Mariell Jessup, MD<br />
David A. Kass, MD<br />
Terry A. Lennie, PhD<br />
W. Robb MacLellan, MD<br />
Kenneth B. Margulies, MD<br />
Gina Mentzer, MD<br />
Shawn M. Merhaut, MSN, CNP<br />
Christopher Newton-Cheh, MD, MPH<br />
Peter S. Pang, MD<br />
Lisa D. Rathman, MSN, CRNP<br />
Joseph G. Rogers, MD<br />
Douglas B. Sawyer, MD, PhD<br />
Sanjiv J. Shah, MD<br />
Julie A. Shinn, MA<br />
Jeffrey M. Testani, MD, MTR<br />
Orly Vardeny, PharmD<br />
David J. Whellan, MD, MHS<br />
Clyde W. Yancy, MD, MSc<br />
The Program Chairs and members of the 2015 Scientific<br />
Program Committee wish to thank all members, past attendees,<br />
and others who submitted session proposals for this year's<br />
meeting. All were given serious consideration, and many were<br />
included, whole or in part, in the final program. In part, as a<br />
result of these proposals, many new speakers will be featured<br />
in this year's meeting. A call for proposals for 2016 will go<br />
out in October.<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
8
General Meeting Information<br />
Meeting Location<br />
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
All meeting activities will be held in the Gaylord National Harbor Convention Center and Hotel. See page 132 for a floor<br />
plan of meeting rooms.<br />
CME Accreditation/Registration<br />
Heart Failure Society of America<br />
6707 Democracy Blvd.<br />
Suite 925<br />
Bethesda, MD 20817<br />
Phone: 301-312-8635<br />
Fax: 888-213-4417<br />
Email: info@hfsa.org<br />
Registration Hours<br />
Friday, September 25.........................12:00 PM – 5:00 PM<br />
Saturday, September 26.......................7:00 AM – 5:00 PM<br />
Sunday, September 27.........................7:00 AM – 5:00 PM<br />
Monday, September 28........................7:00 AM – 5:00 PM<br />
Tuesday, September 29........................7:00 AM – 10:00 AM<br />
Included in Registration Fee<br />
The registration fee includes meeting materials, admission to scientific sessions, satellite symposia, receptions (some invitation<br />
only), exhibits and activities in the Exhibit Hall, and complimentary food events.<br />
Meeting Sessions Online<br />
In response to requests from previous attendees, HFSA will provide the scientific sessions online free-of-charge for 2015<br />
meeting attendees for 30 days following the meeting. Sessions also will be available for purchase for reference throughout<br />
the year. See the Sessions OnDemand desk located outside the Exhibit Hall.<br />
Opening Reception<br />
The opening reception (wine and hors d’ oeuvres) is Saturday, September 26, 6:00 – 8:00 PM in the Exhibit Hall (Prince<br />
George’s Exhibit Hall B&C).<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
9
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
General Meeting Information (continued)<br />
Poster Receptions<br />
The first Poster Reception will be held in the Exhibit Hall in conjunction with the opening reception, Saturday evening,<br />
6:00 – 8:00 PM. The reception will take place from 6:00-8:00pm with posters presented from 6:30 - 7:30pm. The second<br />
will be on Sunday in the Exhibit Hall following Sessions. The reception will take place from 5:15 pm - 6:30 pm with posters<br />
presented from 5:30 pm - 6:30 pm. There will be no reception Monday.<br />
Food Policy<br />
The Physician Payment Sunshine Act, part of the Affordable Care Act, requires that manufacturers of drugs and devices<br />
report to CMS certain payments and items of value given to physicians. These items of value include meals at CME activities,<br />
such as this annual meeting. For this reason, the following food and refreshments provided at the 2015 HFSA Annual<br />
Scientific Meeting will be paid for out of registration fees and the HFSA operating budget: the opening reception, the poster<br />
receptions, early morning refreshments, and coffee breaks.<br />
No Smoking Policy<br />
HFSA and The Gaylord National Harbor prohibit smoking in all meeting and hotel areas. Thank you for your cooperation.<br />
Video/Photography Policy<br />
HFSA staff members, as well as official HFSA photographers/videographers, are the only ones authorized to photograph<br />
and film events and educational sessions throughout the Annual Scientific meeting and will be identified by name badges.<br />
The photographs and videos taken at the HFSA Annual Scientific Meeting are used exclusively by HFSA for promotional<br />
purposes and continuing education offerings. They may be used in the association’s publications or on its Web site, and they<br />
may appear in programs or other HFSA promotional materials.<br />
If you are at an event or session at which an HFSA photographer is present and you do not wish to be photographed, please<br />
identify yourself to the photographer and your request will be respected.<br />
Special Needs<br />
The HFSA strives to hold meetings that are accessible to all. Please let us know if you have special needs. Contact Nikki<br />
Ahmetaj, Global Meetings and Incentives at nikki@gmimeetings.com (908)-358-3082<br />
Annual Business Meeting<br />
The annual business meeting is scheduled for 7:30 AM Tuesday in Chesapeake L.<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
10
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
General Meeting Information (continued)<br />
Questions<br />
There will be an information booth staffed by HFSA in the Maryland Hallway. Please visit the HFSA booth with conference, membership<br />
or resource related questions. Questions about the local area, restaurants or travel should be addressed with the hotel front<br />
desk or concierge. Tickets for the Faculty and Fundraising dinner may be purchased at the Onsite Registration Counter outside<br />
Prince George’s Exhibit Hall B&C.<br />
Speaker Ready Room – Chesapeake F<br />
Saturday, September 26........................8:00 AM – 6:00 PM<br />
Sunday, September 27..........................6:30 AM – 6:00 PM<br />
Monday, September 28.........................6:30 AM – 6:00 PM<br />
Tuesday, September 29.........................6:30 AM – 11:00 AM<br />
Press Room – Price George’s Exhibit Hall B Registration Office<br />
Saturday, September 26........................10:00 AM – 5:00 PM<br />
Sunday, September 27..........................10:00 AM – 5:00 PM<br />
Monday, September 28..........................7:00 AM – 5:00 PM<br />
Tuesday, September 29...........................7:00 AM – 11:00 AM<br />
All late breaking presentations embargoed until they have are presented.<br />
Exhibit Hall Schedule<br />
Please visit our exhibitors and thank them for supporting the HFSA Annual Scientific Meeting. Exhibits are located in the<br />
Prince George’s B&C Exhibit Hall. See page 107 for a list of exhibitors and locations.<br />
Saturday, September 26.........................6:00 PM – 8:00 PM<br />
Sunday September 27.........................10:00 AM – 6:30 PM<br />
Monday, September 28.......................10:00 AM – 2:00 PM<br />
Email from the Exhibit Hall<br />
Email stations will be located in the Exhibit Hall for attendees to check e-mail.<br />
There will be a cell phone charging station next to the email station and one by the HFSA Information booth.<br />
WiFi<br />
Complimentary WiFi is available in the hotel lobby and public areas.<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
11
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
General Meeting Information (continued)<br />
Poster Sessions<br />
Posters are displayed in the Exhibit Hall from 6:00 PM Saturday through 2:00 PM Monday. Presenters will be at their posters<br />
6:30-7:30 PM Saturday during the Opening Reception and 5:30-6:30 PM Sunday during the Poster Reception. Posters<br />
range from basic science topics to clinical and outcomes studies. They represent some of the newest work being done in the<br />
field on heart failure. Please take advantage of this opportunity to see interesting work and to encourage new investigators.<br />
New this year: All posters will be presented during the times the exhibit hall is open.<br />
Posters on display:<br />
Saturday, September 26...................6:00 PM – 8:00 PM<br />
Sunday, September 27...................10:00 AM – 6:30 PM<br />
Monday, September 28 .................10:00 AM - 1:30 PM<br />
Presenters at their posters:<br />
Saturday, September 26...................6:30-7:30 PM<br />
Sunday, September 27.....................5:30-6:30 PM<br />
2015 HFSA Satellite/Scientific Program Supporting Companies<br />
CME Satellite Symposia: Meeting Supporters: Advertisers:<br />
Amgen Arbor Pharmaceuticals, LLC Amgen<br />
Arbor Pharmaceuticals, LLC Cytokinetics Cytokinetics<br />
ReardenCME Medtronic Novartis Pharmaceuticals Corporation<br />
Relypsa, Inc Novartis Pharmaceuticals Corporation Roche<br />
ResMed St. Jude Medical scPharmaceuticals<br />
St. Jude Medical Thoratec Corporation Thoratec Corporation<br />
ZS Pharma<br />
Hands-on Workshops: Non-CME Industry Corporate Members:<br />
Abiomed Expert Theaters: Amgen<br />
Biotronik Amgen Bayer<br />
Boston Scientific Novartis Pharmaceuticals Corporation Cytokinetics<br />
CardiacAssist Roche GE Healthcare<br />
HeartWare scPharmaceuticals Medtronic<br />
Maquet Thoratec Corporation Novartis Pharmaceuticals Corporation<br />
Medtronic<br />
St. Jude Medical<br />
Thoratec Corporation<br />
A Special Thank You: Thank you to WomenHeart, Mended Hearts, Heart Brothers and The National Minority Quality Forum<br />
for their work on heart failure initiatives and their collaboration with HFSA on improving quality care to patients.<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
12
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Continuing Education Credit Information<br />
Scientific Program<br />
Physicians: The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical<br />
Education to provide continuing medical education for physicians. The Heart Failure Society of America designates this live<br />
activity for a maximum of 24.5 AMA PRA Category 1 Credits.<br />
Nurses: This Program Has Been Approved by the American Association of Critical Care Nurses (AACN) for a total of<br />
23.25 Contact Hours, File Number 00019357.<br />
Pharmacists: The CU Skaggs School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation<br />
Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). This program has been<br />
accredited for 24.25 contact hours of knowledge-based CPE, and pharmacists may earn up to 18.75 hours of credit<br />
due to concurrent presentations. To earn credit, participants must complete all online evaluations for programs<br />
attended and provide their NABP eProfile ID number and month and day of their birthdate. CE credit will be uploaded to<br />
CPE monitor within 60 days.<br />
Clinical Fundamentals I: The Immune Response in Cardiovascular Disease - 0008-9999-15-083-L01-P, Transitions in Heart<br />
Failure Care: It's Not Just About Hospital to Home - 0008-9999-15-084-L01-P, The Prevention of Heart Failure: Targets and<br />
Strategies - 0008-9999-15-085-L01-P, Excellence in Translational Science: Bench to Bedside - 0008-9999-15-086-L01-P,<br />
New Concepts in the Pathophysiology of HFpEF - 0008-9999-15-088-L01-P, How to Troubleshoot a VAD -<br />
0008-9999-15-089-L01-P, Guideline Session: Unique Heart Failure Populations: What Makes Them "Special"? -<br />
0008-9999-15-090-L01-P, Managing VAD Complications - 0008-9999-15-091-L01-P, Clinical Fundamentals II: FAQs<br />
About Heart Failure Drug Therapy - 0008-9999-15-092-L01-P, Putting the "Self" Back in Self-Care: Innovative Strategies<br />
to Improve Heart Failure Self-Care - 0008-9999-15-093-L01-P, Controversies in Cardio-oncology 0008-9999-15-094-L01-P,<br />
How to Manage Diuretic Resistance: What to Do When the Fluid Won't Come Off - 0008-9999-15-095-L01-P, What's New<br />
and Emerging in Heart Failure Pharmacology - 0008-9999-15-096-L01-P, Alternative Therapies for Heart Failure: Fact or<br />
Fiction? - 0008-9999-15-097-L01-P, Clinical Fundamentals III: Acute Heart Failure - 360 0008-9999-15-098-L01-P, Pharmacogenetics<br />
of Heart Failure and Transplant: Additive or Redundant - 0008-9999-15-098-L01-P<br />
Satellite Symposia<br />
Physicians: The Heart Failure Society of America is accredited by the Accreditation Council for Continuing Medical Education<br />
to provide continuing medical education for physicians. The Heart Failure Society of America designates each live<br />
activity for a maximum of 1.0/1.5 AMA PRA Category 1 Credits.<br />
Nurses: See satellite listings in this book or satellite handout materials for nursing credit statements.<br />
Presenter/Planner Disclosure Information<br />
The Heart Failure Society of America has a disclosure policy that requires oral presenters to disclose financial relationships<br />
with relevant commercial entities.<br />
Speaker disclosure information is available at http://www.hfsa.org/hfsa-wp/wp/disclosures2015/ Speakers also have a disclosure<br />
slide at the beginning of each presentation.<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
13
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Continuing Education Credit Information (continued)<br />
Scientific Program Learning Objectives<br />
Following this meeting, attendees will be able to:<br />
1. Describe the epidemiology of heart failure and implement strategies for the prevention of heart failure.<br />
2. Describe current knowledge about the scientific basis of heart failure.<br />
3. Identify the findings of basic science research and current clinical trials and describe their implications for<br />
current and future heart failure therapy.<br />
4. Implement optimal guideline-based therapeutic options for heart failure, including pharmacologic agents, non-pharmaco<br />
logic options, such as diet and exercise; and implantable devices.<br />
5. Manage comorbidities including hypertension, diabetes, depression, sleep apnea, and chemotherapy.<br />
6. Demonstrate awareness of psychosocial, economic, regulatory, and ethical issues in the treatment of patients with heart failure.<br />
7. Implement strategies for effective management of the patient with heart failure, incorporating the family, encouraging<br />
self-care, and employing the team approach.<br />
8. Outline strategies for transitioning patients from inpatient to outpatient care and for reducing hospital readmissions.<br />
9. Engage in performance measurement and other site-based research.<br />
10. Outline strategies for more effective communication with patients, families, and other health professionals.<br />
Specific learning objectives for the scientific session and satellite symposia are listed in the program book.<br />
Competencies Addressed<br />
The 2015 scientific program contains content that addresses the following ABMS core competencies:<br />
• Patient care<br />
• Medical knowledge<br />
• Interpersonal and communication skills<br />
• Professionalism<br />
• Systems-based practice<br />
Sessions also address the following ABIM-specified competency areas in advanced heart failure and transplant cardiology:<br />
• Epidemiology and risk factors<br />
• Pathophysiology of heart failure<br />
• Hemodynamics and hemodynamic monitoring<br />
• Heart failure and normal ejection fraction<br />
• Heart failure with renal dysfunction/cardiorenal syndrome<br />
• Diagnostic tests and procedures<br />
• Acute decompensation of chronic heart failure<br />
• Subsets of patients with heart failure, including women, the elderly, and different racial or ethnic groups<br />
• Heart failure comorbidities<br />
• Heart failure and pregnancy<br />
• Cardiomyopathies<br />
• Pharmacotherapy<br />
• Implantable devices<br />
• Heart transplant<br />
• Mechanical circulatory support<br />
• End-of-life issues<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
14
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Continuing Education Credit Information (continued)<br />
Evaluations<br />
An evaluation must be completed in order to receive a credit certificate for the scientific meeting or for satellite symposia.<br />
All evaluations will be electronic and will be formatted for smartphones, tablets and computers. They can also be accessed using<br />
the CE kiosks in the registration area. The evaluation form for the scientific program will be accessible during and after the meeting.<br />
Evaluations for satellites will be accessible after completion of each satellite. An email will be sent to attendees providing the<br />
website address to access evaluation forms and credit certificates. See more information about CE certificates elsewhere in this<br />
booklet.<br />
Pharmacists will be asked to complete a survey for each day of the meeting. Pharmacists who do not have the link to the surveys<br />
should check at the registration desk. For questions related to continuing pharmacy education, please call (303) 724-4298 or email<br />
sop.ContinuingEducation@ucdenver.edu<br />
Credit Certificates<br />
Physician and nursing continuing education credit certificates for the scientific meeting and for satellite symposia can be requested<br />
onsite using smartphones, tablets, computers or the CE kiosks in the registration area or after the meeting at the following site:<br />
http://ceu.experientevent.com/hfs151/. As noted above, evaluations must be completed before certificates will be issued. Certificates<br />
can be printed out or emailed. Pharmacists should follow ACPE procedures. For more information, go to www.hfsa.org<br />
under Annual Scientific Meeting > CE Credit Information.<br />
Certificates will be issued only to individuals registered for the annual meeting. If necessary, attendance will be verified based on information<br />
collected by hand-held scanners at meeting room entrances. CME credit cannot be earned with an exhibitor or guest badge.<br />
Meeting Content<br />
The 2015 HFSA Annual Scientific Meeting provides a forum for the open exchange and discussion of research results and scientific<br />
advancements in the field of heart failure; however, HFSA makes no representation or warranty as to the truth, originality,<br />
or accuracy of the information presented. Nor are the views expressed by the individual speakers necessarily the view of HFSA.<br />
HFSA supports the ACCME’s policy on evidence-based content and encourages faculty to adhere to these standards when preparing<br />
a presentation.<br />
Liability Statement<br />
Disclaimer: The Heart Failure Society of America (HFSA) cannot accept, and hereby specifically disclaims, any liability for<br />
death, injury, any loss, cost or expense suffered or incurred by any person if such loss is caused by, arises from or results from<br />
the act, default or omission of any person other than an employee or agent of HFSA. In particular, neither HFSA nor its agents<br />
can accept, and hereby specifically disclaims, any liability for losses arising from, caused by, or resulting from, the provision or<br />
non-provision of services provided by the hotels, companies, or transport operators. Neither HFSA nor its agents can accept, and<br />
hereby specifically disclaims, liability for losses suffered by reason of war including threat of war, riots and civil strife, terrorist<br />
activity, natural disaster, weather, fire, flood, drought, technical, mechanical or electrical breakdown within any premises visited<br />
by delegates and/or participants in connection with the meeting, industrial disputes, government action, regulations or technical<br />
problems that affect or may affect the services provided in connection with the meeting. HFSA is not able to warrant and does not<br />
warrant that a particular person will appear as a speaker. As a condition to any participation in or attendance at the Annual Scientific<br />
Meeting or any function associated or affiliated herewith, each attendee and participant accepts the foregoing disclaimer.<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
15
2015 Abstract Reviewers<br />
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Nancy Albert, RN, PhD<br />
Cleveland, OH<br />
Gregory Ewald, MD<br />
St. Louis, MO<br />
Stuart Katz, MD<br />
New York, NY<br />
Heather Ross, MD<br />
Toronto, ON<br />
Larry Allen, MD, MHS<br />
Aurora, CO<br />
James Fang, MD<br />
Salt Lake City, UT<br />
Marvin Konstam, MD<br />
Boston, MA<br />
Stuart Russell, MD<br />
Baltimore, MD<br />
Amrut Ambardekar, MD<br />
Aurora, CO<br />
Gary Michael Felker, MD<br />
Durham, NC<br />
Maria Kontaridis, PhD<br />
Boston, MA<br />
Marc Semigran, MD<br />
Boston, MA<br />
Inder Anand, MD, PhD<br />
Minneapolis, MN<br />
Mona Fiuzat, PharmD<br />
Durham, NC<br />
David Lanfear, MD, MS<br />
Detroit, MI<br />
Sanjiv Shah, MD<br />
Chicago, IL<br />
Martha Biddle, PhD, APRN, CCNS<br />
Lexington, KY<br />
Gregg Fonarow, MD<br />
Los Angeles, CA<br />
Daniel Levine, MD<br />
Providence, RI<br />
Garrick Stewart, MD<br />
Boston, MA<br />
Burns Blaxall, PhD<br />
Cincinnati, OH<br />
Michael Givertz, MD<br />
Boston, MA<br />
Douglas Mann, MD<br />
St. Louis, MO<br />
Wilson Tang, MD<br />
Cleveland, OH<br />
Barry Borlaug, MD<br />
Rochester, MN<br />
Steven Goldman, MD<br />
Tucson, AZ<br />
Kenneth Margulies, MD<br />
Philadelphia, PA<br />
John Teerlink, MD<br />
San Francisco, CA<br />
Bikyem Bozkurt, MD, FACC<br />
Houston, TX<br />
Stephen Gottlieb, MD<br />
Baltimore, MD<br />
Paul Mather, MD<br />
Philadelphia, PA<br />
Jeffrey Testani, MD<br />
New Haven, CT<br />
John Burnett Jr., MD<br />
Rochester, MN<br />
Barry Greenberg, MD<br />
La Jolla, CA<br />
Gina Mentzer, MD<br />
Lincoln, NE<br />
Jeffrey Teuteberg, MD<br />
Pittsburgh, PA<br />
Javed Butler, MD, MPH<br />
Stony Brook, NY<br />
Roger Hajjar, MD<br />
New York, NY<br />
Shawn Merhaut, MSN, CNP<br />
Cleveland, OH<br />
James Udelson, MD<br />
Boston, MA<br />
Sheryl Chow, PharmD<br />
Pomona, CA<br />
Karol Harshaw-Ellis, MSN<br />
Durham, NC<br />
Leslie Miller, MD<br />
Tampa, FL<br />
Orly Vardeny, PharmD<br />
Madison, WI<br />
Misook Chung, PhD<br />
Lexington, KY<br />
Akshay Desai, MD<br />
Boston, MA<br />
Anita Deswal, MD, MPH<br />
Houston, TX<br />
Victoria Vaughan Dickson, PhD,<br />
CRNP, MSN<br />
New York, NY<br />
Mark Drazner, MD<br />
Dallas, TX<br />
Shannon Dunlay, MD<br />
Rochester, MN<br />
Peter Eckman, MD<br />
Minneapolis, MN<br />
Paul Heidenreich, MD, MS<br />
Palo Alto, CA<br />
J. Thomas Heywood, MD<br />
La Jolla, CA<br />
Tamara Horwich, MD, MS<br />
Los Angeles, CA<br />
Sharon Hunt, MD<br />
Palo Alto, CA<br />
James Januzzi, MD<br />
Boston, MA<br />
Brian Jaski, MD<br />
San Diego, CA<br />
Mariell Jessup, MD<br />
Philadelphia, PA<br />
Alan Miller, MD<br />
Jacksonville, FL<br />
Christopher Newton-Cheh, MD, MPH<br />
Boston, MA<br />
Robert Page, II, PharmD, MSPH<br />
Aurora, CO<br />
Peter Pang, MD<br />
Indianapolis, IN<br />
Ileana Pina, MD, MPH<br />
New York, NY<br />
Lisa Rathman, MSN, CRNP<br />
Lancaster, PA<br />
Joseph Rogers, MD<br />
Durham, NC<br />
Hector Ventura, MD, FACC,<br />
FACP<br />
New Orleans, LA<br />
Lynne Warner Stevenson, MD<br />
Boston, MA<br />
David Whellan, MD, MHS<br />
Philadelphia, PA<br />
Clyde Yancy, MD, MSc<br />
Chicago, IL<br />
Michael Zile, MD<br />
Charleston, SC<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
16
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty 2015 HFSA Annual Scientific Meeting and Satellite Symposia<br />
Keith Aaronson, MD, MS<br />
University of Michigan<br />
Ann Arbor, MI<br />
Zoltan P. Arany, MD, PhD<br />
University of Pennsylvania<br />
Philadelphia, PA<br />
Eugene Braunwald, MD<br />
Harvard<br />
Boston, MA<br />
Monica Colvin, MD, MS<br />
University of Minnesota<br />
Ann Arbor, MN<br />
Jamil Aboulhosn, MD<br />
University of California<br />
Los Angeles, CA<br />
Pavan Atluri, MD<br />
University of Pennsylvania<br />
Philadelphia, PA<br />
Michael Bristow, MD, PhD<br />
University of Colorado<br />
Aurora, CO<br />
Leslie Cooper, MD<br />
Mayo Clinic<br />
Rochester, MN<br />
William Abraham, MD<br />
Ohio State University<br />
Columbus, OH<br />
Patricia Adams, BSN<br />
Duke University<br />
New Haven, CT<br />
Kirkwood Adams, MD<br />
University of North Carolina<br />
Chapel Hill, NC<br />
Tariq Ahmad, MD, MPH<br />
Yale University<br />
New Haven, CT<br />
Nancy Albert, PhD, RN, CHFN<br />
Cleveland Clinic<br />
Cleveland, OH<br />
Larry Allen, MD, MHS<br />
University of Colorado<br />
Aurora, CO<br />
Amrut Ambardekar, MD<br />
University of Colorado<br />
Aurora, CO<br />
Susan Ammon, MSN, NP<br />
San Francisco VAMC<br />
San Francisco, CA<br />
Inder Anand, MD, PhD<br />
VA Medical Center<br />
Minneapolis, MN<br />
Allen Anderson, MD<br />
Northwestern University<br />
Chicago, IL<br />
Lori Anderson, RN<br />
Tampa General Hospital<br />
Tampa, FL<br />
Stefan Anker, MD, PhD<br />
Charite Campus Virchow Klinikum<br />
Berlin, Germany<br />
Dipanjan Banerjee, MD<br />
Stanford University<br />
Palo Alto, CA<br />
Bradley Bart, MD<br />
Hennepin County Medical Center<br />
Minneapolis, MN<br />
Arvind Bhimaraj, MD, MPH<br />
Methodist DeBakey Heart and<br />
Vascular Institute<br />
Houston, TX<br />
Martha Biddle, PhD, APRN, CCNS<br />
University of Kentucky<br />
Lexington, KY<br />
Robert M. Blanton Jr., MD<br />
Tufts Medical Center<br />
Boston, MA<br />
Burns Blaxall, PhD<br />
Cincinnati Children's Hospital<br />
Cincinnati, OH<br />
Barry Bleske, PharmD<br />
University of Michigan<br />
Ann Arbor, MI<br />
Michale Bohm, MD, PhD<br />
University of Saarland<br />
Homburg/Saar, Germany<br />
Barry Borlaug, MD<br />
Texas Children's Hospital<br />
Rochester, MN<br />
Robert Bourge, MD<br />
University of Alabama<br />
Birmingham, AL<br />
Rebecca Boxer, MD, MS<br />
University of Colorado<br />
Denver, CO<br />
Biykem Bozkurt, MD<br />
Baylor College of Medicine<br />
Houston, TX<br />
John Burnett, MD<br />
Mayo Clinic<br />
Rochester, MN<br />
Javed Butler, MD, MPH<br />
Stony Brook University<br />
Stony Brook, NY<br />
Antonio Cabrera, MD<br />
Texas Children's Hospital<br />
Houston, TX<br />
Robert Califf, MD<br />
US Food and Drug Administration<br />
Silver Spring, MD<br />
Peter Carson, MD<br />
Washington VAMC<br />
Washington, DC<br />
John Chin, MD<br />
Sutter Medical Center<br />
Sacramento, CA<br />
Julio Chirinos, MD<br />
Pennsylvania Cardiovascular Institute<br />
Philadelphia, PA<br />
Sheryl Chow, PharmD<br />
Western University of Health Science<br />
Pomona, CA<br />
Misook Chung, PhD<br />
University of Kentucky<br />
Lexington, KY<br />
John Cleland, MD<br />
Imperial College<br />
Harefield, Middlesex, UK<br />
Jay Cohn, MD<br />
University of Minnesota<br />
Minneapolis, MD<br />
Paolo C. Colombo, MD<br />
Columbia University<br />
New York, NY<br />
Maria Rosa Costanzo, MD<br />
Midwest Heart Specialist - Advocate<br />
Heart Institute<br />
Naperville, IL<br />
William Cotts, MD<br />
Advocate Christ Hospital<br />
Oak Lawn, IL<br />
Patricia Davidson, PhD, Med, RN<br />
John Hopkins University<br />
Baltimore, MD<br />
William Dec, MD<br />
Massachusetts General Hospital<br />
Boston, MA<br />
Prakash Deedwania, MD<br />
University San Francisco California<br />
Fresno, CA<br />
Christopher deFilippi, MD<br />
University of Maryland<br />
Baltimore, MD<br />
Rebecca Dekker, PhD, RN, APRN<br />
University of Kentucky<br />
Lexington, KY<br />
Cheryl Dennison Himmelfarb,<br />
RN, PhD<br />
Johns Hopkins University<br />
Baltimore, MD<br />
Eugene DePasquale, MD<br />
University of California<br />
Los Angeles, CA<br />
Akshay Desai, MD<br />
Brigham and Women's Hospital<br />
Boston, MA<br />
Victoria Dickson, PhD, CRNP, MSN<br />
New York University<br />
New York, NY<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
17
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty 2015 HFSA Annual Scientific Meeting and Satellite Symposia<br />
Robert DiDomenico, PharmD<br />
University of Illinois at Chicago<br />
Chicago, IL<br />
Thomas DiSalvo, MD, MPH, MBA<br />
Vanderbilt University<br />
Nashville, TN<br />
Maghee Disch, MSN, RN, CNL<br />
Ohio State University<br />
Columbus, OH<br />
Gregory Ewald, MD<br />
Washington Univeristy School of<br />
Medicine<br />
St. Louis, MO<br />
Beth Fahlberg, PhD<br />
University of Wisconsin<br />
Madison, WI<br />
DeLisa Fairweather, PhD<br />
Johns Hopkins University<br />
Baltimore, MD<br />
Alan Go, MD<br />
Kaiser Permanante<br />
Oakland, CA<br />
Lee R. Goldberg, MD, MPH<br />
University of Pennsylvania<br />
Philadelphia, PA<br />
Sarah Goodlin, MD<br />
Portland VAMC<br />
Portland, OR<br />
Ray Hershberger, MD<br />
Ohio State University<br />
Columbus, OH<br />
Thomas Heywood, MD<br />
Scripps Clinic<br />
La Jolla, CA<br />
Joseph Hill, MD, PhD<br />
Univeristy of Texas Southwestern<br />
Dallas, TX<br />
Stavros Drakos, MD, PhD<br />
University of Utah<br />
Salt Lake City, UT<br />
James Fang, MD<br />
University of Utah<br />
Salt Lake City, UT<br />
Steven Gottlieb, MD<br />
University of Maryland<br />
Baltimore, MD<br />
Carolyn Ho, MD<br />
Brigham & Womens Hospital<br />
Boston, MA<br />
Mark Drazner, MD<br />
University of Texas Southwestern<br />
Dallas, TX<br />
Arthur Feldman, MD<br />
Temple University<br />
Philadelphia, PA<br />
Kathleen Grady, PhD, APN, FAAN<br />
Northwestern University<br />
Chicago, IL<br />
Jennifer Ho, MD<br />
Boston University<br />
Boston, MA<br />
Daniel Dries, MD, MPH<br />
Temple Health<br />
Philadelphia, PA<br />
Michael Felker, MD<br />
Duke Clinical Research Center<br />
Durham, NC<br />
Barry Greenberg, MD<br />
University of California<br />
San Diego, CA<br />
Seth Hollander, MD<br />
Stanford University<br />
Palo Alto, CA<br />
Dan Duprez, MD<br />
University of Minnesota<br />
Minneapolis, MN<br />
Gerasimos Filippatos, MD<br />
University of Athens<br />
Athens, Greece<br />
Roger Hajjar, MD<br />
Mount Sinai<br />
New York, NY<br />
Steven Houser, MD<br />
Temple University<br />
Philadelphia, PA<br />
Jean-Bernard Durand, MD<br />
University of Texas Southwestern<br />
Houston, TX<br />
Mona Fiuzat, PharmD<br />
Duke University<br />
Durham, NC<br />
Michele Hamilton, MD<br />
Cedars Sinai Heart Institute<br />
Los Angeles, CA<br />
Jonathan Howlett, MD<br />
University of Calgary<br />
Calgary, AB, Canada<br />
Peter Eckman, MD<br />
University of Minnesota<br />
Minneapolis, MN<br />
Gregg Fonarow, MD<br />
University of California<br />
Los Angeles, CA<br />
Joshua Hare, MD<br />
University of Miami<br />
Miami, FL<br />
Eileen Hsich, MD<br />
Cleveland Clinic Foundation<br />
Cleveland, OH<br />
Howard J. Eisen, MD<br />
Drexel University<br />
Philadelphia, PA<br />
Thomas Force, MD<br />
Vanderbilt University<br />
Nashville, TN<br />
Karol Harshaw-Ellis, MSN<br />
Duke University<br />
Durham, NC<br />
Scott Hummel, MD, MS<br />
University of Michigan<br />
Ann Arbor, MI<br />
Uri Elkayam, MD<br />
University of Southern California<br />
Los Angeles, CA<br />
Gary Francis, MD<br />
University of Minnesota<br />
Minneapolis, MN<br />
Paul Hauptman, MD<br />
St. Louis University<br />
St. Louis, MO<br />
Sharon A. Hunt, MD<br />
Stanford University<br />
Palo Alto, CA<br />
David Ellison, MD<br />
Oregon Health Science University<br />
Portland, OR<br />
Hanna Gaggin, MD<br />
Massachusetts General Hospital<br />
Boston, MA<br />
Paul Heidenreich, MD<br />
Stanford University<br />
Palo Alto, CA<br />
Leonard Ilkhanoff<br />
Inova Fairfax Hospital<br />
Vienna, VA<br />
Murray Epstein, MD<br />
University of Miami<br />
Miami, FL<br />
Julie Gee, RN, PhD<br />
VA Medical Center<br />
Cleveland, OH<br />
Seongkum Heo, PhD, RN<br />
University of Arkansas<br />
Little Rock, AR<br />
James Januzzi, MD<br />
Massachusetts General Hospital<br />
Boston, MA<br />
Lorraine Evangelista, RN, PhD<br />
University of California<br />
Irvine, CA<br />
Michael Givertz, MD<br />
Brigham & Womens Hospital<br />
Boston, MA<br />
Adrian Hernandez, MD<br />
Duke University<br />
Durham, NC<br />
Mariell Jessup, MD<br />
University of Pennsylvania<br />
Philadelphia, PA<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
18
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty 2015 HFSA Annual Scientific Meeting and Satellite Symposia<br />
Susan Joseph, MD<br />
Baylor College of Medicine<br />
Houston, TX<br />
Marvin Konstam, MD<br />
Tufts Medical Center<br />
Boston, MA<br />
Greg Lewis, MD<br />
Massachusetts General Hospital<br />
Boston, MA<br />
Paul McKie, MD<br />
Mayo Clinic<br />
Rochester, MN<br />
David Joyce, MD<br />
Mayo Clinic<br />
Minneapolis, MN<br />
Rajan Krishnamani, MD<br />
Advanced Cardiovascular Institute<br />
Mason, OH<br />
Ronglih Liao, PhD<br />
Brigham & Women's Hospital<br />
Boston, MA<br />
Rhondalyn McLean, MD<br />
Johns Hopkins Hospital<br />
Baltimore, MD<br />
Corrine Jurgens, RN, PhD<br />
Stony Brook University<br />
Stony Brook, NY<br />
Teresa Kruisselbrink, MD<br />
Mayo Clinic<br />
Rochester, MN<br />
Peter Libby, MD<br />
Harvard<br />
Boston, MA<br />
John McMurray, MD<br />
Western Infirmary<br />
Glasgow, UK<br />
Suraj Kapa, MD<br />
Mayo Clinic<br />
Rochester, MN<br />
Valentina Kutyifa, MD, PhD<br />
University of Rochester<br />
Rochester, NY<br />
JoAnn Lindenfeld, MD<br />
Vanderbilt University<br />
Nashville, TN<br />
Dennis McNamara, MD<br />
University of Pittsburgh<br />
Pittsburgh, PA<br />
Navin Kapur, MD<br />
Tufts Medical Center<br />
Boston, MA<br />
Bonnie Ky, MD, MSCE<br />
University of Pennsylvania<br />
Philadelphia, PN<br />
Peter Liu, MD<br />
University of Ottawa Heart Institute<br />
Ontario, Canada<br />
Mandeep Mehra, MD<br />
Brigham & Women's Hospital<br />
Boston, MA<br />
Peter Karpawich, MD<br />
The Children's Hospital of Michigan<br />
Detroit, MI<br />
Neal Lakdawala, MD<br />
Brigham & Women's Hospital<br />
Boston, MA<br />
Carlin Long, MD<br />
University of Colorado<br />
Denver, CO<br />
Robert Mentz, MD<br />
Duke University<br />
Durham, NC<br />
David Kass, MD<br />
Johns Hopkins University<br />
Baltimore, MD<br />
Carolyn Lam, MB. BS<br />
National Heart Centre<br />
Singapore<br />
Alan Maisel, MD<br />
University of California<br />
San Diego, CA<br />
Marco Metra, MD<br />
University of Brescia<br />
Brescia, Italy<br />
Jason Katz, MD<br />
University of North Carolina<br />
Chapel Hill, NC<br />
David Lanfear, MD, MS<br />
Henry Ford Hospital<br />
Detroit, MI<br />
Douglas Mann, MD<br />
Washington University<br />
St. Louis, MO<br />
Alan Miller, MD<br />
University Florida HSC<br />
Jacksonville, FL<br />
Daniel P Kelly, MD<br />
Sanford Burnham Prebys Medical<br />
Discovery Institute<br />
Orlando, FL<br />
Richard Kitsis, MD<br />
Albert Einstein College of Medicine<br />
Bronx, NY<br />
Dalane Kitzman, MD<br />
Wake Forest Baptist Health<br />
Winston-Salem, NC<br />
Liviu Klein, MD, MS<br />
University of California<br />
San Francisco, CA<br />
Walter Koch, PhD<br />
Temple University<br />
Philadelphia, PA<br />
Robb Kociol, MD<br />
Beth Israel Deaconess Medical Center<br />
Boston, MA<br />
Ann Laramee, MSN, APRN-BC<br />
University of Vermont<br />
Burlington, VT<br />
Christopher Lee, RN, PhD, FAHA<br />
Oregon Health & Science University<br />
Portland, OR<br />
Terry Lennie, PhD<br />
University of Kentucky<br />
Lexington, KY<br />
Wayne C Levy, MD<br />
University of Washington<br />
Seattle, WA<br />
Martin LeWinter, MD<br />
University of Vermont<br />
Burlington, VT<br />
Connie Lewis, MD, MPH<br />
Vanderbilt University<br />
Nashville, TN<br />
Kenneth Margulies, MD<br />
University of Pennsylvania<br />
Philadelphia, PA<br />
David Markham, MD<br />
Emory University<br />
Atlanta, GA<br />
Martin Maron, MD<br />
Tufts Medical Center<br />
Boston, MA<br />
Mathew Maurer, MD<br />
Columbia University<br />
New York, NY<br />
Ernest Mazzaferri, MD<br />
Ohio State University<br />
Columbus, OH<br />
Peter McCullough<br />
Baylor University<br />
Dallas, TX<br />
Leslie Miller, MD<br />
Heart and Vascular Institute<br />
Clearwater, FL<br />
Wayne L. Miller, MD, PhD<br />
Mayo Clinic<br />
Rochester, MD<br />
Debra Moser, DNSc, RN<br />
University of Kentucky<br />
Lexington, KY<br />
Maria Mountis, DO<br />
Cleveland Clinic<br />
Cleveland, OH<br />
Matthew Movsesian, MD<br />
Univesity of Utah<br />
Salt Lake City, UT<br />
Wilfried Mullens, MD<br />
Ziekenhuis Oos Limburg Genk<br />
University<br />
Genk, Belgium<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
19
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty 2015 HFSA Annual Scientific Meeting and Satellite Symposia<br />
Jean Nappi, PharmD<br />
University of South Carolina<br />
Charleston, SC<br />
J. Herbert Patterson, PharmD<br />
University of North Carolina<br />
Chapel Hill, NC<br />
Michael Rich, MD<br />
Washington University<br />
St. Louis, MO<br />
Andrew Sauer, MD<br />
University of Kansas<br />
Kansas City, KS<br />
Ali Nsair, MD<br />
University of California<br />
Los Angeles, CA<br />
Sara Paul, DNP, FNP<br />
Catawba Valley Cardiology<br />
Hickory, NC<br />
John Rickard, MD<br />
John Hopkins University<br />
Baltimore, MD<br />
Douglas Sawyer, MD, PhD<br />
Vanderbilt University<br />
Nashville, TN<br />
Jose Nativi-Nicolau, MD<br />
University of Utah<br />
Salt Lake City, UT<br />
W. Frank Peacock, MD<br />
Baylor College of Medicine<br />
Houston, TX<br />
Barbara Riegel, DNSc, RN<br />
University of Pennsylvania<br />
Philadelphia, PA<br />
Erik Schelbert, MD<br />
University of Pittsburgh<br />
Pittsburgh, PA<br />
Matthew Needleman, MD<br />
Walter Reid National Military<br />
Medical Center<br />
Bethesda, MD<br />
Ivan Netuka, MD, PhD<br />
Institute for Clinical and<br />
Experimental Medicine<br />
Prague, Czech Republic<br />
Christopher Newton-Cheh,<br />
MD, MPH<br />
Massachusetts General Hospital<br />
Boston, MA<br />
Christopher O'Connor, MD<br />
Inova Heart & Vascular Institute<br />
Falls Church, VA<br />
Guilherme Oliveira, MD<br />
University Hospitals Cas<br />
Medical Center<br />
Cleveland, OH<br />
Milton Packer, MD<br />
University of Texas Southwestern<br />
Dallas, TX<br />
Francis Pagani, MD, PhD<br />
University of Michigan<br />
Ann Arbor, MI<br />
Robert Page, PharmD, MSPH<br />
University of Colorado<br />
Denver, CO<br />
Peter Pang, MD<br />
Indiana University<br />
Indianapolis, IN<br />
Bray Patrick-Lake<br />
Duke University<br />
Durham, NC<br />
Naveen Pereira, MD<br />
Mayo Clinic<br />
Rochester, MN<br />
Michael Petty, RN, PhD,<br />
CCNS, ACNS<br />
University of Minnesota<br />
Richfield, MN<br />
Kerry Pickworth, PharmD<br />
Ohio State Medical Center<br />
Columbus, OH<br />
Ileana Pina, MD, MPH<br />
Albert Einstein College of Medicine<br />
New York, NY<br />
Sean Pinney, MD<br />
Mount Sinai<br />
New York, NY<br />
Bertram Pitt, MD<br />
University of Michigan<br />
Ann Arbor, MI<br />
Juan Carlos Plana, MD<br />
Cleveland Clinic<br />
Cleveland, OH<br />
Eduardo Rame, MD<br />
University of Pennsylvania<br />
Philadelphia, PA<br />
Lisa Rathman, MSN, CRNP<br />
Lancaster General Health<br />
Lancaster, PA<br />
Margaret Redfield, MD<br />
Mayo Clinic<br />
Rochester, MN<br />
Jonathan Rich, MD<br />
Northwestern University<br />
Chicago, IL<br />
Jo Ellen Rodgers, PharmD<br />
University of North Carolina<br />
Chapel Hill, NC<br />
Joseph Rogers, MD<br />
Duke University<br />
Durham, NC<br />
Heather Ross, MD<br />
The Toronto Hospital<br />
Toronto, Canada<br />
Henri Roukoz, MD<br />
University of Minnesota<br />
Minneapolis, MN<br />
Frederick Ruberg, MD<br />
Boston Medical Center<br />
Boston, MA<br />
Frank Ruschitzka, MD<br />
University Hospital Zurich<br />
Zurich, Switzerland<br />
Stuart Russell, MD<br />
John Hopkins University<br />
Baltimore, MD<br />
Hani Sabbah, PhD<br />
Henry Ford Health System<br />
Detroit, MI<br />
Mitchell Saltzberg, MD<br />
Christiana Care Health System<br />
Newark, DE<br />
Flora Sam, MD<br />
Boston Medical Center<br />
Boston, MA<br />
Javier Sanz, MD<br />
Mount Sinai Hospital<br />
New York, NY<br />
Douglas Schocken, MD<br />
Duke University<br />
Durham, NC<br />
Marc Semigran, MD<br />
Massachusetts General Hospital<br />
Boston, MA<br />
Ravi Shah, MD<br />
Massachusetts General Hospital<br />
Boston, MA<br />
Sanjiv Shah, MD<br />
Northwestern University<br />
Chicago, IL<br />
Monica Shah, MD, MHS<br />
National Heart Lung & Blood<br />
Institute<br />
Bethesda, MD<br />
Eduard Shantsila, MD, PhD<br />
University of Birmingham<br />
Birmingham, UK<br />
Hiroaki Shimokawa, MD<br />
Tohoku University<br />
Sendai, Japan<br />
Roxanne Siemeck, MSN, APRN<br />
Advocated Christ Medical Center<br />
Oak Lawn, IL<br />
Marc Silver, MD<br />
Advocate Christ Medical Center<br />
Oak Lawn, IL<br />
Scott Solomon, MD<br />
Brigham and Women's Hospital<br />
Boston, MA<br />
Johannes-Peter Stasch, PharmD, PhD<br />
Bayer Pharma AG<br />
Wupertal, Germany<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
20
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty 2015 HFSA Annual Scientific Meeting and Satellite Symposia<br />
Randall Starling, MD<br />
Cleveland Clinic<br />
Cleveland, OH<br />
Gregg Stone, MD<br />
Columbia University<br />
New York, NY<br />
Alan Storrow, MD<br />
Vanderbilt University<br />
Nashville, TN<br />
Nancy Sweitzer, MD, PhD<br />
University of Arizona<br />
Tucson, AZ<br />
Wilson Tang, MD<br />
Cleveland Clinic<br />
Cleveland, OH<br />
Ryan Tedford, MD<br />
Johns Hopkins University<br />
Baltimore, MD<br />
John Teerlink, MD<br />
University of California<br />
San Francisco, CA<br />
Jeffry Testani, MD, MTR<br />
Yale University<br />
New Haven, CT<br />
Jeffrey Teuteberg, MD<br />
University of Pittsburgh<br />
Pittsburgh, PA<br />
Christine Thompson, MS, RN, CNS<br />
Stanford Healthcare<br />
Stanford, CA<br />
Guillermo Torre-Amione, MD, PhD<br />
The Methodist Hospital<br />
Houston, TX<br />
Jeffrey Towbin, MD<br />
University of Cincinatti<br />
Cincinnati, OH<br />
James Udelson, MD<br />
Tufts Medical Center<br />
Boston, MA<br />
Nir Uriel, MD<br />
University of Chicago<br />
Chicago, IL<br />
Orly Vardeny, PharmD<br />
University of Wisconsin<br />
Madison, WI<br />
Eric Velazquez, MD<br />
Duke University<br />
Durham, NC<br />
Niraj Varma, MD, PhD<br />
Cleveland Clinic<br />
Cleveland, OH<br />
Hector O. Ventura, MD<br />
Ochsner Clinic Foundation<br />
New Orleans, LA<br />
Renu Virmani, MD, FACC<br />
CV Path Institute<br />
Gaithersburg, MD<br />
Rey Vivo, MD<br />
University of California<br />
Los Angeles, CA<br />
Joyce Wald, MD<br />
University of Pennsylvania<br />
Philadelphia, PA<br />
Mary Norine Walsh, MD<br />
St. Vincent Heart Center<br />
Indianapolis, IN<br />
Paul Wang, MD<br />
Stanford University<br />
Stanford, CA<br />
Alberta Warner, MD<br />
VA Greater Los Angeles<br />
Los Angeles, CA<br />
Lynne Warner Stevenson, MD<br />
Brigham and Women's Hospital<br />
Boston, MA<br />
Cheryl Westlake, PhD<br />
Asuza University<br />
Azusa, CA<br />
Laura F. Wexler, MD<br />
University of Cincinatti<br />
Cincinnati, OH<br />
David Whellan, MD, MHS<br />
Thomas Jefferson University<br />
Philadelphia, PA<br />
Maria Fe White, NP<br />
Cedars Sinai<br />
Los Angeles, CA<br />
James White, MD, PhD<br />
University of Calgary<br />
Calgary, AB<br />
Joshua Willey, MD<br />
Columbia University<br />
New York, NY<br />
Susan Wingate, RN, PhD<br />
National Institute of Health<br />
Gaithersburg, MD<br />
Ronald Witteles, MD<br />
Stanford University<br />
Stanford, CA<br />
Matthew J. Wolf, PhD<br />
Duke University<br />
Durham, NC<br />
Jia-Rong Wu, PhD, RN<br />
University of North Carolina<br />
Chapel Hill, NC<br />
Kzuhiro Yamamoto, MD, PhD<br />
Tottori University<br />
Tottori, Japan<br />
Clyde Yancy, MD, MSc<br />
Northwestern University<br />
Chicago, IL<br />
Edward Yeh, MD<br />
University of Texas<br />
Houston, TX<br />
Quincy Young, PhD<br />
Providence Health<br />
Vancouver, BC, Canada<br />
Payman Zamani, MD<br />
Universit of Pennsylvania<br />
Philadelphia, PA<br />
Faiez Zannad, MD, PhD<br />
Universite de Lorraine<br />
Vandoeuvrer, France<br />
Michael Zile, MD<br />
Medical University of South Carolina<br />
Charleston, SC<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
21
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Program-at-a-Glance<br />
Saturday September 26<br />
New in 2015 Program Begins Saturday Morning<br />
TIME SESSION 1 SESSION 2 SESSION 3 SESSION 4 SESSION 5 HOW<br />
10:30-12:30 Clinical Fundamentals<br />
I: The Immune<br />
Response in Cardiovascular<br />
Disease<br />
Potomac C<br />
12:30-1:30 Lunch<br />
1:30-3:30 Recent Advances in<br />
the Management of<br />
Myocarditis<br />
(Joint Session with<br />
Myocarditis Foundation)<br />
Potomac D<br />
3:30-4:00 Break<br />
3:45-5:15 Satellite Symposium:<br />
Achieving Heart Rate<br />
Control: The Role of I f<br />
Inhibition<br />
(1.5 hours)<br />
National Harbor 2-3<br />
5:00-6:00 Nursing Reception<br />
Cherry Blossom Ballroom<br />
Foyer<br />
6:00-8:00 Exhibit Hall:<br />
Opening Reception<br />
Prince George's B-C<br />
7:30-8:30 Speed Mentoring<br />
Cherry Blossom Ballroom<br />
Foyer<br />
8:30-10:00 Early Career Reception<br />
Cherry Blossom Ballroom<br />
Foyer<br />
Transitions in Heart<br />
Failure Care: It’s Not<br />
Just About Hospital to<br />
Home<br />
National Harbor 10-11<br />
The Prevention of Heart<br />
Failure: Targets and<br />
Strategies<br />
(Joint Session with<br />
AHA)<br />
Potomac C<br />
Satellite Symposium:<br />
Contemporary and<br />
Future Management<br />
of Heart Failure in the<br />
African American<br />
Population (1.5 hours)<br />
National Harbor 10-11<br />
Pharmacy Reception<br />
Cherry Blossom Ballroom Foyer<br />
Poster Reception<br />
Prince George's B-C<br />
Hemodynamics in Heart<br />
Failure<br />
(Joint Session with<br />
SCAI)<br />
Potomac D<br />
Tool Kit for the Evaluation<br />
and Selection of the<br />
Patient for MCS<br />
(Joint Session with<br />
ICCAC-VAD)<br />
National Harbor 10-11<br />
Ask the Experts: Challenging Clinical Situations<br />
in MCS<br />
National Harbor 2-3<br />
Excellence in<br />
Translational Science:<br />
Bench to Bedside<br />
Potomac 5-6<br />
Moderated Poster Session I - 6:30pm - 7:30pm<br />
Prince George's B-C<br />
Disposition Decision<br />
Making<br />
From the ER<br />
(Joint Session with<br />
SAEM)<br />
National Harbor 2-3<br />
Hands-on Workshop 1:<br />
CRT<br />
Potomac 1-2<br />
Hands-on Workshop 1:<br />
CRT (repeat)<br />
Potomac 1-2<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
22
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Program-at-a-Glance<br />
Sunday September 27<br />
TIME SESSION 1 SESSION 2 SESSION 3 SESSION 4 SESSION 5 HOW HOW<br />
6:30-7:30 Continental Breakfast<br />
7:00-8:00 Satellite Symposium<br />
Hyperkalemia in<br />
Heart Failure:<br />
New Data, Emerging<br />
Options<br />
Potomac C<br />
Satellite Symposium<br />
Sleep-Disordered<br />
Breathing in Heart<br />
Failure: Targeted<br />
Treatments for Improved<br />
Outcomes<br />
National Harbor 10-11<br />
Satellite Symposium:<br />
Remote Monitoring of Patients with HF: Making it Work in Practice<br />
Potomac D<br />
8:05-10:00 Awards and Plenary Session: The Economic Model of Heart Failure Care: Policy and Reform<br />
Maryland A-C<br />
10:00-10:30 Policy and Reform<br />
10:30-12:00 Heart Failure Trials:<br />
The Year in Review<br />
Maryland B<br />
12:00-1:30 Lunch Break and Poster Viewing<br />
12:15-1:15 How to:<br />
Change Behavior<br />
Maryland A<br />
1:15-1:30 Break<br />
1:30-3:00 Guideline Session:<br />
Unique Heart<br />
Failure Populations<br />
What Makes Them<br />
“Special?”<br />
Maryland B<br />
3:00-3:30 Break<br />
3:30-5:00 Late Breaking<br />
Clinical Trials<br />
Maryland B<br />
5:15-6:30 Exhibit Hall:<br />
Poster Reception<br />
Potomac C<br />
Cutting Edge<br />
Concepts in Device<br />
Therapy for Heart<br />
Failure<br />
(Joint Session with HRS)<br />
National Harbor 10-11<br />
How to:<br />
Troubleshoot a<br />
VAD<br />
National Harbor 10-11<br />
Cardiac Amyloidosis<br />
Maryland A<br />
Moving From the<br />
Problem to the<br />
Solution: Integrating<br />
a Palliative<br />
Approach in Heart<br />
Failure<br />
Management<br />
Maryland A<br />
Moderated Poster Session II<br />
5:30pm – 6:30pm<br />
Prince Georges B-C<br />
What is the Best<br />
Way to Measure<br />
Congestion in the<br />
Patient with Heart<br />
Failure?<br />
Potomac C<br />
How to:<br />
Opportunities in<br />
Early Career Nursing<br />
Potomac 5-6<br />
NHLBI Special<br />
Session: Heart<br />
Failure Clinical<br />
Trials –<br />
Strategies to<br />
Optimize<br />
Enrollment<br />
Maryland C<br />
Managing VAD<br />
Complications<br />
Maryland C<br />
New Concepts in<br />
the Pathophysiology<br />
of HFpEF<br />
National Harbor 2-3<br />
How to: Cases in<br />
the Evaluation and<br />
Management of<br />
Right Heart Failure<br />
in the Patient with<br />
Pulmonary Arterial<br />
Hypertension<br />
Potomac C<br />
From Tele-Monitoring<br />
to Tele-Management<br />
and Electronic<br />
and Mobile-Health<br />
in Heart Failure<br />
Potomac C<br />
From Bench to<br />
Bedside: Emerging<br />
Therapies for the<br />
Failing Myocardium<br />
Potomac C<br />
Born This Way: The<br />
Role of Genetic<br />
Testing in<br />
Cardiomyopathy<br />
Potomac D<br />
Rapid Fire Abstracts<br />
Maryland C<br />
6:30-9:00 Faculty Reception and Fundraiser (6:30) Faculty Dinner and Fundraiser (7:30) (ticket required)<br />
Hands-on Workshop 2:<br />
Acute Cardiogenic<br />
Shock with Peripherally<br />
Implanted<br />
Devices<br />
10:30am - 12:30pm<br />
Potomac 1-2<br />
Hands-on Workshop 2:<br />
Acute Cardiogenic<br />
Shock with Peripherally<br />
Implanted<br />
Devices (repeat)<br />
1:30pm - 3:30pm<br />
Potomac 1-2<br />
Hands-on Workshop 3:<br />
Echo Made Simple<br />
for the Multidisciplinary<br />
Heart<br />
Failure Team<br />
10:30am - 12:30pm<br />
Potomac 3-4<br />
Hands-on Workshop 3:<br />
Echo Made Simple<br />
for the Multidisciplinary<br />
Heart Failure<br />
Team (repeat)<br />
1:30pm - 3:30pm<br />
Potomac 3-4<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
23
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Program-at-a-Glance<br />
Monday September 28<br />
TIME SESSION 1 SESSION 2 SESSION 3 SESSION 4 SESS 5 / HOW HOW<br />
6:30-7:30 Continental Breakfast<br />
7:15-8:15 Clinical Fundamentals II:<br />
FAQ’s About Heart<br />
Failure<br />
Drug Therapy<br />
Potomac C<br />
Satellite Symposium:<br />
Improving Patient<br />
Outcomes and Reducing<br />
Re-Admission Rates in<br />
Chronic Heart Failure<br />
Maryland C<br />
Satellite Symposium:<br />
RAAS and RAASi in<br />
Chronic Heart Failure<br />
Maryland A<br />
8:15-8:30 Break<br />
8:30-10:00 Case Discussion-Clinical<br />
Conundrums<br />
Maryland B<br />
10:00-10:30 Break<br />
10:30-12:00 Managing the VAD<br />
Outpatient<br />
Maryland C<br />
12:00-1:30 Lunch Break and Poster Viewing<br />
12:15-1:15 How to:<br />
Use Cardiac<br />
Rehabilitation<br />
in Heart Failure<br />
Maryland C<br />
1:15-1:30 Break<br />
Nursing Research<br />
Award<br />
Maryland A<br />
Putting the “Self” back<br />
in Self-Care: Innovative<br />
Strategies to Improve<br />
Heart Failure Self-Care<br />
(Joint Session with<br />
AAHFN)<br />
Maryland A<br />
Rapid Fire Abstracts<br />
Potomac C<br />
JNC Young Investigators<br />
Award: Clinical/<br />
Integrative<br />
Maryland C<br />
Controversies in<br />
Cardiooncology<br />
Maryland D<br />
How to:<br />
Manage Diuretic<br />
Resistance: What to Do<br />
When the Fluid Won’t<br />
Come Off<br />
Maryland D<br />
JNC Young<br />
Investigators Award:<br />
Basic Science<br />
Maryland 1-2<br />
The “Hidden Gems”<br />
of Heart Failure<br />
Publishing<br />
Potomac C<br />
How to:<br />
Conduct Bedside<br />
Assessment in Heart<br />
Failure<br />
Maryland 1-2<br />
1:20-1:30 Awards Presentation - JNC Young Investigators Award: Clinical/Integrative, JNC Young Investigators Award:<br />
Basic Science and Nursing Research Award<br />
Maryland B<br />
Cardiovascular<br />
Magnetic Resonance<br />
Imaging for the<br />
Heart Failure Specialist<br />
Potomac C<br />
Hands-on Workshop 4:<br />
Advanced Troubleshooting<br />
with Durable<br />
VADs<br />
10:30am - 12:30pm<br />
Maryland 3-4<br />
Hands-on Workshop 5:<br />
Cardiopulmonary<br />
Function Testing<br />
10:30am - 12:30pm<br />
Maryland 5-6<br />
How to:<br />
How to Manage Sleep Apnea in Heart Failure<br />
Maryland A<br />
1:30-3:00 Hyde Park Session<br />
Maryland B<br />
Load, Unloading,<br />
Remodeling and<br />
Recovery<br />
Maryland C<br />
What’s New and<br />
Emerging in Heart<br />
Failure Pharmacology?<br />
Maryland A<br />
Hands-on Workshop 4:<br />
Advanced Troubleshooting<br />
with Durable<br />
VADs (repeat)<br />
1:30pm - 3:30pm<br />
Maryland 3-4<br />
Hands-on Workshop 5:<br />
Cardiopulmonary<br />
Function Testing<br />
(repeat)<br />
1:30pm - 3:30pm<br />
Maryland 5-6<br />
3:00-3:30 Break<br />
3:30-5:00 Debate<br />
Potomac C<br />
Alternative Therapies<br />
for Heart Failure: Fact<br />
or Fiction?<br />
Maryland A<br />
Emergency<br />
Management of<br />
VAD Patients<br />
(Joint Session with<br />
ISHLT)<br />
Maryland C<br />
How to Interpret<br />
Biomarker Studies<br />
Maryland D<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
24
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Program-at-a-Glance<br />
Tuesday September 29<br />
TIME SESSION 1 SESSION 2 SESSION 3 SESSION 4<br />
6:30-7:30 Continental Breakfast<br />
7:00-8:15 Clinical Fundamentals III:<br />
Acute Heart Failure 360<br />
Maryland C<br />
Managing the Patient with<br />
Newly Diagnosed Heart Failure<br />
Maryland A<br />
The Periphery in Heart Failure:<br />
More Than an Innocent Bystander<br />
Potomac C<br />
8:15-8:30 Break<br />
8:30-9:45 Interventional Structural Devices<br />
for Heart Failure<br />
Potomac C<br />
Right Sided Heart Failure:<br />
What Do We Do When Orthopnea is<br />
Traded for Ascites?<br />
Maryland A<br />
Heart Failure Clinics:<br />
The Evidence, the Need and the<br />
Redesign<br />
Maryland C<br />
Interventions for<br />
Vulnerable Patients<br />
Maryland D<br />
9:45-10:15 Break<br />
10:15-11:30 Update on Peripartum<br />
Cardiomyopathy and Pregnancy<br />
Associated Heart Failure<br />
Maryland C<br />
Pharmacogenetics of Heart Failure<br />
and Transplant: Additive or Redundant?<br />
Maryland A<br />
New Clinical Insights<br />
into HFpEF<br />
Potomac C<br />
11:30 MEETING ADJOURNS<br />
See You Next Year in Florida!<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
25
Program-at-a-Glance<br />
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
HFSA 2015 Annual Scientific Meeting<br />
Special Events and Exhibit Hall Activities<br />
Saturday September 26<br />
5:00 PM – 6:00 PM Nursing Reception* Cherry Blossom Ballroom Foyer<br />
Supported by St. Jude Medical<br />
5:00 PM – 6:00 PM Pharmacy Reception* Cherry Blossom Ballroom Foyer<br />
6:00 PM – 8:00 PM Exhibit Hall Opening Reception Exhibit Hall Prince Georges’ B-C<br />
6:15 PM – 7:15 PM Industry Expert Theater (see pg. 100) Exhibit Hall Prince Georges’ B-C Booth 100<br />
Sponsored by Novartis Pharmaceuticals<br />
6:30 PM - 7:30 PM Poster Reception I Exhibit Hall Prince Georges’ B-C<br />
6:30 PM – 7:30 PM Moderated Poster Session I Exhibit Hall Prince Georges’ B-C<br />
7:30 PM – 8:30 PM Speed Mentoring* Cherry Blossom Ballroom<br />
Supported by St. Jude Medical<br />
8:30 PM – 10:00 PM Early Career Reception* Cherry Blossom Ballroom<br />
Supported by St. Jude Medical<br />
Sunday September 27<br />
10:10 AM – 10:40 AM Industry Expert Theater (see pg. 100) Exhibit Hall Prince Georges’ B-C Booth 100<br />
Sponsored by Thoratec Corporation<br />
12:10 PM – 1:10 PM Industry Expert Theater (see pg. 100) Exhibit Hall Prince Georges’ B-C Booth 100<br />
Sponsored by Roche Diagnostics<br />
3:10 PM – 3:40 PM Industry Expert Theater (see pg. 101) Exhibit Hall Prince Georges’ B-C Booth 100<br />
Sponsored by scPharmaceuticals<br />
5:15 PM – 6:15 PM Industry Expert Theater (see pg. 101) Exhibit Hall Prince Georges’ B-C Booth 100<br />
Sponsored by Amgen<br />
5:30 PM – 6:30 PM Poster Reception II Exhibit Hall Prince Georges’ B-C<br />
5:30 PM – 6:30 PM Moderated Poster Session II Exhibit Hall Prince Georges’ B-C<br />
6:30 PM – 7:30 PM Faculty/Fundraiser Dinner Reception Cherry Blossom Ballroom Foyer<br />
Supported by Thoratec Corporation<br />
7:30 PM – 10:00 PM Faculty/Fundraiser Dinner & Show Cherry Blossom Ballroom<br />
Supported by Novartis Pharmaceuticals<br />
Monday September 28<br />
8:30 AM – 9:30 AM Industry Expert Theater (see pg. 101) Exhibit Hall Prince Georges’ B-C Booth 100<br />
Sponsored by Amgen<br />
10:10 AM – 10:40 AM Industry Expert Theater (see pg. 101) Exhibit Hall Prince Georges’ B-C Booth 100<br />
Sponsored by Thoratec Corporation<br />
12:10 PM – 1:10 PM Industry Expert Theater (see pg. 102) Exhibit Hall Prince Georges’ B-C Booth 100<br />
Sponsored by Novartis Pharmaceuticals<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
26
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Tuesday September 29<br />
7:30 AM – 8:30 AM HFSA Business Meeting Chesapeake L<br />
Industry Expert Theatres are non-CME educational activities held in dedicated space in the exhibit hall. They allow industry<br />
experts an opportunity to provide clinical updates and educate attendees on current therapies, disease states, products and<br />
pipeline activities while remaining close to the action in the exhibit hall. Sessions are formatted for learning and are a great<br />
way to receive higher level interaction and engagement with company representatives. See page 100-101 for a full schedule of<br />
Industry Expert Theater sessions<br />
*These events by invitation only.<br />
Award Winners:<br />
Lifetime Achievement Award<br />
2014 Recipient:<br />
Gary Francis, MD – University of Minnesota Medical School<br />
2015 Recipient:<br />
Sidney Goldstein, MD – Wayne State University School of<br />
Medicine. Supported by Cytokinetics<br />
JNC New Investigator Integrative Physiology/<br />
Clinical Award<br />
2014 Recipients:<br />
1st: Payman Zamani, MD - University of Pennsylvania<br />
2nd: Christopher Sparrow, MD - Washington University in St.<br />
Louis<br />
2015 Recipients:<br />
Selected at 2015 HFSA Annual Scientific Meeting<br />
Nursing Investigator Research Award<br />
2014 Recipients:<br />
1st: Carolyn Miller Reilly, RN, PhD - Emory University<br />
2nd: Ming Fen Tsai, MD - Chang Gung University of Science<br />
and Technology<br />
2015 Recipients:<br />
Selected at 2015 HFSA Annual Scientific Meeting<br />
Clinical Excellence in Nursing Award<br />
2014 Recipient:<br />
Karol Harshaw-Ellis, MSN - Duke University Health System-Division<br />
of Heart Failure<br />
2015 Recipient:<br />
Diane Gauthier, MS, RNP-BC - Boston University School of<br />
Medicine<br />
JNC New Investigator Basic Science Award<br />
2014 Recipients:<br />
1st: Silvio Antoniak, PhD - University of North Carolina<br />
2nd (tie): Robert Baumgartner, MD - Molecular Cardiology<br />
Research Institute, Tufts Medical Center<br />
Anthony S. Fargnoli, MS - Carolinas HealthCare System<br />
2015 Recipients:<br />
Selected at 2015 HFSA Annual Scientific Meeting<br />
Nursing Leadership Award<br />
2014 Recipient:<br />
Christopher S. Lee, RN, PhD, FAHA - Oregon Health &<br />
Science University<br />
2015 Recipient:<br />
Sandra Dunbar, RN, DSN - Nell Hodgson Woodruff School of<br />
Nursing Emory University. Supported by Cytokinetics<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
27
2015 SESSIONS<br />
19th Annual Scientific Assembly<br />
September 26 – 29, 2015<br />
Gaylord National Harbor • National Harbor, Maryland<br />
Sessions Begin Saturday morning at 10:30am
SATURDAY, SEPTEMBER 26<br />
10:30 AM – 12:30PM<br />
Potomac C<br />
Clinical Fundamentals I: The Immune<br />
Response in Cardiovascular Disease<br />
Moderators: Amrut Ambardekar, Aurora, CO<br />
Sharon Hunt, Palo Alto, CA<br />
10:30 The Nuts and Bolts of Basic Immunology<br />
Maria Rosa Costanzo, Naperville, IL<br />
10:50 Inflammation as a Pathophysiologic Mechanism<br />
in Heart Failure<br />
Paolo Colombo, New York, NY<br />
11:10 The Role of the Immune Response in Myocarditis<br />
Peter Liu, Toronto, ON, Canada<br />
11:30 The Immunology of Cardiac Allograft Rejection<br />
Sharon Hunt, Palo Alto, CA<br />
11:50 Targeting Inflammation in the Development of<br />
Cardiovascular Diseaase<br />
Peter Libby, Boston, MA<br />
12:10 Panel Discussion<br />
12:30 Adjourn<br />
10:30 AM – 12:30 PM<br />
National Harbor 10-11<br />
Transitions in Heart Failure Care:<br />
It’s Not Just About Hospital to Home<br />
Moderators: Larry Allen, Aurora, CO<br />
Susan Ammon, San Francisco, CA<br />
10:30 Post-Hospital Care Programs: Gems or Stones<br />
Nancy Albert, Cleveland, OH<br />
10:55 Coordinators versus Checklists to Achieve<br />
Clinical Outcomes<br />
Robb Kociol, Boston, MA<br />
11:20 Common Patient Issues Affecting Transition Care<br />
Mary Norine Walsh, Indianapolis, IN<br />
11:45 Transitioning to End-of-Life<br />
Ann Laramee, Burlington, VT<br />
12:10 Panel Discussion<br />
12:30 Adjourn<br />
Learning Objective: Manage transitions in heart failure care<br />
with effective programs and attention to patient needs.<br />
Abstracts/posters of interest: 273, 112, 274, 303<br />
Learning Objective: Describe the role of the immune response<br />
in cardiovascular disease, including heart failure.<br />
Abstracts/posters of interest: 40, 44, 47, 55, 76, 197,<br />
199, 284<br />
29
SATURDAY, SEPTEMBER 26<br />
10:30 AM – 12:30 PM<br />
Potomac D<br />
Hemodynamics in Heart Failure<br />
(Joint Session with SCAI)<br />
Moderators: Barry Borlaug, Rochester, MN<br />
Gregory Ewald, St. Louis, MO<br />
10:30 Basics of Hemodynamics in the Cath Lab<br />
Mark Drazner, Dallas, TX<br />
10:50 Hemodynamic Assessment Pre-VAD/Transplant<br />
James Fang, Salt Lake City, UT<br />
11:10 The Hemodynamics of HFpEF<br />
Barry Borlaug, Rochester, MN<br />
11:30 Hemodynamics of MCS<br />
Nir Uriel, Chicago, IL<br />
11:50 TAVR and MitraClip Hemodynamics<br />
Olcay Aksoy, Los Angeles, CA<br />
12:10 Panel Discussion<br />
Faculty<br />
12:30 Adjourn<br />
Learning objective: Identify the role of hemodynamics in<br />
heart failure assessment and management.<br />
Abstracts/posters of interest: 181, 178, 18, 165, 151, 304<br />
10:30 AM – 12:30 PM<br />
National Harbor 2-3<br />
Ask the Experts: Challenging Clinical<br />
Situations in MCS<br />
Moderators: Maria Mountis, Cleveland, OH<br />
Guillermo Torre-Amione, Houston, TX<br />
10:30 LVAD in Restrictive Cardiomyopathy<br />
Naveen Pereira, Rochester, MN<br />
10:55 LVAD in Chemotherapy-Induced Cardiomyopathy<br />
Guilherme Oliveira, Cleveland, OH<br />
11:20 LVAD in Children<br />
Antonio Cabrera, Houston, TX<br />
11:45 LVAD in Women<br />
Eileen Hsich, Cleveland, OH<br />
12:10 LVAD in Morbidly Obese Patients<br />
Ali Nasair, Los Angeles, CA<br />
12:30 Adjourn<br />
Learning Objective: Identify critical issues and clinically<br />
sound responses in the management of challenging MCS<br />
patients.<br />
Abstracts/posters of interest: 53, 219, 68, 72, 79<br />
30
SATURDAY, SEPTEMBER 26<br />
10:30 AM – 12:30 PM<br />
Potomac 1-2<br />
Hands-On Workshop 1<br />
CRT: Indications, Optimization, Device<br />
Interrogation, Interpreting the Data,<br />
Troubleshooting<br />
(Limited enrollment, preregistration required)<br />
Chair: Liviu Klein, San Francisco, CA<br />
10:30 Start<br />
12:30 Adjourn<br />
Learning Objective: Describe indications for CRT, identify<br />
CRT devices, and demonstrate their use and interrogation.<br />
Supported by educational grants from Biotronik, Boston<br />
Scientific, Medtronic, and St. Jude Medical<br />
1:30 PM – 3:30 PM<br />
Potomac D<br />
Recent Advances in the Management of<br />
Myocarditis<br />
(Joint Session with Myocarditis Foundation)<br />
Moderators: Leslie T. Cooper, Jr., Rochester, MN<br />
Sharon A. Hunt, Palo Alto, CA<br />
1:30 Recent Translational Studies in Cardiovascular<br />
Inflammation<br />
DeLisa Fairweather, Baltimore, MD<br />
1:55 Epidemiology, Mechanisms and Prevention of<br />
Sudden Death in Myocarditis<br />
Renu Virmani, Gaithersburg, MD<br />
1:30 PM – 3:30 PM<br />
Potomac C<br />
The Prevention of Heart Failure: Targets<br />
and Strategies (Joint Session with AHA)<br />
Moderators: Mariell Jessup, Philadelphia, PA<br />
Biykem Bozkurt, Houston, TX<br />
1:30 Salt Control in the Population to Prevent HF<br />
Pro: Scott Hummel, Ann Arbor, MI<br />
Con: Javed Butler, Stony Brook, NY<br />
1:50 HTN Rx for Prevention of HF<br />
Clyde Yancy, Chicago, IL<br />
2:05 Discussion<br />
Hummel, Butler, Yancy<br />
2:15 DD: Can it be Stopped from Causing Heart Failure<br />
Margaret Redfield, Rochester, MD<br />
2:30 Biomarkers for Prediction and Prevention of<br />
Heart Failure – Beyond BNP<br />
Jennifer Ho, Boston, MA<br />
2:45 Nurse-Practitioner-Based Community Outreach<br />
to Control Lifestyle Issues Leading to Heart Failure<br />
Connie Lewis, Nashville, TN<br />
3:00 Discussion<br />
3:30 Adjourn<br />
Learning Objective: Outline strategies for the prevention of<br />
heart failure, identifying pros and cons.<br />
2:20 Cardiac MRI for Diagnosis and Prognosis in<br />
Suspected Myocarditis<br />
James White, Calgary, AB, Canada<br />
2:45 Techniques to Improve the Diagnosis Value of<br />
Endomyocardial Biopsy<br />
Suraj Kapa, Rochester, MN<br />
3:10 Panel Discussion<br />
3:30 Adjourn<br />
Learning Objective: Describe recent advances in myocarditis<br />
diagnosis, prognosis, and management.<br />
Abstracts/posters of interest: 312, 237, 193, 161<br />
31
SATURDAY, SEPTEMBER 26<br />
1:30 PM – 3:30 PM<br />
National Harbor 10-11<br />
Tool Kit for the Evaluation and Selection<br />
of the Patient for MCS (Joint Session<br />
with ICCAC-VAD)<br />
Moderators: Michael Petty, Minneapolis, MN<br />
Lee Goldberg, Philadelphia, PA<br />
1:30 New Metrics for Assessing the Progression of<br />
Heart Failure: More than VO 2<br />
!<br />
Robb Kociol, Boston, MA<br />
1:45 Who Does Poorly with MCS? INTERMACS<br />
and Beyond<br />
Lynne Warner Stevenson, Boston, MA<br />
2:00 Evaluating Psychosocial Risk: Is an Identified<br />
Caregiver Enough?<br />
Lori Anderson, Tampa, FL<br />
2:15 MCS as a Means to Evaluation Adherence:<br />
Expensive Test or Justifiable Alternative?<br />
Jeffery Teuteberg, Pittsburgh, PA<br />
2:30 Have We Agreed How to Assess the Right Ventricle?<br />
Pavan Atluri, Philadelphia, PA<br />
2:45 What Do We Know About Moving from ECMO<br />
to VAD?<br />
Francis Pagani, Ann Arbor, MI<br />
3:00 My Single Biggest Mistake on Selection<br />
Faculty<br />
3:15 Panel Discussion<br />
Faculty<br />
3:30 Adjourn<br />
Learning Objective: Use effective strategies for the selection<br />
of patients for mechanical circulatory support.<br />
Abstracts/posters of interest: 244, 9, 145, 62, 230<br />
1:30 PM – 3:30 PM<br />
Potomac Rooms 5-6<br />
Excellence in Translational Science:<br />
Bench to Bedside<br />
Moderators: Thomas Force, Nashville, TN<br />
Peter Libby, Boston, MA<br />
1:30 Cellular and Molecular Mechanisms<br />
(sGC/pGC/cGMP/PKG)<br />
David Kass, Baltimore, MD<br />
1:45 Soluble Guanylyl Cyclase: From Biology to<br />
Drug Discovery<br />
Johannes-Peter Stasch, Wuppertal, Germany<br />
2:00 Particulate Guanylyl Cyclase: From Biology to<br />
Drug Discovery<br />
John Burnett, Jr., Rochester, MN<br />
2:15 What Genetics Have Told Us About sGC and<br />
pGC Pathways in CV Disease<br />
Christopher Newton-Cheh, Boston, MA<br />
2:30 sGC Therapeutics for Heart Failure and Pulmonary<br />
Hypertension<br />
Marc Semigran, Boston, MA<br />
2:45 Natriuretic Peptides for Acute and Chronic<br />
Heart Failure<br />
Christopher O’Connor, Falls Church, VA<br />
3:00 A New Paradigm in cGMP Therapeutics:<br />
ARNI’s, PARADIGM and Beyond<br />
Milton Packer, Dallas, TX<br />
3:15 Panel Discussion<br />
3:30 Adjourn<br />
Learning Objective: Describe new findings in translational<br />
science and their implications for heart failure treatment.<br />
32
SATURDAY, SEPTEMBER 26<br />
1:30 PM – 3:30 PM<br />
National Harbor 2-3<br />
Disposition Decision Making From the ER<br />
(Joint Session with SAEM)<br />
Moderators: David Lanfear, Detroit, MI<br />
Alan Storrow, Brentwood, TN<br />
1:30 Hospital Admission – The Path of Least Resistance<br />
Alan Storrow, Nashville, TN<br />
1:50 Identifying Low-Risk and Impediments to Safe<br />
Discharge<br />
Adrian Hernandez, Durham, NC<br />
2:10 What Happens in an Observation Unit?<br />
Maghee Disch, Columbus, OH<br />
2:30 Optimizing Post- Discharge Care- ED and OU<br />
Transitions<br />
Karol Harshaw-Ellis, Durham, NC<br />
2:50 ED vs. Hospital Discharge: Should Endpoints<br />
Be the Same?<br />
Peter Pang, Indianapolis, IN<br />
3:10 Panel Discussion<br />
3:30 Adjourn<br />
Learning Objective: Identify critical factors in effective<br />
heart failure disposition decisions in the ER.<br />
1:30 PM – 3:30 PM<br />
Potomac Room 1-2<br />
Hands-On Workshop 1 (Repeat)<br />
CRT: Indications, Optimization, Device<br />
Interrogation, Interpreting the Data,<br />
Troubleshooting<br />
(Limited enrollment, preregistration required)<br />
3:45 PM – 5:15 PM<br />
National Harbor 2-3<br />
Satellite Symposium:<br />
Achieving Heart Rate Control: The Role<br />
of I f<br />
Inhibition<br />
Chair:<br />
John R. Teerlink, San Francisco, CA<br />
3:45 Opening Remarks<br />
John R. Teerlink, San Francisco, CA<br />
3:50 The Role Of Heart Rate And Conventional<br />
Therapies In Heart Failure<br />
Marco Metra, Brescia, Italy<br />
4:10 The Role Of I f<br />
Inhibition In Coronary Artery<br />
Disease<br />
Jeffrey S. Borer, Brooklyn, NY<br />
4:30 Targeted Heart Rate Lowering In Heart Failure:<br />
The Role Of I f<br />
Inhibition<br />
Michael Böhm, Homburg/Saar, Germany<br />
4:50 Panel Discussion with Q&A<br />
All Faculty<br />
5:10 Closing Remarks<br />
Learning Objectives:<br />
1. Discuss the potential prognostic importance of heart rate<br />
in cardiovascular disease<br />
2. Summarize current evidence-based treatment approaches<br />
to heart-rate reduction in HF<br />
3. Evaluate the effect of I f<br />
in<br />
4. Identify the appropriate clinical applicability of I f<br />
inhibtion<br />
in HF<br />
Supported by an educational grant from Amgen<br />
Chair: Liviu Klein, San Francisco, CA<br />
1:30 Start<br />
3:30 Adjourn<br />
Learning Objective: Describe indications for CRT, identify<br />
CRT devices, and demonstrate their use and interrogation.<br />
Supported by educational grants from Biotronik, Boston<br />
Scientific, Medtronic, and St. Jude Medical<br />
33
SATURDAY, SEPTEMBER 26<br />
3:45 PM – 5:15 PM<br />
National Harbor 10-11<br />
Satellite Symposium:<br />
Contemporary and Future Management<br />
of Heart Failure in the African American<br />
Population<br />
Chair:<br />
Clyde W. Yancy, Chicago, IL<br />
3:45 Introduction, Program Overview and Pre-Test<br />
Clyde W. Yancy, Chicago, IL<br />
3:50 Epidemiology of Heart Failure<br />
Clyde W. Yancy, Chicago, IL<br />
4:05 Contemporary Treatment – Lessons Learned<br />
from GWTG-HF and Other Registries<br />
Gregg C. Fonarow, Los Angeles, CA<br />
4:30 Exploring New Treatment Paradigms for HF in<br />
African Americans<br />
Dennis McNamara, Venetia, PA<br />
6:00 PM – 8:00 PM<br />
Exhibit Hall -<br />
Prince George's B-C<br />
Opening Reception and Poster Reception<br />
Presenters at their Posters 6:30-7:30<br />
See Page 100-101 for a list of Industry Expert Theaters and<br />
other Exhibit Hall Activities.<br />
An exhibitor list can be found on page 107.<br />
Moderated Poster Session I<br />
6:30 Poster Professors<br />
John Chin, Sacramento, CA<br />
Thomas DiSalvo, New Haven, CT<br />
Martin LeWinter, Burlington, VT<br />
7:30 Adjourn<br />
4:55 Panel Discussion, Questions & Answers<br />
All Faculty<br />
5:15 Program Concludes<br />
Learning Objectives:<br />
1. Review the epidemiology, disease mechanisms, and<br />
natural history of heart failure in the African American<br />
population.<br />
2. Discuss real-world treatment experiences in African<br />
Americans with heart failure.<br />
3. Describe evolving treatment strategies for HF in African<br />
Americans stemming from genotypic characterization<br />
and ongoing treatment challenges in this population.<br />
Supported by an educational grant from<br />
Arbor Pharmaceuticals, LLC.<br />
34
SUNDAY, SEPTEMBER 27<br />
6:30 AM<br />
Meeting Level Foyers<br />
Light Breakfast<br />
7:00 AM – 8:00 AM<br />
Potomac C<br />
Satellite Symposium:<br />
Hyperkalemia in Heart Failure: New<br />
Data, Emerging Options<br />
Chair:<br />
Javed Butler, Stony Brook, NY<br />
7:00 Opening Remarks<br />
Javed Butler, Stony Brook, NY<br />
7:05 Potassium Homeostasis: Implications for Heart<br />
Failure Management<br />
Peter A. McCullough<br />
7:20 The Impact of Hyperkalemia and Renal Impairment<br />
on Clinical Outcomes in Heart Failure<br />
Javed Butler, Stony Brook, NY<br />
7:35 Emerging Management Options for Hyperkalemia:<br />
Where Are We Headed?<br />
Marvin A. Konstam, Boston, MA<br />
7:50 Faculty Panel Discussion<br />
Moderator: Javed Butler, Stony Brook, NY<br />
8:00 Closing Remarks<br />
Javed Butler, Stony Brook, NY<br />
Learning Objectives:<br />
1. Describe mechanisms of potassium homeostasis and<br />
pathogenesis of hyperkalemia in heart failure<br />
2. Define the impact of hyperkalemia and renal impairment<br />
on clinical outcomes in heart failure<br />
3. Identify current clinical challenges in treatment of acute<br />
and recurrent hyperkalemia<br />
4. Describe emerging therapies for hyperkalemia and the<br />
data supporting their effectiveness in patients with heart<br />
failure<br />
7:00 AM – 8:00 AM<br />
National Harbor 10-11<br />
Satellite Symposium:<br />
Sleep Disordered Breathing in Heart<br />
Failure: Targeted Treatment for Improved<br />
Outcomes<br />
Chair:<br />
Maria Rosa Costanzo, Naperville, IL<br />
7:00 Welcome and Overview<br />
Maria Rosa Costanzo, Naperville, IL<br />
7:05 Sleep Disordered Breathing: A Major Comorbidity<br />
in Heart Failure<br />
Christopher M. O’Connor, Falls Church, VA<br />
7:15 Differential Diagnosis and Clinical Features of<br />
Obstructive and Central Sleep Apnea<br />
Laura Wexler, Cincinnati, OH<br />
7:25 Treatment Options in Comorbid Sleep Disordered<br />
Breathing<br />
Susan Joseph, Houston, TX<br />
7:40 How to Incorporate Clinical Care for Sleep<br />
Disordered Breathing in the Heart Failure<br />
Sara C. Paul, Hickory, NC<br />
7:50 Panel Discussion and Audience Q&A (All)<br />
8:00 Adjourn<br />
Learning Objectives:<br />
1. Describe the clinical significance of sleep disordered<br />
breathing in heart failure<br />
2. Describe current findings concerning sleep disordered<br />
breathing in heart failure and the effectiveness of available<br />
treatment options<br />
3. Make decisions about treatment strategies for heart failure<br />
patients with sleep disordered breathing<br />
4. Outline a practical approach to the evaluation and<br />
management of patients with heart failure and sleep<br />
disordered breathing.<br />
Supported by an educational grant from ResMed<br />
Supported by an educational grant from ZsPharma<br />
35
SUNDAY, SEPTEMBER 27<br />
7:00 AM – 8:00 AM<br />
Potomac D<br />
Satellite Symposium:<br />
Remote Monitoring of Patients with<br />
Heart Failure: Making it Work in Practice<br />
Chair:<br />
Larry A. Allen, Denver, CO<br />
7:00 Introduction: The Former Future of Remote<br />
Monitoring<br />
Larry A. Allen, Denver, CO<br />
7:05 Beyond CHAMPION: Recent Data and Updates<br />
on Remote PA Pressure Monitoring<br />
William T. Abraham, Columbus, OH<br />
7:15 Remote Monitoring in Context: Programmatic<br />
Integration, Staff Training, and Work Flow<br />
Margaret M. Redfield, Rochester, MN<br />
7:25 Boots on the Ground: Cath Lab Implications,<br />
Data Management, and Algorithms for Medication<br />
Adjustment<br />
Rita A. Jermyn, New York, NY<br />
7:35 Cases, Audience Q&A and Panel Discussion<br />
Faculty<br />
8:00 Adjourn<br />
Learning Objectives:<br />
1. Describe the goals and obstacles of remote monitoring of<br />
patients with heart failure.<br />
2. Discuss the how the findings of clinical trials of implantable<br />
hemodynamic monitoring apply to real-world practice.<br />
3. Outline strategies for the implementation of implantable<br />
hemodynamic monitoring in clinical practice.<br />
4. Identify patient scenarios in which implantable hemodynamic<br />
monitoring could affect treatment and hospitalization.<br />
Supported by an educational grant from St. Jude Medical<br />
8:05 AM- 10:00 AM<br />
Maryland A & C<br />
8:05 Opening Remarks<br />
Michele Blair, Bethesda, MD<br />
8:15 Lifetime Achievement Award<br />
Presented by: Paul Hauptman, St.Louis, MO<br />
Hani Sabbah, Detroit, MI<br />
8:20 Clinical Excellence in Nursing Award<br />
Presented by: Maria Fe White, Los Angeles, CA<br />
8:25 Nursing Leadership Award<br />
Presented by: Victoria Dickson, New York, NY<br />
Plenary Session:<br />
The Economic Model of Heart Failure Care<br />
Moderators: JoAnn Lindenfeld, Nashville, TN<br />
Clyde Yancy, Chicago, IL<br />
8:30 Cardiovascular Drugs, Devices and Tobacco at<br />
the FDA<br />
Robert Califf, Silver Spring, MD<br />
9:05 The Evolving Economics of Heart Failure Care<br />
Jim Field, Washington DC<br />
9:40 Panel Discussion<br />
10:00 Adjourn<br />
Learning Objective: Describe economic models of heart failure<br />
care, including the role of regulatory agencies.<br />
10:00 AM<br />
Exhibit Hall -<br />
Prince George's B-C<br />
Exhibit Hall Opens<br />
See Page 100-101 for a list of Industry Expert Theaters and<br />
other Exhibit Hall Activities.<br />
An exhibitor list can be found on page 107.<br />
36
SUNDAY, SEPTEMBER 27<br />
10:30 AM - 12:00 PM<br />
Maryland Ballroom B<br />
Heart Failure Trials: The Year in Review<br />
Moderators: William Dec, Boston, MA<br />
Hector Ventura, New Orleans, LA<br />
10:30 Evaluation of ReDS<br />
William Abraham, Columbus, OH<br />
10:50 Ferric Carboxmaltose in Iron Deficient Heart Failure<br />
Patients: A Meta-Analysis on Individual Patient Data<br />
Stefan Anker, Berlin, Germany<br />
11:10 Randomized, Placebo-Controlled, Double-Blind<br />
Phase 2a Study of the Safety and Efficacy of the<br />
Recombinant Human Neuregulin-1<br />
Barry Greenberg, La Jolla, CA<br />
11:30 Baroreflex Activation Therapy for the Treatment<br />
of Heart Failure with a Reduced Ejection Fraction<br />
William Abraham, Columbus, OH<br />
11:50 Panel Discussion<br />
12:00 Adjourn<br />
Learning Objective: Outline key findings of recent key<br />
trials in heart failure and their potential impact on practice.<br />
Abstracts/posters of interest: 41, 245, 93, 252, 260, 250, 88<br />
10:30 AM - 12:00 PM<br />
National Harbor 10-11<br />
Cutting Edge Concepts in Device Therapy<br />
for Heart Failure (Joint Session with HRS)<br />
Moderators: John Chin, Sacramento, CA<br />
JoAnn Lindenfeld, Nashville, TN<br />
10:30 Electricity or Catheters for HF: What is Coming<br />
Down the Pike?<br />
Paul Wang, Stanford, CA<br />
10:45 Individualizing Resynchronization Therapy: Is This<br />
the Way to Move Forward?<br />
Niraj Varma, Cleveland, OH<br />
11:00 Wearable Cardioverter Defibrillators in the Newly<br />
Diagnosed Heart Failure Patient: Is There a Role?<br />
Valentina Kutyifa, Rochester, MN<br />
11:15 Electrical Therapies for the Heart Failure Patient:<br />
When Do We Get the Palliative Team Involved?<br />
JoAnn Lindenfeld, Nashville, TN<br />
11:30 Atrial Fibrillation in the HF Patient: Working<br />
Through the Double Whammy?<br />
Frank Ruschitzka, Zurich, Switerland<br />
11:45 Panel Discussion<br />
Faculty<br />
12:00 Adjourn<br />
Learning Objective: Identify clinical issues and new options<br />
in device therapy for the heart failure patient.<br />
37
SUNDAY, SEPTEMBER 27<br />
10:30 AM - 12:00 PM<br />
Potomac C<br />
What is the Best Way to Measure Congestion<br />
in the Patient with Heart Failure?<br />
Moderators: John Cleland, Harefield Middlesex, UK<br />
Mark Dunlap, Cleveland, OH<br />
10:30 History and Physical Examination<br />
Mark Drazner, Dallas TX<br />
10:45 Patient Assessment of Congestion<br />
Susan Wingate, Gaithersburg, MD<br />
11:00 Biomarkers, Hemoconcentration and Blood<br />
Volume Measurements<br />
James Januzzi, Boston MA<br />
11:15 Right Heart Catheterization<br />
Barry Borlaug, Rochester MN<br />
11:30 Implantable Monitors<br />
J. Thomas Heywood, La Jolla, CA<br />
11:45 Panel Discussion<br />
Faculty<br />
12:00 Adjourn<br />
Learning Objective: Use appropriate techniques and tools in<br />
the measurement of congestion in the heart failure patient.<br />
10:30 AM - 12:00 PM<br />
National Harbor 2-3<br />
New Concepts in the Pathophysiology of<br />
HFpEF<br />
Moderators: Peter Carson, Washington, DC<br />
Dalane Kitzman, Winston-Salem, NC<br />
10:30 Ventricular Function and Hemodynamic<br />
Mechanisms in HFpEF<br />
Michael Zile, Charleston, SC<br />
10:45 Thinking Outside the Box (Thorax): Impact of the<br />
Vasculature and Periphery in HFpEF<br />
Julio Chirinos, Philadelphia, PA<br />
11:15 What Makes the Ventricle So Stiff? Endothelial<br />
Dysfunction, Fibrosis, or Both?<br />
Carolyn Lam, Singapore<br />
11:30 Stressing the System: The Role of Exercise Testing<br />
to Phenotype HFpEF<br />
Gregory Lewis, Boston, MA<br />
11:45 Panel Discussion<br />
Faculty<br />
12:00 Adjourn<br />
Learning Objective: Describe new concepts in the pathophysiology<br />
of HFpEF and their implicaitons for practice.<br />
10:30 AM - 12:00 PM<br />
Potomac D<br />
Born This Way: The Role of Genetic Testing<br />
in Cardiomyopathy<br />
Moderators: Eugene DePasquale, Los Angeles, CA<br />
Neal Lakdawala, Boston, MA<br />
10:30 Dilated Cardiomyopathy: Genes and Beyond<br />
Jeffrey Towbin, Cincinnati, OH<br />
10:45 Hypertrophic Cardiomyopathy<br />
Carolyn Ho, Boston, MA<br />
11:00 ARVC<br />
Ray Hershberger, Columbus, OH<br />
11:15 Restrictive Cardiomyopathy<br />
Mathew Maurer, New York, NY<br />
11:30 Role of Genetic Counseling<br />
Teresa Kruisselbrink, Rochester, MN<br />
11:45 Panel Discussion<br />
Faculty<br />
12:00 Adjourn<br />
Learning Objective: Outline the effective use of genetic<br />
testing in selected cardiomyopathies.<br />
Abstracts/posters of interest: 193, 48, 206<br />
11:00 New insights into the Molecular Mechanisms of<br />
HFpEF<br />
Flora Sam, Boston, MA<br />
38
SUNDAY, SEPTEMBER 27<br />
10:30 AM – 12:30 PM<br />
Potomac 1-2<br />
Hands-On Workshop 2:<br />
Acute Management of Cardiogenic<br />
Shock with Peripherally Implanted<br />
Devices<br />
(Limited enrollment, preregistration required)<br />
Chair: Navin Kapur,Boston, MA<br />
Co-Chair: Arvind Bhimaraj, Houston, TX<br />
Robb Kociol, Boston, MA<br />
10:30 Start<br />
12:30 Adjourn<br />
Learning Objective: Describe management goals in cardiogenic<br />
shock, identify percutaneous devices used in the management<br />
of cardiogenic shock, and demonstrate their uses.<br />
Supported by educational grants from Abiomed, Cardiac<br />
Assist, Maquet, and Thoratec.<br />
10:30 AM - 12:30 PM<br />
Potomac 3-4<br />
Interactive Workshop 3:<br />
Echo Made Simple for the Multidisciplinary<br />
Heart Failure Team<br />
(Limited enrollment, preregistration required)<br />
Moderators: Victoria Dickson, New York, NY<br />
Maria Fe White, Los Angeles, CA<br />
10:30 Introduction to Flow, Planes and Physics of<br />
Echocardiography<br />
Alberta Warner, Los Angeles, CA<br />
10:55 Common and Uncommon Echo Pathologies in Heart<br />
Failure<br />
Leslie Miller, Clearwater, FL<br />
11:20 Case studies in Echo Imaging and Hemodynamics<br />
Michele Hamilton, Los Angeles, CA<br />
12:10 Question & Answer<br />
Faculty<br />
12:30 Adjourn<br />
This interactive workshop is designed to demystify echocardiographic<br />
imaging in heart failure patients. It is intended<br />
for the non-cardiologist participants of the annual HFSA<br />
meeting, nurses, NPs, PAs, Pharmacists, and students and<br />
other members of the HF Multidisciplinary team.<br />
Learning Objective: Describe how echocardiography<br />
works, interpret selected images, and describe implications<br />
for clinical practice.<br />
12:15 PM - 1:15 PM<br />
Maryland A<br />
How to Change Behavior<br />
Moderators: Peter Eckman, Minneapolis, MN<br />
Seongkum Heo, Little Rock, AR<br />
12:15 Using Motivational Interviewing to Promote<br />
Behavioral Change<br />
Barbara Riegel, Philadelphia, PA<br />
12:25 Addressing the Enviornment Challenges to<br />
Challenges to Changing Behavior<br />
Terry Lennie, Lexington, KY<br />
12:35 Helping Patients Engage in Effective Self-Care<br />
Corrine Jurgens, Stony Brook, NY<br />
12:45 Supporting Caregivers to Change Patient Behavior<br />
Misook Chung, Lexington, KY<br />
12:55 Roundtable<br />
Faculty<br />
1:15 Adjourn<br />
Learning Objective: Use proven strategies to change patient<br />
behavior, helping patients engage in effective self-care.<br />
Abstracts/posters of interest: 92, 173, 176, 174, 144<br />
11:45 Clinical Implications for Advanced Practice<br />
Nursing and Physician Assistants<br />
Michele Hamilton, Los Angeles, CA<br />
11:30 Role of Genetic Counseling<br />
Teresa Kruisselbrink, Rochester, MN<br />
39
SUNDAY, SEPTEMBER 27<br />
12:15 PM - 1:15 PM<br />
National Harbor 10-11<br />
How to Troubleshoot a VAD<br />
Moderators: Allen Anderson, Chicago, IL<br />
Rhondalyn McLean, Baltimore, MD<br />
12:15 What are the Critical Differences Between the<br />
Continuous Flow VAD’S<br />
Nir Uriel, Chicago IL<br />
12:25 What is a Ramp Study and How is One Done?<br />
Eduardo Rame, Philadelphia, PA<br />
12:35 What is the Role of Measuring Hemodynamics –<br />
What Does it Add?<br />
Dipanjan Banerjee, Stanford, CA<br />
12:45 Anticoagulation and Anti-Platelets: Now What?<br />
Randall Starling, Cleveland, OH<br />
12:55 How Can Imaging Help Problem Solve?<br />
Eric Velazquez, Durham, NC<br />
1:05 Frequently Asked Questions<br />
Faculty<br />
1:15 Adjourn<br />
Learning Objective: Identify techniques for troubleshooting<br />
VADs in patients with heart failure.<br />
12:15 PM- 1:15 PM<br />
Potomac 5-6<br />
How to: Opportunities in Early Career<br />
Nursing<br />
Moderators: Patricia Davidson, Baltimore, MD<br />
Sara Paul, Hickory, NC<br />
Early Career Leader in Heart Failure<br />
Christopher Lee, Portland, OR<br />
Early Career Clinician/Scientist in Heart Failure<br />
Martha Biddle, Lexington, KY<br />
Early Career Clinician in Heart Failure<br />
Karol Harshaw-Ellis, Durham, NC<br />
Early Career Academic Scientist in Heart Failure<br />
Rebecca Dekker, Lexington, KY<br />
Learning Objective: Discuss leadership, clinical, and scientific<br />
opportunities in nursing practice.<br />
12:15 PM- 1:15 PM<br />
Potomac C<br />
How to: Cases in the Evaluation and<br />
Management of Right Heart Failure in<br />
the Patient with Pulmonary Arterial<br />
Hypertension<br />
12:15 Assessment of Right Ventricular Function in<br />
Pulmonary Arterial Hypertension<br />
Mandeep Mehra, Boston MA<br />
Management of Right Heart Failure in Pulmonary<br />
Arterial Hypertension<br />
Johnathan D. Rich, Chicago, IL<br />
Learning Objective: Use effective management strategies for patients<br />
with right heart failure and pulmonary arterial hypertension.<br />
40
SUNDAY, SEPTEMBER 27<br />
12:15 PM – 1:15 PM<br />
Maryland C<br />
Rapid Fire Abstracts I<br />
Moderators: John Burnett, Rochester, MN<br />
Matthew Wolf, Durham, NC<br />
12:15 Trends and Outcomes of Patients with Adult<br />
Congenital Heart Disease with Pulmonary<br />
Hypertension listed for Orthotopic Heart<br />
Traplantation in the United Network for Organ<br />
Sharing Database<br />
Yamini Krishnamurthy 1 , 2 , Lauren B. Cooper 3 , 2 , Di Lu 2 ,<br />
Jacob N. Schroder 3 , Joseph G. Rogers 3 , 2 , Carmelo A.<br />
Milano 3 , Adrian F. Hernandez 3 , 2 , Chetan B. Patel 3 , 2 .<br />
1<br />
Duke University School of Medicine, Durham, NC;<br />
2<br />
Duke Clinical Research Institute, Durham, NC; 3 Duke<br />
University Medical Center, Durham, NC<br />
12:20 Cardiac Transplantation for Older Patients:<br />
Characteristics and Outcomes in the<br />
Septuagenarian Population<br />
Lauren B. Cooper 1 , Di Lu 2 , Robert J. Mentz 2 , Joseph<br />
G. Rogers 2 , Carmelo A. Milano 2 , G. Michael Felker 2 ,<br />
Jacob N. Schroder 2 , Adrian F. Hernandez 2 , Chetan<br />
B. Patel 2 . 1 Duke University, Durham, NC; 2 Duke<br />
University, Durham, NC<br />
12:25 Obese Patients Have Improved Ten-Year Survival<br />
after CRT-D Implantation<br />
Alison L. Wand, E. Wilson Grandin, Payman Zamani,<br />
J. Eduardo Rame, Ralph J. Verdino. University of<br />
Pennsylvania, Philadelphia, PA<br />
12:30 Decompensated Heart Failure Admissions are<br />
Inaccurately Identified by Centers for Medicare<br />
and Medicaid Services; Administrative Data<br />
Zachary L. Cox 1 , 2 , Pikki Lai 1 , Connie M. Lewis 1 ,<br />
Daniel J. Lenihan 1 . 1 Vanderbilt University Medical<br />
Center, Nashville, TN; 2 Lipscomb University College<br />
of Pharmacy, Nashville, TN<br />
12:35 Efficacy of LCZ696 Persists at Lower than Target<br />
Doses in the PARADIGM-HF trial<br />
Orly Vardeny 1 , Brian Claggett 2 , John J.V. McMur<br />
ray 3 , Milton Packer 4 , Jean Rouleau 5 , John R.<br />
Teerlink 6 , Michael Zile 7 , Karl Swedberg 8 , Martin<br />
Lefkowitz 9 , Victor Shi 9 . 1 University of Wisconsin,<br />
Madison, WI; 2 Brigham and Women's Hospital, Boston,<br />
MA; 3 University of Glasgow, Glasgow, United<br />
Kingdom; 4 UT Southwestern, Dallas, TX; 5 Univer<br />
sity of Montreal, Montreal, QC, Canada; 6 UCSF,<br />
San Francisco, CA; 7 MUSC, Charleston, SC;<br />
8<br />
University of Gothenburg, Gothenburg, Sweden;<br />
9<br />
Novartis Pharmaceuticals, East Hanover, NJ<br />
12:40 Inadequate Heart Rate Control in Ambulatory<br />
Patients with Systolic Heart Failure Despite<br />
Broad Beta Blocker Utilization: A Single Center<br />
Experience<br />
Kenneth D. Varian, Kevin Chagin, Justin L.<br />
Grodin, Frederik Verbrugge, Alex Milinovich,<br />
Michael W. Kattan, W.H. Wilson Tang. Cleveland<br />
Clinic Foundation, Cleveland, OH<br />
12:45 Remote Monitoring Program for Heart Failure<br />
Patients Discharged to Skilled Nursing Facilities<br />
to Improve Outcomes<br />
Mitchell T. Saltzberg 1 , Kelly A. Whitmarsh 2 ,<br />
Alexander Cheryl 3 , Vivek K. Reddy 4 . 1 Christi<br />
anaCare Health System, Newark, DE; 2 Chris<br />
tianaCare Health System, Newark, DE; 3 Christiana<br />
Care Health System, Newark, DE; 4 IPC Health<br />
Care, Newark, DE<br />
12:50 Bedside Hemodynamic Profiles in Acute Decompensated<br />
Heart Failure: Clinical Uncertainty<br />
May Identify Higher Risk<br />
Deepa M. Gopal, John D. Groarke, Adriana Luk,<br />
Emer Joyce, Sachin P. Shah, Eldrin F. Lewis, Neal K.<br />
Lakdawala, Anju Nohria. Brigham and Women's Hos<br />
pital, Boston, MA<br />
12:55 Lack of Improvement in 30-day Readmission<br />
Rates for Patients Hospitalized with Heart Failure:<br />
Data from Get with the Guidelines-Heart Failure<br />
Registry<br />
Kristin E. Bergethon 1 , Christine Ju 1 , Adam D.<br />
DeVore 1 , 2 , N. Chantelle Hardy 1 , Gregg C. Fon<br />
arow 3 , Clyde W. Yancy 4 , Paul A. Heidenreich 5 , 6 ,<br />
Deepak L. Bhatt 7 , 8 , Eric D. Peterson 1 , 2 , Adrian F.<br />
Hernandez 1 , 2 . 1 Duke Clinical Research Insti<br />
tute, Durham, NC; 2 Duke University School of<br />
Medicine, Durham, NC; 3 Ahmanson-UCLA Car<br />
diomyopathy Center, UCLA, Los Angeles, CA;<br />
4<br />
Northwestern University, Feinberg School of<br />
Medicine, Chicago, IL; 5 Veterans Affairs Palo Alto<br />
Health Care System, Palo Alto, CA; 6 Stanford<br />
University, Stanford, CA; 7 Brigham and Women's<br />
Hospital, Boston, MA; 8 Harvard Medical School,<br />
Boston, MA<br />
1:00 Identification of Stage D Heart Failure Patients:<br />
Clinical Assessment Versus ESC Heart Failure<br />
Association Criteria<br />
Mariyah Yazdani, Jeffrey S. Hedley, Ayman S. Tah<br />
han, Andrew A. McCue, Raghda Al-Anbari, Alanna<br />
A. Morris, Andrew L. Smith, Vasiliki V. Georgiopoulou,<br />
Andreas P. Kalogeropoulos. Emory Uni<br />
versity, Atlanta, GA<br />
41
SUNDAY, SEPTEMBER 27<br />
1:05 Lung Impedance-guided Therapy of Patients<br />
with Chronic Heart Failure Improves Clinical<br />
Outcome<br />
Michael Shochat 1 , Avraham Shotan 1 , Mark Ka<br />
zatsker 1 , Ilia Kleiner 2 , Iris Dahan 1 , Aya Asif 1 ,<br />
David Blondheim 1 , Simcha Meisel 1 . 1 Hillel Yaffe<br />
Heart Institute, Hadera, Israel; 2 Soroki Medical<br />
Center, Beer Sheva, Israel<br />
1:10 Rapid and Highly Accurate Prediction of Poor<br />
Diuretic Natriuretic Response in Patients with<br />
Heart Failure<br />
Jennifer Simon, Chukwuma Onyebeke, Susan J.<br />
Cheng, Jeffrey M. Testani. Yale University School<br />
of Medicine, New Haven, CT<br />
1:15 Adjourn<br />
Learning Objectives: Discuss findings from recent research in<br />
HF and their implications for research and clinical practice.<br />
1:30 PM – 3:00 PM<br />
Maryland B<br />
Guideline Session: Unique Heart Failure<br />
Populations: What Makes Them "Special"?<br />
Moderators: Michael Givertz, Boston, MA<br />
Nancy Sweitzer, Tucson, AZ<br />
1:30 African Americans with Heart Failure: Epidemiology<br />
and Genetics<br />
Monica Colvin, Ann Arbor, MI<br />
1:45 Hispanics with Heart Failure: Socioeconomics<br />
and Comorbidities<br />
Rey P. Vivo, Los Angeles, CA<br />
2:00 South Asians with Heart Failure: Vascular<br />
Function and Coronary Disease<br />
Eduard Shantsila, Birmingham, UK<br />
1:30 PM – 3:00 PM<br />
Maryland A<br />
Cardiac Amyloidosis<br />
Moderators: Amrut Ambardekar, Aurora, CO<br />
Jose Nativi-Nicolau, Salt Lake City, UT<br />
1:30 The Cardiotoxicity of Amyloid Proteins<br />
Ronglih Liao, Boston, MA<br />
1:45 Imaging in Cardiac Amyloidosis: From ECG to<br />
Echocardiography to MRI<br />
Javier Sanz, New York, NY<br />
2:00 Emerging Therapies for AL Cardiac Amyloidosis<br />
Allen Anderson, Chicago, IL<br />
2:15 Emerging Disease Modifying Therapies for<br />
Transthyretin Cardiac Amyloidosis<br />
Mathew Maurer, New York, NY<br />
2:30 Defibrillators, Cardiac Transplantation, and<br />
Mechanical Support in Cardiac Amyloidosis:<br />
Too Little, Too Late, or Novel and Underutilized<br />
Marc Semigran, Boston, MA<br />
2:45 Panel Discussion<br />
Faculty<br />
3:00 Adjourn<br />
Learning Objective: Describe the effective use of imaging<br />
to diagnose cardiac amyloidosis and identify emerging<br />
therapies.<br />
Abstracts/posters of interest: 203, 201, 22, 189, 307, 133<br />
2:15 Women with Heart Failure: Hypertension and<br />
Remodeling<br />
Jennifer E. Ho, Boston, MA<br />
2:30 Older Adults with Heart Failure: Frailty and<br />
Polypharmacy<br />
Alan S. Go, Oakland, CA<br />
2:45 Roundtable Discussion<br />
Faculty<br />
3:00 Adjourn<br />
Learning Objective: Outline guidelines for the treatment of<br />
unique heart failure populations.<br />
Abstracts/posters of interest: 22, 20, 195, 103, 99, 265, 105,<br />
110, 175, 12, 118, 229, 216, 61<br />
42
SUNDAY, SEPTEMBER 27<br />
1:30 PM – 3:00 PM<br />
Maryland C<br />
NHLBI Special Session:<br />
Heart Failure Clinical Trials - Strategies<br />
to Optimize Enrollment<br />
Moderators: Monica Shah, Bethesda, MD<br />
Eugene Braunwald, Boston, MA<br />
1:30 Opening Remarks<br />
Eugene Braunwald, Boston, MA<br />
1:32 Why is Enrollment is Important in HF Trials?<br />
Monica Shah, Bethesda, MD<br />
1:42 Strategy to Optimize Enrollment – Consider<br />
New Models for Trials<br />
John McMurray, Glasgow, UK<br />
1:54 Strategy to Optimize Enrollment – Consider<br />
Randomized Registry Trials<br />
Gregg Fonarow, Los Angeles, CA<br />
2:06 Strategy to Optimize Enrollment – Partner with<br />
Health Systems<br />
Christopher O’Connor, Falls Church, VA<br />
2:18 Srategey to Optimize Enrollment – Engage<br />
Patients<br />
Bray Patrick Lake, Durham, NC<br />
2:30 Srategey to Optimize Enrollment – Test<br />
Protocol Feasibility<br />
Patricia Adams, Durham, NC<br />
2:40 From TIMI 1 to 61: Ten Tips on Conducting<br />
Clinical Trials<br />
Eugene Braunwald, Boston, MA<br />
2:50 Panel Discussion<br />
Faculty<br />
2:58 Concluding Remarks<br />
Monica Shah, Bethesda, MD<br />
3:00 Adjourn<br />
Learning Objective: Describe strategies to optimize enrollment<br />
in heart failure clinical trials.<br />
1:30 PM – 3:00 PM<br />
Potomac C<br />
From Tele-monitoring to Tele-management<br />
and Electronic and Mobile-Health in Heart<br />
Failure<br />
Moderators: Julie Gee, Cleveland OH<br />
David Whellan, Philadelphia, PA<br />
1:30 Heart Failure Tele-Monitoring<br />
Larry Allen, Denver, CO<br />
1:50 Heart Failure Implantable Sensors<br />
Robert Bourge, Birmingham, AL<br />
2:10 E-Health / M-Health Heart Failure Management<br />
Nancy Albert, Cleveland, OH<br />
2:30 Panel Discussion: The Strengths and Concerns of<br />
Tele-monitoring, Tele-management and E- and<br />
M-health<br />
Faculty<br />
3:00 Adjourn<br />
Learning Objective: Identify tools for remote monitoring of<br />
patients with heart failure.<br />
Abstracts/posters of interest: 540, 466, 375, 67<br />
1:30 PM – 3:30 PM<br />
Potomac 1-2<br />
Hands-On Workshop 2 (Repeat)<br />
Acute Management of Cardiogenic<br />
Shock with Peripherally Implanted<br />
Devices<br />
(Limited enrollment, preregistration required)<br />
Chair: Navin Kapur,Boston, MA<br />
Co-Chair: Arvind Bhimaraj, Houston, TX<br />
Robb Kociol, Boston, MA<br />
1:30 Start<br />
3:30 Adjourn<br />
Learning Objective: Describe management goals in cardiogenic<br />
shock, identify percutaneous devices used in the management<br />
of cardiogenic shock, and demonstrate their uses.<br />
Supported by educational grants from Abiomed, Cardiac<br />
Assist, Maquet, and Thoratec.<br />
43
SUNDAY, SEPTEMBER 27<br />
1:30 PM – 3:30 PM<br />
Potomac 3-4<br />
Interactive Workshop 3 (Repeat)<br />
Echo Made Simple for the Multidisciplinary<br />
Heart Failure Team<br />
(Limited enrollment, preregistration required)<br />
Moderators: Victoria Dickson, New York, NY<br />
Maria Fe White, Los Angeles, CA<br />
1:30 Introduction to Flow, Planes and Physics of<br />
Echocardiography<br />
Alberta Warner, Los Angeles, CA<br />
1:55 Common and Uncommon Echo Pathologies in<br />
Heart Failure<br />
Leslie Miller, Clearwater, FL<br />
2:20 Case studies in Echo Imaging and Hemodynamics<br />
Michele Hamilton, Los Angeles, CA<br />
2:45 Clinical Implications for Advanced Practice<br />
Nursing and Physician Assistants<br />
Michele Hamilton, Los Angeles, CA<br />
3:10 Question & Answer<br />
Faculty<br />
3:30 Adjourn<br />
This interactive workshop is designed to demystify echocardiographic<br />
imaging in heart failure patients. It is intended<br />
for the non-cardiologist participants of the annual HFSA<br />
meeting, nurses, NPs, PAs, Pharmacists, and students and<br />
other members of the HF Multidisciplinary team.<br />
Learning Objective: Describe how echocardiography<br />
works, interpret selected images, and describe implications<br />
for clinical practice.<br />
3:30 PM – 5:00 PM<br />
Maryland B<br />
Late Breaking Clinical Trials<br />
Moderators: Gary Francis, Minneapolis, MN<br />
John McMurray, Glasgow, UK<br />
3:30 Follow-Up Results from AUMENT-HF:<br />
A Multicenter Randomized Controlled Clinical<br />
Trial of the Efficacy of Left Ventricular Augmentation<br />
with Algisyl-LVR in the Treatment of Heart Failure<br />
Douglas Mann, St. Louis, MO<br />
3:40 Commentary<br />
William Abraham, Columbus, OH<br />
3:45 HeartMate 3 CE Mark Study<br />
Ivan Netuka, Prauge, Czech Republic<br />
3:55 Commentary<br />
Marvin Konstam, Boston, MA<br />
4:00 Neural Cardiac Therapy for Heart Failure<br />
(NECTAR-HF)<br />
Faiez Zannad, Vandoeuvre, France<br />
4:10 Commentary<br />
Inder Anand, Minneapolis, MN<br />
4:15 Aquarpheresis Versus Diuretics and Hospitalization<br />
for Heart Failure Trial (AVOID-HF)<br />
Maria Rosa Costanzo, Naperville, IL<br />
4:25 Commentary<br />
Clyde Yancy, Chicago, IL<br />
4:30 Cupid 2: A Phase2b Trial Investigating the Efficacy<br />
and Safety of Intracoronary Administration of<br />
AAV/SERCA2a in Patients with Advanced Heart<br />
Failure<br />
Barry Greenberg, La Jolla, CA<br />
4:40 Commentary<br />
John Burnett, Rochester, MN<br />
4:45 ENCORE Study<br />
Inder Anand, Minneapolis, MN<br />
4:55 Commentary<br />
Mandeep Mehra, Boston, MA<br />
5:00 Adjourn<br />
Learning Objective: Describe the results of recent clinical<br />
trials in heart failure and discuss their clinical implications.<br />
3:30 PM – 5:00 PM<br />
Maryland A<br />
Moving From the Problem to the Solution<br />
Integrating a Palliative Approach in Heart<br />
Failure Management<br />
Moderators: Beth Fahlberg, Madison, WI<br />
Sarah Goodlin, Portland, OR<br />
3:30 Shared Decision Making in Heart Failure:<br />
Making Palliative Care a Reality<br />
Larry Allen, Denver, CO<br />
3:50 Managing Breathlessness in Heart Failure<br />
Patricia Davidson, Baltimore, MD<br />
4:10 Managing Patients with Left Ventricular Assist<br />
Devices: Having Crucial Conversations<br />
Stuart Russell, Baltimore, MD<br />
44
SUNDAY, SEPTEMBER 27<br />
4:30 Integrating Spiritual Aspects in Heart Failure Care<br />
Cheryl Westlake, Asuza, CA<br />
4:50 Panel Discussion<br />
Kathleen Grady, Chicago, IL<br />
John Teerlink, San Francisco, CA<br />
Faculty<br />
5:00 Adjourn<br />
Learning Objective: Outline an effective palliative approach<br />
in heart failure management and describe specific strategies.<br />
Abstracts/posters of interest: 153, 313, 175, 134, 303, 113<br />
3:30 PM – 5:00 PM<br />
Maryland C<br />
Managing VAD Complications<br />
Moderators: Monica Colvin, Ann Arbor, MI<br />
Joyce Wald, Philadelphia, PA<br />
3:30 GI Bleeding in Continuous Flow VADs<br />
Maria Mountis, Cleveland, OH<br />
3:45 Acquired Von Willebrand Syndrome in Continuous<br />
Flow VADs<br />
David Joyce, Rochester, MN<br />
4:00 Thrombosis in Continuous Flow VADs<br />
JoAnn Lindenfeld, Nashville, TN<br />
4:15 Cerebrovascular Disease in Continuous Flow<br />
VADs: A Neurologic Perspective<br />
Joshua Willey, New York, NY<br />
4:30 Systemic Vascular Reactivity in Continuous<br />
Flow VADs<br />
Joseph Rogers, Durham, NC<br />
4:45 Panel Discussion<br />
Faculty<br />
5:00 Adjourn<br />
Learning Objective: Describe effective strategies for managing<br />
selected complications in HF patients with VADs.<br />
3:30 PM – 5:00 PM<br />
Potomac C<br />
From Bench to Bedside: Emerging Therapies<br />
for the Failing Myocardium<br />
Moderators: Michael R. Bristow, Aurora, CO<br />
Kenneth B. Margulies, Philadelphia, PA<br />
3:30 Targeting Calcium Handling Defects (with Gene<br />
Therapy)<br />
Roger Hajjar, New York, NY<br />
3:45 Targeting Abnormal Cardiac Metabolism<br />
Daniel P. Kelly, Olrando, FL<br />
4:00 Targeting Fibrosis in the Failing Heart<br />
Carlin S. Long, Denver, CO<br />
4:15 Targeting Pathological Hypertrophy<br />
Steven Houser, Philadelphia, PA<br />
4:30 Targeting Cell Death Pathways<br />
Richard Kitsis, New York, NY<br />
4:45 GRK2 Inhibition as an Emerging Heart Failure<br />
Therapy<br />
Walter Koch, Philadelphia, PA<br />
5:00 Adjourn<br />
Learning Objective: Identify emerging therapies for the failing<br />
myocardium, and discuss their implications for clinical practice.<br />
Abstracts/posters of interest: 208, 256, 255, 252, 182, 85,<br />
120, 256<br />
5:15 PM – 6:30 PM<br />
Exhibit Hall -<br />
Prince George's B-C<br />
Poster Reception<br />
Presenters at their Posters 5:30 - 6:30<br />
See Page 100-101 for a list of Industry Expert Theaters and<br />
other Exhibit Hall Activities.<br />
An exhibitor list can be found on page 107.<br />
Moderated Poster Session II<br />
5:30 Poster Professors<br />
Douglas Sawyer, Nashville, TN<br />
Michael Rich, St. Louis, MO<br />
Faiez Zannad, Vandoeuvre, France<br />
6:30 Adjourn<br />
6:30 PM - 10:00 PM<br />
Cherry Blossom<br />
Fundraising & Faculty Dinner<br />
(All invited to attend. Tickets available at registration desk)<br />
6:30 Reception<br />
7:30 Dinner<br />
8:15 Entertainment: Laughter is the Best Medicine!<br />
Healthcare humorist Diana Jordan<br />
45
MONDAY, SEPTEMBER 28<br />
6:30 AM – 7:15 AM<br />
Meeting Level Foyers<br />
Light Breakfast<br />
7:15 AM – 8:15 AM<br />
Maryland C<br />
Satellite Symposium:<br />
Improving Patient Outcomes and Reducing<br />
Re-Admission Rates in Chronic Heart Failure<br />
7:15 AM – 8:15 AM<br />
Maryland A<br />
Satellite Symposium:<br />
Update on RAAS Inhibition in Chronic Heart<br />
Failure: Real World Considerations<br />
Chair:<br />
James L. Januzzi, Jr., Boston, MA<br />
Chair:<br />
Murray Epstein, Miami FL<br />
7:15 Program Overview<br />
James L. Januzzi, Jr., Boston, MA<br />
7:20 Heart Failure Hospitalization: The Epidemiology,<br />
Pathophysiology, and Diagnosis of Chronic Heart<br />
Failure vs. Acute Heart Failure<br />
James L. Januzzi, Jr., Boston, MA<br />
7:30 Current and Emerging Therapeutics for the<br />
Management of Chronic Heart Failure<br />
Barry H. Greenberg, San Diego, CA<br />
7:45 Optimizing Treatment Plans, Overcoming<br />
Barriers to Care, and Improving Patients Outcomes<br />
in Chronic Heart Failure<br />
Ileana L. Piña, New York, NY<br />
8:00 Questions and Answers<br />
Faculty<br />
Learning objectives:<br />
1. Discuss the epidemiology, pathophysiology, and diagno<br />
sis of chronic heart failure and how management goals<br />
for chronic heart failure differs from acute heart failure<br />
2. Review the data on the current and emerging therapeu<br />
tics for the management of chronic heart failure<br />
3. Apply evidence based strategies to optimize pharmaco<br />
logical treatment, overcome barriers to care, and<br />
improve outcomes in patients with chronic heart failure<br />
Supported by an educational grant from Amgen<br />
7:15 Introduction<br />
Murray Epstein, Miami, FL<br />
7:20 RAAS and RAASi - State of the Art Review and<br />
Evolving Perspectives<br />
Bertram Pitt, Ann Arbor, MI<br />
7:35 RAASi in CHF, CKD and T2DM<br />
Daniel Duprez, Minneapolis, MN<br />
7:50 Mandated Guidelines and the Real World Clinical<br />
Arena<br />
Murray Epstein, Miami, FL<br />
8:00 Panel Discussion<br />
Faculty<br />
8:15 Adjourn<br />
Learning objectives:<br />
1. Describe current knowledge of RAAS and RAAS inhibition<br />
including emerging approaches and future directions<br />
2. Describe the data on RAASi in specific patient populations<br />
including CHF patients with CKD and/or T2DM<br />
3. Describe current guidelines for the management of CHF<br />
and RAASi.<br />
4. Understand the gaps between mandated guidelines and<br />
current clinical realities<br />
5. Describe emerging therapeutic approaches to maintaining<br />
and managing RAASi therapy in patients with CHF<br />
Supported by an educational grant from ReardenCME made<br />
possible by Relypsa, Inc.<br />
46
MONDAY, SEPTEMBER 28<br />
7:00 AM- 8:15 AM<br />
Potomac C<br />
Clinical Fundamentals II: FAQ’s About<br />
Heart Failure Drug Therapy<br />
Moderators: Mariell Jessup, Philadelphia, PA<br />
Jo Ellen Rodgers, Chapel Hill, NC<br />
Discussion Panel:<br />
John Chin, Sacramento, CA<br />
Daniel Dries, Philadelphia, PA<br />
Gerasimos Filippatos, Athens, Greece<br />
Heather Ross, Toronto, ON, Canada<br />
Mark Semigran, Boston, MA<br />
7:00 Case 1 & FAQs:<br />
55-year-old male with HTN, diabetes, and history of childhood<br />
asthma is admitted with new onset heart failure, LVEF<br />
20%. He has non-critical CAD and is stable after 2 days of<br />
IV diuretic. His BP is now 140/90 mmHg, and his heart rate<br />
is 70 bpm. Renal function is normal.<br />
Which ACE-inhibitor would you start?<br />
When do you start the beta-blocker?<br />
When do you start the MRA?<br />
Which beta-blocker would you start?<br />
Do you follow the NT-proBNP?<br />
How high would the creatinine have to be before you would<br />
not start an ACE-I?<br />
Is there anyone who would start an ARB first? What if the<br />
patient was Asian?<br />
What other tests are needed before discharge?<br />
What do you use as discharge criteria?<br />
Does he need a heart failure cardiologist to follow him?<br />
Would you evaluate his hypertension? Would his race matter<br />
in this answer?<br />
Would you start a statin? If so, which one and at what dose?<br />
7:20 Case 2 & FAQs:<br />
55-year-old woman has been followed for a dilated cardiomyopathy<br />
for several years by a board-certified advanced<br />
heart failure cardiologist and is on evidence-based therapy<br />
at the highest tolerated doses. She has had to stop working<br />
as a teacher, and is only able to do light chores at home.<br />
She is not volume overloaded but is profoundly fatigued.<br />
She has a single-lead ICD. Her BP is 90/50 mmHg, and her<br />
heart rate is 55 bpm. Renal function is normal.<br />
Would you order a VO2 max?<br />
Would you perform a right heart cath?<br />
Would you perform a left heart cath?<br />
Is there a role for MRI now?<br />
Would you order any biomarkers? If so, which ones?<br />
Would you admit her to the hospital?<br />
What hemodynamics would compel you to decrease her<br />
medications?<br />
What hemodynamics would compel you to add medicines?<br />
What circumstances would compel you to add an inotrope?<br />
What triggers do you use to initiate a transplant evaluation?<br />
What is your weight cut-off for transplant? How about for<br />
VAD?<br />
What is your age cut-off for transplant?<br />
7:40 Case 3 & FAQs:<br />
55 year old male has a dilated cardiomyopathy for unclear<br />
reasons. He has refused left heart cath in the past.<br />
He has long standing hypertension, recent diabetes and is<br />
a 40 pack year cigarette smoker. He is now admitted with<br />
acute decompensated heart failure. He is approximately 20<br />
pounds increased from his last office visit weight. His BP<br />
is 90/50mmg, heart rate 110/min, somewhat irregular. On<br />
examination, he is warm and volume overloaded. Renal<br />
function is normal. In the emergency room, he is given 40<br />
IV furosemide with little urine output over the next hour.<br />
Would you give a higher dose of furosemide?<br />
Would you give a thiazide diuretic like metalozone?<br />
Is there a role for nesiritide?<br />
When would you consider invasive hemodynamic testing?<br />
Does he need admission?<br />
Does your program transplant active cigarette smokers?<br />
How about marijuana?<br />
How high would a troponin have to be before you take him<br />
to the cath lab?<br />
8:00 Additional Audience FAQs<br />
8:00 Adjourn<br />
Learning objective: Identify important decision points in<br />
drug therapy for heart failure, and describe effective management<br />
strategies.<br />
Abstracts/posters of interest: 102, 98, 99, 96, 97, 101, 103<br />
8:30 AM – 10:00 AM<br />
Maryland B<br />
Case Discussion – Clinical Conundrums<br />
Moderators: Sara Paul, Hickory, NC<br />
Lynne Warner Stevenson, Boston MA<br />
Panelists:<br />
Robert DiDomenico, Chicago, IL<br />
Joseph Hill, Dallas, TX<br />
Alan Miller, Jacksonville, FL<br />
Christine Thompson, Stanford CA<br />
Sana Al-Khatib, Durham, SC<br />
10:00 Adjourn<br />
Learning Objective: Using practice guidelines, research<br />
findings, and clinical experience, make management decisions<br />
about difficult cases in heart failure.<br />
47
MONDAY, SEPTEMBER 28<br />
8:30 AM – 10:00 AM<br />
Maryland A<br />
Nursing Research Award<br />
Moderators: Victoria Dickson, New York, NY<br />
Maria Fe White, Los Angeles, CA<br />
8:30 ASC Methylation and Expression are Associated<br />
with Depressive Symptoms, Anxiety, and Quality<br />
of Life in Heart Failure<br />
Brittany Butts 1 , Rebecca A. Gary 1 , Sandra B.<br />
Dunbar 1 , Javed Butler 2 . 1 Emory University, Atlanta,<br />
GA; 2 Stony Brook University, Stony Brook, NY<br />
8:45 Women's Experiences Being Diagnosed with<br />
Peripartum Cardiomyopathy<br />
Rebecca L. Dekker 1 , Christine H. Morton 2 , Paula<br />
Singleton 3 , Audrey Lyndon 4 . 1 University of Kentucky,<br />
Lexington, KY; 2 Stanford University,<br />
Stanford, CA; 3 Leeds University, Leeds, United<br />
Kingdom; 4 University of California San Francisco,<br />
San Francisco, CA<br />
9:00 Assessment of the Accuracy of the Diagnosis for<br />
Heart Failure in a Large Metropolitan Health Care<br />
System and the Impact on Readmission Rates<br />
Sandra Carey, Giovanna Saracino, Cara A. East,<br />
Paul A. Grayburn, Ravi C. Vallabhan, Kyle Bass,<br />
William Shutze Jr, Shelley A. Hall. Baylor Scott &<br />
White Health, Dallas, TX<br />
9:15 Right Ventricular Dysfunction is an Independent<br />
Predictor of Length of Stay Following Left<br />
Ventricular Assist Device Implantation<br />
Rachel Clarke, Amanda R. Vest, Linda Ordway,<br />
Michael S. Kiernan, David DeNofrio. Tufts Medical<br />
Center, Boston, MA<br />
9:30 An Acceptability and Feasibility Study of Decision<br />
Aids for Patients and Their Caregivers Considering<br />
Destination Therapy Left Ventricular Assist Device<br />
Colleen K. McIlvennan 1 , Jocelyn S. Thompson 2 , Daniel D.<br />
Matlock 3 , Joseph C. Cleveland 4 , Larry A. Allen 1 . 1 University<br />
of Colorado, Aurora, CO; 2 University of Colorado,<br />
Aurora, CO; 3 University of Colorado, Aurora, CO;<br />
4<br />
University of Colorado, Aurora, CO<br />
9:45 Using Shared Medical Appointments to Decrease<br />
Readmission Rates<br />
Donna Walker 1 , Renee Marincic 2 . 1 Euclid Hospital,<br />
Euclid, OH; 2 Euclid Hospital, Euclid, OH<br />
10:00 Adjourn<br />
*10-minute presentation, 5 minute discussion<br />
Learning Objectives: Discuss the results of recent nursing<br />
research and its implications for the care of patients with<br />
heart failure.<br />
8:30 AM – 10:00 AM<br />
Maryland C<br />
JNC Young Investigators Award: Clinical/<br />
Integrative<br />
Moderators: Jay Cohn, Minneapolis, MN<br />
Bertram Pitt, Ann Arbor, MI<br />
8:30 Correlation Between Coronary Sinus, Arterial<br />
and Venous BNP Levels in Subjects with<br />
Reduced Left Ventricular Systolic Function<br />
Zubair Shah, Arun Mahankali Sridhar, Reza Masoomi,<br />
Mark Wiley, Buddhadeb Dawn, Kamal Gupta. University<br />
of Kansas Medical Center, Kansas City, MO<br />
8:45 Mortality in Status 2 Patients Listed for Heart Transplantation<br />
in the United States: Will Understanding<br />
Mode of Death Help Justify Implantationof Left<br />
Ventricular Assist Devices Into Less Sick Patients?<br />
Alanna A. Morris 1 , Andreas Kalogeropoulos 1 , Anita<br />
Kelkar 1 , Robert T. Cole 1 , Divya Gupta 1 , Duc Nguyen 2 ,<br />
S. Raja Laskar 1 , Andrew Smith 1 , J. David Vega 2 . 1 Emory<br />
University, Atlanta, GA; 2 Emory University, Atlanta, GA<br />
9:00 Patients With HF Show High Degrees of Moderate to<br />
Severe Cognitive Impairment Despite Normal<br />
MMSE Testing<br />
Deepak J. Pattanshetty, Dana Cook, Sonika Malik, Mark<br />
E. Dunlap. Metrohealth Campus of Case Western Reserve<br />
University, Cleveland, OH<br />
9:15 Bridging Anticoagulation After CF-LVAD Implantation<br />
Indra Bole 1 , Bethany Tellor 2 , Michael Nassif 3 , David<br />
Raymer 3 , Anjan Tibrewala 1 , Scott Silvestry 4 , Justin Vader<br />
3 , Shane LaRue 3 . 1 Washington University School of<br />
Medicine, Saint Louis, MO; 2 Washington University<br />
School of Medicine, Saint Louis, MO; 3 Washington<br />
University School of Medicine, Saint Louis, MO; 4<br />
Washington University School of Medicine, Saint Louis, MO<br />
9:30 Cardiac Rotational Mechanics as a Predictor of<br />
Favorable Functional and Structural Response<br />
After Mechanical Unloading With Cardiac Assist<br />
Devices in Advanced Heart Failure Patients<br />
Michael J. Bonios 1 , James Wever Pinzon 1 , Josef Stehlik 1 ,<br />
Abdallah Kfoury 2 , Edward M. Gilbert 1 , Rami Alharethi 2 ,<br />
Jose Nativi-Nicolau 1 , Craig H. Selzman 1 , Mohammad<br />
Alsari 1 , Bruce Reid 2 , Stephen H. McKellar 1 , Antigone<br />
Koliopoulou 1 , William Caine 2 , Dean Y. Li 1 , James Fang 1 ,<br />
Stavros G. Drakos 1 . 1 University of Utah, Salt Lake City,<br />
UT; 2 Intermountain Medical Center, Salt Lake City, UT<br />
9:45 Outcomes After Cardiopulmonary Resuscitation<br />
Among Patients Hospitalized with Heart Failure<br />
Justin S. Sadhu, Michael W. Rich. Washington<br />
University in St. Louis, Saint Louis, MO<br />
10:00 Adjourn<br />
*10 minute presentation, 5 minute discussion<br />
Learning Objective: Discuss the results of recent heart failure<br />
research and their implications for treatment.<br />
48
MONDAY, SEPTEMBER 28<br />
8:30 AM – 10:00 AM<br />
Maryland 1-2<br />
JNC Young Investigators Award:<br />
Basic Science<br />
Moderators: Steven Houser, Philadelphia, PA<br />
Walter Koch, Philadelphia, PA<br />
8:30 Acute Blood Pressure, Renal and cGMP Responses<br />
to the Novel Designer Natriuretic Peptide ZD100 in<br />
Spontaneously Hypertensive Rats<br />
Alessia Buglioni 1 , Jeson S. Sangaralingham 1 ,<br />
Gerald E. Harders 1 , Brenda K. Huntley 1 , Horng H.<br />
Chen 1 , 2 , John C. Burnett 1 , 2 . 1 Mayo Clinic, Rochester,<br />
MN; 2 Zumbro Discovery, Rochester, MN<br />
8:53 Oxidative Stress Induced Modulation of Platelet<br />
Integrin αIIbβ3 Expression and Shedding During<br />
Major Bleeding in Heart Failure Patients Supported<br />
By Continuous Flow Left Ventricular<br />
Assist Devices<br />
Nandan K. Mondal 1 , Zengsheng Chen 1 , Jun Ding 1 ,<br />
Mike Sobieski 1 , Si Pham 2 , Steven Koenig 1 , Bartley<br />
P. Griffith 2 , Mark S. Slaughter 1 , Zhongjun J. Wu 1 .<br />
1<br />
University of Louisville School of Medicine,<br />
Louisville, KY; 2 University of Maryland School of<br />
Medicine, Baltimore, MD<br />
9:15 Rapid Restoration of Transplanted Stem Cell<br />
Bioenergetics By Metabolic Scaffolds That Promote<br />
Cell Adhesion and Provide Substrates<br />
Junaid Afzal, Angel Chan, Mehmet Fatih Karakas,<br />
Kirubel Woldemichael, Stella Vakrou, Brian<br />
O'Rourke, M Roselle Abraham. Johns Hopkins<br />
University, Baltimore, MD<br />
9:38 Temporal Assessment of Endothelial to Mesenchymal<br />
Transition as a Contributor to Fibrosis in a Mouse<br />
Model of Heart Failure<br />
Cesar Uribe, Andrea M. Cordero-Reyes, Keith<br />
A. Youker, Guha Ashrith, Barry H. Trachtenberg,<br />
Jerry D. Estep, Guillermo Torre-Amione, John P.<br />
Cooke, Arvind Bhimaraj. The Methodist Hospital,<br />
Houston, TX<br />
10:00 Adjourn<br />
8:30 AM – 10:00 AM<br />
Potomac C<br />
Cardiovascular Magnetic Resonance<br />
Imaging for the Heart Failure Specialist<br />
Moderators: Eric Velazquez, Durham, NC<br />
James Udelson, Boston, MA<br />
8:30 Introduction<br />
8:35 Scar Imaging in Cardiomyopathy and Heart<br />
Failure: "Non-Ischemic" Dilated Cardiomyopathy<br />
Eric Schelbert, Pittsburgh, PA<br />
8:50 CMR in Infiltrative and Inflammatory<br />
Cardiomyopathies<br />
Frederick Ruberg, Boston, MA<br />
9:05 CMR in Hypertrophic Cardiomyopathy<br />
Martin Maron, Boston, MA<br />
9:20 New Frontiers in Cardiac MR Research: Where<br />
Do We Go from Here?<br />
Ravi Shah, Boston, MA<br />
9:35 Panel Discussion<br />
Faculty<br />
10:00 Adjourn<br />
Learning Objective: Describe the uses of cardiovascular MRI<br />
in heart failure diagnosis and management.<br />
Abstracts/posters of interest: 161<br />
10:00 AM<br />
Exhibit Hall -<br />
Prince George's B-C<br />
Exhibit Hall Opens<br />
See Page 100-101 for a list of Industry Expert Theaters and<br />
other Exhibit Hall Activities.<br />
An exhibitor list can be found on page 107.<br />
*14 minute presentation, 8- minute discussion<br />
Learning objective: Discuss the results and implications of<br />
basic science research in heart failure.<br />
49
MONDAY, SEPTEMBER 28<br />
10:30 AM – 12:00 PM<br />
Maryland C<br />
Managing the VAD Outpatient<br />
Moderators: Jason Katz, Chapel Hill, NC<br />
Roxanne Siemeck, Oak Lawn, IL<br />
10:30 Alarms and Device Malfunction: Handling the<br />
Calls from Home<br />
William Cotts, Oak Lawn, IL<br />
10:45 Patient and Caregiver Psychosocial Issues<br />
Quincy Young, Vancouver, Canada<br />
11:00 Using the Echocardiogram: Should Imaging Be<br />
Protocol Driven?<br />
Andrew Sauer, Chicago, IL<br />
11:15 Recovery Inclusive of Biomarkers<br />
Tarek Ahmad, Durham, NC<br />
11:30 How to Improve the Functional Capacity of the<br />
VAD Patient<br />
Seth Hollander, Stanford, CA<br />
11:45 Panel Discussion<br />
Faculty<br />
12:00 Adjourn<br />
Learning Objective: Effectively manage VAD outpatients,<br />
addressing medical, psychosocial, and functional issues.<br />
10:30 AM – 12:00 PM<br />
Maryland A<br />
Putting the “Self” Back in Self-Care:<br />
Innovative Strategies to Improve Heart<br />
Failure Self-Care (Joint Session with<br />
AAHFN)<br />
Moderators: Victoria Dickson, New York, NY<br />
Connie Lewis, Nashville, TN<br />
10:30 Why is Self-Care so Difficult?<br />
Corrine Jurgens, Stony Brook, NY<br />
10:50 Managing Medications at Home<br />
Kerry Pickworth, Columbus, OH<br />
11:10 Using Technology to Engage Patients and<br />
Caregivers in Self-Care<br />
Misook Chung, Lexington, KY<br />
11:30 Engaging patients with Health Literacy Barriers<br />
Jia-Rong Wu, Chapel Hill, NC<br />
11:50 Panel Discussion<br />
Faculty<br />
12:00 Adjourn<br />
Learning Objective: Describe effective self-care and outline<br />
strategies for engaging HF patients in self-care.<br />
Abstracts/posters of interest: 95, 110, 119, 229, 253<br />
50
MONDAY, SEPTEMBER 28<br />
10:30 AM – 12:00 PM<br />
Maryland D<br />
Controversies in Cardio-Oncology<br />
Moderators: Thomas Force, Nashville, TN<br />
Ron Witteles, Stanford, CA<br />
10:30 Left Ventricular Dysfunction With Herceptin-<br />
To Hold or Not to Hold?<br />
Bonnie Ky, Philadelphia, PA<br />
10:50 Myocardial Biopsy for Anthracycline Toxicity—<br />
When, How and What For?<br />
Jean-Bernard Durand, Houston, TX<br />
11:10 Tracking Cardiotoxicity with Myocardial<br />
Strain—What Now?<br />
Juan Carlos Plana, Houston, TX<br />
11:30 Cardioprotection in Chemotherapy Recipients<br />
Edward T. H. Yeh, Houston, TX<br />
11:45 Panel Discussion<br />
Faculty<br />
12:00 Adjourn<br />
Learning Objective: Identify cardiotoxicity in chemotherapy<br />
recipients and use effective management and cardioprotective<br />
strategies.<br />
Abstracts/posters of interest: 26<br />
10:30 AM – 12:00 PM<br />
Maryland C<br />
The “Hidden Gems” of Heart Failure<br />
Publishing<br />
Moderators: Gary Francis, Minneapolis, MN<br />
Jay N. Cohn, Minneapolis, MN<br />
10:30 The Best of JCF<br />
Paul Hauptmann, St. Louis, MO<br />
10:43 The Best of JACC: Heart Failure<br />
Christopher O’Connor, Falls Church, VA<br />
10:56 The Best of Circulation: Heart Failure<br />
James Udelson, Falls Church, VA<br />
11:09 The Best of European Journal of Heart Failure<br />
Marco Metra, Brescia, Italy<br />
11:22 The Best of the Journal of Heart & Lung<br />
Transplant<br />
Mandeep Mehra, Boston, MA<br />
11:35 The Best of the Journal of Cardiovascular Nursing<br />
Debra Moser, Lexington, KY<br />
11:48 Panel Discussion/Q&A with Journal Editors –<br />
Challenges in Publishing, Questions<br />
12:00 Adjourn<br />
Learning Objective: Identify key research findings published<br />
in leading heart failure journals and discuss their implications for<br />
practice.<br />
Abstracts/posters of interest: 553, 137, 297, 448, 497, 315, 311,<br />
484<br />
51
MONDAY, SEPTEMBER 28<br />
10:30 AM – 12:30 PM<br />
Maryland 3-4<br />
Hands-On Workshop 4:<br />
Advanced Troubleshooting with Durable VADs<br />
(Limited enrollment, preregistration required)<br />
Chair: Joseph Rogers, Durham, NC<br />
Co-Chair: Selma Mohammed, Rochester, MN<br />
Robb Kociol, Boston, MA<br />
10:30 Start<br />
12:30 Adjourn<br />
Learning Objective: Describe common or difficult issues in<br />
the management of VAD patients and strategies for troubleshooting.<br />
Abstracts/posters of interest: 72, 59, 54, 132, 224<br />
Supported by educational grants from Heartware and<br />
Thoratec<br />
10:30 AM – 12:00 PM<br />
Maryland 5-6<br />
Hands-On Workshop 5:<br />
Cardiopulmonary Function Testing<br />
(Limited enrollment, preregistration required)<br />
Chair: Gregory Lewis, Boston, MA<br />
10:30 Start<br />
12:00 Adjourn<br />
Learning Objective: Describe and demonstrate the effective<br />
use of cardiopulmonary testing in heart failure.<br />
12:15 PM – 1:15 PM<br />
Maryland C<br />
How to Use Cardiac Rehabilitation in<br />
Heart Failure<br />
Ileana Pina, New York, NY<br />
Stuart Russell, Baltimore, MD<br />
David Whellan, Philadelphia, PA<br />
Maria Fe White, Los Angeles, CA<br />
1:15 Adjourn<br />
Learning Objective: Describe the role of cardiac rehabilitation<br />
in HF and outline an effective patient program.<br />
12:15 PM – 1:15 PM<br />
Potomac C<br />
Rapid Fire Abstracts II<br />
Moderators: Joseph Rogers, Durham, NC<br />
Paul J. Hauptman, St. Louis, MO<br />
12:15 Peripheral Metabolite Pattern in Heart Failure<br />
Patients is an Independent Predictor of Survival<br />
David E. Lanfear 1 , Stephen Gardell 2 , Albert Levin 1 ,<br />
Jia Li 1 , Keoki Williams 1 , Hani Sabbah 1 , Nicole<br />
Zeld 1 . 1 Henry Ford Health System, Detroit, MI;<br />
2<br />
Sanford Burnham Research Institute, Orlando, FL<br />
12:20 Genetic Factors Influencing B-type Natriuretic<br />
Peptide Mediated Production of Cyclic Guanosine<br />
Mono Phosphate and Blood Pressure Effects<br />
in Heart Failure Patients<br />
David Lanfear 1 , Raza Abbas 1 , Badri Padhukasahasram 1 ,<br />
Ramesh C. Gupta 1 , David Langholz 2 , W. Wilson Tang 3 ,<br />
L. Keoki Williams 1 , Hani N. Sabbah 1 . 1 Henry Ford<br />
Hospital, Detroit, MI; 2 Spectrum Health, Grand Rapids,<br />
MI; 3 Cleveland Clinic Foundation, Cleveland, OH<br />
12:25 Burden of Heart Failure and Treatment Practices<br />
Among Patients with HIV Infection in an Era of<br />
Contemporary Antiretroviral Therapy<br />
Sadeer G. Al-Kindi, Guilherme H. Oliveira, Chris<br />
T. Longenecker. University Hospitals Case Medical<br />
Center, Cleveland, OH<br />
12:30 In-Vitro Exposure of Isolated Failing Cardiomyocytes<br />
to Vepoloxamer (Purified Poloxamer 188) Limits<br />
Unregulated Calcium Entry into the Cell<br />
Ramesh C. Gupta 1 , Vinita Sing-Gupta 1 , Marty<br />
Emanuele 2 , Hani N. Sabbah 1 . 1 Henry Ford Health<br />
System, Detroit, MI; 2 Mast Therapeutics, Inc., San<br />
Diego, CA<br />
12:35 NEOD001 Demonstrates Cardiac and Renal<br />
Biomarker Responses in a Phase 1/2 Study in<br />
Patients with AL Amyloidosis and Persistent<br />
Organ Dysfunction<br />
Michaela Liedtke 1 , Heather Landau 2 , Ray Comenzo<br />
3 , David Seldin 4 , Brendan Weiss 5 , Jeffrey<br />
Zonder 6 , Jackie Walling 7 , Gene Kinney 8 , Martin<br />
Koller 8 , Morie A. Gertz 9 . 1 Stanford University<br />
School of Medicine, Stanford, CA; 2 Memorial<br />
Sloan-Kettering Cancer Center, New York, NY;<br />
3<br />
Tufts Medical Center, Boston, MA; 4 Boston<br />
University, Boston, MA; 5 University of Pennsylvania,<br />
Philadelphia, PA; 6 Karmanos Cancer Institute,<br />
Detroit, MI; 7 JW Consulting, Hillsborough, CA;<br />
8<br />
Prothena Biosciences, South San Francisco, CA;<br />
9<br />
Mayo Clinic, Rochester, MN<br />
52
MONDAY, SEPTEMBER 28<br />
12:40 A Pharmacogenetic Investigation of Intravenous<br />
Furosemide in Decompensated Heart Failure: A<br />
Meta-Analysis of 3 Clinical Trials<br />
Simon de Denus 1 , Jean L. Rouleau 1 , Douglas L.<br />
Mann 2 , Gordon S. Huggins 3 , Thomas P. Cappola 4 ,<br />
Svati H. Shah 5 , Julianna Keleti 6 , Yassamin Feroz<br />
Zada 1 , Sylvie Provost 1 , Amina Bardhadi 1 , Michael<br />
S. Phillips 1 , Valérie Normand 1 , Ian Mongrain 1 , Marie-Pierre<br />
Dubé 1 . 1 Montreal Heart Institute, Montreal,<br />
QC, Canada; 2 Washington University School<br />
of Medicine, St. Louis, MO; 3 Tufts Medical Center,<br />
Boston, MA; 4 University of Pennsylvania, Philadelphia,<br />
PA; 5 Division of Cardiology, Duke University<br />
School of Medicine, Durham, NC; 6 National Heart,<br />
Lung, and Blood Institute, Bethesda, MD<br />
12:45 Baseline Characteristics Predict the Presence<br />
of Amyloid on Endomyocardial Biopsy Among<br />
Patients With Heart Failure With Preserved<br />
Ejection Fraction<br />
Van-Khue Ton, Aditya Bhonsale, Marc K. Halushka,<br />
Charles Steenbergen, Edward Kasper, Ryan<br />
J. Tedford, Ilan Wittstein, Kavita Sharma, Stuart<br />
Russell, Daniel P. Judge. Johns Hopkins Hospital,<br />
Baltimore, MD<br />
1:05 Effect of Corin Deficiency and Mutation on<br />
Cardiac Natriuretic Peptide Processing in the<br />
Intact Heart Under Cardiac Pressure-Overload<br />
Conditions<br />
Bin Xu, Temple University, Philadelphia, PA<br />
1:10 Telomere Integrity as a Genetic Marker of<br />
Effective Treatment for Advanced Heart Failure<br />
Cara Statz 1 , Judith Brown 2 , Aleksandra Ras 1 , Kev<br />
in Ballard 1 , Dharma Desai 2 , Daniel Fusco 1 , Jona<br />
than Hammond 1 , Jason Gluck 1 , Detlef Wencker 3 .<br />
1<br />
Hartford Hospital, Hartford, CT; 2 University of<br />
Connecticut, Storrs, CT; 3 University of Kansas<br />
Medical Center, Kansas City, KS<br />
1:15 Adjourn<br />
Learning Objective: Discuss findings from recent research<br />
in HF and their implications for research and clinical practice.<br />
12:50 Contemporary Natural History, Mechanical<br />
Circulatory Support Needs and Post-Transplant<br />
Outcomes of Patients With Myocarditis Listed<br />
for Heart Transplantation<br />
Chantal Elamm, Sadeer Al-Kindi, Mahazarin Ginwalla,<br />
Rodolfo Benatti, Mobolaji Ige, Mohammadkattea,<br />
Chang kim, Guilherme Oliveira. University<br />
Hospitals of Cleveland, Cleveland, OH<br />
12:55 Central-Line Associated Bloodstream Infections<br />
Related to Inpatient Pulmonary Artery Catheterization<br />
among Patients Waiting for Heart<br />
Transplantation<br />
Usama Daimee, Katherine Dodd, Saadia Sherazi,<br />
Lynn Fine, Christine Hay, Eugene Storozynsky,<br />
Jeffrey Alexis, Leway Chen, University of Rochester<br />
Medical Center, Rochester, NY<br />
1:00 Relevance of Changes in Serum Creatinine<br />
During a Heart Failure Trial of Decongestion:<br />
Insights From the DOSE Trial<br />
Meredith A. Brisco 1 , Michael R. Zile 1 , Jennifer<br />
Simon 2 , W.H. Wilson Tang 3 , Jeffrey M. Testani 2 .<br />
1<br />
Medical University of South Carolina, Charleston,<br />
SC; 2 Yale University School of Medicine, New<br />
Haven, CT; 3 The Cleveland Clinic Foundation,<br />
Cleveland, OH<br />
53
MONDAY, SEPTEMBER 28<br />
12:15 PM – 1:15 PM<br />
Maryland D<br />
How to Manage Diuretic Resistance:<br />
What to Do When the Fluid Won’t Come<br />
Off<br />
12:15 What is Diuretic Resistance?<br />
Wilfried Mullens, Genk, Belgium<br />
12:25 Increase the Dose of the Loop Diutetic<br />
Michael Felker, Durham, NC<br />
12:35 Combination Diuretic Therapy<br />
David Ellison, Portland, OR<br />
12:45 Ultrafiltration<br />
Bradley Bart, Minneapolis, MN<br />
1:00 Panel Discussion<br />
Faculty<br />
1:15 Adjourn<br />
Learning Objective: Use appropriate options to reduce<br />
fluid overload in the management of patients with diuretic<br />
resistance.<br />
12:15 PM – 1:15 PM<br />
Maryland A<br />
How to Manage Sleep Apnea in Heart<br />
Failure<br />
12:15 Why is Sleep Apnea So Bad for the Heart Failure<br />
Patient?<br />
Stephan Gottlieb, Baltimore, MD<br />
12:25 Studies of Mask-Based Therapies in Heart Failure<br />
Susan Joseph, Houston, TX<br />
12:35 Novel Implantable Devices for Treating Sleep Apnea<br />
Maria Rosa Costanzo, Chicago, IL<br />
12:45 Patient Management<br />
William Abraham, Columbus, OH<br />
1:00 Panel Discussion<br />
Faculty<br />
1:15 Adjourn<br />
Learning Objective: Describe the significance of sleep<br />
apnea in heart failure and use effective management tools<br />
and options.<br />
12:15 PM – 1:15 PM<br />
Maryland 1-2<br />
How to Conduct Bedside Assessment in<br />
Heart Failure<br />
James Fang, Salt Lake City, UT<br />
Gregory Lewis, Boston, MA<br />
Jonahtan Howlett, Calgary, Alberta, Canada<br />
12:15 Adjourn<br />
Learning Objective: Describe key principles and strategies<br />
for bedside assessment in heart failure.<br />
54
MONDAY, SEPTEMBER 28<br />
1:20 PM – 3:00 PM<br />
Maryland B<br />
Announcement of Awards<br />
JNC New Investigator Award: Basic Science<br />
Presented by: Steven Houser, Philadelphia, PA<br />
Walter Koch, Philadelphia, PA<br />
JNC New Investigator Award: Clinical/Integrative<br />
Presented by: Jay Cohn, Minneapolis, MN<br />
Bertram Pitt, Ann Arbor, MI<br />
Nursing Research Award<br />
Presented by: Victoria Dickson, New York, NY<br />
Hyde Park Session<br />
Moderators: Douglas Shocken, Durahm, NC<br />
Stefan Anker, Berlin, Germany<br />
1:30 The Big Box Approach: How Wal-Mart, Sam’s<br />
Club and Target Fail Clinical Trials<br />
Peter Carson, Washington, DC<br />
1:48 A New Core Measure HF<br />
Hector Ventura, New Orleans, LA<br />
2:06 Medicare Changes List of Quality Core Measures<br />
for Heart Failure After Study Finds that Computers<br />
Failed to Educate Patient Upon Marking a Check<br />
Box in the EMR for Discharge Instructions and<br />
Ultrasound Waves Cure Heart Failure - A Mocking<br />
Finding for the Get With the Guidelines Initiative<br />
Arvind Bhimaraj, Houston, TX<br />
1:30 PM – 3:00 PM<br />
Maryland C<br />
Load, Unloading, Remodeling and Recovery<br />
Moderators: Keith Aaronson, Ann Arbor, MI<br />
Douglas Mann, St, Louis, MO<br />
1:30 Patterns, Mechanisms, and Clinical Implications<br />
of Ventricular Remodeling<br />
Marvin Konstam, Boston, MA<br />
1:50 Pharmacological Unloading of the Right and<br />
Left Ventricle: From Pathophysiology to Therapy<br />
Ryan Tedford, Baltimore, MD<br />
2:10 Mechanical Ventricular Unloading and Reverse<br />
Remodeling: From VAD Registries to Prospective<br />
Investigations<br />
Stavros Drakos, Salt Lake City, UT<br />
2:30 Types of Mechanical Unloading to Enhance<br />
Reverse Remodeling and Cardiac Recovery:<br />
From Animal Models to Clinical Applications<br />
Thomas Force, Nashville, TN<br />
2:50 Panel Discussion<br />
Faculty<br />
3:00 Adjourn<br />
Learning objective: Describe ventricular remodeling in<br />
heart failure and discuss the clinical implications of pharmacological<br />
and device unloading.<br />
2:24 Perverse Incentives: Rats Tails and the Transplant<br />
Waiting List<br />
Matthew Movsesian, Salt Lake City, UT<br />
2:42 Are Heart Failure Doctors Chimpanzees?<br />
Stephen Gottlieb, Baltimore, MD<br />
3:00 Adjourn<br />
Learning objective: Discuss new insights and perspectives<br />
on important issues in HF research and clinical practice.<br />
55
MONDAY, SEPTEMBER 28<br />
1:30 PM – 3:00 PM<br />
Maryland A<br />
What’s New and Emerging in Heart Failure<br />
Pharmacology?<br />
Moderators: Mona Fiuzat, Durham, NC<br />
Scott Solomon, Boston, MA<br />
1:30 New and Emerging Drugs for Acute Heart Failure<br />
Milton Packer, Dallas, TX<br />
1:50 New and Emerging Drugs for Heart Failure<br />
with Reduced Ejection Fraction<br />
John McMurray, Glasgow, UK<br />
2:10 New and Emerging Drugs for Heart Failure<br />
with Preserved Ejection Fraction<br />
Orly Vardeny, Madison, WI<br />
2:30 What’s New and Emerging in Cell Therapy?<br />
Joshua Hare, Miami, FL<br />
2:50 Panel Discussion: Implications for Practice<br />
Faculty<br />
3:00 Adjourn<br />
Learning Objective: Identify new and emerging drugs in<br />
heart failure and their implications for practice.<br />
1:30 PM – 3:30 PM<br />
Maryland 3-4<br />
Hands-On Workshop 4 (Repeat):<br />
Advanced Troubleshooting with Durable<br />
VADs<br />
(Limited enrollment, preregistration required)<br />
Chair: Joseph Rogers, Durham, NC<br />
Co-Chair: Selma Mohammed, Rochester, MN<br />
Robb Kociol, Boston, MA<br />
1:30 Start<br />
3:30 Adjourn<br />
Learning Objective: Describe common or difficult issues in<br />
the management of VAD patients and strategies for troubleshooting.<br />
Supported by educational grants from Heartware and<br />
Thoratec<br />
1:30 PM – 3:00 PM<br />
Maryland 5-6<br />
Hands-On Workshop 5 (Repeat):<br />
Cardiopulmonary Function Testing<br />
(Limited enrollment, preregistration required)<br />
Chair: Gregory Lewis, Boston, MA<br />
1:30 Start<br />
3:00 Adjourn<br />
Learning Objective: Describe and demonstrate the effective<br />
use of cardiopulmonary testing in heart failure.<br />
56
MONDAY, SEPTEMBER 28<br />
3:30 PM – 5:00 PM<br />
Potomac C<br />
Debates<br />
Moderators: Thomas Force, Nashville, TN<br />
Marvin Konstam, Boston, MA<br />
3:30 Pro: Routine Genetic Screening for All Individuals<br />
Diagnosed with Non-Ischemic Cardiomyopathy<br />
Ray Hershberger, Columbus, OH<br />
3:45 Con: Routine Genetic Screening for All Individuals<br />
Diagnosed with Non-Ischemic Cardiomyopathy<br />
John Cleland, Harefiled Middlesex, UK<br />
4:00 Discussion<br />
4:15 Case Based Debate Presentation<br />
Javed Butler, Stony Brook, NY<br />
72-year old white female with history of heart<br />
failure with systolic dysfunction with a known left<br />
ventricular ejection fraction of 25% assessed 6<br />
months ago, diabetes mellitus for 10 year, and<br />
chronic kidney disease. She presents to the emergency<br />
room with progressively worsening heart<br />
failure signs and symptoms for 5 days. She denies<br />
any changes in diet or medication non-compliance.<br />
No symptoms of infection. No chest pain, syncope,<br />
or palpitations. She is currently on lisinopril<br />
10mg qd, carvedilol 12.5 bid, digoxin 0.125 qd,<br />
furosemide 40 po bid, and insulin.<br />
On physical examination, her vital signs included,<br />
blood pressure 100/68, heart rate 92, respiratory<br />
rate 21, O2 saturation of 94%<br />
JVP 10 cm<br />
Chest: Bilateral basilar rales<br />
Cardiovascular: Regular rhythm, S1+S2, 2/6 HSM LSB<br />
Abdomen: Liver tip palpable on deep inspiration.<br />
No ascites, no tenderness, no distension<br />
Lower extremities: Bilateral 2+ pitting edema<br />
4:30 She was started on furosemide 80 mg IV bid and<br />
home medications were continued. On day 2, she<br />
is feeling better and has a net negative urine output<br />
of 1.8 liters. Her morning labs show a serum Cr of<br />
2.3 mg/dl.<br />
Should her lisinopril be held while actively being<br />
diuresed and restarted at discharge?<br />
Opinion 1: Lynne Warner Stevenson, Boston MA<br />
Opinion 2: Joshua Hare, Miami, FL<br />
4:40 On day 5th of admission, she is feeling better and<br />
ambulating and the decision is made to discharge<br />
the patients. The intern tells you that they ordered<br />
BNP level with morning labs and it came back at<br />
1423 pg/ml.<br />
Should you discharge the patients or keep her<br />
another few days to diurese more and lower BNP<br />
levels?<br />
Opinion 1: Alan Maisel, San Diego, CA<br />
Opinion 2: Kirkwood Adams, Chapel Hill, NC<br />
4:50 The patient is ready for discharge. She lost 7 lbs.<br />
and is feeling good. Her vital signs are stable and<br />
she is ambulating. Her labs on the morning of<br />
discharge include sodium 136 meq/L, potassium<br />
4.6 meq/L, and creatinine 1.8 mgdl (eGFR 36). In<br />
preparation for discharge, she was placed back on<br />
all her usual pre-admission medications.<br />
Should she be started on aldosterone antagonist at<br />
discharge?<br />
Opinion 1: Adrian Hernandez, Durham, NC<br />
Opinion 2: Gregg Fonarow, Los Angeles, CA<br />
5:00 Adjourn<br />
Learning Objective: Outline arguments for and against<br />
routine genetic screening in individuals with non-ischemic<br />
cardiomypathy and discuss treatment options for selected<br />
HF cases.<br />
Her initial testing showed: Sodium 134 meq/L,<br />
K4.5 meq/L, Cr. 1.9 mg/dl, BNP 1958 pg/ml<br />
ECG: NSR, non-specific ST-T changes<br />
Chest X Ray: Prominent venous congestion<br />
4:20 On admission, should she be put on a strict low<br />
salt and fluid restriction diet?<br />
Opinion 1: Paul Hauptman, St. Louis, MO<br />
Opinion 2: W. H. Wilson Tang, Cleveland, OH<br />
57
MONDAY, SEPTEMBER 28<br />
3:30 PM – 5:00 PM<br />
Maryland A<br />
Alternative Therapies for Heart Failure:<br />
Fact or Fiction?<br />
Moderators: Sheryl Chow, Los Angeles, CA<br />
Orly Vardeny, Madison, WI<br />
3:30 Neutraceuticals: Hawthorn, Co-enzyme Q10,<br />
Omega-3’s<br />
Barry Bleske, Ann Arbor, MI<br />
3:45 High Dose Vitamins, Vitamin D<br />
Rebecca Boxer, Denver, CO<br />
4:00 Diet<br />
Terry Lennie, Lexington, KY<br />
4:15 Alternative Agents to Avoid<br />
Jean Nappi, Charleston, SC<br />
4:30 Counseling Patients about Alternative Therapies<br />
Robert Page II, Denver, CO<br />
4:45 Panel Discussion<br />
Faculty<br />
5:00 Adjourn<br />
Learning Objective: Describe the evidence base for selected<br />
alternative therapies for heart failure and counsel patients<br />
with questions about alternative therapies.<br />
Abstracts/posters of interest: 159, 91, 106<br />
3:30 PM – 5:00 PM<br />
Maryland C<br />
Emergency Management of VAD Patients<br />
(Joint Session with ISHLT)<br />
Moderator: Mandeep Mehra, Boston, MA<br />
Sean Pinney, New York, NY<br />
3:30 VAD Patients with Heart Failure<br />
Joseph Rogers, Durham, NC<br />
3:50 Cardiac Arrest and Arrhythmias<br />
Henri Roukoz, Minneapolis, MN<br />
4:00 Trauma<br />
W. Frank Peacock, Houston, TX<br />
4:10 Device Failure and Malfunction<br />
Nir Uriel, Chicago, IL<br />
4:20 GI Bleeding<br />
Maria Mountis, Cleveland, OH<br />
4:30 Neurovascular Events<br />
Jeffrey Teuteberg, Pittsburgh, PA<br />
4:40 Panel Discussion<br />
Faculty<br />
5:00 Adjourn<br />
Learning Objective: Identify management strategies for<br />
VAD emergencies such as GI bleeding, cardiac arrest, and<br />
neurovascular events.<br />
58
MONDAY, SEPTEMBER 28<br />
3:30 PM – 5:00 PM<br />
Maryland D<br />
How to Interpret Biomarker Studies<br />
Moderators: Inder Anand, Minneapolis, MN<br />
Deedwania Prakash, San Francisco, CA<br />
3:30 Overview of Biomarkers in Heart Failure<br />
James Januzzi, Boston, MA<br />
3:43 Can We Use Biomarkers to Prevent Heart Failure?<br />
Christopher deFilippi, Baltimore, MD<br />
3:56 What Have We Learned from Natriuretic<br />
Guided Trials<br />
Hanna Gaggin, Boston, MA<br />
4:09 Biomarkers of Cardio-Renal Syndrome<br />
Jeffrey Testani, New Haven, CT<br />
4:22 Biomarkers and Heart Failure Devices<br />
Tariq Ahmad, Durham, NC<br />
4:35 Monitoring Cancer Therapeutics Using Biomarkers<br />
Bonnie Ky, Philadelphia, PA<br />
4:48 Biomarkers and Acute Heart Failure<br />
G. Michael Felker, Durham, NC<br />
5:00 Adjourn<br />
Learning Objective: Describe the current role of biomarkers<br />
in heart failure diagnosis and management.<br />
59
TUESDAY, SEPTEMBER 29<br />
7:00 AM – 8:15 AM<br />
Maryland A<br />
Managing the Patient with Newly Diagnosed<br />
Heart Failure<br />
Moderators: David Whellan, Philadelphia, PA<br />
Hector Ventura, New Orleans, LA<br />
7:00 Approaches and Challenges to Making the<br />
Diagnosis<br />
Marvin Konstam, Boston, MA<br />
7:15 Determining Etiology: Implications For Further<br />
Management<br />
Biykem Bozkurt, Houston, TX<br />
7:30 Initiating Therapy. Getting It Right from the Start<br />
Barry Greenberg, San Diego, CA<br />
7:45 Stratifying Risk and Preventing SCD<br />
Wayne Levy, Seattle, WA<br />
8:00 Bad News and Good News – Patient and Family<br />
Education For New Diagnosis<br />
Ann Laramee, Burlington, VT<br />
8:15 Adjourn<br />
Learning Objective: Effectively diagnose, determine etiology,<br />
initiate therapy and strategy risk in patients with newly<br />
diagnosed heart failure.<br />
7:00 AM – 8:15 AM<br />
Maryland C<br />
Clinical Fundamentals III: Acute Heart<br />
Failure 360<br />
Moderators: Gerasimos Filippatos, Athens, Greece<br />
Laura Wexler, Cincinnati, OH<br />
7:00 Current Concepts in the Pathophysiology of<br />
Acute Heart Failure<br />
Stefan Anker, Berlin, Germany<br />
7:15 Acute Heart Failure - Past Trials<br />
Christopher O’Connor, Falls Church, VA<br />
7:30 What’s Next in Acute Heart Faillure: Ongoing<br />
Trials<br />
John Teerlink, San Francisco, CA<br />
7:45 Regulations Impacting the Management of<br />
Acute Heart Failure<br />
Paul Heidenreich, San Francisco, CA<br />
8:00 How to Treat Acute Heart Failure- Tips from a<br />
Master Clinician<br />
Mariell Jessup, Philadelphia, PA<br />
8:15 Adjourn<br />
Learning Objective: Describe the pathophysiology of acute<br />
heart failure, key trial results, and clinical strategies for<br />
managing patients.<br />
Abstracts/posters of interest: 32, 304, 254, 135, 123<br />
60
TUESDAY, SEPTEMBER 29<br />
7:00 AM – 8:15 AM<br />
Potomac C<br />
The Periphery in Heart Failure: More<br />
Than an Innocent Bystander<br />
Moderators: Michelle Hamilton, Los Angeles, CA<br />
Stuart Katz ,New York, NY<br />
7:00 Arterial Stiffness, Wave Reflections and Heart<br />
Failure<br />
Julio A. Chirinos, Boston, MA<br />
7:15 Systemic Arterial Vasodilation in Heart Failure:<br />
HFrEF vs. HFpEF<br />
Rajan Krishnamani, Mason, OH<br />
7:30 Skeletal Muscle in Heart Failure<br />
Dalane Kitzman, Winston-Salem, NC<br />
7:45 The Role of the Microcirculation in Exercise<br />
Intolerance in Heart Failure<br />
Payman Zamani, Philadelphia, PA<br />
8:00 Panel Discussion<br />
Faculty<br />
8:15 Adjourn<br />
Learning Objective: Describe the role of the periphery in<br />
heart failure.<br />
8:30 AM – 9:45 AM<br />
Potomac C<br />
Interventional Structural Devices for<br />
Heart Failure<br />
Moderators: Flora Sam, Boston, MA<br />
Gregg Stone, New York, NY<br />
8:30 TAVR in Heart Failure Patients with Severe<br />
Aortic Stenosis<br />
Olcay Aksoy, Los Angeles, CA<br />
8:45 MitraClip for Functional Mitral Regurgitation<br />
in Heart Failure<br />
Gregg Stone, New York, NY<br />
9:00 Percutaneous Left Ventricular Partitioning in<br />
Ischemic Heart Failure<br />
Ernest Mazzaferri, Columbus, OH<br />
9:15 Inter-Atrial Shunts<br />
William Abraham, Columbus, OH<br />
9:30 Panel Discussion<br />
Faculty<br />
9:45 Adjourn<br />
Learning Objective: Identify new interventional structural<br />
devices, how they function, and their roles in heart failure<br />
management.<br />
61
TUESDAY, SEPTEMBER 29<br />
8:30 AM – 9:45 AM<br />
Maryland A<br />
Right Sided Heart Failure: What Do We Do<br />
When Orthopnea is Traded for Ascites?<br />
Moderators: Liviu Klien, San Francisco, CA<br />
Wayne Miller, Rochester, MN<br />
8:30 RV Dysfunction in Heart Failure: Assessment,<br />
Causes and Implications<br />
Mandeep Mehra, Boston MA<br />
8:45 Pulmonary Hypertension in Left Heart Disease<br />
Causing Right Heart Failure<br />
Howard J. Eisen, Philadelphia, PA<br />
9:00 Tricuspid Regurgitation: Mediator, Abettor or<br />
Barometer of Right Heart Failure?<br />
Barry Borlaug, Rochester, MN<br />
9:15 Treatment of Right Heart Failure<br />
Mitchell Saltzberg, Neward, DE<br />
9:30 Right Heart Failure and Cardiorenal Syndrome<br />
Jeffrey Testani, New Haven, CT<br />
8:30 AM – 9:45 AM<br />
Maryland C<br />
Heart Failure Clinics: The Evidence, the<br />
Need and the Redesign<br />
Moderators: J. Herbert Patterson, Chapel Hill, NC<br />
Marc Silver, Oak Lawn, IL<br />
8:30 Key Issues for the Heart Failure Clinic<br />
Akshay Desai, Boston, MA<br />
8:50 Essential Adjuncts for Chronic Heart Failure<br />
Management<br />
Ileana Pina, New York, NY<br />
9:10 Emerging Technology to Enhance Clinic Care<br />
Thomas Heywood, La Jolla, CA<br />
9:30 Panel Discussion<br />
Faculty<br />
9:45 Adjourn<br />
Learning Objective: Identify key issues for the heart failure<br />
clinic, essential components, and strategies for success.<br />
9:45 Adjourn<br />
Learning Objective: Describe the mechanisms and presentation<br />
of right heart failure, its relationship to cardiorenal<br />
syndrome, and current treatment options.<br />
Abstracts/posters of interest: 181, 18, 25, 15, 224<br />
62
TUESDAY, SEPTEMBER 29<br />
8:30 AM – 9:45 AM<br />
Maryland D<br />
Interventions for Vulnerable Patients<br />
Moderators: Debra Moser, Lexington, KY<br />
Lisa Rathman, Lancaster, PA<br />
8:30 Cultural Adaptation of an Educational Intervention<br />
Karen Vuckovi, Chicago, IL<br />
8:42 Addressing Education for Rural and Remote<br />
Heart Failure Populations<br />
Debra Moser, Lexington, KY<br />
8:54 Educational Interventions for Older Populations<br />
Lorraine Evangelista, Irvine, CA<br />
9:06 Addressing Cultural Issues in an Urban African<br />
American Population<br />
Cheryl R. Dennison Himmelfarb, Baltimore, MD<br />
9:18 Addressing Cultural Issues in Hispanic Populations<br />
Victoria Dickson, New York, NY<br />
9:30 Panel Discussion<br />
Faculty<br />
9:45 Adjourn<br />
Learning Objective:Identify vulnerable patients with heart<br />
failure and outline strategies for cultural and educational<br />
issues.<br />
Abstracts/posters of interest: 175, 176, 119<br />
10:15 AM – 11:45 AM<br />
Maryland C<br />
Update on Peripartum Cardiomyopathy<br />
and Pregnancy Associated Heart Failure<br />
Moderators: Amrut Ambardekar, Aurora, CO<br />
Paul McKie, Rochester, MN<br />
10:30 Final Outcome Status for 1st North American<br />
Prospective IPAC Study of PPCM/PAC: Risk<br />
Profile For Recovery/Non-Recovery<br />
Uri Elkayam, Los Angeles, CA<br />
10:45 Differential Diagnosis of Heart Failure in Pregnancy:<br />
Towards an Earlier Diagnosis/recognition<br />
David Markham, Atlanta, GA<br />
11:00 Role of Cardiac Magnetic Resonance (CMR) in<br />
PPCM/PAC<br />
Erik Schelbert, Pittsburgh, PA<br />
11:15 New Insights into the Mechanisms of Peripartum<br />
Cardiomyopathy<br />
Zoltan P. Arany, Cincinnati, OH<br />
11:30 Potential Newer Intervention Strategies in<br />
PPCM/PAC for Those at Highest Risk for<br />
Non-Recovery<br />
Michael M. Givertz, Boston, MA<br />
11:45 Adjourn<br />
Learning Objective: Describe the importance of early<br />
diagnosis and identify emerging intervention strategies in<br />
peripartum cardiomyopathy and pregnancy associated HF.<br />
63
TUESDAY, SEPTEMBER 29<br />
10:15 AM – 11:30 AM<br />
Maryland A<br />
Pharmacogenetics of Heart Failure and<br />
Transplant: Additive or Redundant?<br />
Moderators: Arthur Feldman, Philadelphia, PA<br />
Michael Bristow, Aurora, CO<br />
10:15 Pharmacogenetics: Overview and Clinical Status<br />
Mona Fiuzat, Durham, NC<br />
10:25 Pharmacogenetics of Beta Blockers: Still Relevant?<br />
Michael Bristow, Aurora, CO<br />
10:38 Optimizing Use of Hydralazine and Isosorbide<br />
Dinitrate: What is the Evidence?<br />
Dennis McNamara, Pittsburgh, PA<br />
10:50 Genetic Contribution of Immunosuppression-<br />
Related Toxicity: Better than Serum Drug<br />
Concentration Monitoring?<br />
David Lanfear, Detroit, MI<br />
11:02 Barriers to Implementation in Practice:<br />
Current State of the Art<br />
Christopher Newton-Cheh, Boston, MA<br />
11:15 Putting It All Together: Panel Discussion<br />
Faculty<br />
11:30 Adjourn<br />
Learning Objective: Describe the relationship between<br />
pharmacogenetics and heart failure and transplantation and<br />
identify potential next steps.<br />
10:15 AM – 11:30 AM<br />
Potomac C<br />
International Session:<br />
New Clinical Insights into HFpEF (Joint<br />
Session with HFA of ESC and Japanese<br />
HF Society)<br />
Moderators: Hiroaki Shimokawa, Sendai, Japan<br />
Robert Mentz, Durham, NC<br />
10:15 What Exactly Is HFpEF and How Do We<br />
Diagnose It?<br />
Kazuhiro Yamamoto, Tottori, Japan<br />
10:27 Managing Comorbidities in HFpEF: What to Do<br />
with Coronary Disease and Atrial Fibrillation<br />
Nancy Sweitzer, Tucson, AZ<br />
10:39 Treating HFpEF: What Have We Learned and<br />
What Is Coming Next?<br />
Margaret Redfield, Rochester, MN<br />
10:51 Phenomics: How Can We Resolve the Heterogeneity<br />
of HFpEF?<br />
Sanjiv Shah, Chicago, IL<br />
11:03 Wave of the Future? Novel Device Therapies in<br />
HFpEF<br />
Wilfried Mullens, Genk, Belgium<br />
11:15 Panel Discussion<br />
Faculty<br />
11:30 Adjourn<br />
Learning Objective: Define HFpEF and its diagnosis and<br />
identify current and emerging treatment options.<br />
Abstracts/posters of interest: 101, 162, 264, 129, 37<br />
64
POSTER RECEPTION I - SATURDAY (pages 65-82)<br />
POSTERS<br />
All posters will be on display Saturday at 6:00 PM - Monday at 1:30 PM<br />
Cardiovascular Physiology .....................................................................................................................................<br />
017<br />
Pulse Amplitude Ratio Measured Using Finger Photoplethysmography During a Valsalva Maneuver Estimates<br />
Pulmonary Capillary Wedge Pressure in Heart Failure Patients<br />
Nisha A. Gilotra, Ryan J. Tedford, Ilan S. Wittstein, Stuart D. Russell, Harry A. Silber. Johns Hopkins Hospital, Baltimore, MD<br />
018<br />
Right Ventricular Stroke Work Index is Inversely Related to Renal Function in Patients with Left Ventricular<br />
Diastolic Heart Failure<br />
Qaiser Shafiq, Bhavana Siddegowda Bangalore, Mohamed Elamin, George Moukarbel, Samer Khouri. University of Toledo<br />
Medical Center, Toledo, OH<br />
019<br />
Assessment of Soluble Fms Like Tyrosine Kinase - 1 in Animal Heart Failure Models<br />
Muhammad Hammadah 1 , Malory Weber 1 , W.H.Wilson Tang 2 . 1 Cleveland Clinic, Cleveland, OH; 2 Cleveland Clinic,<br />
Cleveland, OH<br />
020<br />
Longitudinal Red Cell Distribution Width Variation in African Americans with Acute Decompensated Heart Failure<br />
is Associated with Increased Readmissions<br />
Carlos D. Davila, Mahek Shah, Kuan-Hsiang Gary Huang, Vincent M. Figueredo. Albert Einstein Medical Center, Philadelphia,<br />
PA<br />
021<br />
Significant Enhancement of ATP-Synthesis in Cardiomyocytes By Electric Microcurrent<br />
Karin Macfelda 1 , Alexander Holly 1 , Johannes Mueller 2 . 1 Medical University of Vienna, Vienna, Austria; 2 Berlin Heals, Berlin,<br />
Germany<br />
022<br />
Features of Transthyretin Cardiomyopathy Patients With 6 Specific Cardiac Genotypes in the THAOS Registry.<br />
Jennifer Schumacher, Leslie Amass, Denis Keohane, Rajiv Mundayat, Moh-Lim Ong. Pfizer Inc., New York, NY<br />
Cardiovascular Structure/ Imaging ..................................................................................................................<br />
023<br />
POCUS as a Tool to Estimate PCWP<br />
James Regan, Sirtaz Adatya, Andrew Olson, Daniel Schnobrich. University of Minnesota, Minneapolis, MN<br />
024<br />
Dilated Cardiomyopathy Causes Significant Derangement in Biventricular Mechanics Not Fully Appreciated By Simply<br />
Measuring Left Ventricular Ejection Fraction Alone<br />
Francisco Lopez-Menendez 1 , Denada Palm 2 , Angel Lopez-Candales 3 . 1 University Of Cincinnati Medical Center, Cincinnati,<br />
OH; 2 University Of Cincinnati Medical Center, Cincinnati, OH; 3 University of Puerto Rico School of Medicine, San Juan,<br />
Puerto Rico<br />
025<br />
Effect of Preload on Right Ventricular Peak Systolic Strain Which Contributes to Right Heart Failure<br />
Chan Seok Park. Catholic University of Korea, Seoul, Korea, Republic of<br />
026<br />
Cardiac Status of Patients Treated With Anthracyclines - A Brazilian Osteosarcoma Study<br />
Maria V. C. Santos, J. A. Soares, G. H. Pinto, C. R. Macedo, C. Dias, A. S. Petrilli, I. Gonçalves, O. Campos, V. A. Moisés,<br />
A. C. C. Carvalho. Universidade Federal de São Paulo, São Paulo, Brazil<br />
65
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
027<br />
Estimation of Pulmonary Capillary Wedge Pressure by Echocardiography: A Simplified Approach<br />
Rajeev Mohan 1 , Hirsch Mehta 1 , 2 , Arvin Narula 1 , Michael Smith 1 , David Rubenson 1 , Allen Johnson 1 , J. Thomas Heywood 1 .<br />
1<br />
Scripps Clinic, La Jolla, CA; 2 San Diego Cardiac Center, San Diego, CA<br />
028<br />
Mitral Annular Motion: A Useful Echocardiographic Measure of Left Ventricular Systolic and Diastolic Function<br />
Francisco Lopez-Menendez 1 , Denada Palm 2 , Angel Lopez-Candales 3 . 1 University of Cincinnati Medical Center, Cincinnati,<br />
OH; 2 University of Cincinnati Medical Center, Cincinnati, OH; 3 University of Puerto Rico School of Medicine, San Juan,<br />
Puerto Rico<br />
029<br />
Echocardiographic Measurements Predictive of Left Ventricular Ejection Fraction Recovery<br />
Patrick Hohl 1 , Richard Pinckney 2 , Martin LeWinter 1 . 1 University of Vermont Medical Center, Burlington, VT; 2 University of<br />
Vermont Medical Center, Burlington, VT<br />
030<br />
Impact of Pre-transplant Cirrhotic Cardiomyopathy on Long-Term Mortality in the Liver Recipients<br />
Thoetchai Peeraphatdit 1 , Niyada Naksuk 2 , Chayakrit Krittanawong 2 , Charat Thongprayoon 3 , Paola Ricci 4 , Roongruedee<br />
Chaiteerakij 5 , Lewis R. Roberts 2 , Kyle Klarich 6 . 1 University of Minnesota, Minneapolis, MN; 2 Mayo Clinic, Rochester, MN;<br />
3<br />
Mayo Clinic, Rochester, MN; 4 Minneapolis Veterans Affairs Health Care System, Minneapolis, MN; 5 Mayo Clinic, Rochester,<br />
MN; 6 Mayo Clinic, Rochester, MN<br />
031<br />
Relationship of Right Ventricular Function and Respiratory Status in a Large Cohort of Duchenne<br />
Muscular Dystrophy<br />
Muddassir Mehmood 1 , Michael D. Taylor 2 , John L. Jefferies 2 , Subha V. Raman 3 , Stephanie Ambach 4 , Wojciech Mazur 5 .<br />
1<br />
Allegheny General Hospital, Pittsburgh, PA; 2 Cincinnati Children’s Hospital, Cincinnati, OH; 3 Ohio State University, Columbus,<br />
OH; 4 University of Cincinnati, Cincinnati, OH; 5 The Christ Hospital, Cincinnati, OH<br />
Biomarkers/Neurohormones/Cytokines ........................................................................................................<br />
032<br />
Minute Ventilation-Targeted Adaptive Servo Ventilation Improves Subendocardial Injury in Acute Decompensated<br />
Heart Failure Patients as Assessed Through Decreases in High-Sensitivity Cardiac Troponin I<br />
Elizabeth Lee 1 , Matt Kawahara 1 , Trenton Gluck 1 , Boris Arbit 1 , 2 , Kathleen Sarmiento 1 , 2 , Atul Malhotra 1 , 2 , Alan Maisel 1 , 2 .<br />
1<br />
Veterans Affairs San Diego Healthcare System, San Diego, CA; 2 University of California, San Diego, La Jolla, CA<br />
033<br />
Relationship Between Serum Neuregulin Level and Subsequent Cardiac Function Among Patients with Systolic<br />
Heart Failure<br />
Ugochukwu O. Egolum, Sandip Zalawadiya, Daniel Lenihan. Vanderbilt University, Nashville, TN<br />
034<br />
The Clinical Implications of Cardiac Troponin I Measured by an “Ultrasensitive” Assay in Acute Decompensated<br />
Heart Failure: Insights from ASCEND-HF<br />
Justin L. Grodin 1 , Adrian F. Hernandez 2 , Javed Butler 3 , Marco Metra 4 , G. Michael Felker 5 , Adrian Voors 6 , John J. McMurray 7 ,<br />
Paul W. Armstrong 8 , Randall C. Starling 1 , Christopher O'Connor 5 , W. H. Wilson Tang 1 . 1 Cleveland Clinic, Cleveland, OH;<br />
2<br />
Duke University Medical Center, Durham, NC; 3 Stony Brook University, Stony Brook, NY; 4 University of Brescia, Brescia,<br />
Italy; 5 Duke University Medical Center, Durham, NC; 6 University of Groningen, Groningen, Netherlands; 7 University of<br />
Glasgow, Glasgow, United Kingdom; 8 University of Alberta, Edmonton, AB, Canada<br />
66
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
035<br />
Association Between Serum Ghrelin levels and Congestive Heart Failure: A Meta Analysis<br />
Pradyumna Agasthi 1 , Sivakanth Aloor 2 , Nchang Taka 1 , Vijaya Sena Reddy Dendi 3 , Avantika Chenna 1 , Anekwe Onwuanyi 4 .<br />
1<br />
Morehouse School of Medicine, Atlanta, GA; 2 University of Miami, Miami, FL; 3 Wright Center for Gaduate Medical Education,<br />
Scranton, PA; 4 Morehouse School of Medicine, Atlanta, GA<br />
036<br />
Adrenomedullin Helps Risk Stratify Patients With Pre-Clinical Diastolic Dysfunction<br />
Jeremy Egnatios 1 , Nick Marston 2 , Boris Arbit 3 , Elizabeth Lee 4 , Hermineh Aramin 4 , Joachim Struck 5 , Alan S. Maisel 3 . 1 University<br />
of California San Diego, San Diego, CA; 2 University of California San Diego and VA-San Diego Health System, San<br />
Diego, CA; 3 University of California San Diego and VA-San Diego Health System, San Diego, CA; 4 VA- San Diego Health<br />
System, San Diego, CA; 5 Sphingotec Gmbh, Berlin, Germany<br />
037<br />
Renal Biomarkers Predict Adverse Outcomes in Heart Failure with Preserved Ejection Fraction<br />
Aaron Singh 1 , Sheldon S. G. Lee 1 , Puay Joo Tan 2 , Huang Pei 2 , Cao Yan 3 , Carmen J. W. Kam 4 , Siang Chew Chai 1 , Tek Siong<br />
Chee 1 , Khim Leng Tong 1 , Gerard K. T. Leong 1 . 1 Changi General Hospital, Singapore, Singapore; 2 Changi General Hospital,<br />
Singapore, Singapore; 3 Changi General Hospital, Singapore, Singapore; 4 Changi General Hospital, Singapore, Singapore<br />
038<br />
Prognostic Implications of Serum Chloride Levels in Patients with Stable Heart Failure<br />
Justin L. Grodin, Frederik H. Verbrugge, Stanely L. Hazen, W. H. WIlson Tang. Cleveland Clinic, Cleveland, OH<br />
039<br />
Predictive Value of 1, 25-dihydroxyvitamin D to PTH(1-84) Ratios for Cardiovascular Death in Heart Failure<br />
Damien Gruson, Sylvie Ahn, Michel Rousseau. Cliniques Universitaires Saint Luc, Brussels, Belgium<br />
040<br />
The Presence of IgG3 Autoantibody Against β1 Adrenergic Receptors is Associated with Favorable Myocardial Recovery<br />
in Patients with Recent Onset Cardiomyopathy - a Post-hoc Analysis of IMAC-2 Study<br />
Yuji Nagatomo 1 , Dennis M. McNamara 2 , Jeffrey D. Alexis 3 , Leslie T. Cooper 4 , G. William Dec 5 , Daniel F. Pauly 6 , Richard<br />
Sheppard 7 , Randall C. Starling 1 , W. H. Wilson Tang 1 . 1 Cleveland Clinic, Cleveland, OH; 2 University of Pittsburgh Medical<br />
Center, Pittsburgh, PA; 3 University of Rochester Medical Center School of Medicine and Dentistry, Rochester, NY; 4 Mayo<br />
Clinic Jacksonville, Jacksonville, FL; 5 Massachusetts General Hospital, Boston, MA; 6 Truman Medical Centers, Kansas<br />
City, MO; 7 Jewish General Hospital, Montreal, QC, Canada<br />
041<br />
Telomere Length as a Biomarker and Potential Contributor of Heart Failure Progression<br />
Elizabeth Silver 1 , Aleksandra Ras 1 , Christine Cosgrove 1 , Patricia Sheiner 1 , Jason Gluck 1 , Detlef Wencker 2 , Cara Statz 1 . 1 Hartford<br />
Hospital, Hartford, CT; 2 University of Kansas Medical Center, Kansas CIty, KS<br />
042<br />
Minute Ventilation-Targeted Adaptive Servo Ventilation Reduces Kidney Injury In Patients With Acute Decompensated<br />
Heart Failure<br />
Matt Kawahara 1 , Boris Arbit 1 , 2 , Elizabeth Lee 1 , Trenton Gluck 1 , Kathleen Sarmiento 1 , 2 , Atul Malhotra 1 , 2 , Alan Maisel 1 , 2 .<br />
1<br />
Veterans Affairs San Diego Healthcare System, San Diego, CA; 2 University of California, San Diego, La Jolla, CA<br />
043<br />
Urinary Angiotensinogen is Increased in Human Heart Failure<br />
Seethalakshmi Iyer, Denise Heublein, Sherry Benike, John C. Burnett Jr.. Mayo Clinic, Rochester, MN<br />
044<br />
Serum Concentrations of Heme Oxigenase-1 are Reduced in Patients with Acute Heart Failure and Preserved Ejection<br />
Fraction<br />
Paulino Alvarez 1 , Andrea M. Cordero-Reyes 1 , Keith A. Youker 1 , Javier Amione-Guerra 1 , Cesar Uribe 1 , Arvind Bhimaraj 1 , Barry<br />
Trachtenberg 2 , Guha Ashrith 2 , Vijay Nambi 3 , Guillermo Torre-Amione 2 , Jerry D. Estep 4 . 1 The Methodist Hospital, Houston,<br />
TX; 2 The Methodist Hospital, Houston, TX; 3 Baylor College of Medicine, Houston, TX; 4 The Methodist Hospital, Houston, TX<br />
67
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
Molecular Biology/Genetics/Cell Therapy ......................................................................................................<br />
045<br />
Presence of Endothelial to Mesenchymal Transition in End Stage Human Myocardial Samples-documentation in<br />
Human Heart Failure for the First Time<br />
Cesar Uribe, Andrea M. Cordero-Reyes, Keith A. Youker, Barry H. Trachtenberg, Guha Ashrith, Jerry D. Estep, Guillermo<br />
Torre-Amione, Erik E. Suarez, John P. Cooke, Arvind Bhimaraj. The Methodist Hospital, Houston, TX<br />
046<br />
Hypoxia Inducible Factor (HIF) Adaptation After Mechanical Circulatory Unloading of the Heart. A Gene Expression<br />
Analysis Study of Paired Myocardial Samples.<br />
Paulino Alvarez, Cesar Uribe, Andrea M. Cordero-Reyes, Keith A. Youker, Guillermo Torre-Amione, Jerry D. Estep. The<br />
Methodist Hospital, Houston, TX<br />
047<br />
Evidence of the Presence of Autoantibodies Specific for β 1 Adrenergic Receptor in Failing Human Heart Tissue<br />
Yuji Nagatomo, Christine S. Moravec, W. H. Wilson Tang. Cleveland Clinic, Cleveland, OH<br />
048<br />
Carriers of Variants of Unknown Significance Have Intermediate Hypertrophic Cardiomyopathy Phenotypes<br />
Patrick J. Warner, Ashley A. Cronkright, Noreen Dolan, Martin Maron, Gordon S. Huggins. Tufts Medical Center, Boston,<br />
MA<br />
049<br />
Neuregulin/ERBB Signaling in Human Ventricular Myocardial Progenitor Cells<br />
Sergey Ryzhov 1 , Oleg Tikhomirov 1 , Rutwik Rath 1 , Douglas B. Sawyer 2 , 1 . 1 Maine Medical Center Research Institute, Scarborough,<br />
ME; 2 Maine Medical Center, Portland, ME<br />
Surgery/Transplantation/Devices ........................................................................................................................<br />
050<br />
Impact of Patient Comorbidities on Post-Implant Outcomes Among Patients Receiving Ventricular Assist Devices in<br />
a Commercially Insured Population<br />
Jiang Tao, Wade Bannister, Charlotte Wu, Frank D. Irwin. Optum, Eden Prairie, MN<br />
051<br />
Predictors of Outcome Using Phase II Cardiac Rehabilitation Data in Patients With Durable, Implanted Left Ventricular<br />
Assist Devices<br />
Kathleen Morris, Jonathan Shirazi, Milena Jani, I-Wen Wang, Kathleen A. Lane, Stanley Taylor, Changyu Shen, Adnan Malik.<br />
IU School of Medicine, Indianapolis, IN<br />
052<br />
Heart rate and respiration during activity measured by an implanted device correlate well with those measured by a<br />
CPX machine<br />
Alan J. Bank 1 , John Chronakos 2 , Kenneth C. Beck 3 , Paji Vitoff 3 , Colleen Delaney 3 , Julie Thompson 3 , Yi Zhang 3 . 1 United<br />
Heart & Vascular Clinic, St Paul, MN; 2 Danbury Hospital, Danbury, CT; 3 Boston Scientific, St Paul, MN<br />
053<br />
The Safety of Right Heart Catheterization in Patients with Continuous-Flow Left Ventricular Assist Devices<br />
Kershaw Patel 1 , Daniel Rodgers 1 , Cory Henderson 1 , Emeka Anyanwu 1 , Savitri Fedson 1 , Gene Kim 1 , Nitasha Sarswat 1 , Colleen<br />
Juricek 2 , Takeyoshi Ota 2 , Valluvan Jeevanandam 2 , Gabriel Sayer 1 , Nir Uriel 1 . 1 University of Chicago, Chicago, IL;<br />
2<br />
University of Chicago, Chicago, IL<br />
68
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
054<br />
Assessment of Pre-LVAD Laboratory Parameters to Predict Post LVAD Early Right Ventricular Failure<br />
Burhan Mohamedali 1 , Gardner Yost 2 , Geetha Bhat 2 . 1 Rush University Medical Center, Chicago, IL; 2 Advocate Christ Medical<br />
Center, Oak Lawn, IL<br />
055<br />
Induction Therapy Prior to Heart Transplantation Leads to Freedom from Antibody-mediated Rejection Without<br />
Increasing Infection<br />
Yevgeniy Brailovsky, Estefania Oliveros, Val Rakita, Vladimir Lakhter, Huaqing Zhao, Daniel Schwartz, Akira Shiose,<br />
Yoshiya Toyoda, Rene Alvarez, Alfred Bove, Eman Hamad. Temple University Hospital, Philadelphia, PA<br />
056<br />
Baseline Pulmonary Function and Outcomes in Patients Receiving Left Ventricular Assist Devices<br />
Suraj Raheja, Cristina Tita, Celeste Williams, Jeffrey A. Morgan, Hassan Nemeh, Yelena Selektor, Chetan Bhardwaj, Robert<br />
Brewer, Jamil Borgi, Mauricio Velez, David E. Lanfear. Henry Ford Hospital, Detroit, MI<br />
057<br />
Relationship of Baseline Right Ventricle Function with Response to Cardiac Resynchronization Therapy<br />
Abhishek Sharma 1 , Ajay Vallakati 2 , Sunny Goel 3 , Carl J. Lavie 4 , John Kassotis 1 , Debabrata Mukherjee 5 , Jason M. Lazar 1 .<br />
1<br />
State University of New York, Downstate Medical Center, Brooklyn, NY; 2 Metrohealth Medical Center, Case Western Reserve<br />
University, Cleveland, OH; 3 Maimonides Medical Center, Brooklyn, NY; 4 John Ochsner Heart and Vascular Institute,<br />
Ochsner Clinical School-the University of Queensland School of Medicine, New Orleans, LA; 5 Texas Tech University, El<br />
Paso, TX<br />
058<br />
Prophylactic Intra-Aortic Balloon Pumping before Implantation of Ventricular Assist Device Improves Perioperative<br />
Clinical Course and Medical Expenses in Patients with INTERMACS Profile II<br />
Teruhiko Imamura 1 , Koichiro Kinugawa 1 , Daisuke Nitta 2 , Masaru Hatano 2 , Osamu Kinoshita 3 , Kan Nawata 3 , Minoru Ono 3 .<br />
1<br />
Graduate School of Medicine, University of Tokyo, Tokyo, Japan; 2 Graduate School of Medicine, University of Tokyo,<br />
Tokyo, Japan; 3 Graduate School of Medicine, University of Tokyo, Tokyo, Japan<br />
059<br />
Clinical Characteristics of Patients with Suspected Left Ventricular Assist Device Thrombosis who Respond to Intensified<br />
Anticoagulation<br />
Demetrios G. Doukas 1 , Neelam Balasubramanian 1 , Stephanie A. Kliethermes 1 , Joseph I. Bailey 1 , Brett Dubner 1 , Edith Boyes<br />
1 , Jefferey P. Schwartz 2 , Alain L. Heroux 1 , Erin Coglianese 3 . 1 Loyola University Medical Center, Maywood, IL; 2 Loyola<br />
University Medical Center, Maywood, IL; 3 Loyola University Medical Center, Maywood, IL<br />
060<br />
Socioeconomic Status May be a Marker of Risk for Clinical Outcomes with Continuous Flow Ventricular Assist Devices<br />
Mustafa Ahmed 1 , Christopher Le 2 , Alexander Bolanos 3 , Juan A. Aranda, Jr 1 , Charles T. Klodell Jr 4 . 1 University of Florida,<br />
Gainesville, FL; 2 University of Florida, Gainesville, FL; 3 University of Florida, Gainesville, FL; 4 University of Florida,<br />
Gainesville, FL<br />
061<br />
Trends in LVADs and Orthotropic Heart Transplantations in the Older and Higher Comorbid Demographicsfor<br />
2003-2011<br />
Zubair Shah 1 , Arun Mahankali Sridhar 1 , Sameer Chaudhari 2 , Buddhadeb Dawn 1 , Gurusher Panjrath 3 . 1 University of Kansas<br />
Medical Center, Kansas city, KS; 2 Beth Israel Medical Center, Newark, Newark, NJ; 3 George Washington University School<br />
of Medicine and Health Sciences, Washington DC, DC<br />
062<br />
Caregiving Affects the Quality of Life of Patients and their Caregivers after Mechanical Circulatory Support<br />
Susan Magasi 1 , Sarah K. Buono 2 , Clyde W. Yancy 3 , Kathleen L. Grady 4 . 1 University of Illinois at Chicago, Chicago, IL;<br />
2<br />
Northwestern University, Chicago, IL; 3 Northwestern University, Chicago, IL; 4 Northwestern University, Chicago, IL<br />
69
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
063<br />
Changes in Pulmonary Function After Left Ventricular Assist Device Implantation<br />
Suraj Raheja, Mauricio Velez, Chetan Bhardwaj, Jeffrey A. Morgan, Robert Brewer, Hassan Nemeh, Yelena Selektor, Celeste<br />
Williams, Jamil Borgi, Cristina Tita, David E. Lanfear. Henry Ford Hospital, Detroit, MI<br />
064<br />
Heart Failure Related Hospitalization and Mortality after Aortic Valve Replacement<br />
Vincent Chan 1 , Fraser Rubens 1 , Maria Koullick 2 , Dan Gutfinger 2 , Manya Harsch 3 , Marc Ruel 1 . 1 University of Ottawa, Ottawa,<br />
ON, Canada; 2 St. Jude Medical, Plymouth, MN; 3 Technomics Research, Minneapolis, MN<br />
065<br />
Invasive Hemodynamics in Severely Obese Patients Following Continuous-Flow Left Ventricular Assist Device<br />
Implantation<br />
Kershaw V. Patel 1 , Cory Henderson 1 , Emeka Anyanwu 1 , Savitri E. Fedson 1 , Gene H. Kim 1 , Nitasha Sarswat 1 , Colleen<br />
Juricek 2 , Takeyoshi Ota 2 , Valluvan Jeevanandam 2 , Gabriel Sayer 1 , Nir Uriel 1 . 1 University of Chicago, Chicago, IL; 2 University<br />
of Chicago, Chicago, IL<br />
066<br />
Safety and Long Term Outcomes of Using Beta Blockers After Heart Transplantation<br />
Amaninderapal S. Ghotra, Christopher Angus, John Price, Kelly McCants, Mark S. Slaughter, Allen Cheng, Andrew<br />
Lenneman, Emma J. Birks. University of Louisville, Louisville, KY<br />
067<br />
Reversibility of Restrictive Pulmonary Function Post Cardiac Transplantation<br />
Carolyn M. Rosner, Gurusher Panjrath, Ramesh Singh, Shashank S. Desai, Anthony J. Rongione. Inova Health System, Falls<br />
Church, VA<br />
068<br />
The Relation Between Liver Dysfunction and Gastrointestinal Bleeding in Patients with Ventricular Assist Devices<br />
David Lowe 1 , Georg Wieselthaler 1 , Liviu Klein 2 . 1 UCSF, San Francisco, CA; 2 UCSF, San Francisco, CA<br />
069<br />
Hemodynamic Effects of Intra-Aortic Balloon Counterpulsation in Patients with Advanced Heart Failure<br />
Lyanne Buiten, Vikram Paruchuri, Duc Thinh Pham, Michael Kiernan, David DeNofrio, Carey Kimmelstiel, Navin K. Kapur.<br />
Tufts Medical Center, Boston, MA<br />
070<br />
Elevated Right Atrial Pressure Predicts Post Heart Transplant Outcomes<br />
Carolyn M. Rosner, Anthony J. Rongione, Gurusher Panjrath, Palak Shah, Shashank S. Desai, Ramesh Singh. Inova Health<br />
System, Falls Church, VA<br />
071<br />
VNS Does Not Reduce Heart Failure Progression in a Canine High Rate Pacing Model of HF<br />
Avram Scheiner. Medtronic, Mounds Veiw, MN<br />
072<br />
Early Elevated Pump Power and Associated Hemolysis Amongst HeartMate II Left Ventricular Assist Devices<br />
Anjan Tibrewala, Michael Nassif, David Raymer, Justin Vader, Shane LaRue, Scott Silvestry, Greg Ewald. Washington<br />
University, St. Louis, MO<br />
073<br />
Discharge Glomerular Filtration Rate (GFR) as a Predictor of Outcomes Post Left Ventricular Assist Device Placement<br />
Burhan Mohamedali 1 , Gardner Yost 2 , Geetha Bhat 2 . 1 Rush University Medical Center, Chicago, IL; 2 Advocate Christ Medical<br />
Center, Oak Lawn, IL<br />
70
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
074<br />
Longevity Performance of St. Jude Medical ICDs at a Single Center<br />
Raffaele Corbisiero 1 , Pherson Charlene 1 , Ellen Cleary 1 , Marlene Belsito 1 , David Muller 2 . 1 Deborah Heart & Lung Center,<br />
Browns Mills, NJ; 2 St Jude Medical, Sylmar, CA<br />
075<br />
Use of Basiliximab is Associated with Similar Outcomes Post Orthotopic Heart Transplantation: A Single Center<br />
Experience<br />
Esther Vorovich, Maria Molina, Tamara Claridge, Mary Williams, Susan Chambers, Christine Gearhart, Patricia Stutman,<br />
Donna Chojnowski, Wilhelmina Maslanek, Payman Zamani, Edo Y. Birati, Anjali T. Owens, Lee R. Goldberg. University of<br />
Pennsylvania, Philadelphia, PA<br />
076<br />
Effect of Donor Blood Transfusions on Post Heart Transplant Outcomes<br />
Carolyn M. Rosner, Ramesh Singh, Gurusher Panjrath, Palak Shah, Shashank S. Desai, Anthony J. Rongione. Inova Health<br />
System, Falls Church, VA<br />
077<br />
HeartMate II to HVAD Device Exchange: What Can We Learn?<br />
Kershaw V. Patel 1 , Emeka Anyanwu 1 , Colleen Juricek 2 , Viktoriya Kagan 2 , Holly Ruedlinger 2 , Whayoun Lee 2 , Takeyoshi<br />
Ota 2 , Gabriel Sayer 1 , Nir Uriel 1 , Valluvan Jeevanandam 2 . 1 University of Chicago, Chicago, IL; 2 University of Chicago, Chicago,<br />
IL<br />
078<br />
Rapid Reversal of Pulmonary Hypertension in Failing Mustard Physiology After Continuous Flow Systemic Ventricular<br />
Assist Device<br />
Joel Simon 1 , Mark Turrentine 2 , I-wen Wang 3 , Marco Caccamo 1 , W. Aaron Kay 1 . 1 Indiana University, Indianapolis, IN; 2 Indiana<br />
University, Riley Hospital for Children, Indianapolis, IN; 3 Indiana University, Indianapolis, IN<br />
079<br />
Anticoagulation Intensity and Thrombotic or Bleeding Outcomes in Outpatients with Continuous Flow Left Ventricular<br />
Assist Devices<br />
Michael E. Nassif, David S. Raymer, Anjan Tibrewala, Gregory A. Ewald, Shane J. LaRue, Justin M. Vader, Brain F. Gage.<br />
Washington University, St. Louis, MO<br />
Electrophysiology/Arrhythmias .............................................................................................................................<br />
80<br />
Diagnostic Yield of a 14 Day Ambulatory ECG Recorder in Patients With Suspected Syncope<br />
Andrew Keibel 1 , Steven Carlson 2 , Leslie Saxon 2 , Philip Chang 2 , Rahul Doshi 2 , Jerold Shinbane 2 , Mary Huntsinger 2 . 1 Keck<br />
Hospital of USC, Los Angeles, CA; 2 Keck Hospital of USC, Los Angeles, CA<br />
81<br />
Impact of Non-apical Right Ventricular Lead Placement on Left Ventricular Reverse Remodeling and Inter-ventricular<br />
Dys-synchrony in Cardiac Resynchronization Therapy: a Meta-analysis<br />
Alok Saurav, Aiman Smer, Muhammad S. Azzouz, Hussam Abuissa, Claire Hunter. Creighton University Medical Center,<br />
Omaha, NE<br />
82<br />
Changes in Left Atrial Appendage Velocities Are Useful Indices to Predict New Onset Atrial Fibrillation Following<br />
Transcatheter Aortic Valve Replacement<br />
Tomo Ando 1 , David Slvout 2 , Cynthia Taub 2 . 1 Mount Sinai Beth Israel, New York, NY; 2 Montefiore Medical Center, Bronx,<br />
NY<br />
71
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
83<br />
Subclinical Paroxysmal Atrial Fibrillation in Outpatients with Heart Failure Detected by a Novel Non-invasive Wireless<br />
Remote Monitoring Platform<br />
Lyle Olson, Virend Somers, Nancy Lexvold, Paul Friedman, Louis Schenck, Bradley Lewis, Charles Bruce. Mayo Clinic,<br />
Rochester, MN<br />
84<br />
Arrhythmic Outcomes in Patients following Explanation of Left Ventricular Assist Devices after Myocardial Recovery<br />
Amaninderapal S. Ghotra, Emma J. Birks, Zeeshan Hussain, Andrew Lenneman, Mark S. Slaughter, Rashmi U. Hottigoudar,<br />
Rakesh Gopinathannair. University of Louisville, Louisville, KY<br />
Clinical Trials .......................................................................................................................................................................<br />
085<br />
Effects of Heart Rate Reduction in Black Patients from the SHIFT (Systolic Heart failure treatment with the If<br />
inhibitor ivabradine Trial) Study<br />
Jeffrey S. Borer 1 , Michel Komajda 2 , Ian Ford 3 , Luigi Tavazzi 4 , Fabienne Dominjon 5 , Juan Maya 6 , Yuna Wu 6 , Christophe Depre<br />
6 , Michael Böhm 7 . 1 State University of New York Downstate Medical Center, New York, NY; 2 University Pierre et Marie<br />
Curie Paris VI, Paris, France; 3 University of Glasgow, Glasgow, United Kingdom; 4 GVM Care & Research, Cotignola, Italy;<br />
5<br />
Institut de Recherches Internationales Servier, Suresnes, France; 6 Amgen Inc., Thousand Oaks, CA; 7 Universitätskliniken<br />
des Saarlandes, Homburg/Saar, Germany<br />
086<br />
Comparison of the Baseline Demographics of the LCZ696 PARADIGM-HF and TITRATION Studies<br />
Fabian Chen 1 , Alan Charney 1 , Jim Gong 1 , Victor Shi 1 , Michele Senni 2 . 1 Novartis, East Hanover, NJ; 2 Azienda Ospedaliera<br />
Papa Giovanni XXIII, Med.Generale 2 Cardiovascolare, Bergamo, Italy<br />
087<br />
Percutaneous Ventricular Restoration (PVR) therapy using the Parachute® Device in Subjects with Ischemic Dilated<br />
Heart Failure: Two Year Meta-Analysis<br />
William T. Abraham. The Ohio State University, Columbus, OH<br />
088<br />
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 is Effective Across the Spectrum of Ejection Fraction in<br />
Heart Failure With Reduced Ejection Fraction<br />
Scott Solomon 1 , Milton Packer 2 , Michael Zile 3 , Karl Swedberg 4 , Jean Rouleau 5 , Martin Lefkowitz 6 , Victor Shi 6 , Akshay<br />
Desai 1 , Brian Claggett 1 , Randall Starling 7 , John J. V. McMurray 8 . 1 Brigham and Women's Hospital, Boston, MA; 2 UT Southwestern,<br />
Dallas, TX; 3 MUSC, Charleston, SC; 4 University of Groninger, groninger, Sweden; 5 University Montreal, Montreal,<br />
QC, Canada; 6 Novartis, E Hanover, NJ; 7 Cleveland Clinic, Cleveland, OH; 8 University of Glasgow, Glasgow, United Kingdom<br />
089<br />
Ivabradine Improves Symptoms and Quality of Life in Chronic Systolic Heart Failure Patients With Different Baseline<br />
Symptom Severity<br />
Christian Zugck 1 , Peter Martinka 2 , Georg Stöckl 2 . 1 Internistische Gemeinschaftspraxis im Steiner Thor, Straubing, Germany;<br />
2<br />
Servier Deutschland GmbH, München, Germany<br />
090<br />
Effect of Comorbidities and Risk Factors on Outcomes and Ivabradine’s Effects in Patients With Chronic Systolic<br />
Heart Failure in the SHIFT Trial<br />
Michael Böhm 1 , Jeffrey S. Borer 2 , Ian Ford 3 , Michel Komajda 4 , Michele Robertson 3 , Luigi Tavazzi 5 , Karl Swedberg 6 . 1 Universitätskliniken<br />
des Saarlandes, Homburg/Saar, Germany; 2 State University of New York Downstate Medical Center, New<br />
York, NY; 3 University of Glasgow, Glasgow, United Kingdom; 4 University Pierre et Marie Curie Paris VI, Paris, France;<br />
5<br />
Maria Cecilia Hospital, Cotignola, Italy; 6 University of Gothenburg, Göteborg, Sweden<br />
72
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
091<br />
Trials are Needed to Evaluate Nutrition Interventions for HF: Analysis of the Federal Nutrition and HF Research<br />
Portfolio<br />
Patrice Desvigne-Nickens 1 , Karen Regan 2 , Rebecca Costello 3 , Abby Ershow 4 . 1 National Heart, Lung, and Blood Institute,<br />
Bethesda, MD; 2 National Institutes of Health, Bethesda, MD; 3 National Insitutes of Health, Bethesda, MD; 4 National Institutes<br />
of Health, Bethesda, MD<br />
092<br />
Remote Wireless Telemonitoring Combined with Health Coaching (Tele-HC) to Lower Readmission Rates for Patients<br />
with Acute Decompensated Heart Failure<br />
Lyle Olson, Shaival Kapadia, Nancy Lexvold, Virend Somers, Paul Friedman, Louis Schenck, Bradley Lewis, Rickey Carter,<br />
Charles Bruce. Mayo Clinic, Rochester, MN<br />
093<br />
Probenecid Improves Cardiac Function in Patients With Heart Failure. Interim Analysis of the Re-Prosper Hf Trial<br />
Mark Gilbert, Nathan Robbins, Ginger Conway, Mohamed Effat, Jack Rubinstein. University of Cincinnati, Cincinnati, OH<br />
094<br />
Post Hoc Analysis of a Multicenter, Randomized, Controlled Study in Patients with Chronic Heart Failure: Factors<br />
Associated with Clinical Composite Response Improved by Adaptive-Servo Ventilation Therapy<br />
Shin-ichi Momomura 1 , Yoshihiko Seino 2 , Yasuki Kihara 3 , Hitoshi Adachi 4 , Yoshio Yasumura 5 , Hiroyuki Yokoyama 6 . 1 Saitama<br />
Medical Center, Jichi Medical University, Saitama, Japan; 2 Nippon Medical School Chiba Hokusoh Hospital, Chiba,<br />
Japan; 3 Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan; 4 Gunma Prefectural<br />
Cardiovascular Center, Gunma, Japan; 5 Osaka National Hospital, Osaka, Japan; 6 National Cerebral and Cardiovascular Center,<br />
Osaka, Japan<br />
095<br />
Cracking the NNT Code: Effect of Ivabradine on Recurrent Hospitalizations<br />
Jennifer K. Rogers 1 , Adrian Kielhorn 2 , Jeffrey S. Borer 3 , Ian Ford 4 , Stuart J. Pocock 1 . 1 London School of Hygiene and<br />
Tropical Medicine, London, United Kingdom; 2 Amgen Inc., Thousand Oaks, CA; 3 State University of New York Downstate<br />
Medical Center, New York, NY; 4 University of Glasgow, Glasgow, United Kingdom<br />
Cardiovascular Pharmacology ...............................................................................................................................<br />
096<br />
The Anti-aldosterone Effects of Torsemide Do Not Lead to Detectable Improvement in Potassium Losses in Patients<br />
Treated for Decompensated Heart Failure<br />
Chukwuma Onyebeke, Jennifer Simon, Susan J. Cheng, Jeffrey M. Testani. Yale University School of Medicine, New Haven, CT<br />
097<br />
Bucindolol Prevents Atrial Flutter via the Beta-1 389 Arg/Gly Adrenergic Receptor Polymorphism<br />
Ryan Aleong 1 , Amrut Ambardekar 1 , Gordan Davis 2 , Michael R. Bristow 1 . 1 University of Colorado, Aurora, CO; 2 ARCA<br />
Biopharma, Westminster, CO<br />
098<br />
The use of Intravenous Iron Therapy in Iron Deficient Patients with Heart Failure with Reduced Ejection Fraction:<br />
Decrease Hospitalizations and Improve in Symptoms and Quality of Life - A Meta-Analysis of Randomized Clinical<br />
Trials<br />
Abel Casso Dominguez 1 , Georges E. El-Hayek 1 , Elizabeth Contreras 2 , Arpit Shah 1 , Saurav Chatterjee 1 , Marrick Kukin 1 .<br />
1<br />
Mount Sinai St. Luke's-Roosevelt Hospital, New York, NY; 2 Instituto Tecnologico de Santo Domingo, Santo Domingo,<br />
Dominican Republic<br />
099<br />
Beta Blocker Survival Benefit in Heart Failure is Associated with ADRB1 Ser49Gly Genotype<br />
David E. Lanfear, Edward L. Peterson, Nicole Zeld, Karen Wells, Hani N. Sabbah, Keoki Williams. Henry Ford Health<br />
System, Detroit, MI<br />
73
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
100<br />
Evaluation of a Sirolimus / Tacrolimus-Minimization Strategy in Heart Transplant Recipients: Can We Avoid Further<br />
Nephrotoxicity?<br />
William L. Baker 1 , Ashley M. Gale 1 , Jason A. Gluck 2 , Joseph A. Radojevic 2 , Lynn F. O'Bara 2 , Andrea D. Murphy 2 , James<br />
Dougherty 3 , Spencer T. Martin 4 . 1 University of Connecticut School of Pharmacy, Storrs, CT; 2 Hartford Hospital, Hartford,<br />
CT; 3 Hartford Hospital, Hartford, CT; 4 Hartford Hospital, Hartford, CT<br />
101<br />
Role of β-Blockers in Patients with Heart Failure with Preserved Ejection Fraction: A Meta-Analysis<br />
Daniel Marks, Ajay Vallakati, Siddharth Reddy, Mark Dunlap. Metrohealth Medical Center, Cleveland, OH<br />
102<br />
Differential Prognostic Effect of Lipophilic Versus Hydrophilic Statins in Heart Failure Patients: A Meta-Analysis of<br />
Randomized Controlled Trials<br />
Hidekatsu Fukuta, Nobuyuki Ohte. Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan<br />
103<br />
Ability to Achieve Target Doses of an Evidence-based Heart Failure Treatment Regimen in an Advanced Heart Failure<br />
Clinic at a Tertiary Care Facility<br />
A. Modany 1 , C. Walter 1 , M. Clarke 2 , J. Klootwyk 3 , K. Stollar 4 , George G. Sokos 2 . 1 Allegheny General Hospital, Pittsburgh,<br />
PA; 2 Allegheny General Hospital, Pittsburgh, PA; 3 Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA; 4 Mylan<br />
School of Pharmacy, Duquesne University, Pittsburgh, PA<br />
Epidemiology/ Prevention .........................................................................................................................................<br />
104<br />
Prognostic Impacts and Temporal Changes of Post-Traumatic Stress Disorder after the Great East Japan Earthquake<br />
in Patients with Heart Failure -A Report from the CHART-2 Study-<br />
Takeo Onose, Yasuhiko Sakata, Masanobu Miura, Soichiro Tadaki, Ryoichi Ushigome, Takeshi Yamauchi, Kenjiro Sato,<br />
Kanako Tsuji, Ruri Abe, Kotaro Nochioka, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa. Tohoku University Graduate<br />
School of Medicine, Sendai, Japan<br />
105<br />
Clinical Profiles and Prognostic Factors in the Elderly Patients with Heart Failure in Japan<br />
-A Report from the CHART-2 Study-<br />
Kenjiro Sato, Yasuhiko Sakata, Satoshi Miyata, Masanobu Miura, Soichiro Tadaki, Ryoichi Ushigome, Takeshi Yamauhi,<br />
Takeo Onose, Kanako Tsuji, Ruri Abe, Kotaro Nochioka, Jun Takahashi, Hiroaki Shimokawa. Department of Cardiovascular<br />
Medicine, Tohoku University Graduate School of Medicine, SENDAI, Japan<br />
106<br />
Effect of Weight Loss on Renal Function in Overweight and Obese Patients with Heart Failure<br />
Marjan Motie, Lorraine Evangelista. University of California Irvine, Irvine, CA<br />
107<br />
Follow up of Patients Unable to Receive Indicated Device Therapy Under the Care of an Advanced Heart Failure<br />
Program in a Developing Country.<br />
Feras Bader 1 , 2 , Guirgis Gabrah 2 , Medhat Soliman 2 , Khalid Zakariea 2 , Smitha Varghese 2 , Sonia Kuruvilla 2 , Ameena Alsayed 2 ,<br />
Fawzia Alkandari 2 , Mustafa Ridha 2 . 1 University of Utah, Salt Lake City, UT; 2 Dabbous Cardiac Center- Adan Hospital, Kuwait<br />
City, Kuwait<br />
74
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
108<br />
The Association of Hemoglobin A1c with Short-term Outcomes in Patients who Have Heart Failure with Preserved<br />
Ejection Fraction and Diabetes: Results from Korean Acute Heart Failure Registry<br />
Hyo-In Choi, Min-Seok Kim, Jae-Joong Kim. Asan Medical Center, Seoul, Korea, Republic of<br />
109<br />
Death Analysis of a Cohort of Blood, Lymphatic Cancer and Breast Cancer Patients Who Have Developed Heart<br />
Failure Following Cancer Treatment.<br />
Robyn A. Clark 1 , Alexandra McCarthy 2 , Munir H. Chowdhury 1 , Narelle Berry 1 , Shahid Ullah 3 , Bogda Koczwara 4 , John Atherton<br />
5 , David Roder 6 . 1 Flinders University, Adelaide, Australia; 2 Queensland University of Technology, Brisbane, Australia;<br />
3<br />
Flinders University, Adelaide, Australia; 4 Flinders University, Adelaide, Australia; 5 University of Queensland, Brisbane,<br />
Australia; 6 University of South Australia, Adelaide, Australia<br />
110<br />
Pericardial Involvement in a Cohort of HIV Infected African Americans in Post HAART Therapy Era_a Changing<br />
Trend<br />
Puvanalingam Ayyadurai, Sridhar Chilimuri. Bronx Lebanon Hospital Center, New York, NY<br />
Quality of Care/Outcomes .........................................................................................................................................<br />
111<br />
Association of HbA1c With Hospitalization Among Patients With Heart Failure and Diabetes<br />
Saul Blecker, Hannah Park, Stuart Katz. NYU School of Medicine, New York, NY<br />
112<br />
Risk Factors for Smoking Re-Abuse Following Heart Transplantation<br />
Jonathan Dunn, Rady Ho, Paul Mather. Thomas Jefferson University Hospital, Philadelphia, PA<br />
113<br />
Achy Breaky Heart - Quality of Life Changes with Progressing Congestive Heart Failure<br />
Tristan Cordier 1 , Lane Slabaugh 2 , Gilbert Haugh 2 , Diana Cusano 2 , Vipin Gopal 2 , George Andrews 2 , Andrew Renda 2 . 1 Humana,<br />
Inc., Atlanta, GA; 2 Humana, Inc., Louisville, KY<br />
114<br />
Centers for Medicare and Medicaid Services’ Heart Failure Report is Not Representative of a Hospital’s Heart Failure<br />
Population<br />
Zachary L. Cox 1 , 2 , Pikki Lai 1 , Connie M. Lewis 1 , Sahar Torabi 2 , Daniel J. Lenihan 1 . 1 Vanderbilt University Medical Center,<br />
Nashville, TN; 2 Lipscomb University College of Pharmacy, Nashville, TN<br />
115<br />
Can the Braden Scale or the Morse Fall Scale Predict Mortality in Hospitalized Patients With Heart Failure?<br />
Victoria V. Dickson 1 , Matthew Carazo 2 , Tina Sadarangani 1 , Sundar Natarajan 2 , Caroline Blaum 2 , Stuart D. Katz 2 . 1 NYU, New<br />
York, NY; 2 NYU, New York, NY<br />
116<br />
Evolution of the Advanced Heart Failure Nurse Coordinator Role<br />
Julie Webster, Blaine Ney, David A. Dean. Piedmont Heart, Atlanta, GA<br />
75
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
117<br />
Heart Failure Readmissions Reduction Intervention Positively Affects Readmissions for HFrEF But not HFpEF<br />
Milena Jani 1 , Joanna Kingery 2 , Irmina Gradus-Pizlo 1 , Azam Hadi 1 , Marco Caccamo 1 , Jose Finet 1 , Adnan Malik 1 . 1 Indiana<br />
University School of Medicine, Indianapolis, IN; 2 IU Health, Indianapolis, IN<br />
118<br />
Health Care Goals, Communication, and Knowledge Among Older ICD Recipients<br />
Yaw Adjei-Poku 1 , Michelle Samuel 1 , Diane Engorn 2 , Daniel Habtemariam 2 , Matthew R. Reynolds 3 , Susan L. Mitchell 2 ,<br />
Daniel B. Kramer 1 . 1 Beth Israel Deaconess Medical Center, Boston, MA; 2 Hebrew SeniorLife Institute for Aging Research,<br />
Boston, MA; 3 Harvard Clinical Research Institute, Boston, MA<br />
119<br />
High Prevalence of Heart Failure (HF) Knowledge Deficits in Hospitalized Chronic Heart Failure Patients-a Single<br />
Center Retrospective Analysis of Quality Data Showing a Need for Better CMS Core Measures<br />
Michael Pudlo, Sarah Homer, Carl Daniel, Susan Bionat, Andrea Creamer, Sayali Ketkar, Arvind Bhimaraj. Houston Methodist<br />
Hospital, Houston, TX<br />
120<br />
Heightened Platelet Re-activity Assessed by Increase in Mean Platelet Volume is Associated With Poor Outcomes in<br />
Stable Heart Failure Patients<br />
Muhammad Hammadah 1 , Danielle M. Brennan 2 , Stanley L. Hazen 2 , W.H.Wilson Tang 2 . 1 Cleveland Clinic, Cleveland, OH;<br />
2<br />
Cleveland Clinic, Cleveland, OH<br />
121<br />
Nursing Home Readmissions Reduced Using a Novel Heart Failure Protocol<br />
Noah Moss 1 , Rekha Bhandari 2 , Jeffrey Bander 1 . 1 Mount Sinai Medical Center, New York, NY; 2 The Allure Group, Brooklyn,<br />
NY<br />
122<br />
Causes and Avoidability of Hospital Readmissions post-Left Ventricular Assist Device Implantation: A One-Year<br />
Analysis<br />
Kavita Sharma, Albert J. Hicks, Natasha Gill, Damon Duquaine, Gerin R. Stevens, Ryan J. Tedford, Daniel P. Judge, Ilan S.<br />
Wittstein, Glenn M. Whitman, Ashish S. Shah, Stuart D. Russell. Johns Hopkins Hospital, Baltimore, MD<br />
123<br />
Predictors of Post-Discharge Mortality in Acute Hospitalized Heart Failure<br />
Larisa G. Tereshchenko 1 , Marcus Vollmer 2 , Silviu Dovancescu 3 , Xiaozhen Chen 4 , Niels Otani 5 , Jiri Sklenar 1 . 1 Oregon Health<br />
and Science University, Portland, OR; 2 University of Greifswald, Greifswald, Germany; 3 Philips Research, Aachen, Germany;<br />
4 Mortara Instrument, Milwaukee, WI; 5 Rochester Institute of Technology, Rochester, NY<br />
124<br />
Using a Risk Model to Predict 30-Day Readmission After Implantable Cardioverter Defibrillator<br />
Sandra Oliver-McNeil 1 , Thomas N. Templin 2 , David E. Haines 1 . 1 Beaumont Health, Royal Oak,MI, Royal Oak, MI; 2 Wayne<br />
State University, Detroit, MI<br />
125<br />
Caregivers’ Perceptions of Illness Severity in Advanced Heart Failure<br />
Judith E. Hupcey, Lisa A. Kitko. The Pennsylvania State University, University Park, PA<br />
126<br />
Remote Specialty Therapeutic Management Enhances Patient-Centered Heart Failure Care in a Rural Community<br />
Setting<br />
Harleen Singh 1 , Jessina C. McGregor 1 , Cindy L. Quale 2 , Kelsie W. Flynn 1 , Samaneh Zhian 1 , Matt Atkinson 1 , Kayla E. Ruhl 1 ,<br />
Kate H. Unterberger 1 , Greg C. Larsen 2 . 1 OSU/OHSU College of Pharmacy, Portland, OR; 2 Portland Veterans Affairs Health<br />
Care System, Portland, OR<br />
76
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
127<br />
A Markov Model-based Monte Carlo Simulation to Assess Variation in Financial Burden and Health Outcomes for<br />
Cardiac Implantable Electronic Devices Based on Device and Patient Characteristics<br />
Juergen A. Klenk 1 , Arnold J. Greenspon 2 , Edmund C. Lau 3 , Jasmine Patel 4 , Jordana K. Schmier 1 , Pamela M. McMahon 5 . 1 Exponent,<br />
Inc., Alexandria, VA; 2 Thomas Jefferson University, Philadelphia, PA; 3 Exponent, Inc., Menlo Park, CA; 4 Exponent,<br />
Inc., Philadelphia, PA; 5 Exponent, Inc., Natick, MA<br />
128<br />
Increased risk of Cerebrovascular Death in Patients with Chemotherapy-Induced Cardiomyopathy<br />
Emile Mehanna, Sadeer G. Al-Kindi, Mobolaji Ige, Sachin Kumar, Mohammad Kattea, Chantal ElAmm, Salil Deo, Rodolfo<br />
D. Benatti, Mahazarin Ginwalla, Soon J. Park, Guilherme H. Oliveira. Advanced Heart Failure & Transplant Center, Harrington<br />
Heart & Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University School of<br />
Medicine, Cleveland, OH<br />
129<br />
Sex Differences in the Management and Outcomes of Heart Failure with Preserved Ejection Fraction in Patients<br />
Presenting to the Emergency Department with Acute Heart Failure<br />
Reka Zsilinszka 1 , Peter Shrader 2 , Adam D. DeVore 3 , Natalie C. Hardy 2 , Robert J. Mentz 3 , Peter S. Pang 4 , W. Frank Peacock 5 ,<br />
Gregg C. Fonarow 6 , Adrian F. Hernandez 3 . 1 Duke University School of Medicine, Durham, NC; 2 Duke Clinical Research<br />
Institute, Durham, NC; 3 Duke Clinical Research Institute, Duke University Medical Center, Durham, NC; 4 Indiana University<br />
School of Medicine, Indianapolis, IN; 5 Baylor College of Medicine, Durham, TX; 6 Ahmanson-University of California,<br />
Ronald Reagan-UCLA Medical Center, Los Angeles (UCLA) Cardiomyopathy Center, Los Angeles, CA<br />
130<br />
Temporal Trends of Digoxin Use in Patients Hospitalized with Heart Failure: Analysis From the American Heart<br />
Association Get With The Guidelines - Heart Failure Registry<br />
Nish Patel 1 , Conrad Macon 1 , Christine Ju 2 , Phillip Schulte 2 , Adrian F. Hernandez 2 , Deepak L. Bhatt 3 , Javed Butler 4 , Clyde W.<br />
Yancy 5 , Gregg C. Fonarow 6 . 1 University of Miami Miller School of Medicine, Miami, FL; 2 Duke Clinical Research Institute,<br />
Durham, NC; 3 Brigham and Woman's Hospital Heart & Vascular Center, Boston, MA; 4 Stony Brook School of Medicine,<br />
Stony Brook, NY; 5 Northwestern University, Chicago, IL; 6 Ronald Reagan-UCLA Medical Center, Los Angeles, CA<br />
131<br />
Pediatric Versus Adult Heart Failure Related Emergency Department Visits in the United States<br />
Joseph W. Rossano 1 , Erika J. Mejia 1 , Kimberly Y. Lin 1 , Eduardo Rame 2 , Matthew J. O'Connor 1 , J. Willaim Gaynor 1 , Stephen<br />
J. Paridon 1 , Robert E. Shaddy 1 . 1 Children's Hospital of Philadelphia, Philadelphia, PA; 2 University of Pennsylvania, Philadelphia,<br />
PA<br />
132<br />
Assessment of Pre-LVAD Hemodynamics to Predict Post LVAD Early RV Failure<br />
Burhan Mohamedali 1 , Gardner Yost 2 , Geetha Bhat 2 . 1 Rush University Medical Center, Chicago, IL; 2 Advocate Christ Medical<br />
Center, Oak Lawn, IL<br />
133<br />
Patient Experience With Light Chain Amyloidosis: A Survey From the Amyloidosis Research Consortium<br />
Isabelle Lousada 1 , Ray Comenzo 2 , Heather Landau 3 , Spencer Guthrie 4 , Giampaolo Merlini 5 . 1 Amyoidosis Research Consortium,<br />
Inc., Boston, MA; 2 Tufts Medical Center, Boston, MA; 3 Memorial Sloan-Kettering Cancer Center, New York, NY;<br />
4<br />
Prothena Biosciences, South San Francisco, CA; 5 Fondazione IRCCS Policlinico San Matteo and University of Pavia,<br />
Pavia, Italy<br />
134<br />
Need to Elicit Patient Preferences for Information About Limited Prognosis in Heart Failure<br />
Arden O'Donnell, Kristen Schaefer, Michelle Young, Kayley Walsh, Adam Porter, Lynne Stevenson, Akshay Desai. Brigham<br />
and Women's Hospital, Boston, MA<br />
77
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
135<br />
Prediction of Post-Discharge Outcomes for Patients Hospitalized with Heart Failure: Results from PROTECT<br />
Mitchell A. Psotka 1 , John R. Teerlink 1 , Karen Chiswell 2 , John G. Cleland 3 , Gad Cotter 4 , Beth A. Davison 4 , Michael M.<br />
Givertz 5 , Marco Metra 6 , Piotr Ponikowski 7 , Adriaan A. Voors 8 , Daniel M. Bloomfield 9 , Christopher M. O'Connor 2 . 1 University<br />
of California San Francisco & San Francisco VA Medical Center, San Francisco, CA; 2 Duke Clinical Research<br />
Institute, Duke University Medical Center, Durham, NC; 3 National Heart & Lung Institute, Royal Brompton & Harefield<br />
Hospitals, Imperial College, London, United Kingdom; 4 Momentum Research, Durham, NC; 5 Brigham and Women's Hospital,<br />
Boson, MA; 6 University of Brescia, Brescia, Italy; 7 Medical University, Clinical Military Hospital, Wroclaw, Poland;<br />
8<br />
University Medical Center Groningen, Groningen, Netherlands; 9 Merck Research Laboratories, Rahway, NJ<br />
136<br />
Combining Psychosocial Dysfunction and Renal Dysfunction in Predicting Outcomes in Patients With Heart Failure:<br />
Is There a Link?<br />
Ashvarya Mangla 1 , Burhan Mohamedali 2 , Rami Doukky 3 , 4 , Elizabeth Avery 5 , DeJuran Richardson 6 , 7 , Lynda H. Powell 6 .<br />
1<br />
Rush University Medical Center, Chicago, IL; 2 Rush University Medical Center, Chicago, IL; 3 Rush University Medical<br />
Center., Chicago, IL; 4 John H. Stroger,Jr. Hospital of Cook County, Chicago, IL; 5 Rush University Medical Center, Chicago,<br />
IL; 6 Rush University Medical Center, Chicago, IL; 7 Lakeforest College, Lakeforest, IL<br />
137<br />
Heart Failure Readmissions Reduction: Implementation and Results Based on Provider Group<br />
Milena Jani 1 , Joanna Kingery 2 , Irmina Gradus-Pizlo 1 , Azam Hadi 1 , Marco Caccamo 1 , Jose E. Finet 1 , Adnan Malik 1 . 1 Indiana<br />
University School of Medicine, Indianapolis, IN; 2 IU Health, Indianapolis, IN<br />
138<br />
Correlation Between Conduction Times and Electrode Distance in CRT Patients<br />
Pedram Kazemian 1 , Raffaele Corbisiero 1 , Ashish Shah 1 , David Muller 2 . 1 Deborah Heart & Lung, Browns Mills, NJ; 2 St<br />
Jude Medical, Sylmar, CA<br />
139<br />
Improving Medication Safety, in High Risk Patients After Discharge<br />
Elaine I. Kim. Baylor Elder House Calls and Transitional Care, Dallas, TX<br />
140<br />
Heart Failure Hospitalizations and 30 Day Readmissions for Quadripolar and Bipolar CRT-D Systems: Results From<br />
a US Single Center Study<br />
Raffaele Corbisiero 1 , Pedram Kazemian 1 , Rupinder Bharmi 2 , Riddhi Shah 2 , David Muller 2 . 1 Deborah Heart & Lung Center,<br />
Browns Mills, NJ; 2 St Jude Medical, Sylmar, CA<br />
141<br />
Nurse Practitioner Run Heart Failure Bridge Clinic Reduces Readmission Rates<br />
Kimberly Cuomo, Stuart Russell, Johana Almansa, Abby Cummings, Hetal Rupani, Arati Kotadia. Johns Hopkins, Baltimore,<br />
MD<br />
142<br />
Timing of Diuretic Administration and Length of Stay in Patients with Acute Decompensated Heart Failure<br />
Lisa M. Fleming 1 , Kenneth Mukamal 2 , Jeffrey Testani 3 , Edward Ullman 4 , Gail Piatkowsky 2 , Steven Horng 4 , Robb Kociol 2 .<br />
1<br />
Tufts Medical Center, Boston, MA; 2 Beth Israel Deaconess Medical Center, Boston, MA; 3 Yale University Medical Center,<br />
New Haven, CT; 4 Beth Israel Deaconess Medical Center, Boston, MA<br />
143<br />
Cardiac Resynchronization Therapy and Kidney Function: The One Year Cardio-Renal Connection<br />
Raffaele Corbisiero 1 , David Muller 2 , Rebecca Armbruster 1 , Kalyan Obalampalli 1 . 1 Deborah Heart & Lung Center, Browns<br />
Mills, NJ; 2 St Jude Medical, Sylmar, CA<br />
78
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
144<br />
Nurse-practitioner-run, Sub-acute Rehabilitation Program for Heart Failure Reduces Hospital Readmission Rates<br />
by Half<br />
Tracy L. Lanoza. Rutgers University, Newark, NJ<br />
145<br />
Psychosocial Risk Assessment in Patients Receiving Ventricular Assist Devices Does not Correlate with Outcomes<br />
Lauren Freid, Estefania Oliveros, D. Schwartz, Yoshiya Toyoda, Akira Shiose, Alfred Bove, Rene Alvarez, Eman Hamad.<br />
Temple University Hospital, Philadelphia, PA<br />
146<br />
Prevalence of Advanced Heart Failure Utilizing the Latest Published Definitions Yields Higher Than Previously Published<br />
Data<br />
Andrea Creamer, Sarah Homer, Michael Pudlo, Carl Daniel, Susan Bionat, Arvind Bhimaraj. Houston Methodist Hospital,<br />
Houston, TX<br />
147<br />
Is Depression Causing the Heart Failure Patient's Readmission?<br />
Katherine Lalor. Lee Memorial Health System, Fort Myers, FL<br />
Clinical Care .........................................................................................................................................................................<br />
148<br />
Constrictive Pericarditis in a Post Cardiac Transplant Patient<br />
Ugochukwu O. Egolum. Vanderbilt University, Nashville, TN<br />
149<br />
Etiology, Characteristics and Clinical Outcomes in High Output Heart Failure: A 15 Year Experience<br />
Yogesh N. V. Reddy, Vojtech Melenovsky, Barry A. Borlaug. Mayo Clinic, Rochester, MN<br />
150<br />
Heart Failure Nurses: Triumph With Titration<br />
Carolyn Devens, Tiffany Berg, Kathleen Miner, Laurie Bicknese. Mayo Clinic Rochester, Rochester, MN<br />
151<br />
Inferior Vena Cava Dilatation Predicts Mortality and Worsening Renal Function in Patients With Chronic Heart<br />
Failure<br />
Abdul Hafidz Muhammad Iqbal, Bayan Soujeri, Hawkey Sean, Daniel Levin, Muhammad Zaid Iskandar, Graham Stewart,<br />
Joanne Sloan, Chim Lang. University of Dundee, Dundee, United Kingdom<br />
152<br />
CMS Readmission Risk Score Predicts Poor Outcomes at Hospitalization<br />
Evelyn Dean 1 , Omima Ali 2 , Kevin F. Kennedy 1 , Anthony Magalski 3 , Bethany A. Austin 3 . 1 Saint Luke's Mid America Heart<br />
Institute, Kansas City, MO; 2 University of Missouri-Kansas City, Kansas City, MO; 3 Saint Luke's Mid America Heart Institute,<br />
Kansas City, MO<br />
153<br />
Heart to Heart: An Innovative Hospice Program for Heart Failure Patients<br />
Abigail Newton 1 , Martha Hager 2 , Ronetta Marhoover 1 , Patricia Pletke 2 , Stephen Rennyson 1 . 1 Centra Health, Lynchburg, VA;<br />
2<br />
Centra Health, Lynchburg, VA<br />
154<br />
Experience of a Newly Established Multidisciplinary Heart Failure Clinic at a VA Hospital<br />
Christina W. Rivers, Angela C. Ross, Nina Giustino, Lonnie Edwards, Siobhan Martin. Edward Hines,Jr. VA Hospital, Hines,<br />
IL<br />
79
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
155<br />
Inpatient Diuretic Dose as a Predictor of Mortality and Re-Admission in Heart Failure<br />
Katherine Picel, Peter Eckman. University of Minnesota, Minneapolis, MN<br />
157<br />
Increased Risk of LVAD Thrombosis in Patients With a Previous History Thromboembolic Event<br />
Scott Lundgren. Univeristy of Nebraska Medical Center, Omaha, NE<br />
158<br />
Non-Invasive Bioelectrical Impedance for Predicting Clinical Outcomes in Outpatients with Heart Failure<br />
Kristin J. Lyons, Michelle K. Bischoff, Gregg C. Fonarow, Tamara B. Horwich. University of California Los Angeles, Los<br />
Angeles, CA<br />
159<br />
Role of Iron Chelation Therapy in Cardiac Hemosiderosis: A Case Series<br />
Abdullah AlMasoud, Ahmad Younes, Sadeer AlKindi, Chantal Elamm, Guilherme Oliveira, Robert Schilz, Jane Little, Mahazarin<br />
Ginwalla. University Hospitals Case Medical Center, Cleveland, OH<br />
160<br />
Delayed Presentation of Amiodarone Induced Thyrotoxicosis Following Heart Transplant<br />
LaVone Smith, Jamie Kennedy, Anthony McCall, Jennifer Kirby, Sula Mazimba. University of Virginia, Charlottesville, VA<br />
161<br />
Incremental Diagnostic and Clinical Utility of Endomyocardial Biopsy Over Cardiac Magnetic Resonance Imaging<br />
Alone in Patients with Unexplained Heart Failure<br />
Nisha A. Gilotra 1 , Mosi K. Bennett 2 , Van-Khue Ton 1 , Nicole Minkove 1 , Adam Shpigel 1 , Nishant Shah 1 , Kristina Montemayor<br />
1 , Allison Hays 1 , Marc K. Halushka 1 , Stuart D. Russell 1 . 1 Johns Hopkins Hospital, Baltimore, MD; 2 Minneapolis Heart<br />
Institute, Minneapolis, MN<br />
162<br />
Heart Failure Preserved Ejection Fraction Patients Benefit From Heart Failure Reduced Ejection Fraction Guidelines<br />
Gregg Steahr, Linda Kelly, Meredith Moore, Brenda Hott. Northside Hospital, Cumming, GA<br />
163<br />
Reevaluating Cardiopulmonary Exercise Testing Modality in Resynchronized Heart Failure Patients: Relevance of<br />
Heart Rate-Adaptive Pacing.<br />
Livia Goldraich, Heather J. Ross, Farid Foroutan, Juarez Braga, Mike Walker, Sean Balmain, Michael A. McDonald. University<br />
of Toronto, Toronto, ON, Canada<br />
164<br />
A New Training Pathway for Advanced Heart Failure/Cardiac Transplant Fellows: Sleep-Disordered Breathing Management<br />
Adam Pleister 1 , Rami Khayat 1 , Robin Germany 2 , William Abraham 3 . 1 The Ohio State University Wexner Medical Center,<br />
Columbus, OH; 2 Respicardia, Inc, Minnetonka, MN; 3 The Ohio State University Wexner Medical Center, Columbus, OH<br />
165<br />
Agreement between Pulmonary Capillary Wedge Pressure and Left Ventricular End Diastolic Pressure in Heart<br />
Transplant Subject; A Single Center Experience<br />
Abbas Bitar 1 , Farah Ammous 2 , Andrew Lenneman 1 , Greg Bell 1 , Allen Cheng 3 , Mark Slaughter 4 , Emma Birks 1 . 1 University of<br />
Louisville, Louisville, KY; 2 University of Louisville, Louisville, KY; 3 University of Louisville, Louisville, KY; 4 University<br />
of Louisville, Louisville, KY<br />
80
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
166<br />
Sleep Quality, Fatigue, and Quality of Life in New York Heart Failure Associate Class II and III Heart Failure Individuals<br />
Jihane Hajj 1 , Hansie Mathelier 1 , Longjian Liu 2 , Brian Drachman 1 , Carol Patton 2 , Michael Dreher 3 . 1 Penn Presbyterian Medical<br />
Center, Philadelphia, PA; 2 Drexel University, Philadelphia, PA; 3 College of New Rochelle, westchester, NY<br />
167<br />
Health Status Trajectories Among Outpatients with Heart Failure<br />
Kelsey Flint 1 , Larry Allen 1 , 2 , Sarah Schmiege 3 , John Rumsfeld 1 , 4 , 2 , David Bekelman 1 , 4 , 2 . 1 University of Colorado, Aurora,<br />
CO; 2 Colorado Cardiovascular Outcomes Research Consortium, Denver, CO; 3 Colorado School of Public Health, Aurora,<br />
CO; 4 VA Eastern Colorado Health Care System, Denver, CO<br />
168<br />
Reduction in Heart Failure Readmissions Using Mobile Technology<br />
Thompson Boyd III 1 , Shelley Hankins 2 , Farhan Hasni 2 , Theresa Rowe 3 , Diane Snipas 3 , Cassandra Demastus 3 , Sandra Zimmerman<br />
3 , Ruth Stabler 3 , Howard J. Eisen 2 . 1 Hahnemann University Hospital, Philadelphia, PA; 2 Drexel University College<br />
of Medicine, Philadelphia, PA; 3 Hahnemann University Hospital, Philadelphia, PA<br />
Management Strategies, Adherence/ Self Care ....................................................................................<br />
169<br />
Device-Measured Rapid Shallow Breathing With Exertion Worsens Prior to Heart Failure Decompensation<br />
Seth Rials 1 , Bela Merkely 2 , Roy Gardner 3 , Viktoria Averina 4 , Robert Sweeney 4 , Yi Zhang 5 , Qi An 4 , John Boehmer 6 . 1 Grant<br />
Medical Center, OhioHealth, Columbus, OH; 2 Semmelweis University Heart Center, Budapest, Hungary; 3 Golden Jubilee<br />
National Hospital, Glasgow, United Kingdom; 4 Boston Scientific, St. Paul, MN; 5 B, St. Paul, MN; 6 Penn State Milton S.<br />
Hershey Medical Center, Hershey, PA<br />
170<br />
Remote Dielectric Sensing (ReDS)- Guided Patient Management of Ambulatory Heart Failure Patients Reduces<br />
Rehospitalization Rates<br />
William T. Abraham 1 , Offer Amir 2 , Jean Marc Weinstein 3 , Aharon Abbo 4 , Tuvia Ben Gal 5 . 1 Ohio State University, Columbus,<br />
OH; 2 Baruch Padeh Medical Center, Tiberias, Israel; 3 Soroka Medical Center, Beer Sheva, Israel; 4 Sensible Medical<br />
Innovations Ltd., Kfar Neter, Israel; 5 Rabin Medical Center, Petah Tikva, Israel<br />
171<br />
Learning Style, Health Literacy, and 90-Day Health Care Utilization in Heart Failure Patients<br />
Cheryl Westlake 1 , Kris Sethares 2 . 1 Azusa Pacific University, Azusa, CA; 2 University of Massachusetts, North Dartmouth,<br />
MA<br />
172<br />
Heart Failure Readmission Reduction Through Care Coordination<br />
Deborah J. Fenner 1 , Sanjeev K. Gulati 2 , Meghan E. Emig 3 . 1 Carolinas HealthCare System, Charlotte, NC; 2 Carolinas Health-<br />
Care System, Charlotte, NC; 3 Carolinas HealthCare System, Charlotte, NC<br />
173<br />
Home Telehealth Done in an Integrated Disease Management Program Results in Substantial Cost Savings and Reduction<br />
in Healthcare Utilization.<br />
Michael G. Dickinson 1 , Kevin L. Vos 2 . 1 Spectrum Health, Grand Rapids, MI; 2 Spectrum Health, Grand Rapids, MI<br />
174<br />
Motivational Interviewing to Improve Self-care for Patients with Chronic Heart Failure: MITI-HF Randomized<br />
Controlled Trial<br />
Ruth M. Masterson Creber 1 , Megan Patey 2 , Christopher S. Lee 3 , Barbara Riegel 2 . 1 Columbia University, New York, NY;<br />
2<br />
University of Pennsylvania, Philadelphia, PA; 3 Oregon Health & Sciences University, Portland, OR<br />
81
POSTER RECEPTION I - SATURDAY<br />
POSTERS<br />
175<br />
Symptomatology and Coping Resources Predict Self-Care in Older Patients with Heart Failure<br />
Lucinda J. Graven 1 , Joan S. Grant 2 , Glenna Gordon 1 . 1 Florida State University, Tallahassee, FL; 2 University of Alabama at<br />
Birmingham, Birmingham, AL<br />
176<br />
Hospital Readmission Rates Among Disadvantaged Heart Failure Patients Enrolled in Outreach Program<br />
Kira McClinton, Marisue Garganta, Marc Lato, Linda Martin, Susan Kilby, Anantharam Kalya. St. Joseph's Hospital and<br />
Medical Center, Phoenix, AZ<br />
82
POSTER RECEPTION II - SUNDAY (pages 83-98)<br />
POSTERS<br />
All posters will be on display Saturday at 6:00 PM - Monday at 1:30 PM<br />
Cardiovascular Physiology ...................................................................................................................................<br />
178<br />
Pulmonary Artery Proportional Pulse Pressure Predicts Adverse Clinical Outcomes in Group 1 Pulmonary<br />
Hypertension (Analysis of the NIH Pulmonary Hypertension Registry)<br />
Sula Mazimba 1 , James Bergin 1 , Jamie L. W. Kennedy 1 , Jose A. Tallaj 2 , Elizabeth Gay 3 , Mohammad Abuannadi 1 , Andrew<br />
Mihalek 3 , Kenneth C. Bilchick 1 . 1 University of Virginia, Charlottesville, VA; 2 University of Alabama at Birmingham, Birmingham,<br />
AL; 3 University of Virginia, Charlottesville, VA<br />
179<br />
Renal Dysfunction Has Limited Role in the Genesis of Diuretic Resistance in Heart Failure<br />
Chukwuma Onyebeke, Jennifer Simon, Susan J. Cheng, Jeffrey M. Testani. Yale University School of Medicine, New Haven,<br />
CT<br />
180<br />
Exercise Oscillatory Breathing is Associated With Ventricular Tachycardia, Atrial Fibrillation and Cardiomyopathy<br />
in Contemporary Patients Undergoing Metabolic Stress Testing<br />
Antonio L. Perez, Timothy Engelman, W.H. Wilson Tang. Cleveland Clinic, Cleveland, OH<br />
181<br />
Indices of Pulsatile and Resistive Afterload and Load-Dependent and Independent Right Ventricular Dysfunction<br />
in HFrEF<br />
E. Wilson Grandin 1 , Gregory S. Troutman 1 , Payman Zamani 1 , Jeremy A. Mazurek 1 , Anjali Vaidya 1 , Pavan Atluri 2 , Ryan J.<br />
Tedford 3 , Paul Forfia 4 , Kenneth B. Margulies 1 , J. Eduardo Rame 1 . 1 University of Pennsylvania, Philadelphia, PA; 2 University<br />
of Pennsylvania, Philadelphia, PA; 3 Johns Hopkins, Baltimore, MD; 4 Temple University, Philadelphia, PA<br />
182<br />
Therapeutic Insights for Heart Failure: In Vivo Comparison Between a Guanylyl Cyclase Receptor A and a Novel<br />
Guanylyl Cyclase Receptor B Activator<br />
S. Jeson Sangaralingham, Gerald E. Harders, Tomoko Ichiki, John C. Burnett Jr. Mayo Clinic, Rochester, MN<br />
183<br />
Improvements in Left Atrial Appendage Velocities Following Transcatheter Aortic Valve Replacement<br />
Tomo Ando 1 , Cynthia Taub 2 , David Slovut 3 . 1 Mount Sinai Beth Israel, New York, NY; 2 Montefiore Medical Center, Montefiore,<br />
NY; 3 Montefiore Medical Center, Bronx, NY<br />
184<br />
Diuretic-Induced Sodium Output is Highly Variable Between Patients Treated for Heart Failure But More Closely<br />
Associated With Hemoconcentration Than Fluid or Weight Loss<br />
Jennifer Simon, Susan J. Cheng, Chukwuma Onyebeke, Jeffrey M. Testani. Yale University School of Medicine, New Haven,<br />
CT<br />
Cardiovascular Structure/ Imaging ..................................................................................................................<br />
185<br />
Systolic Ejection Time is an Independent Predictor of Incident Heart Failure in a Community Based Cohort Free of<br />
Heart Failure<br />
Tor Biering-Sørensen 1 , Gabriela Querejeta Roca 1 , Sheila Hegde 1 , Amil Shah 1 , Brian Clagett 1 , Thomas H. Mosley 2 , Kenneth R. Butler<br />
2 , Scott D. Solomon 1 . 1 Brigham and Women’s Hospital, Boston, MA; 2 University of Mississippi Medical Center, Jackson, MS<br />
186<br />
Right Ventricular Outflow Tract Doppler Envelope Notching Predicts Pulmonary Vascular Resistance in Patients with<br />
Advanced Liver Disease<br />
Marcella Manicardi 1 , 2 , Jana Svetlichnaya 1 , Van Selby 1 , Munir Janmohamed 1 , Francis Yao 1 , John Roberts 1 , Teresa De Marco 1 .<br />
1<br />
University of California, San Francisco, CA; 2 Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy<br />
83
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
187<br />
Association of 4-Tiered Classification of Left Ventricular Hypertrophy With Adverse Cardiovascular Outcomes in the<br />
General Population<br />
Sonia Garg 1 , James de Lemos 1 , Colby Ayers 1 , Michel Khouri 2 , Ambarish Pandey 1 , Jarett D. Berry 1 , Ronald M. Peshock 1 ,<br />
Mark H. Drazner 1 . 1 UT Southwestern, Dallas, TX; 2 Duke University, Durham, NC<br />
188<br />
Improved Anemia as a Predictor of Reverse Remodeling and Prognosis Following Kidney Transplantation in Patients<br />
with Cardiac Dysfunction<br />
Nael Hawwa 1 , Kevin Shrestha 2 , Muhammad Hammadah 2 , Daniel Yeo 3 , Richard Fatica 4 , W. H. Wilson Tang 1 . 1 Cleveland<br />
Clinic, Cleveland, OH; 2 Cleveland Clinic, Cleveland, OH; 3 Tan Tock Seng Hospital, Singapore, Singapore; 4 Cleveland Clinic,<br />
Cleveland, OH<br />
189<br />
Multicenter Experience of Technetium Pyrophosphate Scanning for Diagnosing TTR Cardiac Amyloid: A Revival in<br />
Nuclear Cardiology<br />
Adam Castano 1 , Martha Grogan 2 , Geoffrey B. Johnson 3 , Angela Dispenzieri 4 , Frederick L. Ruberg 5 , John L. Berk 6 , Edward J.<br />
Miller 7 , Mathew S. Maurer 1 , Sabahat Bokhari 8 . 1 Columbia University Medical Center, New York, NY; 2 Mayo Clinic, Rochester,<br />
MA; 3 Mayo Clinic, Rochester, MN; 4 Mayo Clinic, Rochester, MN; 5 Boston University Amyloidosis Center, Boston, MA;<br />
6<br />
Boston University Amyloidosis Center, New York, NY; 7 Boston University School of Medicine, Boston, MA; 8 Columbia<br />
University Medical Center, New York, NY<br />
190<br />
Echocardiographic Predictors of Heart Failure in Hypertrophic Cardiomyopathy Secondary to Hypertension<br />
Manminder Bhullar 1 , Manmeet Singh 1 , Amarbhir Bhullar 2 , Amir Najafi 2 , Robert Ferdman 2 , Chandra Katikireddy 1 . 1 UCSF<br />
Fresno, Fresno, CA; 2 UCSF Fresno, Fresno, CA<br />
191<br />
Improvement in Left Atrial Appendage Velocities Following Transcatheter Aortic Valve Replacement is Associated<br />
with Better Outcome in Patients with Severe Aortic Stenosis<br />
Tomo Ando 1 , David Slovut 2 , Cynthia Taub 2 . 1 Mount Sinai Beth Israel, New York, NY; 2 Montefiore Medical Center, Bronx,<br />
NY<br />
192<br />
Potential Utility of Longitudinal Radial Strain Imaging in the Routine Assessment of Patients on Mechanical Circulatory<br />
Support: A Feasibility Study<br />
Saad S. Ahmad, Angel Lopez Candales. University of Cincinnati, Cincinnati, OH<br />
193<br />
Cluster Analysis in Idiopathic Dilated Cardiomyopathy (IDC): Opportunity to Define Pathogenesis?<br />
Monica P. Revelo 1 , Eliza B. Hammond 2 , Greg L. Snow 3 , Stavros G. Dakros 4 , Kim M. Molina 5 , Dylan V. Miller 6 , Edward M.<br />
Gilbert 4 , Elizabeth H. Hammond 7 , Abdalah G. Kfoury 8 . 1 University of Utah Health Care System, Salt Lake City, UT; 2 North<br />
Carolina School of Science and Mathematics, Durham, NC; 3 Statistical DataCenter, LDS Hospital, Intermountain Healthcare,<br />
Salt Lake City, UT; 4 University of Utah Health Care System, Salt Lake City, UT; 5 Primary Childrens Hospital, Salt Lake<br />
City, UT; 6 Intermountain Medical Center, Salt Lake City, UT; 7 LDS Hospital, Intermountain Healthcare, Salt Lake City, UT;<br />
8<br />
Intermountain Medical Center, Salt Lake City, UT<br />
Biomarkers/Neurohormones/Cytokines ........................................................................................................<br />
194<br />
Hyponatremia Patterns During Hospitalization for Acute Heart Failure<br />
Frederik H. Verbrugge 1 , Justin L. Grodin 1 , Wilfried Mullens 2 , David O. Taylor 1 , Randall C. Starling 1 , W.H. Wilson Tang 1 .<br />
1<br />
Cleveland Clinic, Cleveland, OH; 2 Ziekenhuis Oost-Limburg, Genk, Belgium<br />
84
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
195<br />
Metabolomic Patterns in Heart Failure Patients Vary Across Demographic and Clinical Factors<br />
David E. Lanfear 1 , Hani N. Sabbah 1 , Albert M. Levin 1 , Yun Wang 1 , Ruicong She 1 , Jia Li 1 , Keoki Williams 1 , Stephen Gardell 2 ,<br />
Nicole Zeld 1 . 1 Henry Ford Health System, Detroit, MI; 2 Sanford Burnham Research Institute, Orlando, FL<br />
196<br />
Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure<br />
Justin L. Grodin 1 , Jennifer Simon 2 , Rory Hachamovitch 1 , Yuping Wu 3 , Gregory Jackson 4 , Meghana Halkar 5 , Randall C. Starling<br />
1 , Jeffrey Testani 6 , W. H. Wilson Tang 1 . 1 Cleveland Clinic, Cleveland, OH; 2 Yale University School of Medicine, New<br />
Haven, CT; 3 Cleveland State University, Cleveland, OH; 4 Medical University of South Carolina, Charleston, SC; 5 Cleveland<br />
Clinic, Cleveland, OH; 6 Yale University School of Medicine, New Haven, CT<br />
197<br />
Novel Protein Glycan Inflammatory Biomarkers Predict Adverse Events in Heart Failure with Preserved Ejection<br />
Fraction<br />
Jacob P. Kelly 1 , 2 , Wynn G. Hunter 3 , Robert W. McGarrah III 1 , 4 , Damian Craig 4 , Carol Haynes 4 , Eric J. Velazquez 1 , 2 , G.<br />
Michael Felker 1 , 2 , Adrian F. Hernandez 1 , 2 , Christopher B. Newgard 4 , Svati H. Shah 1 , 1 , William E. Kraus 4 , 1 . 1 Duke University<br />
Medical Center, Durham, NC; 2 Duke Clinical Research Institute, Durham, NC; 3 Duke University School of Medicine,<br />
Durham, NC; 4 Duke Molecular Physiology Institute, Durham, NC<br />
198<br />
Hypochloremia is Strongly and Independently Associated with Mortality in Patients with Chronic Heart Failure<br />
Jennifer Simon 1 , Chukwuma Onyebeke 1 , Susan J. Cheng 1 , Justin Grodin 2 , W. H. Wilson Tang 2 , Jeffrey M. Testani 1 . 1 Yale<br />
University School of Medicine, New Haven, CT; 2 The Cleveland Clinic, Cleveland, OH<br />
199<br />
Elevated Plasma Interleukin-6, Endothelin-1, and Matrix Metalloproteinase-9 in Heart Failure Patients are Associated<br />
With the Need for Advanced Therapies and Mortality<br />
Eitan A. Friedman 1 , Ugochukwu O. Egolum 1 , David C. Shisler 1 , John A. Todd 2 , Joel Estis 2 , Niamh Nolan 2 , Adnan Shah 2 ,<br />
Daniel J. Lenihan 1 . 1 Vanderbilt University, Nashville, TN; 2 Singulex, Inc., Alameda, CA<br />
200<br />
Big-Endothelin-1 Transpulmonary Capillary Gradient is Increased in HFpEF, not Endothelin-1<br />
Bhavana Siddegowda Bangalore, Qaiser Shafiq, Mohamed Elamin, Samer Khouri. University of Toledo, Toledo, OH<br />
201<br />
Clinical Characteristics of Survivors and Non-Survivors with Immunoglobulin Light Chain (AL) Cardiac Amyloid<br />
Heart Failure<br />
Usman Tahir 1 , John S. Kim 1 , Lawreen Connors 2 , Flora Sam 3 . 1 Boston University Medical Center, Boston, MA; 2 Boston University<br />
School of Medicine, Boston, MA; 3 Boston University Medical Center, Boston, MA<br />
202<br />
Early Improvement Of Dyspnea And Neurohormonal Status Using Minute Ventilation-Targeted Adaptive Servo Ventilation<br />
In Acute Heart Failure<br />
Boris Arbit 1 , 2 , Matt Kawahara 1 , Elizabeth Lee 1 , Trenton Gluck 1 , Kathleen Sarmiento 1 , 2 , Atul Malhotra 1 , 2 , Alan Maisel 1 , 2 .<br />
1<br />
Veterans Affairs San Diego Healthcare System, San Diego, CA; 2 University of California, San Diego, La Jolla, CA<br />
203<br />
Elevated Hepatocyte Growth Factor is Associated With Worse Prognosis in Cardiac Amyloidosis<br />
Eitan A. Friedman, Kelsey Tomasek, Yan Ru Su, Douglas B. Sawyer, Daniel J. Lenihan. Vanderbilt University, Nashville, TN<br />
204<br />
Plasma Aldosterone and Heart Failure in the General Community<br />
Alessia Buglioni, Valentina Cannone, Jeson S. Sangaralingham, Christopher G. Scott, Richard J. Rodeheffer, John C. Burnett.<br />
Mayo Clinic, Rochester, MN<br />
85
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
Molecular Biology/Genetics/Cell Therapy .....................................................................................................<br />
206<br />
MicroRNA-130a Regulation of Desmocollin2 in a Novel Model of Arrhythmogenic Cardiomyopathy<br />
Stefan Mazurek, Tyler Calway, Cynthia Harmon, Gene H. Kim. University of Chicago Medicine, Chicago, IL<br />
208<br />
Induced Pluripotent Stem Cell Derived Cardiomyocyte Scaffold Improves Electro-Mechanical Coupling and Left<br />
Ventricular Function in Rats With Heart Failure<br />
Jordan J. Lancaster 1 , Elizabeth Juneman 1 , Pablo Sanchez 1 , Kyle Weigand 1 , Talal Moukabary 1 , Nicole Lahood 1 , Joseph J.<br />
Bahl 1 , Steven Goldman 2 . 1 Sarver Heart Center, Tucson, AZ; 2 Southern Arizona VA Health Care System, Tucson, AZ<br />
209<br />
Bone Marrow Stem Cell Derived Cardiomyocyte Precursors Differentiated on Nanofiber Scaffolds Attenuate Scar<br />
Formation in a Rat Model of Myocardial Infarction<br />
Edward D. Marks, Arun Kumar. University of Delaware, Newark, DE<br />
Surgery/Transplantation/Devices ........................................................................................................................<br />
210<br />
Right Vagus Nerve Stimulation With a Novel Self-Sizing<br />
Cuff Electrode Improves Left Ventricular Function in Dogs With Heart Failure<br />
Hani N. Sabbah 1 , Mengjun Wang 1 , Kefei Zhang 1 , Ramesh C. Gupta 1 , Maxime Lemonnier 2 , Andrew Khair 2 , Melanie Mallemeester<br />
2 , Christine Henry 2 . 1 Henry Ford Health System, Detroit, MI; 2 Sorin Group, Clamart, France<br />
211<br />
Impact of Pulmonary Function Tests on Outcomes in Patients after Left Ventricular Assist Device Implantation<br />
Amaninderapal S. Ghotra 1 , Zeeshan Hussain 1 , Nirmanmoh Bhatia 2 , Rafael Perez 1 , Allen Cheng 1 , Mark S. Slaughter 1 , Andrew<br />
Lenneman 1 , Emma J. Birks 1 . 1 University of Louisville, Louisville, KY; 2 Vanderbilt University, Nashville, TN<br />
212<br />
Region and Insurance Status Impacts LVAD Utilization for Patients Listed for Heart Transplantation<br />
Anita A. Kelkar, Yi-An Ko, Andreas Kalogeropoulos, Andrew L. Smith, David Vega, Alanna A. Morris. Emory University School<br />
of Medicine, Atlanta, GA<br />
213<br />
Fifteeen Years of Cardiac Resynchronization Pacing for Heart Failure Among Congenital Heart Patients: Direct<br />
Contractility not Guidelines Determines Responders<br />
Peter P. Karpawich, Yamuna Sanil, Neha Bansal, Kathleen Zelin. The Children's Hospital of Michigan, Wayne State University, Detroit, MI<br />
214<br />
Preoperative Iodine-123 Meta-Iodobenzylguanidine Imaging is a Novel Predictor of Left Ventricular Reverse Remodeling<br />
during Left Ventricular Assist Device Treatment<br />
Teruhiko Imamura 1 , Koichiro Kinugawa 1 , Daisuke Nitta 2 , Masaru Hatano 2 , Osamu Kinoshita 3 , Kan Nawata 3 , Minoru Ono 3 .<br />
1<br />
Graduate School of Medicine, University of Tokyo, Tokyo, Japan; 2 Graduate School of Medicine, University of Tokyo, Tokyo,<br />
Japan; 3 Graduate School of Medicine, University of Tokyo, Tokyo, Japan<br />
216<br />
The Impact of Frailty in an Elderly Population on Outcomes After Destination Therapy LVAD Placement: The Greater<br />
New York Geriatric Cardiology Consortium<br />
Deena S. Goldwater 1 , Victoria V. Dickson 2 , Cecilie Gjerde 2 , Jeff Goldsmith 3 , Nathan E. Goldstein 4 , Evelyn M. Horn 5 , Anu Lala 2 , Gordon<br />
R. Reeves 6 , Alex Reyentovich 2 , Melana Yuzefpolskaya 7 , Mathew S. Maurer 7 , Sean P. Pinney 1 . 1 Icahn School of Medicine at Mount Sinai<br />
Hospital, New York, NY; 2 New York University School of Medicine, New York, NY; 3 Columbia Mailman School of Public Health, New<br />
York, NY; 4 Icahn School of Medicine at Mount Sinai Hospital, New York, NY; 5 Weill Cornell Medical College, New York Presbyterian<br />
Hospital, New York, NY; 6 Thomas Jefferson University, Philadelphia, PA; 7 Columbia University Medical Center, New York, NY<br />
86
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
217<br />
Insights into the Failing Fontan Circulation: Impact of Dominant Ventricular Morphology on Ventricular-Arterial<br />
Coupling in Adults with Fontan Circulation<br />
Hirofumi Saiki, Benjamin W. Eidem, Martha Grogan, Margaret M. Redfield. Mayo Clinic, Rochester, MN<br />
218<br />
Preoperative Risk Model for Prediction of Pump Thrombosis in LVADs<br />
David Raymer, Michael Nassif, Anuradha Godishala, Christopher Sparrow, Eric Novak, Vaiibhav Patel, Shane LaRue, Gregory<br />
Ewald, Justin Vader. Washington University / Barnes-Jewish Hospital, St. Louis, MO<br />
219<br />
Durable Bi-ventricular Support in INTERMACS 1 Patients Using the Heartware HVAD System in the Right Atrial<br />
Position<br />
Hao Tran, David Cork, Eric Adler, Victor Pretorius. University of San Diego, California, La Jolla, CA<br />
220<br />
A Single, Non-Academic Experience with Use of ECPR<br />
Peter Barrett, Vivek Rajagopal, Erin Sheffield, Lynn Pfaender, Julie Webster, Andrew Boyle, David Dean. Piedmont Heart,<br />
Atlanta, GA<br />
221<br />
Impact of Pre-Transplant Ventricular Assist Device Implantation on Adult Heart Transplant Outcomes in a Commercially<br />
Insured Population<br />
Wade Bannister, Charlotte Wu, Jiang Tao, Frank D. Irwin. Optum, Eden Prairie, MN<br />
222<br />
Transvenous Stimulation of Cardiac Autonomic Inputs Improves Subacute Canine Hemodynamics<br />
Michael Cuchiara, Scott Purcell, Jean Darnieder, Michael Romero, Stephen Masson. NeuroTronik, Durham, NC<br />
223<br />
Cognitive Improvement After Left Ventricular Assist Device Implant<br />
Michelle M. Hudson 1 , Mary E. Haines 1 , Thomas A. Schwann 2 , George V. Moukarbel 3 , Samer Khouri 4 , Allison Meyers-Fabian<br />
1 , Mark R. Bonnell 2 . 1 University of Toledo Medical Center, Toledo, OH; 2 University of Toledo Medical Center, Toledo,<br />
OH; 3 University of Toledo Medical Center, Toledo, OH; 4 University of Toledo Medical Center, Toledo, OH<br />
224<br />
Prevalence and Correlation of Non Functional Tricuspid Regurgitation to Right Ventricular Failure in Patients with CF-LVADs<br />
Cesar Y. Guerrero-Miranda 1 , Omar Saeed 1 , Anna Koulova 2 , Julia Shin 1 , Snehal R. Patel 1 , David D’Alessandro 3 , Daniel Goldstein<br />
3 , Ulrich Jorde 1 , Daniel Sims 1 . 1 Montefiore Medical Center - Albert Einstein College of Medicine, Bronx, NY; 2 Mt Sinai<br />
St Lukes-Roosevelt Hospital, New York, NY; 3 Montefiore Medical Center - Albert Einstein College of Medicine, Bronx, NY<br />
225<br />
Health Literacy as a Predictor of Adverse Outcomes after Implantation of Left Ventricular Assist Device<br />
David Raymer, Justin Vader, Anne Platts, Michael Nassif, Scott Silvestry, Gregory Ewald, Shane LaRue. Washington University<br />
/ Barnes-Jewish Hospital, St. Louis, MO<br />
226<br />
Smoking is Associated With Pump Thrombosis After Left Ventricular Assist Device Implantation<br />
Vaiibhav Patel 1 , Michael Nassif 2 , David Raymer 2 , Brian Pierce 1 , Justin Vader 2 , Greg Ewald 2 , Shane LaRue 2 . 1 Washington<br />
University, Saint Louis, MO; 2 Washington University, Saint Louis, MO<br />
227<br />
Long Term Support of Acute, Refractory Cardiogenic Shock with an Extracorporeal, Continuous Flow Ventricular<br />
Assist Device: A Seven Year Experience<br />
James M. Meza 1 , Yamini Krishnamurthy 2 , Laura Blue 1 , Jacob Schroder 1 , Chetan B. Patel 3 , Carmelo A. Milano 1 , Mani A.<br />
Daneshmand 1 . 1 Duke University Medical Center, Durham, NC; 2 Duke University School of Medicine, Durham, NC; 3 Duke<br />
University Medical Center, Durham, NC<br />
87
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
228<br />
Normalization of Hemodynamics Following LVAD Implantation May be Related to Improved Long Term Outcome<br />
Emeka C. Anyanwu 1 , Kershaw Patel 1 , Cory Henderson 1 , Savitri E. Fedson 2 , Gene H. Kim 2 , Nitasha Sarswat 2 , Colleen<br />
Juricek 2 , Takeyoshi Ota 3 , Valluvan Jeevanandam 3 , Gabriel Sayer 2 , Nir Uriel 2 . 1 University of Chicago Medicine, Chicago, IL;<br />
2<br />
University of Chicago Medicine, Chicago, IL; 3 University of Chicago Medicine, Chicago, IL<br />
230<br />
Development of a Preoperative Risk Model that Predicts Gastrointestinal Bleeding after Implantation of Continuous-Flow<br />
LVADs<br />
Christopher T. Sparrow, Michael E. Nassif, David S. Raymer, Paul M. Lavigne, Eric Novak, Shane J. LaRue, Joel D. Schilling,<br />
Gregory A. Ewald, Justin M. Vader. Washington University in Saint Louis, St. Louis, MO<br />
231<br />
Diagnosis of Left Ventricular Assist Device (LVAD) Pump Thrombosis Using Fibrin-Specific 99mTc Imaging Agent<br />
Gregory A. Ewald, Grace Cui, Michael Scott, Michael E. Nassif, Shane J. LaRue, Justin M. Vader, David S. Raymer, Walter<br />
Akers, Scott Silvestry, Akinobu Itoh, Samuel Achilefu, Gregory Lanza. Washington University, St. Louis, MO<br />
232<br />
Clinical Outcomes Associated with INTERMACS Defined Right Ventricular Failure After LVAD Implantation<br />
Brian R. Pierce 1 , David Raymer 2 , Anuradha Godishala 1 , Christopher Sparrow 2 , Michael Nassif 2 , Shane LaRue 2 , Gregory<br />
Ewald 2 , Justin Vader 2 . 1 Barnes-Jewish Hospital, Saint Louis, MO; 2 Barnes-Jewish Hospital, Saint Louis, MO<br />
233<br />
Impact of Cytomegalovirus on Survival After Heart Transplant: analysis of 20,000 Patients from the UNOS Registry Data<br />
Guha Ashrith, Ahmed Daoud, Larry D. Teeter, Javier Amione-Guerra, Andrea M. Cordero-Reyes, Edward Gravis, Barry H.<br />
Trachtenberg, Arvind Bhimaraj, Osama A. Gaber, Scott Scheinin, Guillermo Torre-Amione, Jerry D. Estep. The Methodist<br />
Hospital, Houston, TX<br />
234<br />
Heart Transplant Donor Characteristics Associated with Worse Outcomes Differ Between Patients who are Bridged<br />
Continuous Flow LVAD and Non-bridged Patients: an Analysis of the UNOS Registry<br />
Guha Ashrith, Larry D. Teeter, Javier Amione-Guerra, Edward A. Gravis, Barry H. Trachtenberg, Arvind Bhimaraj, Osama<br />
A. Gaber, Brian Bruckner, Guillermo Torre-Amione, Jerry D. Estep. The Methodist Hospital, Houston, TX<br />
235<br />
Scripted Nurse Visits: A Resource-efficient Palliative Care Model for Destination VADs<br />
Mary E. Moyer, James Kirkpatrick, Nina O'Connor. Hospital of the University of Pennsylvania, Philadelphia, PA<br />
236<br />
Diabetic Patients Experience Delayed Improvement in Renal Function Post CF-LVAD Implantation<br />
Allison P. Levin 1 , Mustafa A. Pamirsad 1 , Jenni Nguyen 1 , Snehal Patel 1 , Omar Saeed 1 , Daniel Sims 1 , David A. D'Alessandro 1 ,<br />
Daniel Goldstein 2 , Ulrich P. Jorde 1 . 1 Montefiore Medical Center, Bronx, NY; 2 Montefiore Medical Center, Bronx, NY<br />
238<br />
Is Education the Key to Success? Association of Formal Education and Outcomes in Left Ventricular Assist Devices<br />
Brent C. Lampert 1 , Robert S. D. Higgins 2 , Gary Phillips 3 , Sitaramesh Emani 1 , Sakima Smith 1 , Bryan A. Whitson 2 , Ahmet<br />
Kilic 2 , Ayesha K. Hasan 1 , Jeffrey J. Teuteberg 4 . 1 The Ohio State University Wexner Medical Center, Columbus, OH; 2 The<br />
Ohio State University Wexner Medical Center, Columbus, OH; 3 The Ohio State University, Columbus, OH; 4 University of<br />
Pittsburgh Medical Center, Pittsburgh, PA<br />
239<br />
Structural and Functional Echocardiographic Responses to Left Ventricular Assist Device Implantation: Focus on<br />
the Right Ventricle<br />
Kunal N. Bhatt, Raghda Al-Anbari, Alanna A. Morris, Andrew L. Smith, Vasiliki V. Georgiopoulou, J. David Vega, Andreas<br />
P. Kalogeropoulos. Emory University, Atlanta, GA<br />
88
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
Electrophysiology/Arrhythmias .............................................................................................................................<br />
240<br />
Optimizing Quadripolar Leads to Reduce Heart Failure Hospitalizations<br />
Alvaro ManriqueGarcia, Vidya Thandra, Samer A. De Oliveira, Judith Mackall, Harish Manyam. University Hospitals Case<br />
Medical Center, Cleveland, OH<br />
241<br />
Safety of Left Atrial Appendage Closure in Patients with Low Ejection Fraction<br />
Sameer Gafoor 1 , Vivek Reddy 2 , Jonathan Halperin 2 , Shephal Doshi 3 , Maurice Buchbinder 4 , Petr Neuzil 5 , Kenneth Huber 6 ,<br />
Brian Whisenant 7 , Saibal Kar 8 , Vijay Swarup 9 , Mathew J. Price 10 , David Holmes 11 , Nicole Gordon 12 , Horst Sievert 1 . 1 Cardio-<br />
Vascular Center Frankfurt, Frankfurt, Germany; 2 Mount Sinai Hospital, New York City, NY; 3 Pacific Heart Institute, Santa<br />
Monica, CA; 4 San Diego Cardiovascular Associates, San Diego, CA; 5 Na Homolce Hospital, Prague, Czech Republic; 6 St.<br />
Luke's Health System, Kansas City, MO; 7 Intermountain Health Care, Salt Lake City, UT; 8 Cedars-Sinai Hospital, Los Angeles,<br />
CA; 9 Arizona Heart Rhythm Center, Phoenix, AZ; 10 Scripps Health, San Diego, CA; 11 Mayo Clinic, Rochester, MN;<br />
12<br />
Boston Scientific, St. Paul, MN<br />
242<br />
High Prevalence of Sub-clinical Cerebral Infarctions in Patients with Heart Failure with Preserved Ejection Fraction<br />
Rebecca J. Cogswell 1 , Faye L. Norby 2 , Rebecca F. Gottesman 3 , Lin Y. Chen 1 , Scott D. Solomon 4 , Amil M. Shah 4 , Alvaro<br />
Alonso 2 . 1 University of Minnesota, Minneapolis, MN; 2 University of Minnesota, Minneapolis, MN; 3 Johns Hopkins, Baltimore,<br />
MD; 4 Brigham and Woman's Hospital, Boston, MA<br />
243<br />
The Success of ICD-delivered ATP Therapy in Heart Failure Patients with Ventricular Tachycardia<br />
Dalia Giedrimiene 1 , Danette Guertin 2 , Jeffrey Kluger 2 . 1 University of Saint Joseph, West Hartford, CT; 2 Hartford Hospital,<br />
Hartford HealthCare, Hartford, CT<br />
244<br />
"Permissive ICD Programming for LVAD Patients"<br />
Dominique Williams, MD 1 , Praveen Rao, MD 2 , Michael Nassif, MD 2 , Eric Novak, MS 2 , Sarah Sandberg, MD 2 , Shane LaRue,<br />
MD 2 , Daniel Cooper, MD 2 , Justin Vader, MD 2 . 1 Washington University School of Medicine, Saint Louis, MO; 2 Washington<br />
University School of Medicine, Saint Louis, MO<br />
Clinical Trials .....................................................................................................................................................................<br />
245<br />
Ranolazine Increases Exercise Capacity in Heart Failure with Preserved Ejection Fraction (HFpEF)<br />
Payman Zamani 1 , Denise Barnard 2 , Annette Contasti 3 , Daniel Blanchard 2 , Ottar Lunde 2 , Johanna Schandera 2 , Melanee<br />
Schimmel 2 , Roxana Ghashghaei 2 , Barry Greenberg 4 . 1 Hospital of the University of Pennsylvania, Philadelphia, PA; 2 UC San<br />
Diego, San Diego, CA; 3 Sharp Memorial Hospital, San Diego, CA; 4 UC San Diego, San Diego, CA<br />
246<br />
Normalization of Serum Potassium With Sodium Zirconium Cyclosilicate (ZS-9) in Patients With Heart Failure<br />
Prakash Deedwania 1 , Ileana L. Piña 2 , Henrik S. Rasmussen 3 , Philip T. Lavin 4 , Bhupinder Singh 3 , Alex Yang 3 , Peter A. Mc-<br />
Cullough 5 . 1 University of California at San Francisco, San Francisco, CA; 2 Albert Einstein COM/Montefiore Medical Center,<br />
Bronx, NY; 3 ZS Pharma, Inc., Coppell, TX; 4 Boston Biostatistics Research Foundation, Framingham, MA; 5 Baylor University<br />
Medical Center, Baylor Heart and Vascular Institute, Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas,<br />
TX<br />
89
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
248<br />
Abstract: Prognostic Implications of Achieving an N-Terminal Pro-B-Type Natriuretic Peptide Level
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
Epidemiology/ Prevention ........................................................................................................................................<br />
262<br />
Coronary Artery Calcium as a Predictor of Incident Heart Failure with Preserved Ejection Fraction: Results from the<br />
Multi-Ethnic Study of Atherosclerosis (MESA)<br />
Kavita Sharma 1 , Haitham Ahmed 1 , Zeina Dardari 1 , Michael G. Silverman 2 , Clyde W. Yancy 3 , Moyses Szklo 4 , Joseph Yeboah<br />
5 , Stuart D. Russell 1 , Roger S. Blumenthal 1 , Michael J. Blaha 1 . 1 Johns Hopkins Hospital, Baltimore, MD; 2 Brigham<br />
and Women's Hospital, Boston, MA; 3 Northwestern University, Feinberg School of Medicine, Chicago, IL; 4 Johns Hopkins<br />
Hospital, Baltimore, MD; 5 Wake Forest University, Salem, NC<br />
263<br />
Efficacy of Preemptive Beta Blockers for Prevention of Cardiotoxicity in Patients Undergoing Hematopoietic Stem<br />
Cell Transplantation<br />
Chang H. Kim 1 , Sadeer Al-Kindi 1 , Ana CDAH de Souza 2 , Joyce Njoroge 2 , Marwan Qattan 3 , Brian D. Hoit 3 , Ann Liner 3 ,<br />
Jamie Wilson 3 , Basem William 4 , Marcos de Lima 4 , Guilherme H. Oliveira 3 . 1 University Hospitals Case Medical Center,<br />
Cleveland, OH; 2 Case Western Reserve University, Cleveland, OH; 3 University Hospitals Case Medical Center, Cleveland,<br />
OH; 4 University Hospitals Seidman Cancer Center, Cleveland, OH<br />
264<br />
The Prevalence of Iron Deficiency in Patients with Heart Failure with Preserved Ejection Fraction and its Association<br />
with Elevated Pulmonary Pressure, Reduced Exercise Capacity and Quality of Life<br />
Tarek Bekfani 1 , Pierpaolo Pellicori 2 , Nicole Ebner 3 , Daniel- A. Morris 1 , Anja Sandek 1 , Wolfram Doehner 1 , John-G Cleland 2 ,<br />
Mitja Lainscak 4 , Stefan-D Anker 3 , Stephan von Haehling 3 . 1 Charité University Hospital, Berlin, Germany; 2 University of<br />
Hull, Hull, United Kingdom; 3 University Medical Center Goettingen, Goettingen, Germany; 4 General Hospital Celje, Celje,<br />
Slovenia<br />
265<br />
Abnormal EKG Finding Associated with Presence and Severity of Sleep Apnea in Hispanic Patients with Obesity and<br />
Diastolic Dysfunction<br />
Johanna P. Contreras, Peter Montan, Eliscer Guzman. Mount Sinai Hospital, New York, NY<br />
266<br />
Prognostic Implications of Visit-to-visit Blood Pressure Variability in the Patients with Heart Failure<br />
Ju-Hee Lee, Sang Min Kim, Sang Yeub Lee, Jang-Whan Bae, Kyung-Kuk Hwang, Dong-Woon Kim, Myeong-Chan Cho.<br />
Chungbuk National University Hospital, Cheongju, Korea, Republic of<br />
267<br />
Circulating cGMP Levels in the General Population: Relationship with Cardiovascular and Renal Diseases<br />
Valentina Cannone 1 , Christopher G. Scott 2 , Kent R. Bailey 2 , Denise M. Heublein 1 , Margaret M. Redfield 1 , Richard J. Rodeheffer<br />
3 , Johannes-Peter Stasch 4 , John C. Burnett Jr. 1 . 1 Cardiorenal Research Laboratory, Mayo Clinic, Rochester, MN;<br />
2<br />
Division of Biostatistics, Mayo Clinic, Rochester, MN; 3 Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN;<br />
4<br />
Bayer, Wuppertal, Germany<br />
268<br />
The Renal-Cardio Connection and the Development of HFpEF : A Population Based Study<br />
Amit K. Jain 1 , Christopher G. Scott 2 , Horng H. Chen 3 . 1 Mayo Clinic and Foundation, Rochester, MN; 2 Mayo Clinic and<br />
Foundation, Rochester, MN; 3 Mayo Clinic and Foundation, Rochester, MN<br />
269<br />
The Role of Aspirin in the Prevention of Coronary Allograft Vasculopathy in Cardiac Transplant Patients<br />
Lane B. Benes 1 , Tiana L. Riley 2 , Catherine M. Murks 2 , Gabriel T. Sayer 2 , Savitri E. Fedson 2 , Nir Y. Uriel 2 , Gene H. Kim 2 .<br />
1<br />
University of Chicago, Chicago, IL; 2 University of Chicago, Chicago, IL<br />
91
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
Quality of Care/Outcomes .........................................................................................................................................<br />
270<br />
A Multi-State Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart<br />
Failure<br />
Jenica N. Upshaw, Marvin A. Konstam, Gordon S. Huggins, Farzad Noubary, David M. Kent. Tufts Medical Center, Boston,<br />
MA<br />
271<br />
Impact of Sociodemographic and Clinical Risk Factors on Hospitalisation Rates Among Ambulatory Patients with<br />
Heart Failure and Preserved Ejection Fraction<br />
Vasiliki V. Georgiopoulou 1 , Gregory Burkman 1 , Raghda Al-Anbari 1 , Nikolaos Spilias 1 , Taylor A. Lebeis 1 , Kanwal Farooq 1 ,<br />
Mariyah Yazdani 1 , Lampros Papadimitriou 2 , Andrew L. Smith 1 , Javed Butler 2 , Andreas P. Kalogeropoulos 1 . 1 Emory University,<br />
Atlanta, GA; 2 Stony Brook University, Stony Brook, NY<br />
272<br />
Making a Case for the Heart Failure ICU - Differences in Characteristics and Care Between Critically Ill Cardiac<br />
Patients With and Without Heart Failure<br />
Jason N. Katz 1 , Anthony Peters 2 , Sarah Waters 2 , Ian Hollis 3 , Brian C. Jensen 1 . 1 University of North Carolina, Chapel Hill,<br />
NC; 2 University of North Carolina, Chapel Hill, NC; 3 University of North Carolina, Chapel Hill, NC<br />
273<br />
Trends in the Use of Guideline-based Therapies Among Dialysis Patients Hospitalized with Heart Failure: Findings<br />
from Get With The Guidelines-Heart Failure<br />
Ambarish Pandey 1 , Harsh Golwala 2 , Adam DeVore 3 , Di Lu 4 , George Madden 5 , Deepak L. Bhatt 6 , Philip Schulte 4 , Paul Heidenreich<br />
7 , Clyde Yancy 8 , Adrian Hernandez 4 , Gregg C. Fonarow 9 . 1 University of Texas Southwestern Medical Center, Dallas,<br />
TX; 2 University of Louisville School of Medicine, Louisville, KY; 3 Duke Clinical Research Institute, Durham, NC, Durham,<br />
NC; 4 Duke Clinical Research Institute, Durham, NC, Durham, NC; 5 University of Oklahoma School of Medicine, Oklahoma<br />
City, OK; 6 Brigham and Women’s Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA; 7 Stanford<br />
University, Palo Alto, CA; 8 Northwestern University, Chicago, IL; 9 Ronald Reagan-UCLA Medical Center, Los Angeles, CA<br />
274<br />
Healthcare Costs in the Last Six Months of Life among Patients with Heart Failure<br />
Jason P. Swindle 1 , Engels N. Obi 2 , Stuart J. Turner 3 , Patricia A. Russo 4 , Cori J. Blauer-Peterson 1 , Lynn A. Wacha 1 , Aylin<br />
Altan 1 . 1 Optum, Inc., Eden Prairie, IL; 2 Rutgers University, Piscataway, NJ; 3 Novartis Pharmaceuticals Corporation, East<br />
Hanover, NJ; 4 DataMed Solutions, Washington, DC<br />
275<br />
Impact of Pulmonary Artery Pressure Monitoring on All-cause 30-day HF Readmissions and Associated Centers for<br />
Medicare and Medicaid Services Hospital Readmissions Reduction Program Penalty<br />
Philip B. Adamson 1 , Rupinder Bharmi 2 , Nirav Dalal 2 , William T. Abraham 3 . 1 St. Jude Medical, Austin, TX; 2 St. Jude Medical,<br />
Sylmar, CA; 3 Ohio State University Heart Center, Columbus, OH<br />
276<br />
Heart Failure is Associated With Worse Quality of Life and Survival But Similar Stroke Risk in Atrial Fibrillation<br />
Tharian S. Cherian 1 , Peter Shrader 2 , Gregg C. Fonarow 3 , Larry A. Allen 4 , Eric D. Peterson 2 , Jonathan Piccini 2 , Laine Thomas<br />
2 , Peter R. Kowey 5 , Paul Burton 6 , Bernard J. Gersh 7 , Kenneth W. Mahaffey 1 . 1 Stanford University, Stanford, CA; 2 Duke<br />
University Medical Center, Durham, NC; 3 University of California, Los Angeles, CA; 4 University of Colorado, Denver, CO;<br />
5<br />
Institute for Medical Research, Wynnewood, PA; 6 Janssen Pharmaceuticals, Inc, Titusville, NJ; 7 Mayo Clinic, Rochester,<br />
MN<br />
92
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
277<br />
A New Measure of Healthcare Resource Utilization in Heart Failure: Development and Content Validity Evaluation<br />
Miyeon Jung, Marita Titler, Penny Riley, Barry Bleske, Susan J. Pressler. University of Michigan, Ann Arbor, MI<br />
279<br />
Vascular Reactivity Analysis in Patients with Continuous Flow Left Ventricular Assist Devices (CF-LVADs) - the Role<br />
of Endothelial Function in Continuous Flow Physiology<br />
Cesar Uribe, Keith A. Youker, Barry H. Trachtenberg, Guha Ashrith, Jerry D. Estep, Guillermo Torre-Amione, Brian A.<br />
Bruckner, John P. Cooke, Arvind Bhimaraj. The Methodist Hospital, Houston, TX<br />
280<br />
Grip Strength Assessment and Early Outcomes in Hospitalized Acute Decompensated Heart Failure: A Prospective<br />
Study<br />
Emer Joyce, Deepa M. Gopal, Adriana Luk, John D. Groarke, Sachin P. Shah, Garrick C. Stewart, Michael M. Givertz,<br />
Mandeep R. Mehra. Brigham and Women's Hospital, Boston, MA<br />
281<br />
Utilization of Aldosterone Receptor Antagonists at Discharge in Patients Hospitalized With Heart Failure and a<br />
Reduced Ejection Fraction<br />
Chris Domenico, Ed Lau, Karen Yiu, John Lindsley, Michael Moranville. Johns Hopkins Hospital, Baltimore, MD<br />
282<br />
Pre-operative Pulmonary Function Tests and Outcomes After Heart Transplantation<br />
Usama Daimee, Heather McGrane-Minton, Todd Massey, Leway Chen, Matthew Kottmann. University of Rochester Medical<br />
Center, Rochester, NY<br />
284<br />
Efficacy and Safety of Anti-thymocyte Globulin for the Treatment of Acute Cellular Rejection in Orthotopic Heart<br />
Transplant<br />
Stacy Crow, Samir J. Patel, Kyle L. Dawson, Andrea M. Cordero-Reyes, Arvind Bhimaraj, Barry H. Trachtenberg, Guha<br />
Ashrith, Jerry D. Estep. The Methodist Hospital, Houston, TX<br />
285<br />
Pulmonary Artery Pressure Guided Heart Failure Management During a ‘Real-World’ Clinical Setting Follow-Up<br />
Period Demonstrated Even Greater Improvement in Clinical Outcomes Than That Achieved in the CHAMPION<br />
Randomized Controlled Trial<br />
Philip B. Adamson 1 , John Henderson 2 , Greg Ginn 2 , Susan Neville 2 , William T. Abraham 3 . 1 St. Jude Medical, Austin, TX; 2 St.<br />
Jude Medical, Atlanta, GA; 3 Ohio State University Medical Center, Columbus, OH<br />
287<br />
Detectable Cardiac Troponin I Predicts Adverse Cardiac Events and Heart Failure Hospitalizations in Stable Heart<br />
Failure Outpatients<br />
Muhammad Hammadah 1 , Vasiliki Georgiopoulou 2 , Andreas Kalogeropoulos 2 , Javed Butler 3 , W.H.Wilson Tang 4 . 1 Cleveland<br />
Clinic, Cleveland, OH; 2 Emory University, Atlanta, GA; 3 Stony brook, Stony brook, NY; 4 Cleveland Clinic, Cleveland, OH<br />
289<br />
Predicting Likelihood of 30-Day Readmission After Heart Failure Hospitalization Using Readily Available Electronic<br />
Health Record Data<br />
Cheryl Bartone, Eugene Chung, Santosh Menon, Gregory Egnaczyk, Thomas O'Brien. The Christ Hospital, Cincinnati, OH<br />
291<br />
Survival and Implantable Cardioverter-Debrillator Deactivation in End-Stage Congestive Heart Failure Patients<br />
Lillian C. Man 1 , Loheetha Ragupathi 2 , Paul Mather 3 . 1 Jefferson University Hospital, Philadelphia, PA; 2 Jefferson University<br />
Hospital, Philadelphia, PA; 3 Jefferson University Hospital, Philadelphia, PA<br />
93
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
292<br />
No Increase in Mortality Seen with β-blocker Treatment in<br />
Heart Failure Patients with Cocaine Use<br />
Peter Nguyen 1 , 2 , Hassan Kamran 1 , Saifullah Nasir 1 , Wenyaw Chan 1 , 2 , 3 , Biykem Bozkurt 1 , 2 , 4 . 1 Baylor College of Medicine,<br />
Houston, TX; 2 Winters Center For Heart Failure Research, Houston, TX; 3 University of Texas School of Public Health,<br />
Houston, TX; 4 Micheal E. Debakey Veterans Affairs Medical Center, Houston, TX<br />
293<br />
Risk Predictors for 30 day Readmission & Length of Stay<br />
Joseph Ingrassia 1 , Richard Soucier 2 , Melissa Woiciechowski 1 , Penny Cyr 2 , Rebecca Crowell 2 . 1 University of Connecticut,<br />
Farmington, CT; 2 St. Francis Hospital and Medical Center, Hartford, CT<br />
294<br />
Elevated Total Bilirubin on Admission is a Marker of Worse 30- and 180-Day Outcomes for Patients With Acute HF:<br />
Insights From ASCEND-HF<br />
Marc Samsky 1 , Allison Dunning 1 , Phillip Schulte 1 , Adam DeVore 1 , Robert Mentz 1 , Chetan Patel 1 , Randall Starling 2 , John<br />
Teerlink 3 , Wilson Tang 2 , Paul Armstrong 4 , Justin Ezekowitz 4 , Marco Metra 5 , Adriaan Voors 6 , John McMurray 7 , Javed Butler 8 ,<br />
Christopher O'Connor 1 , Adrian Hernandez 1 . 1 Duke University, Durham, NC; 2 Cleveland Clinic, Cleveland, OH; 3 University<br />
of California, San Francisco, San Francisco, CA; 4 University of Alberta, Edmonton, AB, Canada; 5 University of Brescia,<br />
Brescia, Italy; 6 University Medical Center Groningen, Groningen, Netherlands; 7 University of Glasgow, Glasgow, United<br />
Kingdom; 8 Stony Brook University, Stony Brook, NY<br />
295<br />
Elevated Transpulmonary Gradient is a Predictor of Survival in Patients with WHO Group II Pulmonary Hypertension<br />
Treated with Continuous-flow Left Ventricular Assist Devices (CF-LVAD)<br />
Javier Amione-Guerra 1 , Andrea M. Cordero-Reyes 1 , Arvind Bhimaraj 1 , Barry H. Trachtenberg 1 , Guillermo Torre-Amione 1 , 2 ,<br />
Jerry D. Estep 1 , Guha Ashrith 1 . 1 The Methodist Hospital, Houston, TX; 2 Tecnológico de Monterrey, Monterrey, Nuevo León,<br />
Mexico<br />
296<br />
Race, Gender and Clinical Characteristics Do Not Predict Outcomes in End-Stage Heart Failure Patients Requiring<br />
Inotropes<br />
Charles D. Nicolais, Reema R. Bhatt, Lauren M. Freid, Eman A. Hamad, Rene J. Alvarez, Alfred A. Bove, Daniel R.<br />
Schwartz. Temple University Hospital, Philadelphia, PA<br />
297<br />
Elevated Heart Rate in Patients with Heart Failure with Reduced Ejection Fraction: Associations with One-Year<br />
Survival and Costs<br />
Adam D. DeVore 1 , Phillip J. Schulte 2 , Robert J. Mentz 1 , N. Chantelle Hardy 2 , Jacob P. Kelly 1 , Eric J. Velazquez 1 , Juan<br />
F. Maya 3 , Adrian Kielhorn 3 , Harshali Patel 3 , Shelby D. Reed 2 , Adrian F. Hernandez 1 . 1 Duke University Medical Center,<br />
Durham, NC; 2 Duke Clinical Research Institute, Durham, NC; 3 Amgen, Inc., Thousand Oaks, CA<br />
298<br />
OptiVol Impedance Threshold Crossing Predicts Patients with Higher Mortality or Hospitalization Risk Among<br />
Medicare Recipients<br />
Jason Brown 1 , 2 , Kenneth Bilchick 3 , Alvaro Alonso 2 , Eduardo Warman 1 . 1 Medtronic PLC, Minneapolis, MN; 2 University of<br />
Minnesota, Minneapolis, MN; 3 University of Virginia, Charlottesville, VA<br />
299<br />
How do Patients with Ventricular Assist Devices Die?_A Look at End of Life Outcomes<br />
Esther S. Pak 1 , Eva Laverty-Wilson 2 , Christyna Zalewski 3 , Wald Joyce 4 , Pavan Atluri 2 , Eduardo Rame 1 , James N. Kirkpatrick<br />
4 . 1 Hospital of the University of Pennsylvania, Philadelphia, PA; 2 Hospital of the University of Pennsylvania, Philadelphia,<br />
PA; 3 Hospital of the University of Pennsylvania, Philadelphia, PA; 4 Hospital of the University of Pennsylvania,<br />
Philadelphia, PA<br />
94
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
300<br />
Medical Management of Patients with the HeartMate II Left Ventricular Assist Devices. A Single Center Experience<br />
Adam F. Burdorf, John Um, Eugenia Raichlin, Eric Rome, Jason Darrah, Sara Varnado, Brian Lowes. University of Nebraska<br />
Medical Center, Omaha, NE<br />
301<br />
The Relationship Between Glucose Variability and In-Hospital Mortality in Patients With Acute Heart Failure Syndrome:<br />
Data From the Korean Acute Heart Failure (KorAHF) Registry<br />
Jaewon Oh 1 , Seok-Min Kang 1 , Eun-Seok Jeon 2 , Jae-Joong Kim 3 , Sang Hong Baek 4 , Myeong-Chan Cho 5 , Shung Chull<br />
Chae 6 , Dong-Ju Choi 7 , Byung-Su Yoo 8 , Byung-Hee Oh 9 . 1 Yonsei University College of Medicine, Seoul, Korea, Republic<br />
of; 2 Sungkyunkwan University College of Medicine, Seoul, Korea, Republic of; 3 University of Ulsan College of Medicine,<br />
Seoul, Korea, Republic of; 4 Catholic University of Korea College of Medicine, Seoul, Korea, Republic of; 5 Chungbuk National<br />
University College of Medicine, Cheongju, Korea, Republic of; 6 Kyungpook National University College of Medicine,<br />
Daegu, Korea, Republic of; 7 Seoul National University Bundang Hospital, Seongnam, Korea, Republic of; 8 Yonsei University<br />
Wonju College of Medicine, Wonju, Korea, Republic of; 9 Seoul National University Hospital, Seoul, Korea, Republic of<br />
302<br />
Heart Failure Supportive Care: Integrating Mortality Risk Modeling Into Heart Failure Care to Impact Outcomes<br />
Mitchell T. Saltzberg 1 , Roshni Guerry 2 , Kelly A. Whitmarsh 3 , Carolyn Moffa 1 , Lisa Keichline 4 . 1 ChristianaCare Health System,<br />
Newark, DE; 2 ChristianaCare Health System, Newark, DE; 3 ChristianaCare Health System, Newark, DE; 4 ChristianaCare<br />
Health System, Newark, DE<br />
303<br />
Inverse Changes in Quality of Life for Patients and Caregivers After Implantation of a Ventricular Assist Device<br />
Julie T. Bidwell, Christopher S. Lee. Oregon Health & Science University, Portland, OR<br />
Clinical Care .........................................................................................................................................................................<br />
304<br />
Trends in use of Swan-Ganz Catheter Among Patients with Acute Decompensated Heart Failure Hospitalization in<br />
United States, 2004 -2012: Did the ESACPE Trial Make a Difference?<br />
Ambarish Pandey 1 , Neetika Garg 2 , Nilay Kumar 3 . 1 University of Texas Southwestern Medical Center, Dallas, TX; 2 Beth<br />
Israel Deaconess Medical Center, Boston, MA; 3 Cambridge Health Alliance/Harvard Medical School, Cambridge, MA<br />
305<br />
Minute Ventilation-Targeted Adaptive Servo Ventilation Protects Renal Function In Acute Decompensated Heart<br />
Failure Patients<br />
Matt Kawahara 1 , Trenton Gluck 1 , Elizabeth Lee 1 , Boris Arbit 1 , 2 , Kathleen Sarmiento 1 , 2 , Atul Malhotra 1 , 2 , Alan Maisel 1 , 2 .<br />
1<br />
Veterans Affairs San Diego Healthcare System, San Diego, CA; 2 University of California, San Diego, La Jolla, CA<br />
306<br />
Prevalence of Heart Failure in Different Sickle Cell Variants by Age, Gender, and Systolic Dysfunction<br />
Sadeer Alkindi, Abdallah Almasoud, Ahmad Younes, Chantal Elamm, Rodolfo Benatti, Guilherme Oliveira, Robert Schilz,<br />
Jane Little, Mahazarin Ginwalla. University Hospitals Case Medical Center, Cleveland, OH<br />
307<br />
Increased Risk of Heart Block in Patients with Cardiac Amyloidosis on Amiodarone<br />
Sadeer Alkindi, Abdullah Almasoud, Ahmad Younes, Chantal Elamm, Rodolfo Benatti, Guilherme Oliveira, Mahazarin Ginwalla.<br />
University Hospitals Case Medical Center, Cleveland, OH<br />
308<br />
Predictors of Early and Late Heart Failure Post-orthotopic Liver Transplantation<br />
Mohammad A. Al-Ani, Forat G. Lutfi, Ameet P. Patel, Vikas Kullar, Angela Dolganiuc, Juan R. Vilaro, Roberto J. Firpi-Morell,<br />
Mustafa M. Ahmed. University of Florida, Gainesville, FL<br />
95
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
309<br />
Correlates of Spirometery to Invasively Measured Pulmonary Arterial Hemodynamics in Advanced Chronic Heart<br />
Failure<br />
Mohammad Alasaad 1 , Justin Grodin 1 , Vijay Ngarajan 2 , W.H. Wilson Tang 1 . 1 Cleveland Clinic Foundation, Cleveland, OH;<br />
2<br />
University of Virginia, Charlottesville, VA<br />
310<br />
The Importance of Defining Red Blood Cell Mass in the Management of Volume Overload Chronic Systolic Heart<br />
Failure<br />
Wayne L. Miller. Mayo Clinic, Rochester, MN<br />
313<br />
Identifying a Strong Association Between Physical and Affective Symptom Clusters in Heart Failure<br />
Quin E. Denfeld 1 , James O. Mudd 2 , Shirin O. Hiatt 1 , Jill M. Gelow 2 , Christopher V. Chien 2 , Christopher S. Lee 1 , 2 . 1 Oregon<br />
Health & Science University, Portland, OR; 2 Oregon Health & Science University, Portland, OR<br />
314<br />
Pre-discharge Bedside Exercise Gas Exchange Measurements Predict 30 Day Heart Failure Patient Readmissions<br />
Gregory D. Lewis 1 , Ashley Dress 1 , Gregory A. Ewald 2 , Jean Flanagan 2 , Peter Eckman 3 , Aaron Eisman 1 , Jennifer Nelson 3 ,<br />
Dean MacCarter 4 , Abraham Kocheril 5 . 1 Massachusetts General Hospital, Boston, MA; 2 Washington University, St. Louis,<br />
MO; 3 Universtiy of Minnesota, Minneapolis, MN; 4 Shape Medical Systems, St. Paul, MN; 5 University of Illinois, Champaign,<br />
IL<br />
315<br />
Case Series Defining Role of External Chest Compressions (ECC) in Patients with Ventricular Assist Device (VAD)<br />
Bhaskar Arora, Jonathan Hammond, Nicole Chomick, Tari Devoe, Nicole Huhn, Jason Gluck. Hartford Hospital, Hartford, CT<br />
317<br />
Prognostic Value of a 6-Minute Walk Test in Patients Undergoing Percutaneous Coronary Intervention: A Prospective<br />
Study.<br />
Bhavin C. Patel 1 , Siddharth A. Wayangankar 1 , Udho Thadani 1 , Pedro Lozano 1 , Faisal Latif 1 , Daniel Zhao 2 , Cheuk Leung 2 ,<br />
Tarun W. Dasari 1 . 1 University of Oklahoma Health Sciences Center, Oklahoma City, OK; 2 University of Oklahoma Health<br />
Sciences Center, Oklahoma City, OK<br />
318<br />
Peripartum Cardiomyopathy Network: Medication and Device Therapy Use in the First Year<br />
Kismet Rasmusson 1 , Dennis McNamara 2 , Deborah Budge 1 , Abdallah Kfoury 1 , Uri Elkayam 3 , Michael Givertz 4 , Richard<br />
Sheppard 5 , Greg Ewald 6 , Eileen Hsich 7 , Kalgi Modi 8 , Rami Alharethi 1 . 1 Intermountain Heart Institute, Salt Lake City, UT;<br />
2<br />
Univesity of Pittsburgh, Pittsburgh, PA; 3 University of Southern California, Los Angeles, CA; 4 Brigham and Women's<br />
Hospital, Boston, MA; 5 Jewish General, Montreal, QC, Canada; 6 Washington University, St. Louis, MO; 7 Cleveland Clinic,<br />
Cleveland, OH; 8 Louisiana State University, Shreveport, LA<br />
320<br />
The Impact of Sleep Apnea Syndrome Post Cardiac Transplantation<br />
Sandra Carey. Baylor Scott & White Health, Dallas, TX<br />
321<br />
Pharmacotherapy for VAD Thrombus: Response Rates and Financial Impact of Anticoagulant Strategies<br />
Lynne Sylvia 1 , Frank Massaro 1 , David DeNofrio 2 , Michael Kiernan 2 . 1 Tufts Medical Center, Boston, MA; 2 Tufts Medical<br />
Center, Boston, MA<br />
96
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
323<br />
Is the Nutritional Risk Index Useful in Advanced Heart Failure Patients?<br />
Gardner Yost 1 , Burhan Mohamedali 2 , Geetha Bhat 1 . 1 Advocate Christ Medical Center, Oak Lawn, IL; 2 Rush University<br />
Medical Center, Chicago, IL<br />
Management Strategies, Adherence/ Self Care ..........................................................................................<br />
324<br />
Student Heart Failure Intervention Project: A Pilot Study of Population Analytics and Outreach<br />
William B. Reichert 1 , Gerard Hoatam 1 , Emily Schmidt 1 , Michael Leher 1 , Arathi Gorur 1 , Anna Jones 1 , Anantharam Kalya 2 ,<br />
Priya Radhakrishnan 2 . 1 Creighton University School of Medicine, Omaha, NE; 2 St. Joseph's Hospital and Medical Center,<br />
Phoenix, AZ<br />
325<br />
Predicting Absolute Risk for Unplanned Cardiovascular Readmissions in Adults With Chronic Heart Failure<br />
Vasiliki Betihavas 1 , Steven A. Frost 2 . 1 Sydney University, Sydney, Australia; 2 University of Western Sydney, Sydney, Australia<br />
326<br />
Reasons for Heart Failure Hospitalization: Nonadherence versus<br />
Worsening Heart Failure<br />
Nisha A. Gilotra, Adam Shpigel, Ike S. Okwuosa, Ruth Tamrat, Deirdre Flowers, Stuart D. Russell. Johns Hopkins Hospital,<br />
Baltimore, MD<br />
327<br />
Feasibility of Remote, Non-Invasive, Wireless, Continuous Real-Time Monitoring of Heart Rate in Heart Failure<br />
Patients<br />
Lyle Olson, Nancy Lexvold, Virend Somers, Paul Friedman, Louis Schenck, Bradley Lewis, Charles Bruce. Mayo Clinic,<br />
Rochester, MN<br />
328<br />
Effect of Telemanagement in Patients Discharged to a Nursing Facility After Heart Failure (HF) Hospitalization.<br />
Santosh G. Menon 1 , Mindy Brewer 2 , Kim Barrows 2 , Tashua Woods-Stroup 2 , Heather Overbeck 3 , Amy Dadosky 4 , Maureen<br />
Corl 4 , Ken Bertke 4 , Natasha Hiles 1 , Tracy Preidt 4 , Stacey Arnold 1 , Kathleen Daly 1 , Eugene Chung 1 . 1 Ohio Heart and Vascular<br />
Center, Cincinnati, OH; 2 Brookwood Retirement Community, Cincinnati, OH; 3 The Christ Hospital, Cincinnati, OH; 4 The<br />
Christ Hospital, Cincinnati, OH<br />
329<br />
Myers Briggs Type Indicator and Outcomes in Heart Failure Patients<br />
Ike S. Okwuosa, Nisha A. Gilotra, Adam Shpigel, Ruth Tamrat, Deirdre Flowers, Kimberly Skarupski, David Yousem, Stuart<br />
D. Russell. Johns Hopkins Hospital, Baltimore, MD<br />
330<br />
The Relationships of Fatigue and Depression to Hospitalizations and Gender Differences in Patients with Heart Failure<br />
Seongkum Heo, Jean McSweeney, Pao-Feng Tsai, Songthip Ounpraseuth. University of Arkansas for Medical Sciences,<br />
Little Rock, AR<br />
97
POSTER RECEPTION II - SUNDAY<br />
POSTERS<br />
331<br />
Impact of a Community-Based Heart Failure Disease Management Program<br />
Gregg Steahr, Linda Kelly, C. Meredith Moore, Brenda Hott. Northside Hospital, Cumming, GA<br />
332<br />
Heart Failure Patients With Dyspnea Had Higher Device-Based Respiratory Rate Than Those Without<br />
Roy S. Gardner 1 , Bela Merkely 2 , Pier Lambiase 3 , Yi Zhang 4 , Qi An 4 , Viktoria Averina 4 , Robert Sweeney 4 , Scott Wehrenberg 5 .<br />
1<br />
Golden Jubilee National Hospital, Glasgow, United Kingdom; 2 Semmelweis University Heart Center, Budapest, Hungary;<br />
3<br />
The Heart Hospital, London, United Kingdom; 4 Boston Scientific, St Paul, MN; 5 Boston Scientific, St Paul, MN<br />
333<br />
The Wisconsin Pharmacy Quality Collaborative - A Statewide Network of Community Pharmacists to Improve Heart<br />
Failure Outcomes<br />
Joseph Rinka 1 , Orly Vardeny 2 , Claudius Mahr 3 , Stacey M. Gardiner 4 , Erika M. Horstmann 5 . 1 Concordia University Wisconsin<br />
School of Pharmacy, Mequon, WI; 2 University of Wisconsin-Madison, Madison, WI; 3 University of Washington, Seattle,<br />
WA; 4 Medical College of Wisconsin, Milwaukee, WI; 5 The Pharmacy Society of Wisconsin, Madison, WI<br />
Late Breaking Clinical Trials .....................................................................................................................................<br />
335<br />
Phase IIb safety and efficacy study of BAY 94-8862 in subjects with worsening chronic heart failure and left ventricular<br />
systolic dysfunction and either type 2 diabetes mellitus with or without chronic kidney disease or moderate chronic kidney<br />
disease alone (ARTS-HF)<br />
Gerasimos Filippatos, Stefan D. Anker, Michael Böhm, Mihai Gheorghiade, Lars Køber, Henry Krum, Aldo P. Maggioni,<br />
Piotr Ponikowski, Adriaan A. Voors, Faiez Zannad, So-Young Kim, Christina Nowack, Giovanni Palombo, Peter Kolkhof,<br />
Nina Kimmeskamp-Kirschbaum, Alexander Pieper, and Bertram Pitt<br />
336<br />
Ferric Carboxymaltose in Iron Deficient Heart Failure Patients: A Meta-Analysis on Individual Patient Data<br />
Anker SD, Comin-Colet J, Filippatos G, Kirwan BA, Ruschitzka F, Arutjunov GP, Motro M , Mori C, Moneuse P, Pocock<br />
SJ, van Veldhuisen DJ, Ponikowski P<br />
337<br />
Evaluation of ReDS-guided Patient Management in Ambulatory Heart Failure Patients At-Risk for Rehospitalization<br />
ReDS-HF Study<br />
William T Abraham, Tuvia Ben Gal, Jean Marc Weinstein, Aharon Abbo, Offer Amir<br />
98
2015 19th Annual Scientific Assembly<br />
EXHIBIT HALL<br />
September 26 – 29, 2015<br />
Gaylord National Harbor • National Harbor, Maryland<br />
Sessions Begin Saturday morning at 10:30am
EXHIBIT HALL ACTIVITIES<br />
Saturday, September 26, 6:00 PM – 8:00 PM<br />
Exhibit Hall Opening Reception<br />
Saturday, September 26, 6:30 PM – 7:30 PM<br />
Poster Reception and Moderated Poster Sessions<br />
Sunday, September 27, 5:30 PM – 6:30 PM<br />
Poster Reception and Moderated Poster Sessions<br />
Industry Expert Theaters<br />
Industry Expert Theatres are non-CME educational activities<br />
held in dedicated space in the exhibit hall. They allow<br />
industry experts an opportunity to provide clinical updates<br />
and educate attendees on current therapies, disease states,<br />
products and pipeline activities while remaining close to the<br />
action in the exhibit hall. Sessions are formatted for learning<br />
and are a great way to receive higher level interaction<br />
and engagement with company representatives.<br />
Educational activities held in the exhibit hall do not provide<br />
continuing education credit.<br />
Saturday, September 26<br />
6:15 PM – 7:15 PM<br />
Exhibit Hall<br />
Targeting Neurohormones in Heart<br />
Failure: The Potential Role of Endogenous<br />
Compensatory Peptides<br />
Faculty:<br />
Milton Packer, MD<br />
Description:<br />
In heart failure (HF), the renin-angiotensin system (RAS)<br />
has been difficult to control possibly because of its predilection<br />
to escape from suppression during long-term treatment.<br />
Several endogenous compensatory peptides (ECPs) can act<br />
as biological antagonists of the RAS, but their activity is<br />
diminished in HF, presumably because of various factors<br />
such as naturetic peptide desensitization, decreased vascular<br />
reactivity, and a marked increase in ECP degradation. This<br />
program will review the physiologic role of these ECPs and<br />
the evidence suggesting their diminished activity as well as<br />
their importance in HF.<br />
Sunday, September 27<br />
10:10 AM – 10:40 AM<br />
Exhibit Hall<br />
Make a Move Sooner: Results from the<br />
ROADMAP Study Comparing LVAD to<br />
Medical Management<br />
Faculty:<br />
Jerry D. Estep, MD, FACC – Houston Methodist Hospital<br />
Joseph Rogers, MD – Duke University School of Medicine<br />
Description:<br />
Learn how to apply the latest clinical results from the<br />
ROADMAP study to your practice. Understand the risk and<br />
benefits of LVAD therapy for non-inotrope dependent advanced<br />
heart failure patients. Learn why the study supports<br />
the use of HeartMate II ® in this patient population.<br />
Sponsored by Amgen<br />
Sponsored by Thoratec Corporation<br />
12:10 PM – 1:10 PM<br />
Exhibit Hall<br />
NT-proBNP in Latest Heart Failure<br />
Treatment<br />
Faculty:<br />
Tariq Ahmad, MD, MPH<br />
Description:<br />
Over the past several years, the clinical utility of testing for<br />
natriuretic peptides has been increasingly recognized. This<br />
program will include analytical and clinical considerations<br />
of NT-proBNP testing as it relates to patient care. Faculty<br />
will also discuss how NT-proBNP can supplement your<br />
judgement in the management of heart failure patients.<br />
Sponsored by Roche<br />
Sponsored by Novartis Pharmaceuticals Corporation<br />
100
EXHIBIT HALL ACTIVITIES<br />
Industry Expert Theaters (continued)<br />
3:10 PM – 3:40 PM<br />
Exhibit Hall<br />
Furosemide 2.0: A Convenient Alternative<br />
to Intravenous Furosemide Treatment<br />
Faculty:<br />
Pieter Muntedam, MD<br />
Description:<br />
scPharmaceuticals is developing furosemide for subcutaneous<br />
delivery by means of a patch pump. In order to be given<br />
subcutaneously, a buffered formulation was developed with<br />
a neutral pH ( 7 . 4 as compared to commercial furosemide<br />
which is alkaline with a pH of around 9 . 0 ). The company is<br />
developing a patch pump for convenient administration of<br />
80<br />
mg. This wold provide "iv-like" diuresis without the need<br />
for iv. Theere are several intended uses: In the pre-acute<br />
patients who do need more than oral alone can provide; in<br />
the post-acute patient to reduce length of stay and; avoidance<br />
of need for iv placement. It is not indicated for use in<br />
emergency situations.<br />
Sponsored by scPharmaceuticals<br />
5:15 PM – 6:15 PM<br />
Exhibit Hall<br />
A New Treatment Approach for Patients<br />
With Chronic Systolic Heart Failure<br />
Faculty:<br />
Sheryl Chow, PharmD<br />
Sponsored by Amgen<br />
Monday, September 28<br />
8:30 AM – 9:30 AM<br />
Exhibit Hall<br />
A New Treatment Approach for Patients<br />
With Chronic Systolic Heart Failure<br />
Faculty:<br />
Vasilios Papademetriou, MD<br />
10:10 AM – 10:40 AM<br />
Exhibit Hall<br />
Navigating Patient Conversations: Tough<br />
Choices with Advanced Heart Failure<br />
Therapies<br />
Faculty:<br />
Larry Allen, MD, MHS – University of Colorado<br />
Sean Pinney, MD – Mount Sinai Medical Center<br />
Description:<br />
Learn how to address the most challenging patient conversations<br />
when speaking with advanced heart failure patients<br />
about LVAD therapy. Discuss case studies highlighting<br />
best practices and techniques to help the conversation be as<br />
effective as possible.<br />
Sponsored by Thoratec Corporation<br />
12:10 PM – 1:10 PM<br />
Exhibit Hall<br />
New Heart Failure Treatment Approved:<br />
Highlights of Prescribing Information<br />
Faculty:<br />
Javed Butler, MD - Stony Brook University<br />
Barry Greenberg, MD - University of California, San Diego<br />
Description:<br />
Join Dr. Javed Butler and Dr. Barry Greenberg as they<br />
present information on a new heart failure medication at<br />
the Novartis Product Theater. Presentation topics will cover<br />
indication and usage, dosage and administration, dosage<br />
forms and strengths, warnings and precautions, adverse<br />
reactions, clinical pharmacology, mechanism of action,<br />
clinical studies, and how supplied/storage and handling.<br />
This presentation provides a thorough review of the clinical<br />
profile for this new heart failure medication.<br />
Sponsored by Novartis Pharmaceuticals Corporation<br />
Sponsored by Amgen<br />
101
EXHIBIT HALL ACTIVITIES<br />
2015 Clinical Trial Row Program Descriptions<br />
These posters will be on display in the Exhibit Hall from<br />
Saturday evening through Monday afternoon. Representatives<br />
will be at posters 6:30 PM – 7:30 PM Saturday and<br />
5:30 PM – 6:30 PM on Sunday during the poster receptions.<br />
These are trials in the planning, recruiting, or follow-up<br />
states.<br />
Trial Name: A Genotype-Directed Comparative Effectiveness<br />
Trial of Bucindolol and Toprol-XL for Prevention<br />
of Symptomatic Atrial Fibrillation/Atrial Flutter in<br />
Patients with Heart Failure<br />
Acronym: GENETIC-AF<br />
Sponsor: ARCA biopharma<br />
Program Description<br />
GENETIC-AF is a Phase 2B/3, double-blind, comparative<br />
effectiveness study evaluating bucindolol vs. metoprolol on<br />
the time to first event of symptomatic AF/AFL in HFREF<br />
patients who are at high risk of AF/AFL recurrence. This<br />
genotype-directed study is enrolling patients with the beta-1<br />
389 Arg/Arg adrenergic receptor (~50% of U.S. population)<br />
GENETIC-AF is currently enrolling patients for the Phase<br />
2B stage of the trial, and site identification for Phase 3 is<br />
ongoing.<br />
Trial Name: DISCOVERY: A Study Examining the<br />
Prevalence of TTR Mutations in Subjects Suspected of<br />
Having Cardiac Amyloidosis<br />
Acronym: DISCOVERY<br />
Sponsor: Alnylam Pharmaceuticals<br />
Program Description<br />
DISCOVERY is a prospective, international, observational<br />
study examining the prevalence of transthyretin (TTR) mutations<br />
in subjects who may have cardiac amyloidosis.<br />
Trial Name: A Phase 3 Multicenter, Multinational,<br />
Randomized, Double-Blind, Placebo-Controlled Study<br />
to Evaluate the Efficacy and Safety of ALN TTRSC in<br />
Patients With Transthyretin (TTR) Mediated Familial<br />
Amyloidotic Cardiomyopathy (FAC)<br />
Acronym: ENDEAVOUR<br />
Sponsor: Alnylam Pharmaceuticals<br />
Program Description<br />
ENDEAVOUR is a phase 3, randomized, double-blind,<br />
placebo-controlled, global study designed to evaluate the<br />
efficacy and safety of revusiran (ALN TTRSC), an investigational<br />
GalNAc-siRNA conjugate, in patients with<br />
transthyretin (TTR)-mediated Familial Amyloidotic Cardiomyopathy<br />
(FAC). The co-primary endpoints of the study are<br />
the change compared to baseline in 6-minute walk distance<br />
(6-MWD) and the percent reduction in TTR burden between<br />
placebo and revusiran treated patients at 18 months.<br />
Trial Name: Safety of Repeat Doses of IV Serelaxin in<br />
Subjects With Chronic Heart Failure<br />
Acronym: RELAX-REPEAT<br />
Sponsor: Novartis Pharmaceuticals<br />
Program Description<br />
A prospective, double-blind, multicenter study evaluating<br />
the safety of repeat 48h IV serelaxin dosing in subjects with<br />
chronic heart failure<br />
Evaluating the safety of repeat 48 hour IV serelaxin dosing<br />
through the detection of anti-serelaxin antibodies and any<br />
related adverse events.<br />
Trial Name: RELAX-AHF-ASIA<br />
Acronym: CRLX030A2302<br />
Sponsor: Novartis Pharmaceuticals<br />
Program Description<br />
Multicenter, randomized, double-blind, placebo controlled<br />
phase III study to evaluate the efficacy, safety and tolerability<br />
of a 48h intravenous infusion of 30 μg/kg/day serelaxin<br />
when added to standard therapy in Asian patients with<br />
acute heart failure.<br />
102
EXHIBIT HALL ACTIVITIES<br />
Clinical Trial Row Descriptions (continued)<br />
Trial Name: Efficacy, safety and tolerability of serelaxin<br />
when added to standard therapy in acute heart failure<br />
patients<br />
Acronym: RELAX-AHF-2<br />
Sponsor: Novartis Pharmaceuticals<br />
Program Description<br />
A randomized, double-blind, placebo-controlled phase III<br />
study to evaluate the efficacy, safety and tolerability of serelaxin<br />
when added to standard therapy in acute heart failure<br />
patients<br />
Trial Name: Randomized, Double-Blind, Placebo<br />
Controlled Study of the Short Term Clinical Effects of<br />
Tolvaptan in Patients Hospitalized for Worsening Heart<br />
Failure with Challenging Volume Management<br />
Acronym: SECRET of CHF<br />
Sponsor: Cardiovascular Clinical Science Foundation<br />
Program Description<br />
This is a randomized, Double-Blind, Placebo-Controlled<br />
Study looking at the Short Term Clinical Effects of Tolvaptan<br />
in Patients Hospitalized for worsening heart failure with<br />
challenging volume management.<br />
Trial Name: Chronic Oral Study of Myosin Activation to<br />
Increase Contractility in Heart Failure (COSMIC-HF):<br />
A Double-blind, Randomized, Placebo-controlled, Multicenter,<br />
Dose Escalation Study<br />
Acronym: COSMIC-HF<br />
Sponsor: Amgen, Inc.<br />
Program Description<br />
COSMIC-HF is a multicenter, randomized, double-blind,<br />
placebo-controlled, dose-escalation study designed to select<br />
an oral modified-release formulation and dose of omecamtiv<br />
mecarbil (OM) for chronic twice daily dosing in patients<br />
with heart failure and left ventricular systolic dysfunction<br />
and to characterize the pharmacokinetics of OM over 20<br />
weeks of treatment.<br />
Trial Name: A Multicenter, International, Phase 3,<br />
Double-blind, Placebo-controlled, randomized study to<br />
evaluate the Efficacy, Safety and Tolerability of Daily<br />
Oral Dosing of Tafamidis Meglumine 20 mg or 80 mg<br />
in Comparison to Placebo in Subjects Diagnosed with<br />
Transthyretin Cardiomyopathy<br />
Acronym: ATTR-ACT<br />
Sponsor: Pfizer<br />
Program Description<br />
Phase 3, Double-blind, Placebo-controlled, Randomized<br />
Study to Evaluate Daily Oral Dosing of Tafamidis Meglumine<br />
20 mg or 80 mg Compared with Placebo in Subjects<br />
Diagnosed with Transthyretin Cardiomyopathy (TTR-CM)<br />
Trial Name: Sensible Medical Innovations Lung Fluid<br />
Status Monitor Allows Reducing Readmission Rate of<br />
the Heart Failure Patients- a randomized controlled<br />
study<br />
Acronym: SMILE<br />
Sponsor: Sensible Medical Innovations Inc.<br />
Program Description<br />
The SMILE study is designed as a prospective, randomized,<br />
controlled, multi-center trial. Patients will be enrolled<br />
during an index hospitalization for acutely decompensated<br />
Heart Failure (ADHF) and will be followed for a minimum<br />
of 3 months or a maximum of 9 months (until the last patient<br />
has completed the 3 month follow-up). Patients will be<br />
blinded to the ReDS readings value.<br />
The Remote Dielectric Sensing (ReDS) device provides<br />
non-invasive measurement of lung fluid content. It comprises<br />
a wearable vest with the embedded sensors and a<br />
bedside console. A measurement reading is provided with<br />
90 seconds. Results are shared with the treating physician<br />
via a secured web portal.<br />
103
EXHIBIT HALL ACTIVITIES<br />
Clinical Trial Row Descriptions (continued)<br />
Trial Name: Study of Efficacy and Safety of LCZ696 in<br />
Heart Failure Patients NYHA Class II-IV with Preserved<br />
Ejection Fraction<br />
Acronym: PARAGON-HF<br />
Sponsor: Novartis<br />
Program Description<br />
Heart failure with preserved ejection fraction(HFpEF) is<br />
prevalent and carries dire consequences. No pharmacologic<br />
therapy have shown benefit in HFpEF. Sacubitril/valsartan<br />
has been shown to be superior to enalapril for the reduction<br />
of cardiovascular (CV) death and HF hospitalization in<br />
patients with HFrEF. The objective of the PARAGON-HF<br />
trial is the compare sacubitril/valsartan to valsartan in<br />
reducing CV death and total HF hospitalizations in patients<br />
with HFpEF.<br />
Reducing the rate of the cv<br />
Trial Name: Baroreflex Activation Therapy for Heart<br />
Failue Pivotal Trial<br />
Acronym: BeAT-HF<br />
Sponsor: CVRx, Inc.<br />
Program Description<br />
The Barostim BeAT-HF Pivotal study is a prospective,<br />
randomized, controlled trial of Baroreflex Activation Therapy<br />
in patients with reduced ejection fraction HF. Subjects<br />
will be randomized in a 1:1 ratio to receive a device plus<br />
optimal medical management or to receive optimal medical<br />
management alone. The primary efficacy endpoint is a<br />
demonstrated reduction between the two arms in events of<br />
cardiovascular mortality or worsening HF that leads to hospitalization,<br />
cardiac assist device or heart transplantation.<br />
Trial Name: Effect of GS-6615 on Exercise Capacity in<br />
Subjects With Symptomatic Hypertrophic Cardiomyopathy<br />
Acronym: LIBERTY-HCM<br />
Sponsor: Gilead Sciences, Inc.<br />
Program Description<br />
Randomized, double-blind, placebo-controlled study to<br />
evaluate the effect of GS-6615 (a potent and selective<br />
inhibitor of the cardiac late sodium current) on exercise<br />
capacity and quality of life in participants with symptomatic<br />
hypertrophic cardiomyopathy (HCM). The primary objective<br />
is to assess the change in exercise capacity in subjects<br />
with symptomatic HCM, as measured by the change in Peak<br />
VO2 from baseline to week 24.<br />
Trial Name: The AdaptResponse trial<br />
Acronym: The AdaptResponse trial<br />
Sponsor: Medtronic PLC<br />
Program Description<br />
AdaptResponse is an event-driven worldwide randomized<br />
trial that will compare patient and healthcare system outcomes,<br />
including mortality, hospitalizations and intervention<br />
for worsening heart failure, in heart failure patients who receive<br />
a cardiac resynchronization therapy (CRT) pacemaker<br />
or CRT-defibrillator with the AdaptivCRT® feature enabled<br />
versus patients receiving standard CRT. Three-thousand<br />
patients with a CRT indication, Left Bundle Branch Block<br />
(Strauss criteria), normal AV conduction,<br />
LVEF 35%, NYHA class II, III, or IV despite optimal<br />
medical therapy will receive CRT and be followed for a<br />
minimum of 24 months to assess superiority of the AdaptivCRT®<br />
feature.<br />
104
EXHIBIT HALL ACTIVITIES<br />
Clinical Trial Row Descriptions (continued)<br />
Trial Name: C-Pulse System: A Heart Assist Device<br />
Clinical Study<br />
Acronym: COUNTER HF<br />
Sponsor: Sunshine Heart, Inc.<br />
Program Description<br />
Sunshine Heart is sponsoring a prospective, multi-center,<br />
randomized trial to assess the safety and efficacy of the<br />
C-Pulse System. The purpose of the study is to determine<br />
whether the use of the C-Pulse as a treatment for patients<br />
in moderate to severe heart failure has demonstrated safety<br />
and efficacy, such that the C-Pulse System merits Food and<br />
Drug Administration (FDA) approval to market the device<br />
in the United States.<br />
Trial Name: ALLogeneic Heart STem Cells to Achieve<br />
Myocardial Regeneration<br />
Acronym: ALLSTAR<br />
Sponsor: Capricor, Inc.<br />
Program Description<br />
Randomized, Double-Blind, Placebo-Controlled Phase I/II<br />
Study of the Safety and Efficacy of<br />
Intracoronary Delivery of Allogeneic Cardiosphere-Drived<br />
Cells in Patients with a Myocardial<br />
Infarction and Ischemic Left Ventricular Dysfunction.<br />
Trial Name: Adjuvant Allogeneic Immuno-modulatory<br />
Progenitor Cell Therapy to Mitigate Incomplete Revascularisation<br />
in Coronary Artery Bypass Grafting<br />
Patients with Narrow Coronary Arteries, Bifurcation<br />
and Trifurcation.<br />
Acronym: Heartcel<br />
Sponsor: Cell Therapy Limited<br />
Program Description<br />
The inherent cardiac anatomical abnormalities of narrow<br />
coronary arteries, bifurcation and trifurcation, confers a<br />
high risk (P
EXHIBIT HALL ACTIVITIES<br />
Clinical Trial Row Descriptions (continued)<br />
Trial Name: Biased Ligand of the Angiotensin receptor<br />
Study in Acute Heart Failure<br />
Acronym: BLAST-AHF<br />
Sponsor: Trevena, Inc.<br />
Program Description<br />
BLAST-AHF is a Phase 2b, international, randomized,<br />
multicenter, double-blind, placebo-controlled, dose ranging<br />
study to explore the efficacy of TRV027 in patients hospitalized<br />
for acute decompensated heart failure. TRV027<br />
is a beta-arrestin biased ligand of the angiotensin II type<br />
1 receptor (AT1R) that competitively inhibits G-protein<br />
activation by angiotensin II, while activating AT1R-specific<br />
beta-arrestin recruitment.<br />
Trial Name: Autologous Bone Marrow Mononuclear<br />
Cells Using the CardiAMP Cell Therapy in Patients<br />
with Post MI Heart Failure<br />
Acronym: CardiAMP Heart Failure Trial<br />
Sponsor: BioCardia Inc.<br />
Program Description<br />
The CardiAMP trial is a prospective, multi-center, randomized,<br />
sham-controlled, patient and evaluator-blinded<br />
pivotal study comparing the CardiAMP Cell Therapy to a<br />
Sham treatment. It is a comprehensive therapeutic for the<br />
treatment of ischemic systolic heart failure, that includes<br />
a companion diagnostic, and is comprised of (i) a cell<br />
potency screening test, (ii) a point of care cell processing<br />
platform, and (iii) a biotherapeutic delivery system.<br />
106
EXHIBIT HALL ACTIVITIES<br />
Exhibitor Listing with Booth Numbers<br />
Abiomed, Inc. Booth #416<br />
Advanced Cardiothoracis Consultants, LL Booth #411<br />
AltaThera Pharmaceuticals Booth #417<br />
American Heart Association/American Stroke Association Booth #312<br />
Amgen Booth #501<br />
Amyloidosis Foundation Booth #615<br />
Arbor Pharmaceuticals, LLC Booth #310<br />
CardiacAssist, Inc Booth #612<br />
CareDx, Inc. Booth #607<br />
Coram CVS/Specialty Infusion Services Booth #412<br />
Cytokinetics, Inc. Booth #307<br />
DAXOR Corporation Booth #414<br />
Elsevier Booth #516<br />
Fresenius Medical Care - UF Complete Booth #415<br />
GeneDX Booth #413<br />
Heart Failure Society of America<br />
Maryland Hallway<br />
Heart Genomics, LLC Booth #616<br />
HeartWare, Inc. Booth #606<br />
Inova Heart and Vascular Institute Booth #207<br />
Integrated Sensing Systems, Inc. Booth #716<br />
Janssen Pharmaceuticals, Inc. Booth #709<br />
Lifemed USA Booth #317<br />
Medtronic, Inc. Booth #314<br />
Millar, Inc. Booth #712<br />
Miller Pharmacal Group Booth #513<br />
Myocarditis Foundation Booth #613<br />
NeuMedx Booth #611<br />
Novartis Pharmaceuticals Corporation Booth #301<br />
OnTrack to Health Booth #514<br />
Option Care Booth #710<br />
Prompt Care Home Infusion, LLC Booth #515<br />
Relypsa, Inc Booth #707<br />
ResMed Booth #407<br />
Roche Diagnostics Booth #511<br />
scPharmaceuticals Booth #617<br />
Sensible Medical Innovations Booth #313<br />
Shape Medical Systems, Inc. Booth #614<br />
Society of Cardiovascular Patient Care Booth #711<br />
Soleo Health Booth #517<br />
St. Jude Medical Booth #701<br />
The American Association of Heart Failure Nurses Booth #806<br />
Thoratec Corporation Booth #510<br />
Wolters Kluwer Health Booth #714<br />
ZOLL Booth #507<br />
ZS Pharma Booth #715<br />
107
IDF<br />
EC<br />
MACH.<br />
34 33<br />
IDF<br />
N710<br />
45<br />
N710<br />
45<br />
N710<br />
45<br />
N710<br />
45<br />
EXHIBIT HALL ACTIVITIES<br />
Service<br />
Desk<br />
CLINICAL TRIAL ROW<br />
Internet<br />
Station<br />
Late<br />
Breaking<br />
Breaking<br />
Abstracts<br />
Posters<br />
121<br />
521<br />
317<br />
416 417<br />
516 517<br />
616 617<br />
716<br />
314<br />
414 415<br />
514 515<br />
614 615<br />
714 715<br />
312<br />
313<br />
412 413<br />
513<br />
612 613<br />
712<br />
310<br />
411<br />
510 511<br />
611<br />
710 711<br />
709<br />
207<br />
307<br />
407<br />
507<br />
606 607<br />
707<br />
806<br />
Product<br />
Theater<br />
301<br />
501<br />
701<br />
100<br />
10'-10"<br />
CHARGING STATION<br />
10'-10"<br />
CHARGING STATION<br />
5'<br />
5'<br />
ENTRANCE ENTRANCE ENTRANCE ENTRANCE<br />
M W<br />
M<br />
W<br />
108
EXHIBIT HALL ACTIVITIES<br />
Exhibitor Descriptions<br />
Abiomed, Inc.…………………………………..……416<br />
22 Cherry Hill Drive<br />
Danvers, MA 01923<br />
978-646-1487<br />
Lillian Garcia Palmer<br />
lpalmer@abiomed.com<br />
Website: www.abiomed.com<br />
Abiomed is a pioneer and global leader in healthcare technology and innovation,<br />
with a mission of RECOVERING HEARTS AND SAVING<br />
LIVES. The Company’s portfolio of products and services offer healthcare<br />
professionals an array of choices across a broad clinical spectrum.<br />
The Company’s flagship Impella device just recently received FDA<br />
approval, stating that use of Impella® 2.5 for elective and urgent high<br />
risk PCI is safe and effective<br />
Advanced Cardiothoracis Consultants, LLC...............411<br />
12155 Golden Bluff Ct<br />
Indianapolis, IN 46235<br />
317.823.9274<br />
Renee Lassinger<br />
reneelassinger@actc4solutions.com<br />
www.actc4solutions.com<br />
Utilizing over 40 years of clinical expertise in cardiothoracic, thoracic<br />
transplant/organ replacement, and advanced heart failure ACTC can<br />
evaluate financial and clinical aspects for programs to increase efficiencies.<br />
Whether a new or well established program, hospital, or insurer<br />
let ACTC assist you in maintaining financial viability and sustaining<br />
growth in today’s challenging healthcare market.<br />
AltaThera Pharmaceuticals…....................………….417<br />
200 S. Wacker Dr. Ste. 3100<br />
Chicago, IL 60606<br />
312.445.8924<br />
Patricia Dunnigan<br />
pdunnigan@altathera.com<br />
Website: www.alththera.com<br />
AltaThera Pharmaceuticals is a specialty pharmaceutical company<br />
focused on critical care therapies to address the unmet medical needs<br />
of patients with severe, and often rare disorders for which few effective<br />
treatments are available.<br />
American Heart Association/American<br />
Stroke Association……..................………....………...312<br />
7272 Greenville Avenue<br />
Dallas, TX 75231<br />
901-605-7055<br />
Kathryn Waggoner<br />
kathryn.waggoner@heart.org<br />
Website: www.heart.org<br />
As the leading organization working to build healthier lives, free of<br />
cardiovascular diseases and stroke, the American Heart Association<br />
is committed to providing medical professionals tools and resources<br />
to improve quality of care for patients.<br />
Amgen…………...................................……………….501<br />
One Amgen Center Drive<br />
Thousand Oaks, CA. 91320<br />
805.313.2743<br />
Brian Lotterman<br />
blotterman@amgen.com<br />
Website: www.amgen.com<br />
Amgen is committed to unlocking the potential of biology<br />
for patients suffering from serious illnesses by discovering,<br />
developing, manufacturing and delivering innovative human<br />
therapeutics. A biotechnology pioneer since 1980, Amgen has<br />
reached millions of patients around the world and is developing<br />
a pipeline of medicines with breakaway potential.<br />
Amyloidosis Foundation……………………………615<br />
7151 North Main Street #2<br />
Clarkston, MI. 48436<br />
248.922.9610<br />
Mary O'Donnell<br />
meo1256@aol.com<br />
Website: www.amyloidosis.org<br />
Amyloidosis Foundation is a non profit whose mission is to support patients<br />
and families while promoting research, education and awareness.<br />
Arbor Pharmaceuticals…………...........……….....…310<br />
6 Concoure Parkway, Suite 1800<br />
Atlanta, GA. 30328<br />
404.418.5305<br />
Wendy Yong<br />
wyong@arborpharma.com<br />
Website: www.arborpharma.com<br />
Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty<br />
pharmaceutical company currently focused on the cardiovascular,<br />
hospital and pediatric markets as well as generics through its Wilshire<br />
division. Visit www.arborpharma.com or send email inquiries to info@<br />
arborpharma.com.<br />
109
EXHIBIT HALL ACTIVITIES<br />
Exhibitor Descriptions (continued)<br />
CardiacAssist, Inc…………………………………...612<br />
240 Alpha Drive<br />
Pittsburgh, PA 15238<br />
412.963.7770<br />
Jill Kuhn<br />
marketing@tandemheart.com<br />
Website: www.tandemhear.com<br />
CardiacAssist, Inc. is the inventor of the world’s most versatile temporary<br />
cardiopulmonary bypass device, The TandemHeart® pump.<br />
Our small pump puts the power of bypass in the palm of your hand by<br />
providing up to 90% of native cardiac power output. The TandemHeart<br />
can be used in a variety of configurations (surgical, percutaneous<br />
cardiac support, percutaneous respiratory support) when paired with<br />
our PROTEK line of cannulae. Visit our booth to learn more about our<br />
latest innovations, PROTEK Duo and Voyager Vest.<br />
CareDx, Inc………………………………………….414<br />
3260 Bayshore Boulevard<br />
Brisbane, CA. 94005<br />
415.287.2313<br />
Jamie Autorino<br />
jautorino@caredxinc.com<br />
Website: www.caredxinc.com<br />
CareDX, Inc. is dedicated to improving the lives or organ transplant<br />
patients through noninvasive diagnostics. By combining<br />
the latest advances in genomics and bioinformatics technology,<br />
CareDx strives to stay at the forefront of organ transplant surveillance<br />
solutions.<br />
Coram CVS/Specialty Infusion Services………..….412<br />
555 17th Street, Suite 1500<br />
Denver, CO. 80202<br />
800.CORAMHC<br />
Chelsea Riscoe<br />
chelsea.riscoe@coramhc.com<br />
Website: www.coramhc.com<br />
Coram, a division of CVS Health, is a leading national provider<br />
of specialty home infusion services. With more than 85 branches<br />
and over 65 infusion suites, Coram offers both national presence<br />
and comprehensive local coverage. Coram’s 30+ years of clinical<br />
expertise and commitment to positive outcomes has earned it a<br />
reputation for excellence nationwide.<br />
Cytokinetics, Inc. …………………………………...307<br />
280 South Grand Ave<br />
South San Francisco, CA 94080<br />
Joanna Goldstein<br />
jgoldstein@cytokinetics.com<br />
Website: www.cytokinetics.com<br />
Cytokinetics, a biopharmaceutical company, is focused on discovering,<br />
developing and commercializing first-in-class muscle activators as potential<br />
treatments for debilitating diseases in which muscle performance<br />
is compromised and/or declining.<br />
DAXOR Corporation…………………...…………..414<br />
350 Fifth Avenue, Suite 7120<br />
New York, NY 10118<br />
212-244-0555<br />
Tina Lake<br />
rdunn@daxor.com<br />
Website: www.daxor.com<br />
Daxor Corporation’s BVA-100® Blood Volume Analyzer is a<br />
semi-automated instrument patented for direct measurement of blood<br />
volume, red cell and plasma volume. The system utilizes the Volumex®<br />
injection kit for a multi-sample blood volume. Measurement of blood<br />
volume is applicable for hypertension, CHF, transfusion, ICU/CCU,<br />
anemia, orthostatic hypotension and syncope.<br />
Elsevier Publishing …………………………….....…516<br />
1600 John F. Kennedy Blvd.<br />
Philadelphia, PA 19103<br />
215-235-3795<br />
Matthew Breen<br />
m.breen@elsevier.com<br />
Website: www.elsevierhealth.com<br />
Elsevier is a world-leading provider of information solutions that enhance<br />
the performance of science, health, and technology professionals,<br />
empowering them to make better decisions, and deliver better care.<br />
Fresenius Medical Care- UF Complete…..…………415<br />
920 Winter Street<br />
Waltham, MA. 02451<br />
781-699-4126<br />
Lisa Caso<br />
lisa.caso@fmc-na.com<br />
Website: www.fmcna.com<br />
UFComplete: A Complete Fluid Management Program for Heart Failure<br />
Patients. We provide ultrafiltration (UF) and post-discharge home<br />
monitoring services to improve outcomes in patients suffering from<br />
heart failure and fluid overload. Specifically, we address the pending<br />
challenges all hospitals face in reducing readmission rates for Heart<br />
Failure and Fluid Overload.<br />
110
EXHIBIT HALL ACTIVITIES<br />
Exhibitor Descriptions (continued)<br />
GeneDx ...............................................………..……….…...413<br />
481 Edward H Ross Dr<br />
Elmwood Park, NJ 07407<br />
800-229-5227 x 8205<br />
Marianne Sansing<br />
msansing@genedx.com<br />
Website: www.genedx.com<br />
GeneDx is highly respected laboratory specializing in genetic<br />
testing for inherited disorders. GeneDx offers sequencing and deletion/duplication<br />
testing for inherited cardiac disorders, mitochondrial<br />
disorders, neurological disorders, inherited cancer disorders,<br />
prenatal disorders and rare genetic disorders. GeneDx also offers<br />
whole exome sequencing, next-generation and microarray-based<br />
testing. Visit www.GeneDx.com or email GeneDx@GeneDx.com<br />
Inova Heart and Vascular Institute .............................207<br />
3300 Gallows Rd<br />
Falls Church, VA 22042<br />
703.776.3022<br />
Gail Walters<br />
gail.walters@inova.org<br />
Website: www.inova.org<br />
Inova Heart and Vascular Institute, headquartered on the Inova<br />
Fairfax Medical Campus, is one of the most complete,<br />
technologically-advanced cardiovascular centers in the<br />
U.S., providing the full spectrum of diagnostic, therapeutic,<br />
surgical and interventional cardiac services, including<br />
Heart Failure, Heart/Lung Transplantation, and Genomics<br />
Research through Inova’s new Center for Personalized<br />
Medicine.<br />
Heart Genomics, LLC………………………………616<br />
523 Michigan Avenue<br />
Miami Beach, FL. 33139<br />
530-563-6488<br />
Joe Gutierrez<br />
jgutierrez@heartgenomics.com<br />
Website: www.heartgenomics.com<br />
Heart Genomics, LLC. Heart Genomics has two different<br />
expression profiling diagnostic tests (“HeartGen5YP” and<br />
HeartGenMYO), which measure gene signatures and provide<br />
a highly accurate assessment of the 5 year prognosis of<br />
heart failure patients, as well as a highly accurate diagnosis<br />
of myocarditis.<br />
Integrated Sensing Systems, Inc ...................……..…716<br />
391 Airport Industrial Dr<br />
Ypsilanti, MI 48198<br />
734.547.9896<br />
Jessica Turner<br />
jturner@mems-iss.com<br />
Website: www.mems-iss.com<br />
Integrated Sensing Systems Inc., designs and manufactures MEMS<br />
based, implantable pressure sensors for cardiac applications. The<br />
TitanTM Wireless Implantable Hemodynamic Monitoring (WIHM)<br />
System is intended to be used as an adjunctive diagnostic tool for<br />
measuring and recording Left Atrium (LA) Hemodynamics, including<br />
rhythm, heart rate, heart rate variability, filling pressure and pressure<br />
waveforms, in both acute and chronic conditions.<br />
HeartWare .......…………………………..………….606<br />
500 Old Connecticut Path<br />
Framingham, MA. 01701<br />
Joanna McNamara<br />
jmcnamara@heartware.com<br />
Website: www.heartware.org<br />
The HVAD® Pump designed to be implanted in the pericardial<br />
space avoiding the more invasive surgical procedures required<br />
with older LVAD technologies. The HVAD Pump is commercially<br />
available around the world.<br />
Janssen Pharmaceuticals, Inc. ..................…………..709<br />
1000 Route 202<br />
Raritan, NJ 08869<br />
908-218-6000<br />
Mary Ann Gengo<br />
mgengo@its.jnj.com<br />
Website: www.janssenpharmaceuticalsinc.com<br />
Janssen Pharmaceuticals, Inc., a pharmaceutical company of Johnson &<br />
Johnson, provides medicines for an array of health concerns in several therapeutic<br />
areas, including: diabetes, mental health, and cardiovascular disease.<br />
111
EXHIBIT HALL ACTIVITIES<br />
Exhibitor Descriptions (continued)<br />
Lifemed USA………………………….........….....….317<br />
7790 Victoria Cir.<br />
Independence, OH 44131<br />
800-571-9079<br />
Murray Maynard<br />
mmaynard@lifemedusa.com<br />
Website: www.lifemedusa.com<br />
LIFEMED USA is the exclusive distributor of the NICaS system, a<br />
bioimpedence technology that allows for the accurate measurement of<br />
Cardiac Output in a non-invasive manner. The NICaS system is quick,<br />
very easy to use and is the only system which is classified by the FDA<br />
as being statistically equivalent to thermodilution. We look forward to<br />
welcoming you to our booth and demonstrating the NICaS system.<br />
Medtronic, Inc…………………………....….………314<br />
710 Medtronic Parkway<br />
Minneapolis, MN 55432<br />
763-505-0289<br />
Brooke Neus<br />
brooke.i.neus@medtronic.com<br />
Website: www.medtronic.com<br />
Through innovation and collaboration, Medtronic improves the lives<br />
and health of millions of people each year. Visit booth #314/316 to<br />
see our solutions to help you manage any heart failure patient. Learn<br />
more about our technology, services and solutions at Medtronic.<br />
com.<br />
Millar, Inc………………………..…………………..712<br />
6001-A Gulf Freeway<br />
Houston, TX. 77023<br />
832-667-7000<br />
Michelle Sanders<br />
msanders@millar.com<br />
Website: www.millar.com<br />
Millar strives to improve patient outcomes through true hemodynamics<br />
data. The Millar Mikro-Cath diagnostic pressure catheter<br />
provides exact data unaffected by patient movement to better<br />
understand the cardiovascular condition. The CD Leycom Inca<br />
PV loop system monitors the ventricular pressure-volume (PV)<br />
relationship, cardiac contractile state and intra-ventricular dyssynchrony<br />
in real-time.<br />
Miller Pharmacal Group, Inc………………………513<br />
350 Randy Road, Suite 2<br />
Carol Stream, IL 60188<br />
800-323-2935<br />
Stephen Wonsil<br />
swonsil@millerpharmacal.com<br />
Website: www.millerpharmacal.com<br />
Miller Pharmacal's 'MG PLUS PROTEIN' (TM) magnesium supplement<br />
treats and prevents the hypomagnesemia caused by diuretics<br />
(or immunosuppressants) without causing the GI disturbances<br />
common with magnesium oxide. Each easy-to-swallow, glazed,<br />
non-enteric coated tablet contains 133 mg of elemental magnesium,<br />
at a fraction of the cost of SLOW-MAG (TM).<br />
The Myocarditis Foundation……………………….613<br />
3518 Echo Mountain Dr<br />
Vingwood, TX 77345<br />
281-713-2962<br />
Genevieve Runmore<br />
genevieve@myocarditisfoundation.org<br />
Website: www.myocarditisfoundation.org<br />
The Myocarditis Foundation is a 501©3 Corporation whose<br />
Mission is to raise awareness on Myocarditis, educate the medical<br />
and public communities on Myocarditis, provide research grants<br />
specific to Myocarditis and emotionally support families affected<br />
by Myocarditis.<br />
NeuMeDx……………………………................……..611<br />
2014 Ford Road, Unit G<br />
Bristol, PA. 19007<br />
215-826-9998<br />
James Gunnerson<br />
jim.gunnerson@neumedx.com<br />
Website: www.neumedx.com<br />
NeuMeDx offers a Noninvasive Cardiac Output Monitor, providing the<br />
clinician with real time hemodynamic parameters to aid in the management<br />
Heart Failure. Utilization of the PhysioFlow’s Signal Morphology-based<br />
Impedance Cardiography (SM-ICG) coupled with appropriate<br />
therapy can impact quality, cost, efficiency and clinical outcomes.<br />
Novartis Pharmaceuticals Corporation……….....…301<br />
One Health Plaza<br />
East Hanover, NJ. 07936<br />
862-778-3505<br />
Patti Travisano<br />
patti.travisano@novartis.com<br />
Website: www.novartis.com<br />
Novartis Pharmaceuticals is dedicated to discovering, developing,<br />
manufacturing and marketing prescription drugs that help meet our<br />
customers’ medical needs and improve their quality of life.<br />
112
EXHIBIT HALL ACTIVITIES<br />
Exhibitor Descriptions (continued)<br />
OnTrack to Health…………………………………..514<br />
23896 N. Lakeshore Drive<br />
Glenwood, MN 56334<br />
320-634-0117<br />
Ronald Luetmer<br />
ronl@ontrack2health.com<br />
Website: www.ontrack2health.com<br />
OnTrack enables patients to self-manage their heart failure by leveraging<br />
mobile devices, providing an accurate, real-time view of medication<br />
adherence, self-care activities, and vital signs; viewable to patients,<br />
providers, and caregivers. With OnTrack, patients take ownership of<br />
their health.<br />
Option Care .....................................................................710<br />
1411 Lake Cook Rd, MS#L109<br />
Deerfield, IL 60015<br />
847-964-8033<br />
Rian Enriquez<br />
rian.enriquez@walgreens.com<br />
Website: www.walgreens.com<br />
Option Care is a leading provider of home infusion services.<br />
It has a staff of more than 1,700 clinical experts and provides<br />
comprehensive support to treat a broad range of acute and chronic<br />
conditions. Option Care provides service through its 90 infusion<br />
pharmacies and 100 alternate treatment sites nationwide.<br />
Prompt Care Home Infusion, LLC. ....……………..515<br />
51 Terminal Ave<br />
Clark, NJ 07066<br />
866-776-6782<br />
Kathy Larson<br />
kathy.larson@promptcare.net<br />
Website: www.promptcare.net<br />
PromptCare Home Infusion provides a full range of home<br />
infusion therapies and utilizes a customized innovative team<br />
approach to support our Stage D heart failure patients and<br />
their caregivers on Inotropic infusions to improve each patient’s<br />
quality of life. We achieve this through early screening<br />
and personalized ongoing patient follow up.<br />
Relypsa, Inc. .............................................……………..707<br />
100 Cardinal Way<br />
Redwood City, CA 94063<br />
650-421-9355<br />
Jeffrey Garland<br />
rbyrne@relypsa.com<br />
Website: www.relypsa.com<br />
Relypsa, Inc. is a biopharmaceutical company whose<br />
mission is to improve patients’ lives through the discovery,<br />
development and delivery of therapeutics that leverage<br />
polymer science and other novel approaches. The company’s<br />
lead product candidate, which has completed Phase<br />
3 clinical trials, is being developed for the treatment of<br />
hyperkalemia. Hyperkalemia is a life-threatening condition<br />
defined as abnormally elevated levels of potassium in the<br />
blood, which can present chronically and acutely. More<br />
information is available at www.relypsa.com<br />
ResMed ..................................................................……..407<br />
9001 Spectrum Center Blvd.<br />
San Diego, CA 92123<br />
858-836-5000<br />
Jennifer Terchek<br />
jennifer.terchek@resmed.com<br />
Website: wwww.resmed.com<br />
ResMed changes lives by developing medical equipment for treating<br />
and managing sleep-disordered breathing and respiratory disorders.<br />
Through 25 years of innovation, we have pioneered solutions to<br />
improve the health of those suffering from these conditions while<br />
raising awareness about the consequences of untreated sleep-disordered<br />
breathing<br />
Roche Diagnostics ................................................……..511<br />
9115 Hague Rd.<br />
Indianapolis, IN 46250<br />
317.440.3613<br />
Bethany Diacou<br />
bethany.diacou@roche.com<br />
Website: www.roche.com<br />
Roche is a leader in research-focused healthcare with combined<br />
strengths in pharmaceuticals and diagnostics. We are the world’s largest<br />
biotech company with truly differentiated medicines in oncology,<br />
virology, inflammation, metabolism and CNS. Roche is also the world<br />
leader in in-vitro diagnostics, tissue-based cancer diagnostics and a<br />
pioneer in diabetes management.<br />
113
EXHIBIT HALL ACTIVITIES<br />
Exhibitor Descriptions (continued)<br />
scPharmaceuticals ....................................................…..617<br />
131 Hartwell Ave., Ste. 215<br />
Lexington, MA 02421<br />
781-301-6706<br />
Katherine Taudvin<br />
ktaudvin@scpharma.com<br />
Website: www.scpharmaceuticals.com<br />
scPharmaceuticals is developing Furosemide 2.0 – a novel formulation<br />
of furosemide for subcutaneous delivery for use with a proprietary patch<br />
pump as a new option for the management of fluid overload in heart<br />
failure. Furosemide 2.0 would provide “iv-like” diuresis without the<br />
need for iv, reducing the resources and costs associated with intravenous<br />
or intramuscular administration<br />
Sensible Medical Innovations ................................…..313<br />
54 W. Yale Loop<br />
Irvine, CA 92604<br />
909-895-9800<br />
Erez Brem<br />
erez.b@sensible-medical.com<br />
Website: www.sensible-medical.com<br />
The Leader in Absolute Lung Fluid Measurement. Sensible has developed<br />
a wearable thoracic fluid status monitor for non-invasive measurement<br />
and monitoring of lung fluid, for patients with fluid management<br />
problems such as patients living with heart failure, taking diuretic<br />
medication or recovering from a coronary artery disease related event.<br />
Shape Medical Systems, Inc. ................................…....614<br />
MedTech Center<br />
5000 Township Parkway<br />
St. Paul, MN 55110<br />
Steve Anderson<br />
sanderson@shapemedsystems.com<br />
Point-of-care based cardiopulmonary light exercise testing system<br />
that determines the likely source and severity of unexplained dyspnea,<br />
assists in optimizing HF therapy, and reduces ADHF-related related to<br />
ADHF. Delegable, quick, easily interpreted and attractively reimbursed<br />
test.<br />
Society of Cardiovascular Patient Care ......................711<br />
6161 Riverside Drive<br />
Dublin, OH 43107<br />
614-408-1303<br />
Colleen Smith<br />
csmith1@scpc.org<br />
Website: www.scpc.org<br />
The Society of Cardiovascular Patient Care assists facilities in their<br />
efforts to create cardiovascular centers of excellence that delivers quality<br />
care and patient satisfaction in a cost sensitive environment. SCPC offers<br />
hospitals the support needed to effectively reduce variations of care and<br />
bridge existing gaps in treatment. www.scpc.org<br />
Soleo Health ...............................................................…..517<br />
950 Calcon Hook Rd, Ste. 19<br />
Sharon Hill, PA 19079<br />
888-244-2340<br />
Jeanne Warsing<br />
jwarsing@soleohealth.com<br />
Website: www.soleohealth.com<br />
Soleo Health is an innovative national provider of home and alternate-site<br />
specialty infusion. Our team of experienced clinicians provides<br />
exceptional care in managing complex disease states through comprehensive<br />
pharmacy, nursing, education, and therapy management<br />
programs.<br />
St. Jude Medical……………………………………..701<br />
6300 Bee Cave Road, Building 2, Suite 100<br />
Austin, TX 78746<br />
512.286.4092<br />
Rachel Stroik<br />
rstroik@sjm.com<br />
Website: www.sjm.com<br />
St. Jude Medical is a global medical device manufacturer dedicated<br />
to transforming the treatment of some of the world’s most expensive<br />
epidemic diseases by creating cost-effective medical technologies that<br />
save and improve lives of patients globally. Clinical focus areas include<br />
cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation.<br />
Visit sjm.com.<br />
114
Exhibitor Descriptions (continued)<br />
The American Association of Heart Failure Nurses….…..806<br />
1120 Route 73, Ste 200<br />
Mt. Laurel, NJ 08054<br />
856-642-4425<br />
Clare MacNab<br />
cmacnab@ahint.com<br />
Website: www.ahint.com<br />
The American Association of Heart Failure Nurses (AAHFN) is a specialty<br />
organization dedicated to advancing nursing education, clinical<br />
practice and research to improve heart failure patient outcomes. We<br />
serve as the interface for sharing ideas, translating research findings into<br />
practice and setting priorities for the future.<br />
The Heart Failure Society of America, Inc. (HFSA) ..........Lvl 2<br />
6707 Democracy Blvd. Ste. 925<br />
Bethesda, MD 20817<br />
Patrick McGary<br />
info@hfsa.org<br />
Website: www.hfsa.org<br />
The Heart Failure Society of America, Inc. (HFSA) represents the first<br />
organized effort by heart failure experts from the Americas to provide<br />
a forum for all those interested in heart function, heart failure, and<br />
congestive heart failure (CHF) research and patient care.<br />
Thoratec Corporation.............………………………510<br />
6035 Stoneridge Drive<br />
Pleasanton, CA 94588<br />
925-847-8600<br />
Cory Ferreira<br />
Kay.gonzales@thoratec.com<br />
Website: www.thoratec.com<br />
Thoratec is a world leader in therapies to address advanced-stage heart<br />
failure. The company's products include the HeartMate II® LVAS<br />
(Left Ventricular Assist Systems) and Thoratec® VAD (Ventricular<br />
Assist Device) with more than 20,000 devices implanted in patients<br />
suffering from heart failure. Thoratec also manufactures and distributes<br />
the CentriMag® & PediMag®/PediVAS®, product lines.<br />
Wolters Kluwer Health………………………......….714<br />
Two Commerce Square<br />
2001 Market Street<br />
Philadelphia, PA 19103<br />
215-521-8300<br />
Joey-Rose Jester<br />
joey-rose.jester@wolterskluwer.com<br />
Website: www.wolterskluwer.com<br />
Wolters Kluwer Health is a global rovider of information, business<br />
intelligence and point-of-care solutions. Brands include Lippincott<br />
Williams & Wilkins, a leading international publisher of medical<br />
books, electronic media and journals including Circulation: Heart<br />
Failure (online journal). We offer specialized publications and software<br />
for physicians, nurses, students and clinicians.<br />
ZOLL ……………………..….....……....…...…..….507<br />
121 Gamma Road<br />
Pittsburgh, PA 15238<br />
412-968-3413<br />
Kathryn Boyle<br />
kboyle@zoll.com<br />
Website: www.zoll.com<br />
ZOLL® LifeVest® wearable defibrillator protects patients at risk<br />
of sudden cardiac arrest, during a patient’s changing condition and<br />
when permanent SCA risk has not been established. The LifeVest<br />
provides patients constant monitoring, immediate protection, and<br />
peace of mind.<br />
ZS Pharma .............................………....…...…...…….715<br />
8-5 Veterans Blvd., Suite 200<br />
Redwood City, CA 94063<br />
650-670-8733<br />
Megan Clifford<br />
mclifford@zspharma.com<br />
Website: www.zspharma.com<br />
ZS Pharma is a publicly traded biopharmaceutical company. ZS<br />
Pharma recently submitted a New Drug Application to the FDA for<br />
its lead product candidate, ZS-9, a new therapeutic option for the<br />
treatment of hyperkalemia.<br />
115
2015 19th Annual Scientific Assembly<br />
THANK YOU<br />
September 26 – 29, 2015<br />
Gaylord National Harbor • National Harbor, Maryland<br />
Sessions Begin Saturday morning at 10:30am
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
Aaronson, Keith 55<br />
Abbas, Raza<br />
52, P257<br />
Abbo, Aharon<br />
P170, P337<br />
Abdullah, Kazeen P101, P214<br />
Abe, Ruri<br />
P104, P105<br />
Abraham, M Roselle 49,<br />
Abraham, William 36, 44, 54, 61, P87, P164<br />
Abraham, William T 35, P087, P170, P275, P285, P337<br />
Abuannadi, Mohammad P178<br />
Abuissa, Hussam P81<br />
Achilefu, Samuel P231<br />
Adachi, Hitoshi P94<br />
Adamson, Philip P275, P285<br />
Adatya, Sirtaz<br />
P23<br />
Adjei-Poku, Yaw P118<br />
Adler, Eric<br />
P219<br />
Afzal, Junaid 49<br />
Agasthi, Pradyumna P35<br />
Ahmad, Saad<br />
P192<br />
Ahmed, Haitham P262<br />
Ahmed, Mustafa P060, P308<br />
Ahn, Sylvie<br />
P39<br />
Akers, Walter<br />
P231<br />
Al-Anbari, Raghda 41, P177, P239, P271<br />
Al-Ani, Mohammad P308<br />
Alasaad, Mohammad P309<br />
Aleong, Ryan<br />
P97<br />
Alexis, Jeffrey 53, P40, P286<br />
Alharethi, Rami 48, P318<br />
Ali, Omima<br />
P152<br />
Alkandari, Fawzia P107<br />
AlKindi, Sadeer 52, 53, P128, P159, P263, P306, P307<br />
Allen, Larry<br />
29, 36, 43, 44, 48, P167, P276<br />
Almansa, Johana P141<br />
Almasoud, Abdallah P159, P306, P307<br />
Alonso, Alvaro 89, 94, P242, P298<br />
Aloor, Sivakanth P35<br />
Alsari, Mohammad 48<br />
Alsayed, Ameena P107<br />
Altan, Aylin<br />
P274<br />
Alvarez, Paulino 67, P44, P46<br />
Alvarez, Rene<br />
P055, P145, P296<br />
Amass, Leslie<br />
P22<br />
Ambach, Stephanie P31<br />
Ambardekar, Amrut 29, 42, 63, P97<br />
Amione-Guerra, Javier P44, P233, P234, P295<br />
Amir, Offer<br />
P170, P337<br />
Ammon, Susan 29<br />
Ammous, Farah P165<br />
An, Qi<br />
P169, P332<br />
Ando, Tomo<br />
P82, P183, P191<br />
Andrews, George P113<br />
Angus, Christopher P66<br />
Anker, Stefan-D 37, 55, 60, P264, P335, P336<br />
Anyanwu, Emeka P53, P65, P77, P228<br />
Aramin, Hermineh P36<br />
Aranda, Jr, Juan P60<br />
Arbit, Boris<br />
P32, P36, P42, P202, p305<br />
Armbruster, Rebecca P143<br />
Armstrong, Paul P34, P294<br />
Arnold, Stacey P328<br />
Arora, Bhaskar P315<br />
Arthur, Susan<br />
P253<br />
Ashrith, Guha<br />
49, P45, P233, P234, P279, P284, P295<br />
Asif, Aya<br />
42, P247, P254<br />
Atherton, John P109<br />
Atkinson, Matt P126<br />
Atluri, Pavan<br />
32, P181, P299<br />
Austin, Bethany P152<br />
Averina, Viktoria P169, P332<br />
Avery, Elizabeth P136<br />
Ayers, Colby<br />
P187<br />
Ayyadurai, Puvanalingam P110<br />
Azzouz, Muhammad P81<br />
Bader, Feras<br />
P107<br />
Bae, Jang-Whan P266<br />
Baek, Sang Hong P301<br />
Bahl, Joseph<br />
P208<br />
Bailey, Joseph<br />
P59<br />
Bailey, Kent<br />
P267<br />
Baker, William P100<br />
Bakris, George P253<br />
Balasubramanian, Neelam P59<br />
Ballard, Kevin 53, P207<br />
Balmain, Sean P163<br />
Bander, Jeffrey P121<br />
Bank, Alan<br />
P52<br />
Bannister, Wade P50, P221<br />
Bansal, Neha<br />
P213<br />
Bardhadi, Amina 53, P259<br />
Barnard, Denise P245<br />
Barrett, Peter<br />
P220<br />
Barrows, Kim<br />
P328<br />
Bart, Bradley 54<br />
Bartone, Cheryl P289<br />
Bass, Kyle 48<br />
Beck, Kenneth P52<br />
Bekelman, David P167<br />
Bekfani, Tarek P264<br />
Bell, Greg<br />
P165<br />
Belsito, Marlene P74<br />
Ben Gal, Tuvia P170, P337<br />
Benatti, Rodolfo P128<br />
Benatti, Rodolfo 53, P237, P306, P307<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
117
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
Benes, Lane<br />
P269<br />
Benike, Sherry P43<br />
Bennett, Mosi<br />
P161<br />
Berg, Tiffany<br />
P150<br />
Bergethon, Kristin 41, P278<br />
Bergin, James<br />
P178<br />
Berk, John<br />
P189<br />
Berman, Lance P253<br />
Berry, Jarett<br />
P187<br />
Berry, Narelle<br />
P109<br />
Bertke, Ken<br />
P328<br />
Betihavas, Vasiliki P325<br />
Bhandari, Rekha P121<br />
Bhardwaj, Chetan P56, P63<br />
Bharmi, Rupinder P140, P275<br />
Bhat, Geetha<br />
P54, P73, P132, P323<br />
Bhatia, Nirmanmoh P211<br />
Bhatt, Deepak<br />
41, P130, P273, P278<br />
Bhatt, Kunal<br />
P239<br />
Bhatt, Reema<br />
P296<br />
Bhimaraj, Arvind 39, 43, 49, 55, P44, P45, P119, P146,<br />
P233, P234, P279, P284, P295<br />
Bhonsale, Aditya 53, P312<br />
Bhullar, Amarbhir P190<br />
Bhullar, Manminder P190<br />
Bicknese, Laurie P150<br />
Bidwell, Julie<br />
40, P303<br />
Biering-Sørensen, Tor P185<br />
Bilchick, Kenneth P178, P298<br />
Bionat, Susan<br />
P119, P145<br />
Birati, Edo<br />
P75<br />
Birks, Emma<br />
P66, P84, P165, P211<br />
Bischoff, Michelle P158<br />
Bitar, Abbas<br />
P165<br />
Blaha, Michael P262<br />
Blanchard, Daniel P245<br />
Blauer-Peterson, Cori P274<br />
Blaum, Caroline P115<br />
Blecker, Saul<br />
P111<br />
Bleske, Barry<br />
58, P277<br />
Blondheim, David 42, P247, P254<br />
Bloomfield, Daniel P135<br />
Blue, Laura<br />
P227<br />
Blumenthal, Roger P262<br />
Boehmer, John P169<br />
Böhm, Michael 33, P85, P90<br />
Bokhari, Sabahat P189<br />
Bolanos, Alexander P60<br />
Bole, Indra 48<br />
Bonios, Michael 48<br />
Bonnell, Mark P223<br />
Borer, Jeffery<br />
33, P85, P90, P95, P250<br />
Borgi, Jamil<br />
P56, P63<br />
Borlaug, Barry 30, 38, 62, P149<br />
Borow, Kenneth P252<br />
Bove, Alfred<br />
P55, P145, P296<br />
Boyd III, Thompson P168<br />
Boyes, Edith<br />
P59<br />
Boyle, Andrew P220<br />
Bozkurt, Biykem 31, 60, P292<br />
Braga, Juarez<br />
P163<br />
Brailovsky, Yevgeniy P55<br />
Braunwald, Eugene 43<br />
Brennan, Danielle P120<br />
Brewer, Mindy P328<br />
Brewer, Robert P56, P63<br />
Brisco, Meredith 52, P251<br />
Bristow, Michael 45, 64, P97<br />
Brown, Jason<br />
P298<br />
Brown, Judith<br />
53, P207<br />
Bruce, Charles P83, P92, P327<br />
Bruckner, Brian P234, P279<br />
Buchbinder, Maurice P241<br />
Budge, Deborah P318<br />
Buglioni, Alessia 49, P204<br />
Buiten, Lyanne P69<br />
Buono, Sarah<br />
P62<br />
Burdorf, Adam P300<br />
Burkman, Gregory P271<br />
Burnett Jr. John 32, P43, P182, P267<br />
Burnett, John<br />
41, 44, 49, P204<br />
Burton, Paul<br />
P276<br />
Bushinsky, David P253<br />
Butler, Javid 31, 35, 48, 57, 102, P034, P130,<br />
P271, P287, P294<br />
Butler, Kenneth P185<br />
Butts, Brittany P78, P11, P117, P137<br />
Caccamo, Marco P78, P117, P137<br />
Caine, William 48<br />
Calway, Tyler<br />
P206<br />
Campos, O<br />
P26<br />
Cannone, Valentina P204, P267<br />
Cappola, Thomas 53<br />
Carazo, Matthew P115<br />
Carey, Sandra<br />
48, P320<br />
Carlson, Steven P80<br />
Carter, Rickey<br />
P92<br />
Carvalho, A<br />
P26<br />
Casso Dominguez, Abel P98<br />
Castano, Adam P189<br />
Chae, Shung Chull P301<br />
Chagin, Kevin 41<br />
Chai, Siang Chew P37<br />
Chaiteerakij, Roongruedee P30<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
118
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
Chambers, Susan P75<br />
Chan, Angel 49<br />
Chan, Vincent<br />
P64<br />
Chan, Wenyaw P292<br />
Chang, Philip<br />
P80<br />
Charlene, Pherson P74<br />
Charney, Alan<br />
P86<br />
Chatterjee, Saurav P98<br />
Chaudhari, Sameer P61<br />
Chee, Tek Siong P37<br />
Chen, Fabian<br />
P86<br />
Chen, Horng<br />
49, P268<br />
Chen, Leway<br />
53, P282<br />
Chen, Lin<br />
P242<br />
Chen, Xiaozhen P123<br />
Chen, Xiongwen P256<br />
Chen, Zengsheng 49<br />
Cheng, Allen<br />
70, P165, P210<br />
Cheng, Susan<br />
42, P96, P179, P184, P198<br />
Chenna, Avantika P35<br />
Cherian, Tharian P276<br />
Cheryl, Alexander 41<br />
Chin, John 34, 47<br />
Chirinos, Julio 38, 61<br />
Chiswell, Karen P135<br />
Cho, Myeong-Chan P266, P301<br />
Choi, Dong-Ju P301<br />
Choi, Hyo-In<br />
P108<br />
Chojnowski, Donna P75<br />
Chomick, Nicole P315<br />
Chowdhury, Munir P109<br />
Chronakos, John P52<br />
Chung, Eugene P289, P328<br />
Chung, Misook L. 39, 50<br />
Chuprun, J. Kurt P256<br />
Clagett, Brian<br />
41, P88, P185<br />
Claridge, Tamara P75<br />
Clark, Robyn<br />
P109<br />
Clarke, M.<br />
P103<br />
Clarke, Rachel 48<br />
Cleary, Ellen<br />
P74<br />
Cleland, John<br />
P135<br />
Cleland, John-G P264<br />
Cleveland, Joseph 48<br />
Coglianese, Erin P59<br />
Cogswell, Rebecca P242<br />
Cohn, Jay N. 48, 51, 55<br />
Cole, Robert 48<br />
Colombo, Paolo 29<br />
Comenzo, Ray 52, P133<br />
Connors, Lawreen P201<br />
Contasti, Annette P245<br />
Contreras, Elizabeth P98<br />
Contreras, Johanna P265<br />
Conway, Ginger P93<br />
Cook, Dana 48<br />
Cooke, John<br />
49, P45, P279<br />
Cooper, Lauren 41<br />
Cooper, Leslie 31, 67, P40<br />
Cooper, Daniel P244<br />
Corbisiero, Raffaele P74, P138, P140, P143<br />
Cordero-Reyes, Andrea 49, 67, P45, P46, P232, P284, P295<br />
Cordier, Tristan P113<br />
Cork, David<br />
P219<br />
Corl, Maureen P328<br />
Cosgrove, Christine P41<br />
Costanzo, Maria Rosa 29, 35, 44, 54<br />
Costello, Rebecca P91<br />
Cotter, Gad<br />
P135<br />
Cox, Zachary<br />
41, P114<br />
Craig, Damian 85, P197<br />
Creamer, Andrea P119, P146<br />
Cronkright, Ashley P48<br />
Crow, Stacy<br />
P284<br />
Crowell, Rebecca P293<br />
Cuchiara, Michael P222<br />
Cui, Grace<br />
P231<br />
Cummings, Abby P141<br />
Cuomo, Kimberly P141<br />
Cusano, Diana P113<br />
Cyr, Penny<br />
P293<br />
D’Alessandro, David P224, P236<br />
Dadosky, Amy P328<br />
Dahan, Iris<br />
41, P254<br />
Daimee, Usama 53, P282<br />
Dakros, Stavros 84, P193<br />
Dalal, Nirav<br />
P275<br />
Daly, Kathleen P328<br />
Daneshmand, Mani P227<br />
Daniel, Carl<br />
P119, P146<br />
Daoud, Ahmed P233<br />
Dardari, Zeina P262<br />
Darnieder, Jean P222<br />
Darrah, Jason<br />
P300<br />
Dasari, Tarun<br />
P317<br />
Davila, Carlos<br />
65, P20<br />
Davis, Gordan P97<br />
Davison, Beth<br />
P135<br />
Dawn, Buddhadeb 48, P61<br />
Dawson, Kyle<br />
P284<br />
de Denus, Simon 53<br />
de Lemos, James P187<br />
de Lima, Marcos P263<br />
De Marco, Teresa P186<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
119
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
De Oliveira, Samer P240<br />
de Souza, Ana<br />
P263<br />
Dean, David<br />
P116, P220<br />
Dean, Evelyn<br />
P152<br />
Dec, G. William 37, 67, P40<br />
Deedwania, Prakash 59, P246<br />
Dekker, Rebecca 40, 48<br />
Delaney, Colleen P52<br />
Demastus, Cassandra P168<br />
Dendi, Vijaya<br />
P35<br />
Denfeld, Quin<br />
P313<br />
Dennison Himmelfarb, Charyl 63<br />
DeNofrio, David 48, P69, P321<br />
Deo, Salil<br />
P128<br />
Depre, Christophe P85<br />
Desai, Akshay<br />
62, P88, P134, P248<br />
Desai, Dharma 53<br />
Desai, Shashank P67, P70, P76<br />
Desvigne-Nickens, Patrice P91<br />
Devens, Carolyn P150<br />
Devoe, Tari<br />
P315<br />
DeVore, Adam 41, P129, P273, P294, P297<br />
Dias, C<br />
P26<br />
Dickinson, Michael P173<br />
Dickson, Victoria 36, 39, 44, 48, 50, 55, 63, P115, P216<br />
DiDomenico, Robert 47<br />
Ding, Jun 49<br />
DiSalvo, Thomas 34<br />
Disch, Maghee 33<br />
Dispenzieri, Angela P189<br />
Dodd, Katherine 53<br />
Doehner, Wolfram P264<br />
Dolan, Noreen P48<br />
Dolganiuc, Angela P308<br />
Domenico, Chris P281<br />
Dominjon, Fabienne P85<br />
Doshi, Rahul<br />
P80<br />
Doshi, Shephal P241<br />
Dougherty, James P100<br />
Doukas, Demetrios P59<br />
Doukky, Rami P136<br />
Dovancescu, Silviu P123<br />
Drachman, Brian P166<br />
Drakos, Stavros 48, 55<br />
Drazner, Mark 30, 38, P187<br />
Dreher, Michael P166<br />
Dress, Ashley<br />
P314<br />
Dries, Daniel 47<br />
Dubé, Marie-Pierre 53<br />
Dubner, Brett<br />
P59<br />
Dunbar, Sandra 27, 48<br />
Dunlap, Mark<br />
38, 48, P101<br />
Dunn, Jonathan P112<br />
Dunning, Allison P294<br />
Duquaine, Damon P122<br />
Durand, Jean-Bernard 51<br />
East, Cara 48<br />
Ebner, Nicole<br />
P264<br />
Eckman, Peter 39, P155, P314<br />
Edwards, Lonnie P154<br />
Effat, Mohamed P93<br />
Egnaczyk, Gregory P289<br />
Egnatios, Jeremy P36<br />
Egolum, Ugochukwu P33, P148, P199<br />
Eidem, Benjamin P217<br />
Eisen, Howard 62, P168<br />
Eisman, Aaron P314<br />
Elamin, Mohamed P18, P200<br />
ElAmm, Chantal 5 3, P128, P159, P306, P307<br />
El-Hayek, Georges P98<br />
Elkayam, Uri<br />
63, P318<br />
Ellison, David 54<br />
Emani, Sitaramesh P238<br />
Emanuele, Marty 52<br />
Emig, Meghan P172<br />
Engelman, Timothy P180<br />
Engorn, Diane P118<br />
Ershow, Abby<br />
P91<br />
Estep, Jerry 49, 100, P44, P45, P46, P233,<br />
P234, P279, P284, P295<br />
Estis, Joel<br />
P199<br />
Evangelista, Lorraine 63, P106<br />
Ewald, Greg 30, P72, P79, P218, P225, P226,<br />
P230, P231, P232, P314, P318<br />
Ezekowitz, Justin P294<br />
Fahlberg, Beth 44<br />
Fang, James 30, 48, 54<br />
Farooq, Kanwal P271<br />
Fatica, Richard P188<br />
Fedson, Savitri P53, P65, P228, P269<br />
Feijo, Maria<br />
Feldman, Arthur 64, P256<br />
Felker, G. Michael 41, 54, 59, P34, P197<br />
Fenner, Deborah P172<br />
Ferdman, Robert P190<br />
Feroz Zada, Yassamin 53<br />
Figueredo, Vincent P20<br />
Fine, Lynn 53<br />
Finet, Jose<br />
P117<br />
Finet, Jose<br />
P137<br />
Firpi-Morell, Roberto P308<br />
Fiuzat, Mona 56, 64<br />
Flanagan, Jean P314<br />
Fleming, Lisa<br />
P142<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
120
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
Flint, Kelsey<br />
P167<br />
Flowers, Deirdre P326, P329<br />
Flynn, Kelsie<br />
P126<br />
Fonarow, Gregg 34, 43, 57, P129, P130, P158,<br />
P273, P276<br />
Ford, Ian<br />
P85, P90, P95<br />
Forfia, Paul<br />
P181<br />
Foroutan, Farid P163<br />
Francis, Gary 27, 44, 51<br />
Freid, Lauren<br />
P145, P296<br />
Friedman, Eitan P199, P203<br />
Friedman, Paul P83, P92, P327<br />
Frost, Steven<br />
P325<br />
Fukuta, Hidekatsu P102<br />
Fusco, Daniel 53<br />
Gaber, Osama<br />
P233, P234<br />
Gabrah, Guirgis P107<br />
Gafoor, Sameer P241<br />
Gage, Brain<br />
P79<br />
Gaggin, Hanna 59<br />
Gale, Ashley<br />
P100<br />
Gao, Erhe<br />
P256<br />
Gardell, Stephen 52, P195<br />
Gardiner, Stacey P333<br />
Gardner, Roy<br />
P169, P332<br />
Garg, Neetika<br />
P304<br />
Garg, Sonia<br />
P187<br />
Garganta, Marisue P176<br />
Gary, Rebecca 48<br />
Gary Huang, Kuan-Hsiang P20<br />
Garza, Dahlia<br />
P253<br />
Gay, Elizabeth P178<br />
Gaynor, J. William P131<br />
Gearhart, Christine P75<br />
Gee, Julie 43<br />
Gelow, Jill<br />
P313<br />
Georgiopoulou, Vasiliki 41, 88, P271, P287<br />
Germany, Robin P164<br />
Gersh, Bernard P276<br />
Gertz, Morie 52<br />
Ghashghaei, Roxana P245<br />
Ghotra, Amaninderapal P66, P84, P211<br />
Giedrimiene, Dalia P243<br />
Gilbert, Edward 48, P193<br />
Gilbert, Mark<br />
P93<br />
Gill, Natasha<br />
P122<br />
Gilotra, Nisha<br />
65, P17, P161, P326, P329<br />
Ginn, Greg<br />
P285<br />
Ginwalla, Mahazarin 53, P128, P159, P306, P307<br />
Giustino, Nina 79, P154<br />
Givertz, Michael 42, 63, P135, P280, P318<br />
Gjerde, Cecilie P216<br />
Gluck, Jason<br />
53, P41, P100, P315<br />
Gluck, Trenton P32, P42, P202, P305<br />
Go, Alan 42<br />
Godishala, Anuradha P218, P232<br />
Goel, Sunny<br />
P57<br />
Goldberg, Lee<br />
32, P75<br />
Golden, Lee<br />
P252<br />
Goldman, Steven P208<br />
Goldraich, Livia P163<br />
Goldsmith, Jeff P216<br />
Goldstein, Daniel P224, P236<br />
Goldstein, Nathan P216<br />
Goldwater, Deena P216<br />
Golwala, Harsh P273<br />
Gonçalves, I<br />
P26<br />
Gong, Jianjian P248<br />
Gong, Jim<br />
P86<br />
Goodlin, Sarah 44<br />
Gopal, Deepa<br />
41, P280<br />
Gopal, Vipin<br />
P113<br />
Gopinathannair, Rakesh P84<br />
Gordon, Glenna P175<br />
Gordon, Nicole P241<br />
Gorur, Arathi<br />
P324<br />
Gottesman, Rebecca P242<br />
Gottlieb, Stephen 54, 55<br />
Gradus-Pizlo, Irmina P117, P137<br />
Grady, Kathleen 45, P62<br />
Grandin, E. Wilson 41, P181<br />
Grant, Joan<br />
P175<br />
Graven, Lucinda P175<br />
Gravis, Edward P233, P234<br />
Grayburn, Paul 48<br />
Greenberg, Barry 37, 44, 46, 60, 102, P245<br />
Greenspon, Arnold P127<br />
Griffith, Bartley 49<br />
Groarke, John<br />
41, P280<br />
Grodin, Justin<br />
41, P34, P38, P194, P196, P198, P309<br />
Grogan, Martha P189, P217<br />
Gruson, Damien P39<br />
Guerrero-Miranda, Cesar P224<br />
Guerry, Roshni P302<br />
Guertin, Danette P243<br />
Gulati, Sanjeev P172<br />
Gupta, Divya 48<br />
Gupta, Kamal 48<br />
Gupta, Ramesh 52, P210<br />
Gutfinger, Dan P64<br />
Guthrie, Spencer P133<br />
Guzman, Eliscer P265<br />
Habtemariam, Daniel P118<br />
Hachamovitch, Rory P196<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
121
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
Hadi, Azam<br />
P117, P137<br />
Hager, Martha<br />
P153<br />
Haines, David<br />
P124<br />
Haines, Mary<br />
P223<br />
Hajj, Jihane<br />
P166<br />
Hajjar, Roger 45<br />
Halkar, Meghana P196<br />
Hall, Shelley 48<br />
Halperin, Jonathan P241<br />
Halushka, Marc 53, P161<br />
Hamad, Eman<br />
P55, P145, P296<br />
Hammadah, Muhammad P19, P120, P188, P287<br />
Hammond, Eliza P193<br />
Hammond, Elizabeth P193<br />
Hammond, Jonathan 52<br />
Hammond, Jonathan P315<br />
Hankins, Shelley P168<br />
Harders, Gerald 49, P182<br />
Hardy, N. Chantelle 41, P297<br />
Hardy, Natalie C. P129<br />
Harmon, Cynthia P206<br />
Harsch, Manya P64<br />
Harshaw-Ellis, Karol 27, 33, 40<br />
Hasan, Ayesha P238<br />
Hasni, Farhan<br />
P168<br />
Hatano, Masaru P58, P214<br />
Haugh, Gilbert P113<br />
Hauptman, Paul 36, 51, 52, 57<br />
Hawwa, Nael<br />
P188<br />
Hay, Christine 53<br />
Haynes, Carol<br />
P197<br />
Hays, Allison<br />
P161<br />
Hazen, Stanely P38, P120<br />
Hedley, Jeffrey 41<br />
Hegde, Sheila<br />
P185<br />
Heidenreich, Paul 41, 60, P273<br />
Henderson, Cory P53, P65, P228<br />
Henderson, John P285<br />
Henry, Christine P210<br />
Henry, Timothy P252<br />
Heo, Seongkum 39, P330<br />
Hernandez, Adrian 33, 41, 57, P34, P129, P130,<br />
P197, P294, P297,<br />
Heroux, Alain<br />
P59<br />
Heublein, Denise P43, P267<br />
Heywood, Thomas J. 38, 62, P27<br />
Hiatt, Shirin<br />
P313<br />
Hicks, Albert<br />
P122<br />
Higgins, Robert P238<br />
Hiles, Natasha P328<br />
Hill, Joseph A. 47<br />
Ho, Carolyn 38<br />
Ho, Jennifer 31, 42<br />
Ho, Rady<br />
P112<br />
Hoatam, Gerard P324<br />
Hohl, Patrick<br />
P29<br />
Hoit, Brian<br />
P263<br />
Hollander, Seth 50<br />
Hollis, Ian<br />
P272<br />
Holly, Alexander P21<br />
Holmes, David P241<br />
Homer, Sarah<br />
P119, P146<br />
Horn, Evelyn<br />
P216<br />
Horng, Steven<br />
P142<br />
Horstmann, Erika P333<br />
Horwich, Tamara P158<br />
Hott, Brenda<br />
P162, P331<br />
Hottigoudar, Rashmi P84<br />
Houser, Steven 45, 49, 55<br />
Hsich, Eileen<br />
30, P318<br />
Huang, Paul<br />
P252<br />
Huber, Kenneth P241<br />
Hudson, Michelle P223<br />
Huggins, Gordon 53, P48, P270<br />
Huhn, Nicole<br />
P315<br />
Hummel, Scott 31<br />
Hunter, Claire<br />
P81<br />
Hunter, Wynn<br />
P197<br />
Huntley, Brenda 49<br />
Huntsinger, Mary P80<br />
Hupcey, Judith P125<br />
Hussain, Zeeshan P84, P211<br />
Hwang, Kyung-Kuk P266<br />
Ichiki, Tomoko P182<br />
Ige, Mobolaji<br />
53, P128<br />
Imamura, Teruhiko P58, P214<br />
Ingrassia, Joseph P293<br />
Irwin, Frank<br />
P50, P221<br />
Ishak, K.<br />
P250<br />
Iskandar, Muhammad Zaid P151<br />
Itescu, Silviu<br />
P252<br />
Itoh, Akinobu<br />
P231<br />
Iyer, Seethalakshmi P43<br />
Jackson, Gregory P196<br />
Jain, Amit<br />
P268<br />
Jani, Milena<br />
P51, P117, P137<br />
Janmohamed, Munir P186<br />
Januzzi, James 38, 46, 59<br />
Jeevanandam, Valluvan P53, P65, P77, P228<br />
Jefferies, John<br />
P31<br />
Jensen, Brian<br />
P272<br />
Jeon, Eun-Seok P301<br />
Jermyn, Rita A. 36<br />
Jessup, Mariell 31, 47, 60<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
122
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
Johnson, Allen P27<br />
Johnson, Geoffrey P189<br />
Jones, Anna<br />
P324<br />
Jorde, Ulrich<br />
P224, P236<br />
Joseph, Susan 35<br />
Joyce, David 45<br />
Joyce, Emer<br />
41, P280<br />
Joyce, Wald<br />
P299<br />
Jr, Charles<br />
P60<br />
Ju, Christine<br />
41, P130<br />
Judge, Daniel<br />
53, P122<br />
Juneman, Elizabeth P208<br />
Jung, Miyeon<br />
P277<br />
Jurgens, Corrine 39, 50<br />
Juricek, Colleen P53, P65, P77, P228<br />
Kagan, Viktoriya P77<br />
Kalogeropoulos, Andreas 41, 48, P212, P239, P271, P287<br />
Kalya, Anantharam P176, P324<br />
Kam, Carmen<br />
P37<br />
Kamran, Hassan P292<br />
Kang, Seok-Min P301<br />
Kansal, Anuraag P250<br />
Kapadia, Shaival P92<br />
Kapa, Suraj 31<br />
Kapur, Navin<br />
39, 43, P69<br />
Kar, Saibal<br />
P241<br />
Karakas, Mehmet Fatih 49<br />
Karpawich, Peter P213<br />
Kasper, Edward 53<br />
Kass, David 32<br />
Kassotis, John<br />
P57<br />
Katikireddy, Chandra P190<br />
Kattan, Michael 41<br />
Kattea, Mohammad 53, P128<br />
Katz, Jason<br />
50, P272<br />
Katz, Stuart<br />
61, P111, P115<br />
Kawahara, Matt P32, P42, P202, P305<br />
Kay, W. Aaron P78<br />
Kazatsker, Mark 41<br />
Kazatsker, Mark P254<br />
Kazemian, Pedram P138, P140<br />
Keibel, Andrew P80<br />
Keichline, Lisa P302<br />
Keleti, Julianna 53<br />
Kelkar, Anita<br />
48, P212<br />
Kelly, Daniel 45<br />
Kelly, Jacob<br />
P197, P297<br />
Kelly, Linda<br />
P162, P331<br />
Kennedy, Jamie P160, P178<br />
Kennedy, Jamie P178<br />
Kennedy, Kevin P152<br />
Kent, David<br />
P270<br />
Keohane, Denis P22<br />
Ketkar, Sayali<br />
P119<br />
Kfoury, Abdalah 48, P193, P318<br />
Khair, Andrew P210<br />
Khayat, Rami<br />
P164<br />
Khouri, Michel P187<br />
Khouri, Samer P18, P200, P223<br />
Kiatchoosakun, Songsak P248<br />
Kielhorn, Adrian P95, P250, P297<br />
Kiernan, Michael 48, P69, P321<br />
Kihara, Yasuki P94<br />
Kilby, Susan<br />
P176<br />
Kilic, Ahmet<br />
P238<br />
kim, Chang<br />
53, P263<br />
Kim, Dong-Woon P266<br />
Kim, Elaine<br />
P139<br />
Kim, Gene<br />
P53, P65, P206, P228, P269<br />
Kim, Jae-Joong P108, P301<br />
Kim, John<br />
P201<br />
Kim, Min-Seok P108<br />
Kim, Sang Min P266<br />
Kim, So-Young P335<br />
Kimmelstiel, Carey P69<br />
Kingery, Joanna P117, P137<br />
Kinney, Gene 52<br />
Kinoshita, Osamu P58, P214<br />
Kinugawa, Koichiro P58, P214<br />
Kirby, Jennifer P160<br />
Kirkpatrick, James P235, P299<br />
Kitko, Lisa<br />
P125<br />
Klarich, Kyle<br />
P30<br />
Klein, Liviu<br />
P68<br />
Kleiner, Ilia 41<br />
Kleiner, Ilia<br />
42, P254<br />
Klenk, Juergen P127<br />
Kliethermes, Stephanie P59<br />
Klootwyk, J.<br />
P103<br />
Kluger, Jeffrey P243<br />
Ko, Yi-An<br />
P212<br />
Koch, Walter<br />
45, 49, 55, P256<br />
Kocheril, Abraham P314<br />
Kociol, Robb<br />
29, 32, 39, 43, 52, 56, P142<br />
Koczwara, Bogda 49, P109<br />
Koenig, Steven 49<br />
Koliopoulou, Antigone 48<br />
Koller, Martin 52<br />
Komajda, Michel P85, P90<br />
Konstam, Marvin 35, P270<br />
Kotadia, Arati<br />
P141<br />
Kottmann, Matthew P282<br />
Koullick, Maria P64<br />
Koulova, Anna P224<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
123
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
Kowey, Peter<br />
P276<br />
Kramer, Daniel P118<br />
Kraus, William P197<br />
Krishnamurthy, Yamini 41, P227<br />
Krittanawong, Chayakrit P30<br />
Krotneva, Stanmira P250<br />
Kukin, Marrick P98<br />
Kullar, Vikas<br />
P308<br />
Kumar, Arun<br />
P209<br />
Kumar, Nilay<br />
P304<br />
Kumar, Sachin P128<br />
Kuruvilla, Sonia P107<br />
Lahood, Nicole P208<br />
Lai, Pikki<br />
41, P114<br />
Lainscak, Mitja P264<br />
Lakdawala, Neal 41<br />
Lakhter, Vladimir P55<br />
Lala, Anu<br />
P216<br />
Lalor, Katherine P147<br />
Lambiase, Pier 53, P332<br />
Lampert, Brent P238<br />
Lancaster, Jordan P208<br />
Landau, Heather 52, P133<br />
Lane, Kathleen P51<br />
Lanfear, David 52, P56, P63, P99, P195<br />
Lang, Chim<br />
P151<br />
Langholz, David 52<br />
Lanoza, Tracy<br />
P144<br />
Lanza, Gregory P231<br />
Larsen, Greg<br />
48, P126<br />
LaRue, Shane P72, P79, P218, P225, P226,<br />
P230, P231, P232, P244<br />
Laskar, S. Raja 48<br />
Latif, Faisal<br />
P317<br />
Lato, Marc<br />
P176<br />
Lau, Edmund<br />
P127, P281<br />
Laverty-Wilson, Eva P299<br />
Lavie, Carl<br />
P57<br />
Lavigne, Paul<br />
P230<br />
Lavin, Philip<br />
P246<br />
Lazar, Jason<br />
P57<br />
Le, Christopher P60<br />
Lebeis, Taylor<br />
P271<br />
Lee, Christopher P174, P303, P313<br />
Lee, Elizabeth<br />
P32, P36, P42, P202, P305<br />
Lee, Ju-Hee<br />
P266<br />
Lee, Sang Yeub P266<br />
Lee, Sheldon<br />
P37<br />
Lee, Whayoun P77<br />
Lefkowitz, Martin 41, P88<br />
Leher, Michael P324<br />
Lemonnier, Maxime P210<br />
Lenihan, Daniel 41, P33, P114, P199, P203<br />
Lenneman, Andrew P66, P84, P165, P211<br />
Leong, Gerard P37<br />
Leung, Cheuk<br />
P317<br />
Levin, Albert<br />
52, P195<br />
Levin, Allison<br />
P236<br />
Levin, Daniel<br />
P151<br />
LeWinter, Martin 34, P29<br />
Lewis, Bradley P83, P92, P327<br />
Lewis, Connie 31, 41, 50, P114<br />
Lewis, Eldrin 41<br />
Lewis, Gregory 38, P314<br />
Lexvold, Nancy P83, P92, P327<br />
Li, Dean 48<br />
Li, Jia<br />
52, P195<br />
Liedtke, Michaela 52<br />
Lin, Kimberly<br />
P131<br />
Lindsley, John P281<br />
Liner, Ann<br />
P263<br />
Little, Jane<br />
P159<br />
Little, Jane<br />
P306<br />
Liu, Longjian<br />
P166<br />
Longenecker, Chris 52<br />
Lopez Candales, Angel P24, P28, P192<br />
Lopez-Menendez, Francisco P24, P28<br />
Lousada, Isabelle P133<br />
Lowe, David<br />
P68<br />
Lowes, Brian<br />
P300<br />
Lozano, Pedro P317<br />
Lu, Di<br />
41, P273<br />
Luk, Adriana<br />
41, P280<br />
Lunde, Ottar<br />
P245<br />
Lundgren, Scott P157<br />
Lutfi, Forat<br />
P308<br />
Lyndon, Audrey 48<br />
Lyons, Kristin<br />
P158<br />
MacCarter, Dean P314<br />
Macedo, C<br />
P26<br />
Macfelda, Karin P21<br />
Mackall, Judith P240<br />
Macon, Conrad P130<br />
Madden, George P273<br />
Magalski, Anthony P152<br />
Magasi, Susan P62<br />
Mahaffey, Kenneth P276<br />
Mahr, Claudius P333<br />
Maisel, Alan<br />
57, P32, P36, P42, P202, P305<br />
Malhotra, Atul P32, P42 P202, P305<br />
Malik, Adnan<br />
P51, P117, P137<br />
Malik, Sonika<br />
48, P7<br />
Mallemeester, Melanie P210<br />
Man, Lillian<br />
P291<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
124
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
Mangla, Ashvarya P136<br />
Manicardi, Marcella P186<br />
Mann, Douglas 44, 53, 55, P259<br />
ManriqueGarcia, Alvaro P240<br />
Manyam, Harish P240<br />
Margulies, Kenneth 45, P181<br />
Marhoover, Ronetta P153<br />
Marincic, Renee 48, P16<br />
Marks, Daniel<br />
P101<br />
Marks, Edward P209<br />
Maron, Martin 49, 68, P48<br />
Marroquin, Oscar P252<br />
Marston, Nick<br />
P36<br />
Martin, Linda<br />
P176<br />
Martin, Siobhan P154<br />
Martin, Spencer P100<br />
Martinka, Peter P89<br />
Maslanek, Wilhelmina P75<br />
Masoomi, Reza 48<br />
Massaro, Frank P321<br />
Massey, Todd<br />
P282<br />
Masson, Stephen P222<br />
Masterson Creber, Ruth P174<br />
Mathelier, Hansie P166<br />
Mather, Paul<br />
P112, P291<br />
Matlock, Daniel 48<br />
Maurer, Mathew 38, 42, P189, P216<br />
Maya, Juan<br />
P85, P297<br />
Mayo, Martha<br />
P253<br />
Mazimba, Sula P160, P178<br />
Mazur, Wojciech P31<br />
Mazurek, Jeremy P181<br />
Mazurek, Stefan P206<br />
McCall, Anthony P160<br />
McCants, Kelly P66<br />
McCarthy, Alexandra P109<br />
McClinton, Kira P176<br />
McCue, Andrew 41<br />
McCullough, Peter 35, P246<br />
McDonald, Michael P163<br />
McGarrah III, Robert P197<br />
McGrane-Minton, Heather P282<br />
McGregor, Jessina P126<br />
McIlvennan, Colleen 48<br />
McKellar, Stephen 48<br />
McMahon, Pamela P127<br />
McMurray, John 41, P34, P88, P248, P294<br />
McNamara, Dennis 34, 64, P40, P318<br />
McSweeney, Jean P330<br />
Mehanna, Emile P128<br />
Mehmood, Muddassir P31<br />
Mehra, Mandeep 40, 44, 51, 58, 62, P280<br />
Mehta, Hirsch<br />
P27<br />
Meisel, Simcha 42, P254<br />
Mejia, Erika<br />
P131<br />
Melenovsky, Vojtech P149<br />
Menon, Santosh P289, P328<br />
Mentz, Robert<br />
41, 64, P129, P294, P297<br />
Merkely, Bela<br />
P169, P332<br />
Merlini, Giampaolo P133<br />
Metra, Marco<br />
33, 51, P34, P135, P294<br />
Meyers-Fabian, Allison P223<br />
Meza, James<br />
P227<br />
Mihalek, Andrew P178<br />
Milano, Carmelo 41, P227<br />
Milinovich, Alex 41<br />
Miller, Dylan<br />
P193<br />
Miller, Edward P189<br />
Miller, Wayne<br />
62, P310<br />
Miner, Kathleen P150<br />
Minkove, Nicole P161<br />
Mitchell, Susan P118<br />
Miura, Masanobu P104, P105<br />
Miyata, Satoshi P104, P105<br />
Modany, Ashley P103<br />
Modi, Kalgi<br />
P318<br />
Moffa, Carolyn P302<br />
Mohamedali, Burhan P54, P73, P132, P136, P323<br />
Mohan, Rajeev P27<br />
Moisés, V<br />
P26<br />
Molina, Kim<br />
P193<br />
Molina, Maria<br />
P75<br />
Momomura, Shin-ichi P94<br />
Mondal, Nandan 49<br />
Mongrain, Ian 53<br />
Montan, Peter<br />
P265<br />
Montemayor, Kristina P161<br />
Moore, Meredith P162, P331<br />
Moranville, Michael P281<br />
Moravec, Christine P47<br />
Morgan, Jeffrey P56, P63<br />
Morris, Alanna 41, 48, P212, P239<br />
Morris, Daniel- A. P264<br />
Morris, Kathleen P51<br />
Morton, Christine 48<br />
Mosley, Thomas P185<br />
Moss, Noah<br />
P121<br />
Motie, Marjan<br />
P106<br />
Moukabary, Talal P208<br />
Moukarbel, George P18, P223<br />
Moyer, Mary<br />
P235<br />
Mudd, James<br />
P313<br />
Mueller, Johannes P21<br />
Muhammad Iqbal, Abdul Hafidz P151<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
125
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
Mukamal, Kenneth P142<br />
Mukherjee, Debabrata P57<br />
Mullens, Wilfried 54, 64, P194<br />
Muller, David<br />
P74, P138, P140, P143<br />
Mundayat, Rajiv P22<br />
Murks, Catherine P269<br />
Murphy, Andrea P100<br />
Nagatomo, Yuji P40, P47<br />
Najafi, Amir<br />
P190<br />
Naksuk, Niyada P30<br />
Nambi, Vijay<br />
P44<br />
Narula, Arvin<br />
P27<br />
Nasir, Saifullah P292<br />
Nassif, Michael 48, P72, P79, P218, P225, P226,<br />
P230, P231, P232, P244<br />
Natarajan, Sundar P115<br />
Nativi-Nicolau, Jose 42, 48<br />
Nawata, Kan<br />
P58, P214<br />
Nelson, Jennifer P314<br />
Nemeh, Hassan P56, P63<br />
Neuzil, Petr<br />
P241<br />
Neville, Susan P285<br />
Newgard, Christopher P197<br />
Newton, Abigail P153<br />
Ney, Blaine<br />
P116<br />
Ngarajan, Vijay P309<br />
Nguyen, Duc 48<br />
Nguyen, Jenni<br />
P236<br />
Nguyen, Peter<br />
P292<br />
Nicolais, Charles P296<br />
Nitta, Daisuke<br />
P58, P214<br />
Njoroge, Joyce P263<br />
Nochioka, Kotaro P104, P105<br />
Nohria, Anju 41<br />
Nolan, Niamh<br />
P199<br />
Norby, Faye<br />
P242<br />
Normand, Valérie 53<br />
Noubary, Farzad P270<br />
Novak, Eric<br />
P218, P230, P244<br />
Obalampalli, Kalyan P143<br />
O'Bara, Lynn<br />
P100<br />
Obi, Engels<br />
P274<br />
O'Brien, Thomas P289<br />
O'Connor, Christopher 32, 35, 43, 51, 60, P34, P135, P294<br />
O'Connor, Matthew P131<br />
O'Connor, Nina P235<br />
O'Donnell, Arden P134<br />
Oh, Byung-Hee P301<br />
Oh, Jaewon<br />
P301<br />
Ohte, Nobuyuki P102<br />
Okwuosa, Ike<br />
P326, P329<br />
Oliveira, Guilherme 30, 52, 53, P128, P159, P263,<br />
P306, P307<br />
Oliver-McNeil, Sandra P124<br />
Oliveros, Estefania P55, P145<br />
Olson, Andrew P23<br />
Olson, Lyle<br />
P83, P92, P327<br />
Ong, Moh-Lim P22<br />
Ono, Minoru<br />
P58, P214<br />
Onose, Takeo<br />
P104, P105<br />
Onwuanyi, Anekwe P35<br />
Onyebeke, Chukwuma 42, P96, P179, P184, P198<br />
Ordway, Linda 48<br />
O'Rourke, Brian 49<br />
Ota, Takeyoshi P53, P65, P77, P228<br />
Otani, Niels<br />
P123<br />
Ounpraseuth, Songthip P330<br />
Overbeck, Heather P328<br />
Owens, Anjali<br />
P75<br />
Packer, Milton 32, 41, 56, P88, P248<br />
Padhukasahasram, Badri 52<br />
Pak, Esther<br />
P299<br />
Palm, Denada<br />
P24, P28<br />
Pamirsad, Mustafa P236<br />
Pandey, Ambarish P187<br />
Pandey, Ambarish P273<br />
Pandey, Ambarish P304<br />
Pang, Peter<br />
33, P129<br />
Panjrath, Gurusher P61, P67, P70, P76<br />
Papadimitriou, Lampros P271<br />
Paridon, Stephen P131<br />
Park, Chan Seok P25<br />
Park, Hannah<br />
P111<br />
Park, Soon<br />
P128<br />
Paruchuri, Vikram P69<br />
Patel, Ameet<br />
P308<br />
Patel, Bhavin<br />
P317<br />
Patel, Chetan<br />
41, P227, P294<br />
Patel, Harshali P250, P297<br />
Patel, Jasmine<br />
P127<br />
Patel, Kershaw P53, P65, P77, P228<br />
Patel, Nish<br />
P130<br />
Patel, Samir<br />
P284<br />
Patel, Snehal<br />
P224, P236<br />
Patel, Vaiibhav P218, P226<br />
Patey, Megan<br />
P174<br />
Pattanshetty, Deepak 48<br />
Patton, Carol<br />
P166<br />
Pauly, Daniel<br />
P40<br />
Peacock, W. Frank 58, P129<br />
Peeraphatdit, Thoetchai P30<br />
Pei, Huang<br />
P37<br />
Pellicori, Pierpaolo P264<br />
Perez, Antonio P180<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
126
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
Perez, Rafael<br />
P211<br />
Perin, Emerson P252<br />
Peshock, Ronald P187<br />
Peters, Anthony P272<br />
Peterson, Edward P99<br />
Peterson, Eric<br />
41, P276<br />
Petrilli, A<br />
P26<br />
Pfaender, Lynn P220<br />
Pham, Duc Thinh P69<br />
Pham, Si 49<br />
Phillips, Gary<br />
P238<br />
Phillips, Michael 53<br />
Piatkowsky, Gail P142<br />
Piccini, Jonathan P276<br />
Picel, Katherine P155<br />
Pierce, Brian<br />
P226, P232<br />
Piña, Ileana<br />
46, 52, 62, P246<br />
Pinckney, Richard P29<br />
Pinney, Sean<br />
58, 86, 101, P216<br />
Pinto, G<br />
P26<br />
Pitt, Bertram<br />
46, 48, 55, P253<br />
Platts, Anne<br />
P225<br />
Pleister, Adam P164<br />
Pletke, Patricia P153<br />
Pocock, Stuart P95<br />
Ponikowski, Piotr P135<br />
Porter, Adam<br />
P134<br />
Powell, Lynda<br />
P136<br />
Preidt, Tracy<br />
P328<br />
Prescott, Margaret P248<br />
Pressler, Susan P277<br />
Pretorius, Victor P219<br />
Price, John<br />
P66<br />
Price, Mathew P241<br />
Provost, Sylvie 53<br />
Psotka, Mitchell P135<br />
Pudlo, Michael P119, P146<br />
Purcell, Scott<br />
P222<br />
Qattan, Marwan P263<br />
Quale, Cindy<br />
P126<br />
Querejeta Roca, Gabriela P185<br />
Radhakrishnan, Priya P324<br />
Radojevic, Joseph P100<br />
Ragupathi, Loheetha P291<br />
Raheja, Suraj<br />
31, P56, P63<br />
Raichlin, Eugenia P300<br />
Rajagopal, Vivek P220<br />
Rakita, Val<br />
P55<br />
Raman, Subha P31<br />
Rame, Eduardo 40, 41, P131, P181, P299<br />
Rao, MD, Praveen P244<br />
Ras, Aleksandra 53, P41<br />
Rasmussen, Henrik P246<br />
Rasmusson, Kismet P318<br />
Rath, Rutwik<br />
P49<br />
Raymer, David 48, P72, P79, P218, P225, P226,<br />
P230, P231, P232<br />
Reddy, Siddharth P101<br />
Reddy, Vivek<br />
41, P241<br />
Reddy, Yogesh P149<br />
Redfield, Margaret 31, 36, 64, P217, P267<br />
Reed, Shelby<br />
P297<br />
Reeves, Gordon P216<br />
Regan, James<br />
P23<br />
Regan, Karen<br />
P91<br />
Reichert, William P324<br />
Reid, Bruce 48<br />
Renda, Andrew P113<br />
Rennyson, Stephen P153<br />
Revelo, Monica P193<br />
Reyentovich, Alex P216<br />
Reynolds, Matthew P118<br />
Rials, Seth<br />
P169<br />
Ricci, Paola<br />
P30<br />
Rich, Michael 45, 48<br />
Richardson, DeJuran P136<br />
Ridha, Mustafa P107<br />
Riegel, Barbara 39, P174<br />
Riley, Penny<br />
P277<br />
Riley, Tiana<br />
P269<br />
Rinka, Joseph<br />
P333<br />
Rivers, Christina P154<br />
Robbins, Nathan P93<br />
Roberts, John<br />
P186<br />
Roberts, Lewis P30<br />
Robertson, Michele P90<br />
Rodeheffer, Richard P204, P267<br />
Roder, David<br />
P109<br />
Rodgers, Daniel P53<br />
Rogers, Jennifer P95<br />
Rogers, Joseph 41<br />
Rome, Eric<br />
P300<br />
Romero, Michael P222<br />
Rongione, Anthony P67, P70, P76<br />
Rosner, Carolyn P67, P70, P76<br />
Ross, Angela<br />
P154<br />
Ross, Heather<br />
47, P163<br />
Rossano, Joseph P131<br />
Rouleau, Jean<br />
41, 53, P88, P248<br />
Rousseau, Michel P39<br />
Rowe, Theresa P168<br />
Rubens, Fraser P64<br />
Rubenson, David P27<br />
Ruberg, Frederick P189<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
127
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
Rubinstein, Jack 49, P93<br />
Ruedlinger, Holly P77<br />
Ruel, Marc<br />
P64<br />
Ruhl, Kayla<br />
P126<br />
Rumsfeld, John P167<br />
Rupani, Hetal<br />
P141<br />
Russell, Stuart 44, 52, 53, P17, P122, P141,<br />
P161, P262, P326, P329<br />
Russo, Patricia P274<br />
Ryzhov, Sergey P49<br />
Sabbah, Hani<br />
36, 52, P99, P195, P210<br />
Sadarangani, Tina P115<br />
Sadhu, Justin 48<br />
Saeed, Omar<br />
P224, P236<br />
Saiki, Hirofumi P217<br />
Sakata, Yasuhiko P104, P105<br />
Saltzberg, Mitchell 41, 68, P302<br />
Sam, Flora<br />
38, 61, P201<br />
Samsky, Marc<br />
P294<br />
Samuel, Michelle P118<br />
Sanchez, Pablo P208<br />
Sandberg, Sarah P244<br />
Sandek, Anja<br />
P264<br />
Sangaralingham, Jeson 49, P182, P204<br />
Sanil, Yamuna P213<br />
Santos, Maria<br />
P26<br />
Saracino, Giovanna 48<br />
Sarmiento, Kathleen P32, P42, P202, P305<br />
Sarswat, Nitasha P53, P65, P228<br />
Sato, Kenjiro<br />
P104, P105<br />
Saurav, Alok<br />
P81<br />
Sawyer, Douglas 45, P49, P203<br />
Saxon, Leslie<br />
P80<br />
Sayer, Gabriel<br />
P53, P65, P77, P228, P269<br />
Schaefer, Kristen P134<br />
Schandera, Johanna P245<br />
Scheiner, Avram P71<br />
Scheinin, Scott P233<br />
Schenck, Louis P83, P92, P327<br />
Schilling, Joel<br />
P230<br />
Schilz, Robert<br />
P159, P306<br />
Schimmel, Melanee P245<br />
Schmidt, Emily P324<br />
Schmiege, Sarah P167<br />
Schmier, Jordana P127<br />
Schnobrich, Daniel P23<br />
Schroder, Jacob 41, P227<br />
Schulte, Philip P130, P273, P294, P297<br />
Schumacher, Jennifer 65, P22<br />
Schumacher, Sarah P256<br />
Schwann, Thomas P223<br />
Schwartz, Daniel P55, P145, P296<br />
Schwartz, Jefferey P59<br />
Scott, Christopher P204, P267, P268<br />
Scott, Michael P231<br />
Sean, Hawkey<br />
P151<br />
Seino, Yoshihiko P94<br />
Selby, Van<br />
P186<br />
Seldin, David 52<br />
Selektor, Yelena P56, P63<br />
Selzman, Craig 48<br />
Senni, Michele P86<br />
Sethares, Kris<br />
P171<br />
Shaddy, Robert P131<br />
Shafiq, Qaiser<br />
P18, P200<br />
Shah, Adnan<br />
P199<br />
Shah, Amil<br />
P185, P242<br />
Shah, Arpit<br />
P98<br />
Shah, Ashish<br />
P122, P138<br />
Shah, Mahek<br />
P20<br />
Shah, Nishant<br />
P161<br />
Shah, Palak<br />
P70, P76<br />
Shah, Riddhi<br />
P140<br />
Shah, Sachin<br />
41, P280<br />
Shah, Svati<br />
52, 53, P197<br />
Shah, Zubair<br />
48, P61<br />
Sharma, Abhishek P57<br />
Sharma, Kavita 52, P122, P262<br />
She, Ruicong<br />
P195<br />
Sheffield, Erin P220<br />
Sheiner, Patricia P41<br />
Shen, Changyu P51<br />
Sheppard, Richard P40, P318<br />
Sherazi, Saadia 52<br />
Shi, Victor<br />
41, P86, P88, P248<br />
Shimokawa, Hiroaki P104, P105<br />
Shin, Julia<br />
P224<br />
Shinbane, Jerold P80<br />
Shiose, Akira<br />
P55, P145<br />
Shirazi, Jonathan P51<br />
Shisler, David<br />
P199<br />
Shochat, Michael 42, P254<br />
Shotan, Avraham 42, P254<br />
Shpigel, Adam P161, P326, P329<br />
Shrader, Peter<br />
P129, P276<br />
Shrestha, Kevin P188<br />
Shutze Jr, William 48<br />
Sibulo Jr, Antonio P248<br />
Siddegowda Bangalore, Bhavana P18, P200<br />
Sievert, Horst<br />
P241<br />
Silber, Harry<br />
P17<br />
Silver, Elizabeth P41<br />
Silverman, Michael P262<br />
Silvestry, Scott 48, P72, P225, P231<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
128
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
Simon, Jennifer 42, 53, P96, P179, P184, P196, P198<br />
Simon, Joel<br />
P78<br />
Sims, Daniel<br />
P224, P236<br />
Sing-Gupta, Vinita 52<br />
Singh, Aaron<br />
P37<br />
Singh, Bhupinder P246<br />
Singh, Harleen P126<br />
Singh, Manmeet P190<br />
Singh, Ramesh P67, P70, P76<br />
Singleton, Paula 48<br />
Skarupski, Kimberly P329<br />
Sklenar, Jiri<br />
P123<br />
Slabaugh, Lane P113<br />
Slaughter, Mark 49, P66, P84, P165, P211<br />
Sloan, Joanne<br />
P151<br />
Slovut, David<br />
P82, P183, P191<br />
Smer, Aiman<br />
P81<br />
Smith, Andrew 41, 48, P212, P239, P271<br />
Smith, LaVone P160<br />
Smith, Michael P27<br />
Smith, Sakima P238<br />
Snipas, Diane<br />
P168<br />
Snow, Greg<br />
P193<br />
Soares, J<br />
P26<br />
Sobieski, Mike 49<br />
Sokos, George P103<br />
Soliman, Medhat P107<br />
Solomon, Scott 56, P88, P185, P242, P248<br />
Somers, Virend P83, P92, P327<br />
Soucier, Richard P293<br />
Soujeri, Bayan P151<br />
Sparrow, Christopher 27, P218, P230, P232<br />
Spilias, Nikolaos P271<br />
Squire, Iain<br />
P248<br />
Sridhar, Arun<br />
48, P61<br />
Stabler, Ruth<br />
P168<br />
Starling, Randall 40, P34, P40, P88, P194, P196, P294<br />
Stasch, Johannes-Peter 32, P267<br />
Stasiv, Yuri<br />
P253<br />
Statz, Cara<br />
53, P41<br />
Steahr, Gregg<br />
P162, P331<br />
Steenbergen, Charles 53<br />
Stehlik, Josef 48<br />
Stevens, Gerin P122<br />
Stevenson, Lynne 32, 47, 57, P134<br />
Stewart, Garrick P280<br />
Stewart, Graham P151<br />
Stöckl, Georg<br />
P89<br />
Stollar, K.<br />
P103<br />
Storozynsky, Eugene 53<br />
Struck, Joachim P36<br />
Stutman, Patricia P75<br />
Su, Yan Ru<br />
P203<br />
Suarez, Erik<br />
P45<br />
Svetlichnaya, Jana P186<br />
Swarup, Vijay<br />
P241<br />
Swedberg, Karl 41, P88, P90, P248<br />
Sweeney, Robert P169, P332<br />
Swindle, Jason P274<br />
Sylvia, Lynne<br />
P321<br />
Szklo, Moyses P262<br />
Tadaki, Soichiro P104, P105<br />
Tahhan, Ayman 41<br />
Tahir, Usman<br />
P201<br />
Taka, Nchang<br />
P35<br />
Takahashi, Jun P104, P105<br />
Tallaj, Jose<br />
P178<br />
Tamrat, Ruth<br />
P326, P329<br />
Tan, Puay Joo<br />
P37<br />
Tang, W. H. Wilson 41, 52, 53, P19, P34, P38, P40,<br />
P47, P120, P180, P188, P194,<br />
P196, P198, P287, P294, P309<br />
Tao, Jiang<br />
P50, P221<br />
Taub, Cynthia<br />
P82, P183, P191<br />
Tavazzi, Luigi<br />
P85, P90<br />
Taylor, David<br />
P194<br />
Taylor, Michael P31<br />
Taylor, Stanley P51<br />
Tedford, Ryan<br />
52, P17, P122, P181<br />
Teerlink, John<br />
41, 60, P135, P294<br />
Teeter, Larry<br />
P233, P234<br />
Tellor, Bethany 48<br />
Templin, Thomas P124<br />
Tereshchenko, Larisa P123<br />
Tesmer, John<br />
P256<br />
Testani, Jeffrey 42, 53, 59, 62, P96, P142, P179,<br />
P184, P196, P198<br />
Teuteberg, Jeffrey 32, 58, P238<br />
Thadani, Udho P317<br />
Thandra, Vidya P240<br />
Thomas, Laine P276<br />
Thompson, Jocelyn 48<br />
Thompson, Julie P52<br />
Thongprayoon, Charat P30<br />
Tibrewala, Anjan 48, P72, P79<br />
Tikhomirov, Oleg P49<br />
Tita, Cristina<br />
P56, P63<br />
Titler, Marita<br />
P277<br />
Todd, John<br />
P199<br />
Tomasek, Kelsey P203<br />
Ton, Van-Khue 53, P161<br />
Tong, Khim Leng P37<br />
Torabi, Sahar<br />
P114<br />
Torre-Amione, Guillermo 49, P44, P45, P46, P233, P234,<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
129
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
P279, P295<br />
Toyoda, Yoshiya P55, P145<br />
Trachtenberg, Barry 49, P44, P45, P233, P234, P279,<br />
P284, P295<br />
Tran, Hao<br />
P219<br />
Traverse, Jay<br />
P252<br />
Troutman, Gregory P181<br />
Tsai, Pao-Feng P330<br />
Tsuji, Kanako<br />
P104, P105<br />
Turner, Stuart<br />
P274<br />
Turrentine, Mark P78<br />
Ullah, Shahid<br />
P109<br />
Ullman, Edward P142<br />
Um, John<br />
P300<br />
Unterberger, Kate P126<br />
Upshaw, Jenica P270<br />
Uribe, Cesar<br />
49, P44, P45, P46, P279<br />
Uriel, Nir<br />
30, 40, 58, P53, P65, P77, P228, P269<br />
Ushigome, Ryoichi P104, P105<br />
Vader, Justin 48, P72, P79, P218, P225, P226,<br />
P230, P231, P232<br />
Vader, MD, Justin P244<br />
Vaidya, Anjali<br />
P181<br />
Vakrou, Stella 49<br />
Vallabhan, Ravi 48<br />
Vallakati, Ajay P57, P101<br />
Vardeny, Orly<br />
41, 56, 58, P333<br />
Varghese, Smitha P107<br />
Varian, Kenneth 41<br />
Varnado, Sara<br />
P300<br />
Vega, David<br />
48, P212, P239<br />
Velazquez, Eric 40, 49, P197, P297<br />
Velez, Mauricio P56, P63<br />
Verbrugge, Frederik 41, P38, P194<br />
Verdino, Ralph 41<br />
Vest, Amanda 48<br />
Vilaro, Juan<br />
P308<br />
Vinereanu, Dragos P248<br />
Vitoff, Paji<br />
P52<br />
Vollmer, Marcus P123<br />
von Haehling, Stephan P264<br />
Voors, Adriaan P34, P135, P294<br />
Vorovich, Esther P75<br />
Vos, Kevin<br />
P173<br />
Wacha, Lynn<br />
P274<br />
Walker, Donna 48<br />
Walker, Mike<br />
P163<br />
Walling, Jackie 52<br />
Walsh, Kayley P134<br />
Walter, C.<br />
P103<br />
Wand, Alison 41<br />
Wang, I-Wen<br />
P51, P78<br />
Wang, Mengjun P210<br />
Wang, Yun<br />
P195<br />
Warman, Eduardo P298<br />
Warner, Patrick P48<br />
Waters, Sarah<br />
P272<br />
Wayangankar, Siddharth P317<br />
Weber, Malory P19<br />
Webster, Julie<br />
P116, P220<br />
Wehrenberg, Scott P332<br />
Weigand, Kyle P208<br />
Weinstein, Jean P170<br />
Weir, Matthew P253<br />
Weiss, Brendan 52<br />
Wells, Karen<br />
P99<br />
Wencker, Detlef 52, P41<br />
Westlake, Cheryl P171<br />
Wever Pinzon, James 48<br />
Whisenant, Brian P241<br />
Whitman, Glenn P122<br />
Whitmarsh, Kelly 41, P302<br />
Whitson, Bryan P238<br />
Wieselthaler, Georg P68<br />
Wiley, Mark 48<br />
William, Basem P263<br />
Williams, Celeste P56, P63<br />
Williams, Keoki 52, P99, P195<br />
Williams, Mary P75<br />
Williams, Dominique P244<br />
Wilson, Jamie<br />
P263<br />
Wittstein, Ilan<br />
52, P17, P122<br />
Woiciechowski, Melissa P293<br />
Woldemichael, Kirubel 49<br />
Woods-Stroup, Tashua P328<br />
Wu, Charlotte<br />
P50, P221<br />
Wu, Yuna<br />
P85<br />
Wu, Yuping<br />
P196<br />
Wu, Zhongjun 49<br />
Xu, Bin<br />
52, P255<br />
Yamauchi, Takeshi P104, P105<br />
Yan, Cao<br />
Yancy, Clyde<br />
41, P37, P62, P130, P262, P273<br />
Yang, Alex<br />
P246<br />
Yao, Francis<br />
P186<br />
Yasumura, Yoshio P94<br />
Yazdani, Mariyah 41, P271<br />
Yeboah, Joseph P262<br />
Yeo, Daniel<br />
P188<br />
Yiu, Karen<br />
P281<br />
Yokoyama, Hiroyuki P94<br />
Yoo, Byung-Su P301<br />
Yost, Gardner<br />
P54, P73, P132, P323<br />
Youker, Keith<br />
49, P44, P45, P46, P279<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
130
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Faculty/Author Index (Numbers preceded by P are poster numbers.)<br />
Younes, Ahmad P159, P306, P307<br />
Young, Michelle P134<br />
Yousem, David P329<br />
Yuzefpolskaya, Melana P216<br />
Zakariea, Khalid P107<br />
Zalawadiya, Sandip P33<br />
Zalewski, Christyna P299<br />
Zamani, Payman 41, P75, P181, P245<br />
Zeld, Nicole<br />
52, P99, P195<br />
Zelin, Kathleen P213<br />
Zhang, Kefei<br />
P210<br />
Zhang, Yi<br />
P52, P169, P332<br />
Zhao, Daniel<br />
P317<br />
Zhao, Huaqing P55<br />
Zhian, Samaneh P126<br />
Zhu, Weizhong P256<br />
Zile, Michael<br />
41, 52, P88, P248<br />
Zimmerman, Sandra P168<br />
Zonder, Jeffrey 52<br />
Zsilinszka, Reka P129<br />
Zugck, Christian P89<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
131
Hotel Overview<br />
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
132
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Prince George's Exhibition Hall<br />
Convention Center Level 1<br />
Ballrooms & Chesapeake Conference Rooms<br />
Convention Center Level 2<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
133
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
National Harbor Conference Rooms<br />
Convention Center Level 3<br />
Hotel within a Hotel<br />
Hotel Meeting Space Level 2<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
134
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Notes<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
135
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Notes<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
136
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Notes<br />
SEPTEMBER 26-29 NATIONAL HARBOR, MARYLAND<br />
137
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
Notes<br />
SEPTEMBER 26-29<br />
NATIONAL HARBOR, MARYLAND<br />
138
2015 HFSA ANNUAL SCIENTIFIC MEETING<br />
2015-2016 Calendar ........................................................................................................................................................<br />
HFSA Dates to Remember<br />
3rd Biennial Comprehensive<br />
Review and Update Course<br />
October 22-25, 2015<br />
Sheraton Tampa East<br />
Tampa, FL<br />
<br />
September 17-20, 2016<br />
Gaylord Palms<br />
Orlando, FL<br />
<br />
September 16-19, 2017<br />
Gaylord Texan<br />
Grapevine, TX<br />
Review<br />
Course<br />
October 2015<br />
S M T W T F S<br />
1 2 3<br />
4 5 6 7 8 9 10<br />
11 12 13 14 15 16 17<br />
18 19 20 21 22 23 24<br />
25 26 27 28 29 30 31<br />
November 2015<br />
S M T W T F S<br />
1 2 3 4 5 6 7<br />
8 9 10 11 12 13 14<br />
15 16 17 18 19 20 21<br />
22 23 24 25 26 27 28<br />
29 30<br />
December 2015<br />
S M T W T F S<br />
1 2 3 4 5<br />
6 7 8 9 10 11 12<br />
13 14 15 16 17 18 19<br />
20 21 22 23 24 25 26<br />
27 28 29 30 31<br />
January 2016<br />
S M T W T F S<br />
1 2<br />
3 4 5 6 7 8 9<br />
10 11 12 13 14 15 16<br />
17 18 19 20 21 22 23<br />
24 25 26 27 28 29 30<br />
31<br />
February 2016<br />
S M T W T F S<br />
1 2 3 4 5 6<br />
7 8 9 10 11 12 13<br />
14 15 16 17 18 19 20<br />
21 22 23 24 25 26 27<br />
28 29<br />
March 2016<br />
S M T W T F S<br />
1 2 3 4 5<br />
6 7 8 9 10 11 12<br />
13 14 15 16 17 18 19<br />
20 21 22 23 24 25 26<br />
27 28 29 30 31<br />
April 2016<br />
S M T W T F S<br />
1 2<br />
3 4 5 6 7 8 9<br />
10 11 12 13 14 15 16<br />
17 18 19 20 21 22 23<br />
24 25 26 27 28 29 30<br />
May 2016<br />
S M T W T F S<br />
1 2 3 4 5 6 7<br />
8 9 10 11 12 13 14<br />
15 16 17 18 19 20 21<br />
22 23 24 25 26 27 28<br />
29 30 31<br />
June 2016<br />
S M T W T F S<br />
1 2 3 4<br />
5 6 7 8 9 10 11<br />
12 13 14 15 16 17 18<br />
19 20 21 22 23 24 25<br />
26 27 28 29 30<br />
July 2016<br />
S M T W T F S<br />
1 2<br />
3 4 5 6 7 8 9<br />
10 11 12 13 14 15 16<br />
17 18 19 20 21 22 23<br />
24 25 26 27 28 29 30<br />
31<br />
August 2016<br />
S M T W T F S<br />
1 2 3 4 5 6<br />
7 8 9 10 11 12 13<br />
14 15 16 17 18 19 20<br />
21 22 23 24 25 26 27<br />
28 29 30 31<br />
Note: meeting starts on Saturday<br />
Annual<br />
Scientific<br />
Meeting<br />
September 2016<br />
S M T W T F S<br />
1 2 3<br />
4 5 6 7 8 9 10<br />
11 12 13 14 15 16 17<br />
18 19 20 21 22 23 24<br />
25 26 27 28 29 30<br />
SEPTEMBER 26-29<br />
NATIONAL HARBOR, MARYLAND<br />
139
ENTRESTO (sacubitril and valsartan) tablets, for oral use<br />
Initial U.S. Approval: 2015<br />
BRIEF SUMMARY: Please see package insert for full prescribing information.<br />
WARNING: FETAL TOXICITY<br />
• When pregnancy is detected, discontinue ENTRESTO as soon as possible<br />
(5.1)<br />
• Drugs that act directly on the renin-angiotensin system can cause injury<br />
and death to the developing fetus (5.1)<br />
1 INDICATIONS AND USAGE<br />
1.1 Heart Failure<br />
ENTRESTO is indicated to reduce the risk of cardiovascular death and<br />
hospitalization for heart failure in patients with chronic heart failure (NYHA<br />
Class II-IV) and reduced ejection fraction.<br />
ENTRESTO is usually administered in conjunction with other heart failure<br />
therapies, in place of an ACE inhibitor or other ARB.<br />
4 CONTRAINDICATIONS<br />
ENTRESTO is contraindicated:<br />
• in patients with hypersensitivity to any component<br />
• in patients with a history of angioedema related to previous ACE inhibitor<br />
or ARB therapy [see Warnings and Precautions (5.2)]<br />
• with concomitant use of ACE inhibitors. Do not administer within 36 hours<br />
of switching from or to an ACE inhibitor [see Drug Interactions (7.1)]<br />
• with concomitant use of aliskiren in patients with diabetes [see Drug<br />
Interactions (7.1)].<br />
5 WARNINGS AND PRECAUTIONS<br />
5.1 Fetal Toxicity<br />
ENTRESTO can cause fetal harm when administered to a pregnant woman.<br />
Use of drugs that act on the renin-angiotensin system during the second<br />
and third trimesters of pregnancy reduces fetal renal function and increases<br />
fetal and neonatal morbidity and death. When pregnancy is detected, consider<br />
alternative drug treatment and discontinue ENTRESTO. However, if<br />
there is no appropriate alternative to therapy with drugs affecting the reninangiotensin<br />
system, and if the drug is considered lifesaving for the mother,<br />
advise a pregnant woman of the potential risk to the fetus [see Use in<br />
Specific Populations (8.1)].<br />
5.2 Angioedema<br />
ENTRESTO may cause angioedema. In the double-blind period of<br />
PARADIGM-HF, 0.5% of patients treated with ENTRESTO and 0.2% of<br />
patients treated with enalapril had angioedema [see Adverse Reactions<br />
(6.1)]. If angioedema occurs, discontinue ENTRESTO immediately, provide<br />
appropriate therapy, and monitor for airway compromise. ENTRESTO must<br />
not be re-administered. In cases of confirmed angioedema where swelling<br />
has been confined to the face and lips, the condition has generally resolved<br />
without treatment, although antihistamines have been useful in relieving<br />
symptoms.<br />
Angioedema associated with laryngeal edema may be fatal. Where there is<br />
involvement of the tongue, glottis or larynx, likely to cause airway obstruction,<br />
administer appropriate therapy, e.g., subcutaneous epinephrine/<br />
adrenaline solution 1:1000 (0.3 mL to 0.5 mL) and take measures necessary<br />
to ensure maintenance of a patent airway.<br />
ENTRESTO has been associated with a higher rate of angioedema in Black<br />
than in non-Black patients.<br />
Patients with a prior history of angioedema may be at increased risk of<br />
angioedema with ENTRESTO [see Adverse Reactions (6.1)]. ENTRESTO<br />
should not be used in patients with a known history of angioedema related<br />
to previous ACE inhibitor or ARB therapy [see Contraindications (4)].<br />
5.3 Hypotension<br />
ENTRESTO lowers blood pressure and may cause symptomatic hypotension.<br />
Patients with an activated renin-angiotensin system, such as volumeand/or<br />
salt-depleted patients (e.g., those being treated with high doses of<br />
diuretics), are at greater risk. In the double-blind period of PARADIGM-HF,<br />
18% of patients treated with ENTRESTO and 12% of patients treated with<br />
enalapril reported hypotension as an adverse event [see Adverse Reactions<br />
(6.1)], with hypotension reported as a serious adverse event in approximately<br />
1.5% of patients in both treatment arms. Correct volume or salt<br />
depletion prior to administration of ENTRESTO or start at a lower dose. If<br />
hypotension occurs, consider dose adjustment of diuretics, concomitant<br />
antihypertensive drugs, and treatment of other causes of hypotension (e.g.,<br />
hypovolemia). If hypotension persists despite such measures, reduce the<br />
dosage or temporarily discontinue ENTRESTO. Permanent discontinuation<br />
of therapy is usually not required.<br />
5.4 Impaired Renal Function<br />
As a consequence of inhibiting the renin-angiotensin-aldosterone system<br />
(RAAS), decreases in renal function may be anticipated in susceptible<br />
individuals treated with ENTRESTO. In the double-blind period of<br />
PARADIGM-HF, 5% of patients in both the ENTRESTO and enalapril groups<br />
reported renal failure as an adverse event [see Adverse Reactions (6.1)].<br />
In patients whose renal function depends upon the activity of the reninangiotensin-aldosterone<br />
system (e.g., patients with severe congestive heart<br />
failure), treatment with ACE inhibitors and angiotensin receptor antagonists<br />
has been associated with oliguria, progressive azotemia and, rarely, acute<br />
renal failure and death. Closely monitor serum creatinine, and down-titrate<br />
or interrupt ENTRESTO in patients who develop a clinically significant<br />
decrease in renal function [see Use in Specific Populations (8.7) and Clinical<br />
Pharmacology (12.3) in the full prescribing information].<br />
As with all drugs that affect the RAAS, ENTRESTO may increase blood urea<br />
and serum creatinine levels in patients with bilateral or unilateral renal<br />
artery stenosis. In patients with renal artery stenosis, monitor renal function.<br />
5.5 Hyperkalemia<br />
Through its actions on the RAAS, hyperkalemia may occur with ENTRESTO.<br />
In the double-blind period of PARADIGM-HF, 12% of patients treated with<br />
ENTRESTO and 14% of patients treated with enalapril reported hyperkalemia<br />
as an adverse event [see Adverse Reactions (6.1)]. Monitor serum potassium<br />
periodically and treat appropriately, especially in patients with risk factors<br />
for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism,<br />
or a high potassium diet. Dosage reduction or interruption of<br />
ENTRESTO may be required [see Dosage and Administration (2.1) in the<br />
full prescribing information].<br />
6 ADVERSE REACTIONS<br />
Clinically significant adverse reactions that appear in other sections of the<br />
labeling include:<br />
• Angioedema [see Warnings and Precautions (5.2)]<br />
• Hypotension [see Warnings and Precautions (5.3)]<br />
• Impaired Renal Function [see Warnings and Precautions (5.4)]<br />
• Hyperkalemia [see Warnings and Precautions (5.5)]<br />
6.1 Clinical Trials Experience<br />
Because clinical trials are conducted under widely varying conditions,<br />
adverse reaction rates observed in the clinical trials of a drug cannot be<br />
directly compared to rates in the clinical trials of another drug and may not<br />
reflect the rates observed in practice.<br />
In the PARADIGM-HF trial, subjects were required to complete sequential<br />
enalapril and ENTRESTO run-in periods of (median) 15 and 29 days,<br />
respectively, prior to entering the randomized double-blind period comparing<br />
ENTRESTO and enalapril. During the enalapril run-in period, 1,102 patients<br />
(10.5%) were permanently discontinued from the study, 5.6% because of<br />
an adverse event, most commonly renal dysfunction (1.7%), hyperkalemia<br />
(1.7%) and hypotension (1.4%). During the ENTRESTO run-in period, an<br />
additional 10.4% of patients permanently discontinued treatment, 5.9%<br />
because of an adverse event, most commonly renal dysfunction (1.8%),<br />
hypotension (1.7%) and hyperkalemia (1.3%). Because of this run-in<br />
design, the adverse reaction rates described below are lower than expected<br />
in practice.<br />
In the double-blind period, safety was evaluated in 4,203 patients treated<br />
with ENTRESTO and 4,229 treated with enalapril. In PARADIGM-HF, patients<br />
randomized to ENTRESTO received treatment for up to 4.3 years, with a<br />
median duration of exposure of 24 months; 3,271 patients were treated for<br />
more than one year. Discontinuation of therapy because of an adverse event<br />
during the double-blind period occurred in 450 (10.7%) of ENTRESTO<br />
treated patients and 516 (12.2%) of patients receiving enalapril.<br />
Adverse reactions occurring at an incidence of ≥5% in patients who were<br />
treated with ENTRESTO in the double-blind period are shown in Table 1.<br />
Table 1: Adverse Reactions Reported in ≥5% of Patients Treated with<br />
ENTRESTO in the Double-Blind Period<br />
ENTRESTO Enalapril<br />
(n = 4,203) (n = 4,229)<br />
% %<br />
Hypotension 18 12<br />
Hyperkalemia 12 14<br />
Cough 9 13<br />
Dizziness 6 5<br />
Renal failure/acute renal failure 5 5<br />
In the PARADIGM-HF trial, the incidence of angioedema was 0.1% in both<br />
the enalapril and ENTRESTO run-in periods. In the double-blind period, the<br />
incidence of angioedema was higher in patients treated with ENTRESTO<br />
than enalapril (0.5% and 0.2%, respectively). The incidence of angioedema<br />
in Black patients was 2.4% with ENTRESTO and 0.5% with enalapril [see<br />
Warnings and Precautions (5.2)].<br />
Orthostasis was reported in 2.1% of patients treated with ENTRESTO compared<br />
to 1.1% of patients treated with enalapril during the double-blind<br />
period of PARADIGM-HF. Falls were reported in 1.9% of patients treated<br />
with ENTRESTO compared to 1.3% of patients treated with enalapril.
Laboratory Abnormalities<br />
Hemoglobin and Hematocrit<br />
Decreases in hemoglobin/hematocrit of >20% were observed in approximately<br />
5% of both ENTRESTO- and enalapril-treated patients in the doubleblind<br />
period in PARADIGM-HF.<br />
Serum Creatinine<br />
Increases in serum creatinine of >50% were observed in 1.4% of patients<br />
in the enalapril run-in period and 2.2% of patients in the ENTRESTO<br />
run-in period. During the double-blind period, approximately 16% of both<br />
ENTRESTO- and enalapril-treated patients had increases in serum creatinine<br />
of >50%.<br />
Serum Potassium<br />
Potassium concentrations >5.5 mEq/L were observed in approximately 4%<br />
of patients in both the enalapril and ENTRESTO run-in periods. During the<br />
double-blind period, approximately 16% of both ENTRESTO- and enalapriltreated<br />
patients had potassium concentrations >5.5 mEq/L.<br />
7 DRUG INTERACTIONS<br />
7.1 Dual Blockade of the Renin-Angiotensin-Aldosterone System<br />
Concomitant use of ENTRESTO with an ACE inhibitor is contraindicated<br />
because of the increased risk of angioedema [see Contraindications (4)].<br />
Avoid use of ENTRESTO with an ARB, because ENTRESTO contains the<br />
angiotensin II receptor blocker valsartan.<br />
The concomitant use of ENTRESTO with aliskiren is contraindicated in<br />
patients with diabetes [see Contraindications (4)]. Avoid use with aliskiren<br />
in patients with renal impairment (eGFR
LCZ696 is<br />
Now Approved as...<br />
vISIT uS AT BooTh 301!<br />
visit www.EntrestoHCP.com Learn more about ENTrEsTo request samples<br />
please see Brief Summary of prescribing Information, including Boxed wArNING, on previous pages.
LCZ696 is<br />
Now Approved as...<br />
vISIT uS AT BooTh 301!<br />
visit www.EntrestoHCP.com Learn more about ENTrEsTo request samples<br />
please see Brief Summary of prescribing Information, including Boxed wArNING, on previous pages.<br />
ENTREsTO is a trademark of Novartis aG.<br />
Novartis Pharmaceuticals Corporation<br />
East Hanover, New Jersey 07936-1080 © 2015 Novartis 8/15 ETr-1320770